PSYCHIATRIC MANAGEMENT IN NEUROLOGICAL DISEASE
PSYCHIATRIC MANAGEMENT IN NEUROLOGICAL DISEASE
Edited by
Edward C. L...
123 downloads
1953 Views
2MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
PSYCHIATRIC MANAGEMENT IN NEUROLOGICAL DISEASE
PSYCHIATRIC MANAGEMENT IN NEUROLOGICAL DISEASE
Edited by
Edward C. Lauterbach, M.D.
Washington, DC London, England
Note: The authors have worked to ensure that all information in this book concerning drug dosages, schedules, and routes of administration is accurate as of the time of publication and consistent with standards set by the U.S. Food and Drug Administration and the general medical community. As medical research and practice advance, however, therapeutic standards may change. For this reason and because human and mechanical errors sometimes occur, we recommend that readers follow the advice of a physician who is directly involved in their care or the care of a member of their family. Books published by the American Psychiatric Press, Inc., represent the views and opinions of the individual authors and do not necessarily represent the policies and opinions of the Press or the American Psychiatric Association. Copyright © 2000 American Psychiatric Press, Inc. ALL RIGHTS RESERVED Manufactured in the United States of America on acid-free paper First Edition 03 02 01 00 4 3 2 1 American Psychiatric Press, Inc. 1400 K Street, N.W. Washington, DC 20005 www.appi.org Library of Congress Cataloging-in-Publication Data A CIP record is on file with the Library of Congress. British Library Cataloguing in Publication Data A CIP record is available from the British Library.
Dedicated to the Creator, my parents, and clinicians who take care of patients with neuropsychiatric illnesses
This page intentionally left blank
Contents Contributors
ix
Introduction to the Clinical Practice Series Judith H. Gold, M.D., F.R.C.P.C.
xi
Preface
xiii
1
Psychiatric Management Principles in Neurological Disease Edward C. Lauterbach, M.D.
1
2
Parkinson’s Disease Morgan L. Levy, M.D. Jeffrey L. Cummings, M.D.
41
3
Huntington’s Disease Neal G. Ranen, M.D.
71
4
Wilson’s Disease (Progressive Hepatolenticular Degeneration) Edward C. Lauterbach, M.D.
93
5
Fahr’s Syndrome Edward C. Lauterbach, M.D.
137
6
Dystonia Edward C. Lauterbach, M.D.
179
7
Stroke Robert G. Robinson, M.D.
219
8
Multiple Sclerosis Steven R. Schwid, M.D. Amy Weinstein, Ph.D. Heather A. Wishart, Ph.D. Randolph B. Schiffer, M.D.
249
9
Acquired Immunodeficiency Syndrome Jorge Luis Maldonado, M.D. Francisco Fernandez, M.D. Joel K. Levy, Ph.D.
271
10
Family Management Issues Edward C. Lauterbach, M.D.
297
Index
305
Contributors Jeffrey L. Cummings, M.D. Augustus S. Rose Professor of Neurology; Professor of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, California Francisco Fernandez, M.D. Professor and Chairman, Department of Psychiatry and Behavioral Neurosciences, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois Edward C. Lauterbach, M.D. Chief, Division of Adult and Geriatric Psychiatry; Professor of Psychiatry and Internal Medicine (Neurology), Department of Psychiatry and Behavioral Sciences and the Department of Internal Medicine (Neurology Section), Mercer University School of Medicine, Macon, Georgia Joel K. Levy, Ph.D. Assistant Professor of Neurology and Physical Medicine/Rehabilitation, Departments of Neurology and Physical Medicine/Rehabilitation, Baylor College of Medicine, Houston, Texas Morgan L. Levy, M.D. Assistant Professor of Psychiatry, Department of Psychiatry, Wake Forest University School of Medicine, Winston-Salem, North Carolina Jorge Luis Maldonado, M.D. Staff Psychiatrist, The Kneibert Clinic, Doctor’s Regional Medical Center, Poplar Bluff, Missouri
ix
x
Psychiatric Management in Neurological Disease
Neal G. Ranen, M.D. Medical Director, Health Pathways Geriatric and Neuropsychiatric Assessment Program, Albright Care Services Inc., York, Pennsylvania; and Clinical Associate Professor of Psychiatry, Pennsylvania State University College of Medicine, Hershey, Pennsylvania Robert G. Robinson, M.D. Paul W. Penningroth Professor and Head, Department of Psychiatry, University of Iowa School of Medicine, Iowa City, Iowa Randolph B. Schiffer, M.D. The Vernon and Elizabeth Haggerton Chair in Neurology, and Chair, Department of Neuropsychiatry and Behavioral Sciences, Texas Tech University Health Sciences Center, Lubbock, Texas Steven R. Schwid, M.D. Assistant Professor of Neurology, University of Rochester Medical Center, Rochester, New York Amy Weinstein, Ph.D. Assistant Professor of Neurology and Psychiatry, University of Rochester Medical Center, Rochester, New York Heather A. Wishart, Ph.D. Assistant Professor of Psychiatry, Neuropsychology Program, Dartmouth Medical School, Lebanon, New Hampshire
Introduction
to the Clinical Practice Series
T
he Clinical Practice Series is dedicated to the support of continuing education and enrichment for the practicing clinician. Books in this series address topics of concern and importance to psychiatrists and other mental health clinicians. Each volume provides up-todate literature reviews and emphasizes the most recent treatment approaches to psychiatric illnesses. Theoretical and scientific data are applied to clinical situations, and case illustrations are used extensively to increase the relevance of the material for the practitioner. Each year the series publishes a number of books dealing with all aspects of clinical practice. From time to time some of these publications may be revised and updated. Some books in the series are written by a single clinician widely acknowledged to be an authority on the topic area; other series books are edited volumes in which knowledgeable practitioners contribute chapters in their areas of expertise. Still other series books have their origins in presentations for an American Psychiatric Association Annual Meeting. All contain the newest research and clinical information available on the subjects discussed. The Clinical Practice Series provides enrichment reading in a compact format specially designed to meet the continuing-education needs of the busy mental health clinician. Judith H. Gold, C.M., M.D., F.R.C.P.C., F.R.A.N.Z.C.P. Series Editor
xi
This page intentionally left blank
Preface Edward C. Lauterbach, M.D.
T
he focus of this volume is on managing psychiatric problems in neurological brain disorders. These illnesses are prevalent in clinical psychiatric practices and impose great morbid and economic burdens. Unique treatment complications inherent to these illnesses can challenge clinical skills. Although books on the psychiatry of Alzheimer’s disease and epilepsy exist, there seems to be no single concise work addressing the clinical psychiatric management of other neurological disorders. Therefore, we have synthesized management principles for these other neurological conditions for which suitable clinical information exists. We have selected key representative neurological disorders. These provide clinical principles useful in managing brain diseases of all types. These illnesses, and brain diseases in general, affect limbic connections with the rest of the nervous system. Each illness presents a distinct psychiatric profile requiring a select management approach tailored to the nature of the illness and the level of the nervous system affected. Management principles set forth in Chapter 1 apply to neurological diseases in general. Ensuing chapters detail techniques valuable for treating specific illnesses. These techniques can be further cross-applied to other neurological illnesses not explicitly addressed here. The disorders surveyed in this volume range from basal ganglia diseases (e.g., Parkinson’s, Huntington’s, and Wilson’s diseases) to illnesses affecting white-matter basal ganglia–cortical circuit projections (e.g., acquired immunodeficiency syndrome [AIDS], multiple xiii
xiv
Psychiatric Management in Neurological Disease
sclerosis). Major movement disorders are covered, including idiopathic dystonia. Diseases with characteristic lesion sites as well as diseases with diffuse or multifocal pathology are discussed. Diseases of the substantia nigra (Parkinson’s), striatum (Huntington’s), putamen (Wilson’s), globus pallidus (Fahr’s), subcortical white matter (AIDS, multiple sclerosis, stroke), and cortex (stroke) are detailed. Physiological disorders (e.g., dystonia), systemic illness (e.g., Wilson’s disease, Fahr’s syndrome, secondary dystonias), and immunological diseases (e.g., AIDS, multiple sclerosis) are considered. Thus, the disorders covered in this volume constitute a representative cross-section of conditions affecting the brain at various levels. We have organized the book for ease of use for the practicing clinician. The first chapter considers important clinical features, psychotherapeutic principles, and pharmacological issues that are critical to successful psychiatric treatment of patients with neurological illnesses. Each subsequent chapter begins with a basic overview of the disorder, followed by a profile of psychiatric disorders occurring in the illness, including drug-induced psychiatric disorders. Each chapter ends with a discussion of specific treatment approaches, including neurological and psychiatric management. In particular, specific pharmacological and psychotherapeutic approaches to treatment of the disease are detailed when available, along with caveats unique to these patients. Explicit information is provided on how to contact and refer patients to support groups. Because these illnesses also dramatically affect family members, the book’s final chapter addresses the family. It is our sincere intent that this book will serve as a time-saving reference that will yield significant clinical dividends in quality of care exceeding many times the initial investment of its purchase. We have summarized and integrated the most recent data in an attempt to formulate a user-friendly approach to comprehensive psychiatric management of patients with neurological illness. The editor’s own private practice experience has convinced him of the need for efficient learning: “so many patients, so little time to read.” Managed care compels outpatient treatment of ever more seriously ill patients with multiple physical illnesses. Knowing these diseases and predicting what may go wrong between outpatient visits is therefore of increasing importance. Recognizing this need, we
Preface
xv
seek to provide a wealth of practical information on a diversity of disorders to assist the busy clinician. We also endeavor to provide a more explicit detailing of management principles than is available elsewhere.
This page intentionally left blank
C H A P T E R
1
Psychiatric Management Principles in Neurological Disease Edward C. Lauterbach, M.D.
T
he focus of this book is on psychiatric conditions in key, representative neurological disorders. These disorders impose great disability and cost on both the patient and the nation (Table 1–1). They also impose substantial complexity of care because of unique treatment considerations. General considerations in neurological disease are offered here and specific aspects of particular conditions are reviewed in the chapters that follow. Neurological disorders disrupt basal ganglia–cortical circuits at various levels. The basal ganglia (Figure 1–1), composed of the striatum and the globus pallidus, are functionally and structurally interposed between the limbic system and the cortex. Basal ganglia–cortical circuits are vital to psychiatry, connecting certain limbic structures to the cerebral cortex and other important brain regions. In addition to limbic inputs, important influences on these circuits include major monoamine projections and other connections. Basal ganglia–cortical circuits constitute essential pathways that integrate and mediate mood, cognition, movement, behavior, and other functions critical to psychiatric disorders (Cummings 1993). The disorders considered in this book have variable causations, presentations, pathologies, and treatments. An equally diverse array of psychopathology in these disorders can variably respond to 1
2
Table 1–1.
Annual incidence, prevalence, and annual cost of neurological disorders
Disorder
Prevalence
Annual cost, $
16,000 50,000 1,500 15,000 35,000
80,000 500,000 25,000 100,000 >1,300,000
>1,000,000,000 6,000,000,000 >250,000,000 >250,000,000 >3,000,000,000
500,000 <10,000
3,000,000 <350,000
>30,000,000,000 5,000,000,000
Note. Annual incidence is provided in terms of new U.S. cases per year; prevalence is U.S. cases; annual cost is total cost to the nation. AIDS = acquired immunodeficiency syndrome. Source. 1995 data obtained from the Office of Scientific and Health Reports, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health.
Psychiatric Management in Neurological Disease
Neurological AIDS Parkinson’s disease Huntington’s disease Dystonias Other motor disorders (including Wilson’s disease and Fahr’s syndrome) Stroke/cerebrovascular Multiple sclerosis
Annual incidence
Psychiatric Management Principles in Neurological Disease
3
Striatum Caudate nucleus Putamen
Lenticular nucleus Putamen Globus pallidus External segment Internal segment
Thalamus
Figure 1–1. Horizontal (axial) image depicting basal ganglia structures and thalamus.
conventional psychiatric treatment and, at times, to treatment of the underlying disorder (e.g., Wilson’s disease). This chapter therefore considers specific diagnostic and treatment principles for managing patients with neurological diseases in general. More detailed considerations of these principles are elaborated elsewhere (see Ovsiew 1992 and Sultzer 1994 for reviews of the neuropsychiatric evaluation).
Approach to Neurological Illnesses: Clinical Recognition, Mental Status, and Neurological Exam Basal ganglia–cortical circuits flow from the cerebral cortex to the striatum (caudate and putamen), to the globus pallidus (internal, ex-
4
Psychiatric Management in Neurological Disease
ternal, and ventral segments), and on to the thalamus, which then projects back to the cerebral cortex (Figure 1–2). An alternative route courses through the reticular portion of the substantia nigra instead of the globus pallidus. These circuits are modulated by inputs from the nigra pars compacta and subthalamic nucleus. Five parallel, functionally segregated circuits between the basal ganglia and the cerebral cortex have been identified, each with its own important clinical consequences (Cummings 1993). These circuits project to anterior cingulate, dorsolateral prefrontal, orbitofrontal, sensorimotor, and oculomotor cortical areas.
Frontal Circuit Signs Certain findings can help localize pathology to dorsolateral prefrontal, orbitofrontal, and anterior cingulate frontal lobe circuits (Table 1–2). Findings consistent with dorsolateral prefrontal circuit disease include reduced verbal fluency, psychomotor slowing, dysexecution, perseveration, stimulus-bound behavior, apathy, and impaired abstraction. Dysexecution refers to difficulty in planning, organizing, and sequencing activities that involve complex problem solving. Dysexecution can be detected by excessive perseverative errors and other abnormalities on neuropsychological testing. Stimulus-bound phenomena are manifest in utilization behavior, wherein a patient will pick up an object in the environment and continuously manipulate it until it is taken away. Orbitofrontal circuit involvement can be signaled by emotional lability, behavioral disinhibition (e.g., manic-like behavior), impulsivity, and impaired insight, judgment, and abstraction. Medial frontal circuit involvement can manifest in sparse verbal output, akinesia or paucity of movement, and apathy. Oculomotor circuit involvement is suggested by jerky ocular pursuit (when the patient is asked to follow a moving target) or saccadic intrusions (wherein the patient’s eyes quickly and involuntarily dart away from and then later return to the target). Jerky pursuit occurs in the parkinsonisms and with nigral and cerebellar lesions; saccadic intrusions can be seen in choreic conditions and caudate nucleus lesions, such as in Huntington’s disease. Sensorimotor circuit findings are usually those of a movement disorder or bizarre paresthesia sensations.
Psychiatric Management Principles in Neurological Disease
5
Figure 1–2. Basal ganglia pathways and their physiology in the normal (nondiseased) state and in Parkinson’s disease (PD), Huntington’s disease (HD), primary dystonia (DT), and hemiballismus (HB). GPe = globus pallidus externa; GPi = globus pallidus interna; SNc = substantia nigra pars compacta; SNr = substantia nigra pars reticulata; STN = subthalamic nucleus; STR = striatum (caudate nucleus and putamen); VL = ventrolateral nucleus of the thalamus. Connections ending in arrowheads indicate excitatory connections; connections ending in a bar signify inhibitory connections. For simplicity, excitatory glutamatergic projections from the cortex to the striatum are not depicted. With the exception of dopaminergic projections from the SNc (D2 receptors are inhibitory and D1 receptors are excitatory), all other inhibitory connections are GABAergic and all other excitatory connections are glutamatergic. In PD, thalamic stimulation of the cortex is reduced due to excessive GPi activity, presumably leading to hypokinesia. In HD, this physiology is reversed, presumably leading to hyperkinetic chorea. In DT, a hyperkinetic physiological state results, distinguished by excessive directpathway (STR-GPi connection) activity predominating over increases in indirect-pathway (STR-GPe) and STN activity. This may, however, be true only for certain DTs. In HB, the extreme movements are consistent with a hyperkinetic physiological state induced by the loss of GPi stimulation by the STN. Source. Adapted from Vitek et al. 1999.
6
Table 1–2.
Psychiatric Management in Neurological Disease
Frontal lobe syndromes
Dorsolateral
Orbitofrontal
Reduced verbal fluency
Medial Sparse verbal output
Psychomotor slowing
Lability
Dysexecution (planning, organizing, sequencing)
Disinhibition
Akinesia
Perseveration Stimulus-bound phenomena (utilization behavior) Apathy
Impulsivity
Impaired abstraction
Impaired judgment, insight, and abstraction
Apathy (occasional)
Signs Localizing to Certain Brain Structures Certain clinical findings sometimes assist in localizing brain pathology. Localization can help in understanding the nature of the illness, predicting disabilities, and planning treatment. Frontal release signs suggest frontal lobe disease and include primitive reflexes (glabellar tap [Meyerson’s sign], grasp, suck, root, palmomental). Decreased verbal fluency and utilization behavior also suggest frontal lobe disease (see “Frontal Circuit Signs” subsection above). Depression is associated with frontal lesions, especially of the left frontal lobe. Mania is often observed in lesions of the right temporal cortex and orbitofrontal regions as well as of the caudate, thalamus, subthalamic nucleus, and cerebellum (see Chapter 7 in this volume). Left cerebellar disturbances can affect caudate and thalamic connections with the right temporal and orbitofrontal cortex (Lauterbach 1996). Obsessions or compulsions may point to frontal lobe disturbance or striatal disease. Right parietal lesions are associated with constructional apraxia (difficulty drawing a complex two- or three-dimensional figure) and neglect (sometimes manifest in a patient’s dressing only the right half of his or her body, or drawing only the right half of a figure). Apraxia can reflect left frontal, left parietal, or callosal lesions. Other neurobehavioral signs that can assist in localizing brain lesions are listed in Table 1–3.
Psychiatric Management Principles in Neurological Disease
Table 1–3.
7
Behavioral findings potentially helpful in localizing neuropathology
Left frontal lobe Broca’s expressive aphasia (can usually comprehend spoken or written language but cannot speak, name, or repeat fluently) Transcortical motor aphasia (like Broca’s, but can repeat fluently) Apraxia (inability to perform complex movements despite intact motor system) Right frontal lobe Reduced social awareness Left temporal lobe Wernicke’s receptive aphasia (comprehension difficulty on reading and listening, repeating, and naming) Verbal amnesia Change in personality Right temporal lobe Amusia (reduced ability to appreciate content of music) Aprosodia (reduced ability to modulate or appreciate the emotional content of speech) Prosopagnosia (reduced ability to recognize familiar faces) Visual amnesia Change in personality Left parietal lobe Angular gyrus syndrome—includes anomia (deficit in naming), alexia with agraphia (deficits in reading and writing), or Gerstmann syndrome—includes apraxia, right–left confusion, finger agnosia (inability to discriminate between fingers), and dyscalculia (difficulty calculating) Right parietal lobe Neglect (inattention to the left hemispace, including left visual field) Constructional apraxia Spatial disorientation and agnosia Left occipital lobe Alexia without agraphia Color agnosia Right occipital lobe Cortical blindness with denial (Anton’s syndrome) (continued)
8
Psychiatric Management in Neurological Disease
Table 1–3.
Behavioral findings potentially helpful in localizing neuropathology (continued)
Right occipital lobe (continued) Topographic spatial disorientation Corpus callosum Apraxia of the left hand Anomia for objects in the left hand Alien hand syndrome (unconsciously motivated wandering hand) Source.
Adapted from Mendez 1996.
Cortical and Subcortical Signs It is possible to distinguish between cortical and subcortical disruptions of basal ganglia–cortical circuits (Table 1–4). Certain features can assist in determining whether cortical or subcortical pathology is present. This distinction is best seen in the comparison between cortical and subcortical dementias. Patients with cortical dementias generally exhibit an inability to learn new material, variably accompanied by aphasia, upper motor neuron signs (see below), and normal psychomotor speed and complex attention (e.g., normal execution of a three-stage command). Dysexecution may or may not be present. Patients with subcortical dementias generally manifest an inability to retrieve learned information (retrieval deficits) but may be capable of learning new information that can be retrieved with memory cues, in contrast to cortical dementia. Speech may be dysarthric, but aphasia is usually absent. Other contrasts with cortical dementia include the presence of extrapyramidal movement disorders, psychomotor slowing, abnormal complex attention, and dysexecution. As with cortical disease, the specific findings in subcortical disease depend on the location of the lesion. Movement disorders are recognized by their form and suggest subcortical pathology. They are often best seen by casually observing the patient without the patient’s awareness, such as in the waiting room and on walking from the waiting room to the office. The finding of a movement disorder with minimal other neurological findings can suggest a basal ganglia disease (e.g., Wilson’s disease, Huntington’s disease, Fahr’s syndrome), whereas diverse, distributed
Psychiatric Management Principles in Neurological Disease
Table 1–4.
9
Cortical versus subcortical dementias
Function Psychomotor speed Complex attention (3-stage command) Executive function Memory
Cortical Normal Normal
Frontal–Subcortical Slow Abnormal
Normal or abnormal Amnesic
Speech
Aphasic
Motor disorder
Pyramidal
Abnormal Retrieval errors (can be cued) Dysarthric (aphasia rarely) Extrapyramidal
neurological findings on exam can suggest a multifocal disease (e.g., multiple sclerosis, acquired immunodeficiency syndrome [AIDS], stroke). Upper motor neuron signs and sensory deficits can result from cortical, subcortical, or noncortical lesions. Upper motor neuron signs—including hemiparesis, hemiplegia, hyperreflexia, spasticity, rigidity, clonus, and Babinski sign (upgoing toe when the plantar surface of the foot is stroked)—point to the motor system (Table 1–5). Sensory deficits point to the sensory system.
Movement Disorders as Localizing Signs The form of the movement disorder can sometimes reveal the location of the pathology (see Table 1–5). Hyperkinetic disorders— wherein the patient exhibits excessive, unwanted, involuntary movements—occur with lesions of the caudate (chorea), putamen (dystonia), subthalamic nucleus (ballismus, chorea), thalamus (chorea, dystonia, ballismus, myoclonus), and cerebellum (myoclonus, tremor). Hypokinetic disorders (the parkinsonisms) usually suggest lesions of the substantia nigra or the globus pallidus. This is not to say that other disorders cannot occur with these lesions, or that such disorders always occur with lesions in these areas. Distinguishing features of parkinsonism, chorea, and dystonia are discussed in the chapters on Parkinson’s disease, Huntington’s disease, and idiopathic dystonia (Chapters 2, 3, and 6, respectively). Ballismus is a ballistic movement that is often of extreme amplitude,
10
Table 1–5.
Psychiatric Management in Neurological Disease
Localizing neurological signs and symptoms
Sign Upper motor neuron signs Sensory deficit Parkinsonism Chorea Dystonia Ballismus Striatal toe, striatal dishing Cerebellar signs, intention tremor Rubral tremor Alien hand syndrome Pathological affect
Potential localizations Motor cortex, internal capsule, pons, pyramidal tracts, corticospinal tracts Parietal cortex, thalamus, brain stem, spinothalamic tracts, dorsal columns Substantia nigra, globus pallidus Caudate, subthalamic nucleus, thalamus Putamen, thalamus, globus pallidus Subthalamic nucleus, thalamus Striatum Cerebellum, cerebellar outflow tracts Red nucleus Thalamus, corpus callosum Corticobulbar tracts, basal ganglia, thalamus, brain stem
especially when affecting the proximal joints such as the shoulder. It is quite striking in severity, usually involving one or both limbs on one side of the body after a subthalamic vascular lesion. Other signs of basal ganglia dysfunction include striatal dishing (hyperextension of the metacarpophalangeal joints) and striatal toe (the great toe spontaneously extends).
Cerebellar Signs The cerebellum influences basal ganglia–cortical circuit physiology (Figure 1–3) and can also be affected in certain basal ganglia diseases (e.g., Wilson’s disease, Fahr’s syndrome). Cerebellar features evident on the neurological exam include cerebellar rebound, ataxia, dysmetria, dysdiadochokinesia, cerebellar speech, and terminal kinetic tremor. Rebound in an upper extremity can be tested for by asking the patient to flex the biceps muscle while the examiner pulls down on the forearm and then suddenly lets go. Patients with cerebellar disease may be unable to quickly adjust their muscle tone to stop flexing and may strike themselves in the face. Therefore, the examiner must
Psychiatric Management Principles in Neurological Disease
11
Figure 1–3. Cerebellar connections. The direction of projection is symbolized from neuronal soma to axonal bouton (e.g., from cerebellum to septum). Amyg = amygdala, CB = cerebellum, DPFC = dorsal prefrontal cortex, Forn = fornix, GP = globus pallidus, HC = hippocampus, LC = locus coeruleus, NA = nucleus accumbens, OBFC = orbitofrontal cortex, PPN = pedunculopontine nucleus, Sept = septum, SN = substantia nigra, Thal = thalamus, TL = temporal lobe, VTA = ventral tegmental area.
interpose his or her other arm between the patient’s forearm and face to protect against this result. Ataxia is seen in side-to-side wandering deviations from the correct path of the limb on finger-to-nose (FTN) testing, heel-to-shin (HTS) exam, or tandem gait (“drunk driving test”). Dysmetria is evident on FTN or HTS tests by stopping before (“undershooting”) or after (“overshooting”) the target. Some patients mask dysmetria by performing the FTN test with excessive slowness, but dysmetria becomes apparent when the patient is required to perform the test more rapidly. Dysdiadochokinesia is elicited by having the patient perform rapid alternating movements, such as repetitive alternating tapping of the dorsal, then ventral hand against the thigh simultaneously with both hands. Dysdiadocho-
12
Psychiatric Management in Neurological Disease
kinesia is manifest in a dyscoordinated, dysrhythmic performance, either unilaterally or bilaterally. Cerebellar speech involves inability to properly control the rate and volume of speech. Thus, speech rate, volume, and tone fluctuate during the course of a sentence, conveying the impression that the patient is intoxicated when, in fact, he or she is not.
Tremors Cerebellar terminal kinetic tremor (i.e., tremor at the end of movement) becomes apparent as the patient approaches the target (e.g., on FTN exam). This type of tremor has also been called “intention tremor” and is distinguishable from action-postural tremor (consistently present throughout the range of movement) and resting tremor (evident at rest and attenuating with movement). Rubral tremor combines elements of all of these other tremors and suggests disease involving the red nucleus in the midbrain.
Psychogenic Findings Despite the tendency to misdiagnose movement disorders as psychogenic (see Chapter 6 in this volume), certain clinical findings can signal the presence of psychogenic movement disorders. In one study of 131 patients with such disorders (Williams et al. 1995), clinical tip-offs to a psychogenic origin included abrupt onset after inciting events; multiple coexisting forms of movement disorders; variable and inconsistent motor manifestations fluctuating during the exam; motor signs incongruous with organic origin; increases in movement severity or complexity on examination of the affected body part; diminished movement severity with distraction or when not under direct scrutiny; excessive startle; incongruous or false neurological signs; response to placebo, suggestion, or psychotherapy; and presence of associated psychiatric symptoms. Of course, none of these findings can be considered pathognomonic (see Chapter 6 in this volume for further diagnostic tip-offs and caveats). Moreover, organic movement disorders are also associated with psychiatric disorders. In addition to the clinical tip-offs listed above, the form of the movement disorder can serve to raise the clinician’s index of suspicion. Some movement disorders are more common than others. In
Psychiatric Management Principles in Neurological Disease
13
the study of Williams et al. (1995), psychogenic dystonia was the most common psychogenic movement disorder, occurring in 82 (62.6%) of 131 patients with psychogenic movement disorders. The next most common psychogenic movement disorder was tremor (in 21 patients [16%]), followed by gait disorder (14 patients [10.7%]), undifferentiated dyskinesias (14 patients [10.7%]), myoclonus (11 patients [8.4%]), parkinsonism (3 patients [2.3%]), tics (2 patients [1.5%]), and stiff man syndrome (1 patient [0.8%]). Some patients had more than one condition. Obviously, the underlying psychopathology must be addressed in order to successfully treat psychogenic conditions. Certain psychiatric disorders have been observed more frequently than others. Among 24 patients with psychogenic movement disorders undergoing psychiatric treatment in the study of Williams et al. (1995), psychiatric diagnoses included conversion disorder (18 patients [75%]), somatization disorder (3 patients [12.5%]), factitious disorder (2 patients [8.3%]), and malingering (1 patient [4.2%]). Nearly all patients (except 1 with oppositional defiant disorder) had associated mood, anxiety, or adjustment disorders. The most common associated diagnosis was dysthymia. DSM Cluster B and C personality disorders were also common, especially dependent personality disorder. Several patients had learning disabilities. Although 3 patients with psychogenic movement disorders did not experience remission and 1 committed suicide, most were quite improved. The most successful treatment was hypnosis, followed by family therapy and then physical therapy. Most of these patients were also on psychotropics. The use of placebo was helpful in 3 cases.
General Principles of Psychiatric Management in Neurological Illnesses Some of the most germane psychiatric treatment considerations in treating neurological patients are summarized below. For a more comprehensive discussion, the reader may wish to supplement this material with other texts, including comprehensive psychotherapy (Forrest 1992) and psychopharmacology (Stoudemire et al. 1995) treatment reviews.
14
Psychiatric Management in Neurological Disease
General Nonpharmacological Treatment Concerns Psychiatrists should be vigilant for disabilities imposed by cognitive deficits, neurobehavioral syndromes, personality changes, affective lability, and more traditional psychiatric diagnoses. DSM-IV (American Psychiatric Association 1994) diagnoses of concern include delirium, dementia, amnestic and other cognitive disorders, and mental disorders due to a general medical condition. Each of these disorders has specific management implications. Special neuropsychiatric treatment concerns. Detection of aphasia, apraxia, agnosia, and other conditions can aid in understanding the nature of the patient’s disability and its psychosocial impact. Elucidating deficits can promote acceptance of limitations and planning of compensatory strategies. Parietal anosognosia, right-hemisphere denial, and organic repression (Weinstein and Friedland 1977) can interfere with treatment. Considerable empathy is needed in dealing with these patients. Patients with orbitofrontal lesions, disinhibition, aggression, hypersexuality, or episodic dyscontrol—including DSM-IV personality change due to a general medical condition (disinhibited, aggressive, and labile types)—may require a quiet environment to prevent overstimulation. Hemineglect can interfere with providing instructions to the patient, and information must be delivered to the correct hemispace in such instances (e.g., stand on the right side of the bed for patients with neglect of the left hemispace). The classical presentation of hemineglect is left-hemispace neglect, which occurs after right parietal lobe lesions; however, neglect can also occur after left-sided lesions. Patients with dementia, cognitive impairment, or amnestic disorders require instructions to be conveyed in a simple, straightforward manner. Patients with dysfunction of subcortical or medial frontal circuits or depression may suffer from amotivation. Communication disorders requiring special effort on the part of both the patient and the psychiatrist include the various aphasias, dysarthria, parkinsonian speech hesitancy, pallilalia, hypophonia, vocal cord dystonia, cerebellar speech, other speech disorders, and thought disorders. Depression is extraordinarily common among people with neu-
Psychiatric Management Principles in Neurological Disease
15
rological disorders. Depression, substance abuse, and suicidality may complicate the treatment course as the patient reacts to disability. Sleep disorders (especially in patients with brain-stem lesions) and sexual disturbances may be caused by the underlying neurological illness (e.g., Huntington’s disease) or its treatment (e.g., Parkinson’s disease). The psychiatrist should monitor the grief process as the patient and family mourn the disease or its functional disabilities. The patient or family may experience guilt, shame, or anger (e.g., parents may engage in self-blame for passing a genetic disease on to their children). Genetic counseling for the patient or family members may be indicated for familial disorders. Neuropsychiatric diagnostic dilemmas. The distinction of apathy from depression chiefly relies on a thorough evaluation of depressive signs and symptoms. The DSM-IV analogue of this behavioral change (apathy) is personality change due to a general medical condition, apathetic type. If depressive cognitions (especially feelings of hopelessness, worthlessness, or pathological guilt), mood, and depressed affect are present, the patient should be treated with antidepressants. If they are absent but reduced affect is apparent, antiapathy agents (bromocriptine, amantadine) may be useful. Limitedsymptom, partially expressed (forme fruste) depression and alexithymia can complicate the diagnosis of apathy. Another problem is the distinction of flat affect from facial akinesia, and of catatonia from parkinsonism. The clinical features of these conditions overlap. Generally, the more symptoms of either disorder are present, the easier the distinction. When the conditions are indiscriminable, the presence of psychosis and response to benzodiazepines may imply flat affect or catatonia, and the absence of psychosis and benzodiazepine nonresponse may imply facial akinesia or parkinsonism. Major depression is associated with both catatonia and parkinsonism; mania is associated with both catatonia and antiparkinsonian medications. Novel neuropsychiatric presentations. Psychiatric disorders may evolve or remit during the course of the illness and must be considered on an ongoing basis. Clinical rating scales are of value to monitor clinical change between visits, reviewed elsewhere (Coffey et al.
16
Psychiatric Management in Neurological Disease
1995). Limited-symptom partial expressions (formes frustes) of psychiatric disorders may sometimes be present, requiring heightened clinical suspicion and necessitating thorough evaluation to determine the diagnosis. Tactile hallucinosis or paresthesias may attend disease of the parietal or temporal lobes, sensory system, thalamus, and basal ganglia and does not necessarily signify primary psychosis or somatization. Certain behaviors should be distinguished from the signs of mania. The childish, impish humor of witzelsucht can be seen in patients with dementia and frontal lobe disease. Disturbed social behavior may attend frontal lobe disease before other symptoms (e.g., cognitive decline) become evident. A wandering, mischievous hand that performs actions that the patient denies intent to perform may signal alien hand syndrome. Pseudobulbar affect with pathological laughter can be distinguished from manic elation or euphoria. The patient with pseudobulbar affect is generally euthymic and may complain of selective loss of control over emotions. Pathological crying or laughter can be triggered by events of mood-incongruent emotional significance. For example, a patient with pathological laughter may laugh uncontrollably after being informed of some terrible tragedy with personal significance. Certain neurological disorders have specific characteristic personality features. For example, patients with epilepsy tend to be moralistic, with intensified religiosity, a sense of urgency and mission, and a tendency toward anger and remorse. (Refer to chapters on specific diseases in this volume for details on the personality traits characteristically seen in these illnesses.) Special neuropsychiatric treatment modalities. Self-help books regarding the disease (e.g., Duvoisin 1984; Mace and Rabins 1991) can be useful to patients and caregivers. Information about the disease often reduces fear of the unknown and fosters acceptance. Both patients and family members can benefit. Support groups exist for some disorders and can provide therapeutic benefits, including socialization, support, education, a sense of control over the illness, and the chance to keep active. Better outcome is associated with attending support groups, although it is not clear whether this improved outcome is cause or effect (Montgom-
Psychiatric Management Principles in Neurological Disease
17
ery et al. 1994). Support group exercise programs can enhance mobility and reduce flexion contractures. Patients can run for office, encouraging preservation of an active, functional lifestyle. Support groups are available for a variety of specific disorders. For guidance on referrals to organizations offering information and resources, contact the Office of Disease Prevention and Health Promotion, U.S. Department of Health and Human Services, P.O. Box 1133, Washington, DC 20013-1133 (phone 1-800-336-4797 or 301-565-4167; fax 301-984-4256). For information about uncommon illnesses, contact the National Organization for Rare Disorders, P.O. Box 8923, New Fairfield, CT 06812-8923 (phone 1-800-999-6673 or 203-746-6518; fax 203-746-6481). Names of support groups and informational resources for spouses of patients can be obtained by contacting the Well Spouse Foundation, 610 Lexington Avenue, Suite 208, New York, NY 10022-6005 (phone 1-800-838-0879 or 212-644-1241; fax 212-644-1338). (See Chapter 10 in this volume for family treatment considerations.) Rehabilitation programs can assist in practical recovery and disability management. Pet therapy may be useful for loneliness and isolation, but the patient’s degree of disability may contraindicate this (e.g., a big dog may knock the patient off his feet; a small animal might lead to problems in a patient who is unable to bend down). Special neuropsychiatric treatment techniques. Management of movement disorders is detailed in the chapters that follow. Gait disturbances in neurological disorders are an important and frustrating source of disability. Impaired sensory, visual, vestibular, and motor systems contribute to gait disturbance, as can frontal apraxia and cerebellar ataxia. Learning to attend more to input from unimpaired systems can improve gait (e.g., attending with greater vigilance to visual input). Patients with visuospatial perceptual problems may require planning and positional mapping to overcome this disability. Running a finger along the wall while walking can provide compensatory sensory information for those with loss of lower-extremity propioception. Apraxia can sometimes be improved with a cane or walker. Parkinsonian freezing can be reduced by avoiding narrow, confined passageways. Gait hesitancy (difficulty initiating gait) can be assisted with the use of mental counting techniques (e.g.,
18
Psychiatric Management in Neurological Disease
“1-2-1-2-1-2 . . . ”). Another technique involves having the spouse rock the patient from foot-to-foot, thereby initiating gait. Any existing foot conditions (e.g., improperly fitting shoes, painful toenails) or other physical impediments should be addressed. Optimizing treatment of the underlying condition may also be helpful (e.g., dopaminergic therapy in Parkinson’s disease, neuroleptics in Huntington’s disease). Orthostatic hypotension caused by underlying diseases (e.g., Shy-Drager parkinsonian syndrome) or treatments (e.g., dopamine agonists) can lead to falls and immobility. Replacement of offending medications, use of support hose, or administration of salt tablets or mineralocorticoids may be useful. Vitamin status should be considered, because treatable gait disorders caused by vitamin deficiency may be present (thiamin, B12 cobalamin, or folate), especially in patients with poor nutritional status. Some patients become phobic of falling and therefore of ambulating (particularly on stairs). Behavior therapy with physical therapists or a personal trainer can often help in these instances. In addition, benzodiazepines, neuroleptics, and sedating agents can sometimes destabilize gait.
General Pharmacological Concerns Double-blind, placebo-controlled studies of psychotropics for psychosis, depression, anxiety, and agitation in neurological diseases have been reviewed recently (Rummans et al. 1999). In general, the choice of psychotropics is initially the same as in traditional treatment, except for the caveats detailed in this book. In particular, clinicians should remain alert for drug interactions with neurological agents. Further, delayed development of compound psychiatric syndromes with differentially responsive components or atypical responsivity can occur with neurological disease (Lauterbach et al. 1994). Strategies to manage noncompliance attributable to attendant neurobehavioral syndromes, amotivation, apathy, cognitive disorders, or depression should be considered. Many patients with neurological illness are elderly, debilitated, or afflicted with disease of other organs. Therefore, the usual rules applying to geriatric psychiatry should be followed. These include considerations of increased drug availability at receptor sites be-
Psychiatric Management Principles in Neurological Disease
19
cause of reduced serum protein, the need for lower initial dosages and slower advances of dosage, functionally prolonged half-lives that result in dose accumulation, reduced metabolism, reduced clearance, and the possibility of therapeutic levels on lower-thancustomary dosages. Patients with neurological disease may also be taking multiple medications, which exponentially increases the possibility of drug interactions. In anticipation of future additions to the regimen by other physicians, drugs with short half-lives are preferred to avoid prolonged clearances in the event of the need for discontinuation (e.g., fluoxetine’s metabolite norfluoxetine can linger for many weeks before eventual clearance). The atypical antipsychotics and the newer antidepressants represent important therapeutic advances. These agents have more favorable side-effect profiles than their predecessors. Theoretically, the lesser proclivity of the atypical antipsychotics (e.g., clozapine, quetiapine, olanzapine, risperidone) to induce extrapyramidal movement disorders is of value in patients with neurological disease who are predisposed to these side effects. However, review of the literature of atypical antipsychotics in these neurological diseases indicates that well-controlled data are scant (Rummans et al. 1999). The few data available suggest mixed results in Parkinson’s disease, with some patients becoming more parkinsonian or delirious on clozapine. As of this writing, a single study (Singh et al. 1997) suggests that risperidone may be the treatment of choice for psychosis in human immunodeficiency virus infection, especially for patients with mania. Although experience is limited and it is too early to declare the superiority of these agents in patients with the neurological diseases considered in this book, it is clear that patients deserve intensive monitoring while on either these agents or conventional neuroleptics, especially those patients with parkinsonian features. The relative absence of anticholinergic effects of the newer antidepressants is a clear theoretical advantage in neurological patients who are predisposed to anticholinergic delirium. Some of the major potential psychotropic–disease and drug– drug interactions are detailed in Tables 1–6 and 1–7, respectively. These and other interactions are elaborated on in greater detail elsewhere (Stoudemire et al. 1995). Furthermore, cytochrome P450 enzyme inhibition by selective serotonin reuptake inhibitors (SSRIs)
Major potential interactions between diseases and psychotropics
Congestive heart failure Cardiac conduction defects
Orthostatic hypotension Dysautonomia
Seizure disorders
Cognitive disorders
Psychiatric Management in Neurological Disease
Hypertension Coronary artery disease
Reduced first-pass effect through liver, increasing plasma drug levels Clozapine can produce hypotension, tachycardia, and dizziness LPNs, TCAs, and carbamazepine prolong conduction times (avoid) Trazodone occasionally produces heart block and ventricular arrhythmias Psychostimulants and venlafaxine can increase blood pressure LPNs, TCAs, MAOIs, and trazodone can produce hypotension, reducing coronary artery perfusion LPNs, clozapine, TCAs, trazodone, MAOIs, carbamazepine, and antihistamines can worsen orthostatic hypotension See orthostatic hypotension LPNs, clozapine, TCAs, paroxetine, MAOIs, carbamazepine, and antihistamines are anticholinergic Bladder outlet obstruction has been reported with trazodone SSRIs are associated with sexual side effects Clozapine, chlorpromazine, lithium, maprotiline, clomipramine, and bupropion are relatively contraindicated Barbiturates, phenytoin, and carbamazepine can lower neuroleptic and TCA levels Valproate can increase neuroleptic and TCA levels Valproate can increase carbamazepine toxicity Anticholinergics, LPNs, clozapine, tertiary-amine TCAs, trazodone, carbamazepine, lithium, antihistamines, and benzodiazepines can lead to delirium, increase cognitive impairment, and impair alertness Neuroleptics may increase sedative effects of barbiturates, and vice versa
20
Table 1–6.
Movement disorders
Hepatic disease
Renal disease
21
(continued)
Psychiatric Management Principles in Neurological Disease
Gait disorders
Lithium can lead to confusion and sedation at low or normal lithium levels Benzodiazepines can lead to behavioral disinhibition USABs (e.g., triazolam) especially likely to produce confusion, dissociation, and anterograde amnesis See orthostatic hypotension, cognitive disorders, and movement disorders (agents that worsen these conditions can lead to impairment of gait) Lithium, valproate, benzodiazepines, beta-blockers, and sedating agents can induce ataxia Antipsychotics can aggravate parkinsonism, dystonia, and akathisia Neuroleptic malignant syndrome is more likely in neurological disease Clozapine can sometimes worsen Parkinson’s disease signs Anticonvulsants, lithium, SSRIs, and antihistamines can worsen action-postural tremors SSRIs can lead to serotonin syndrome SSRIs can produce or worsen akathisia, dystonia, myoclonus, dyskinesias, and, rarely, parkinsonism Buspirone can produce tremor and persistent dystonia Avoid long-half-life drugs Anticonvulsants and many other drugs can further impair liver function Hydrazide MAOIs can be hepatotoxic Avoid benzodiazepines that are oxidized before glucuronidation Avoid LABs (dose accumulation can occur) Quazepam can accumulate Avoid long-half-life drugs Avoid lithium for mood stabilization if possible
Major potential interactions between diseases and psychotropics (continued)
Pulmonary disease
Blood dyscrasias
Note. LAB = long-acting benzodiazepine; LPN = low-potency neuroleptic; MAOI = monoamine oxidase inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant; USAB = ultra-short-acting benzodizepine. Source. Charney et al. 1995; DePaulo 1984; Koczerginski et al. 1989; Lauterbach 1993, 1995; Lauterbach and Shillcutt 1997; Ray et al. 1989; Stoudemire and Fogel 1987; Stoudemire et al. 1995.
Psychiatric Management in Neurological Disease
Avoid MAOIs (hypertensive crises with respiratory agents) Benzodiazepines (especially LABs), barbiturates, and beta-blockers can compromise respiration LPNs, clozapine, carbamazepine, and valproate can suppress bone marrow Avoid clozapine
22
Table 1–6.
Potential drug–drug interactions
Aspirin Type 1A antiarrhythmics Propafenone Warfarin, digitoxin, digoxin
Can increase valproate level LPNs and TCAs prolong conduction times (avoid these agents) Can elevate TCA levels SSRIs, TCAs, and MAOIs can increase anticoagulant effect Increased risk for hypertensive hemorrhagic stroke in MAOI hypertensive crisis Lithium may increase digitalis toxicity Carbamazepine increases warfarin metabolism (decreases anticoagulant effect) Psychostimulants can increase prothrombin times Clonidine Neuroleptics can reduce the efficacy on blood pressure control Beta-blockers Increase psychotropic hypotension Increase neuroleptic levels Thiazide diuretics, spironolactone, Increase lithium levels triamterene Calcium channel blockers Variable effects on lithium levels Diltiazem increases carbamazepine to toxic levels Verapamil Bradycardia with lithium Increases carbamazepine to toxic levels ACE inhibitors (e.g., enalapril) Occasional elevated lithium levels Carbamazepine Carbamazepine levels can be lowered by quinidine, phenytoin, warfarin, clozapine, and propranolol Carbamazepine toxicity increased by diltiazem and verapamil
23
(continued)
Psychiatric Management Principles in Neurological Disease
Table 1–7.
Potential drug–drug interactions (continued)
Carbamazepine (continued)
Phenytoin Barbiturates
Benzodiazepines Sympathomimetics
Psychiatric Management in Neurological Disease
Valproate
Carbamazepine induces cytochrome P450 (CYP) 3A3/4/5 Increases the metabolism of anticoagulants Can increase prothrombin times Can lower TCAs, neuroleptic, clozapine, valproate, and benzodiazepine levels SSRIs can increase carbamazepine levels Can increase prothrombin times Can inhibit platelet aggregation Aspirin can increase valproate levels Can increase TCAs, carbamazepine 10-11 epoxide, benzodiazepine (except lorazepam), and phenobarbital levels Can be increased by chlorpromazine Can be decreased by carbamazepine, phenytoin, and phenobarbital Can displace protein-bound phenytoin and carbamazepine Can lower TCAs, neuroleptics, and carbamazepine levels SSRIs, psychostimulants, and carbamazepine can increase phenytoin levels Can lower TCAs, neuroleptics, and carbamazepine levels Can increase carbamazepine 10-11 epoxide levels SSRIs and psychostimulants can increase barbiturate levels Can be potentiated by MAOIs SSRIs can increase benzodiazepine levels Can be potentiated by MAOIs Hypertensive crisis with MAO-A inhibitors
24
Table 1–7.
Fatality, dystonia, and other movement disorders with antipsychotics Hypertensive crisis with MAO-A inhibitors Discontinue before starting antidepressants Serotonin syndrome can result with serotonergic psychotropics Can lower lithium and benzodiazepine levels MAO-A inhibitors contraindicated
Note. ACE = angiotensin-converting enzyme; LPN = low-potency neuroleptic; MAOI = monoamine oxidase inhibitor; MAO-A = monoamine oxidase type A; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant. Source. Charney et al. 1995; DePaulo 1984; Stoudemire and Fogel 1987; Stoudemire et al. 1995.
Psychiatric Management Principles in Neurological Disease
Metoclopramide L-dopa Selegiline Serotonin agonists Theophylline and aminophylline
25
26
Psychiatric Management of Neurological Diseases
may lead to drug–drug interactions with cardiac or other medications the patient may be taking (Table 1–8). These interactions occur with a wide variety of antiarrhythmics, calcium channel blockers, beta-blockers, and warfarin (Nemeroff et al. 1996). The list of interactions of SSRIs with these other drugs seems to be continually growing, and caution is therefore indicated when prescribing these antidepressants. Among the SSRIs, citalopram may be the least likely to produce P450 interactions. Venlafaxine may produce P450 inhibition less frequently than SSRIs. Nevertheless, it is wise to monitor blood levels of cardiac and other drugs during treatment to ensure that such interactions are not occurring, given that new interactions are still being reported. Additional considerations in certain types of patients follow. Heart disease. The treating psychiatrist should consider obtaining an electrocardiogram prior to treating depressed neurological patients, because heart disease may be present (for example, in stroke, Wilson’s disease). Bupropion or one of the SSRIs may be a better choice than tricyclic antidepressants (TCAs) if conduction problems are present. In a study of 36 patients with severe heart disease and DSM-III (American Psychiatric Association 1980) major depression, bupropion was found to be free of effects on myocardial contractility and conduction, although blood pressure was increased (Roose et al. 1991). In an open-label trial, sertraline did not significantly change heart rate, blood pressure, cardiac conduction, or ejection fraction in post–myocardial infarction patients (Shapiro et al. 1999). In contrast to the findings for sertraline, a study of fluoxetine in cardiac patients revealed a 6% decrease in heart rate, a 2% increase in supine blood pressure, and a 7% increase in ejection fraction, although conduction, arrhythmias, and orthostatic blood pressure were unaffected (Roose et al. 1998). Four percent of the patients suffered an adverse cardiovascular event. However, these and newer agents have not been adequately investigated in patients with arrhythmias or heart failure. Moreover, P450 interactions of SSRIs with cardiovascular drugs warrant careful attention to patient selection. Beta-blockers are useful for action-postural tremors and akathisia. Major concerns regarding psychotropic administration in cardiovascular and other diseases are listed in Table 1–6.
Potential cytochrome P450 (CYP) interactions with selective serotonin reuptake inhibitors (SSRIs)
Drug Analgesics Acetaminophen Codeine Dextromethorphan Phenacetin Cardiovascular agents Anticoagulants Warfarin Beta-blockers Metoprolol Propranolol Antiarrhythmics Amiodarone Encainide Flecainide Mexiletine Propafenone
CYP 1A2 (fluvoxamine)
CYP 2D6 CYP 3A4 CYP 2C (fluoxetine, sertraline, (fluoxetine, sertraline, (fluoxetine, sertraline, fluvoxamine, fluvoxamine, fluvoxamine) paroxetine, citalopram) nefazodone)
+
+ + +
+
+
+
+
+
+
+ + + + + + + +
+
27
(continued)
Psychiatric Management Principles in Neurological Disease
Table 1–8.
CYP 1A2 (fluvoxamine)
Antiarrhythmics (continued) Quinidine Lidocaine Calcium channel blockers Verapamil Diltiazem Nifedipine Lipid-lowering agents Lovastatin Gastrointestinal agents Omeprazole Cisapride Phosphodiesterase inhibitors Caffeine Theophylline
CYP 2D6 CYP 3A4 CYP 2C (fluoxetine, sertraline, (fluoxetine, sertraline, (fluoxetine, sertraline, fluvoxamine, fluvoxamine, fluvoxamine) paroxetine, citalopram) nefazodone) +
+ +
+ +
+ + + +
+ +
+ +
+
Psychiatric Management in Neurological Disease
Drug
Potential cytochrome P450 (CYP) interactions with selective serotonin reuptake inhibitors (SSRIs) (continued)
28
Table 1–8.
Psychiatric Management Principles in Neurological Disease
+ + + + + + + + + +
+
+ +
+
+ + + +
29
Hypoglycemics Tolbutamide Oncologic agents Vincristine Vinblastine Immunosuppressants Cyclosporine Steroids Dexamethasone Estrogen Testosterone Antibiotics Erythromycin Clarithromycin Antifungals Ketoconazole Protease inhibitors Indinavir Nelfinavir Ritonavir Saquinavir Cognitive enhancers Tacrine Donepezil
+ (continued)
Potential cytochrome P450 (CYP) interactions with selective serotonin reuptake inhibitors (SSRIs) (continued)
Antipsychotics Haloperidol Perphenazine Thioridazine Risperidone Clozapine Remoxipride Pimozide Olanzapine Quetiapine Anticonvulsants Carbamazepine Ethosuximide Hexobarbital Mephobarbital Phenytoin
CYP 1A2 (fluvoxamine) +
+ + + + + +
+
+ +
+
+ + + + + + +
Psychiatric Management in Neurological Disease
Drug
CYP 2D6 CYP 3A4 CYP 2C (fluoxetine, sertraline, (fluoxetine, sertraline, (fluoxetine, sertraline, fluvoxamine, fluvoxamine, fluvoxamine) paroxetine, citalopram) nefazodone)
30
Table 1–8.
Psychiatric Management Principles in Neurological Disease
Antidepressants Tetracyclics Maprotiline Tricyclics Amitriptyline Nortriptyline Imipramine Desipramine Clomipramine Others Bupropion Mirtazapine Mianserin Trazodone Venlafaxine Nefazodone Monoamine oxidase inhibitors Moclobemide Anxiolytics Alprazolam Diazepam Midazolam
+ +
+
+
+
+
+
+
+ + + + +
+ + + +
+ + + + +
+
+
+
+ + +
31
(continued)
Potential cytochrome P450 (CYP) interactions with selective serotonin reuptake inhibitors (SSRIs) (continued)
Anxiolytics (continued) Triazolam Clonazepam Antihistamines Astemizole Terfenadine Loratadine
CYP 1A2 (fluvoxamine)
+ + + + +
Note. Partial listing of some of the more important potential drug interactions in neurological patients. The strongest inhibitors of cytochrome P450 2D6 are paroxetine, followed by fluoxetine. The weakest 2D6 inhibitors are citalopram and fluvoxamine. Although venlafaxine is considered a weaker inhibitor than the antidepressants listed, it can also inhibit 2D6.
Psychiatric Management in Neurological Disease
Drug
CYP 2D6 CYP 3A4 CYP 2C (fluoxetine, sertraline, (fluoxetine, sertraline, (fluoxetine, sertraline, fluvoxamine, fluvoxamine, fluvoxamine) paroxetine, citalopram) nefazodone)
32
Table 1–8.
Psychiatric Management Principles in Neurological Disease
33
Dysautonomia and orthostatic hypotension. Sympathomimetics used to treat neurological patients with dysautonomia or hypoventilation can lead to anxiety and hypertensive reactions with monoamine oxidase inhibitors (MAOIs). Psychotropics with anticholinergic actions (Table 1–6) and anticholinergics used to treat dystonia and parkinsonism may worsen dysautonomia and produce gastroparesis, tachycardia, dry mouth, blurred vision, and urinary retention. Coadministration of antipsychotics and metoclopramide can lead to severe dystonia that can sometimes prove fatal (Lauterbach 1992). Many drugs can worsen orthostatic hypotension and induce sexual dysfunction, usually through alpha1 receptor blockade. Many of these agents (see Table 1–6) can also be quite anticholinergic. Highpotency neuroleptics, bupropion, and SSRIs might be preferred, although SSRIs have also been associated with sexual side effects, potentially compounding the sexual dysfunctions seen in some dysautonomias. Bupropion may improve erectile failure, and bupropion and desipramine may be useful for anorgasmia (Charney et al. 1995). Bladder outlet obstruction has been reported with trazodone, and paroxetine has sometimes been reported to exhibit clinically significant anticholinergic effects. Seizure disorders. Among antipsychotics, molindone, fluphenazine, thioridazine, and mesoridazine may cause the least reduction in seizure threshold (Edwards et al. 1986; Luchins et al. 1984). Among antidepressants, desipramine, MAOIs, and SSRIs reduce the seizure threshold the least and thus are preferred in treating depressed patients with seizures (Charney et al. 1995). Clozapine, lithium, maprotiline, clomipramine, and bupropion are best avoided in patients at risk for seizures (Charney et al. 1995). The risk of seizures with clozapine is dose related: 1%–2% at doses up to 300 mg/day, 3%–4% at between 300 mg/day and 600 mg/day, and 5% at 600–900 mg/day (Stoudemire et al. 1995). Blood levels for anticonvulsants should be followed, since many psychotropics interact with these agents (Tables 1–7 and 1–8). When valproate is coadministered with carbamazepine, it may displace carbamazepine from protein binding sites and raise the concentration of carbamazepine’s 10-11 epoxide, thereby increasing carbamazepine bioavailability and, potentially, toxicity without increasing clinically detectable blood levels (Stoudemire et al. 1995).
34
Psychiatric Management in Neurological Disease
Cognitive disorders. Many agents (Table 1–7) can further impair cognition in patients with cognitive disorders. High-potency neuroleptics, risperidone, the newer antidepressants, and buspirone carry the least risk for cognitive impairment. Among TCAs, the secondary amines (e.g., nortriptyline, desipramine) have the least potential for causing impairment. SSRI treatment has been associated with several forms of myoclonus, some producing significant distress to the patient (Bharucha and Sethi 1996; Lauterbach 1994). Patients with central nervous system disease may show confusion and sedation on lower levels of lithium than those causing such effects in the general population (DePaulo 1984). Although trazodone and the benzodiazepines can calm agitation in the cognitively impaired, they can sometimes also produce behavioral disinhibition. Ultra-short-acting benzodiazepines (e.g., triazolam) are more likely than long-acting agents to produce acute confusion, dissociation, and anterograde amnesis (Stoudemire et al. 1995), but long-acting benzodiazepines (e.g., clonazepam, flurazepam) can accumulate over several weeks to toxic levels in patients with reduced clearance (e.g., Wilson’s disease with liver complications). Despite having benzodiazepine-1 receptor affinity, quazepam can also accumulate to toxic levels (Stoudemire et al. 1995). Buspirone is less likely than the benzodiazepines to impair cognition and thus is a logical alternative in patients with cognitive impairment attributable to benzodiazepines. Pathological affect. Pathological affect can respond to SSRIs, antidepressants, lithium, L-dopa, amantadine, and methylphenidate (Lauterbach and Schweri 1991; also see Chapter 7 in this volume). Gait disorders. Agents that impair cognition, reduce arousal, or lead to hypotension, parkinsonism, or ataxia can also impair gait. Lithium and valproate can induce or amplify gait ataxia. Carbamazepine can cause dose-related ataxia, diplopia, and sedation, each of which can destabilize gait. Benzodiazepines are associated with hip fractures in the elderly. In a study of 4,501 elderly people taking benzodiazepines compared with 24,041 control subjects, the relative risk for hip fracture was increased 70% by long half-life and 10% by short half-life benzodiazepines (Ray et al. 1989). This increase in risk was observed after controlling for demographic and other clinical factors. Shorter-acting benzodiazepines include alprazolam, triazo-
Psychiatric Management Principles in Neurological Disease
35
lam, lorazepam, and oxazepam. Clonazepam added to therapeutic levels of lithium has led to ataxia and dysarthria (Koczerginski et al. 1989). Movement disorders. Clozapine, quetiapine, olanzapine, risperidone, and low-potency neuroleptics are less apt to aggravate parkinsonism than are high-potency neuroleptics. Nevertheless, these agents can certainly elicit parkinsonism and other movement disorders, and patients should be closely monitored. Neuroleptic malignant syndrome is a possibility in patients taking antipsychotics, given that this condition tends to evolve in patients with neurological impairment and debilitation, especially if dehydration is also present (Stoudemire et al. 1995). In contrast to their ability to precipitate acute neuroleptic-induced dystonia, neuroleptics can either improve or worsen other dystonias (see Chapter 6 in this volume). The heterocyclic antidepressant amoxapine can metabolize to variable concentrations of the neuroleptic loxapine. Clozapine has many side effects, including cognitive impairment, but it can reduce L-dopa dyskinesia, as can the SSRIs and buspirone. Improvement in dystonia and parkinsonism has been reported with clozapine, although double-blind trials in Parkinson’s disease patients have disclosed worsened parkinsonism and precipitation of delirium with clozapine (Rummans et al. 1999). Psychosis may be induced by neurological medications (e.g., dopamine agonists) and can sometimes remit with dosage reduction. In Parkinson’s disease patients, the drug selegiline should be discontinued at least 14 days prior to commencing treatment with antidepressant agents (5 weeks before fluoxetine) because of reported fatalities due to drug interactions. Vigilance for the serotonin syndrome (ataxia, nystagmus, confusion, fever, tremor, and myoclonus) is necessary when combining serotonergic agents with MAOIs or SSRIs. Although probably rare, visual hallucinations and illusions have occurred when SSRIs were administered to Parkinson’s disease patients being treated with L-dopa (Lauterbach 1993). SSRIs can induce a wide variety of movement disorders (Leo 1996). Although SSRIs usually have no effect on parkinsonism and dystonia, they variably improve or worsen different forms of myoclonus and dystonia (Lauterbach 1994, 1995). SSRIs can sometimes improve L-dopa dyskinesia in Parkinson’s disease. Coadministra-
36
Psychiatric Management in Neurological Disease
tion of MAOIs and L-dopa can trigger hypertensive crises, although each of these agents individually can cause hypotension. Electroconvulsive therapy may be useful in some cases of Parkinson’s disease as well as some cases of dystonia (Lauterbach and Moore 1990). Lithium and valproate can amplify ataxia. Benzodiazepines and beta-blockers improve action-postural tremors. Buspirone has led to tremor and persistent dystonia (LeWitt et al. 1993). Hepatic and renal disease. Portal hypertension reduces first-pass effects, and patients with liver disease should be started on one-third to one-half the usual dose of antidepressants until blood levels have been determined or tolerance to side effects occurs. Short-acting agents (e.g., paroxetine instead of fluoxetine) are used because of extended-half-life considerations. Among anxiolytics, oxazepam, temazepam, and lorazepam are directly glucuronidated without first being oxidized and thus are the preferred agents in this class. The tyramine diet required with MAOIs may make these agents an unpalatable option in a patient already on a renal or hepatic diet. Nonhydrazide MAOIs have less hepatotoxic potential than do hydrazide MAOIs. Anticonvulsants should be avoided in liver disease, as should lithium in patients with renal disease. Drug plasma levels should be frequently monitored when possible, especially in patients on dialysis. Pulmonary disease and blood dyscrasias. Hypoventilation can attend neurological diseases, particularly Parkinson’s disease. Concerns regarding sympathomimetics have already been detailed (see “Dysautonomia and orthostatic hypotension,” above). Anticholinergic agents can reduce tracheobronchial secretions in asthma and chronic obstructive pulmonary disease. Steroids carry their own psychiatric risks. Benzodiazepines can impair ventilatory status; buspirone is a logical alternative. Blood dyscrasia can attend Wilson’s disease. Interactions of concern in pulmonary disease and blood dyscrasias are listed in Tables 1–6 and 1–7.
Summary Diseases affecting basal ganglia–cortical circuits are devastating in terms of functional impairment and economic costs. A panoply of
Psychiatric Management Principles in Neurological Disease
37
psychiatric, behavioral, and neurological conditions can occur in these diseases. Certain features can help to localize pathology. Movement disorders are particularly common in basal ganglia–cortical diseases. Psychiatric management involves determining deficits and helping the patient adjust to them, employing specific treatment approaches. Principles of pharmacotherapy involve consideration of drug effects on the underlying illness, associated conditions, other drugs in the regimen, and special proclivities to side effects unique to the condition. A cautious, conservative approach is warranted. Self-help books, support groups, family education and therapy, and, at times, genetic counseling can represent important treatment options in these disorders.
References American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition. Washington, DC, American Psychiatric Association, 1980 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994 Bharucha KJ, Sethi KD: Complex movement disorders induced by fluoxetine. Mov Disord 11:324–326, 1996 Charney DS, Miller HL, Licinio J, et al: Treatment of depression, in The American Psychiatric Press Textbook of Psychopharmacology. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1995, pp 575–601 Coffey CE, Cummings JL, Duffy JD, et al: Assessment of treatment outcomes in neuropsychiatry: a report from the Committee on Research of the American Neuropsychiatric Association. J Neuropsychiatry Clin Neurosci 7:287–289, 1995 Cummings JL: Frontal-subcortical circuits and human behavior. Arch Neurol 50:873–880, 1993 DePaulo JR Jr: Lithium. Psychiatr Clin North Am 7:587–599, 1984 Duvoisin RC: Parkinson’s Disease: A Guide for Patient and Family, 2nd Edition. New York, Raven, 1984 Edwards JG, Long SK, Sedgwick EM, et al: Antidepressants and convulsive seizures: clinical, electroencephalographic, and pharmacological aspects. Clin Neuropharmacol 9:329–360, 1986
38
Psychiatric Management in Neurological Disease
Forrest DV: Psychotherapy of patients with neuropsychiatric disorders, in The American Psychiatric Press Textbook of Neuropsychiatry, 2nd Edition. Edited by Yudofsky SC, Hales RE. Washington, DC, American Psychiatric Press, 1992, pp 703–739 Koczerginski D, Kennedy SH, Swinson RP: Clonazepam and lithium—a toxic combination in the treatment of mania? Int Clin Psychopharmacol 4:195–199, 1989 Lauterbach EC: Haloperidol-induced dystonia and parkinsonism on discontinuing metoclopramide: implications for differential thalamocortical activity. J Clin Psychopharmacol 12:442–443, 1992 Lauterbach EC: Dopaminergic hallucinosis with fluoxetine in Parkinson’s disease (letter). Am J Psychiatry 150:1750, 1993 Lauterbach EC: Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick’s disease. Mov Disord 9:343–346, 1994 Lauterbach EC: Fluoxetine, buspirone, myoclonus, and dystonia (letter). Am J Psychiatry 152:1697, 1995 Lauterbach EC: Bipolar disorders, dystonia, and compulsion after dysfunction of the cerebellum, dentatorubrothalamic tract, and substantia nigra. Biol Psychiatry 40:726–730, 1996 Lauterbach EC, Moore NC: Parkinsonism-dystonia syndrome and ECT (letter). Am J Psychiatry 147:1249–1250, 1990 Lauterbach EC, Schweri MM: Amelioration of pseudobulbar affect by fluoxetine: possible alteration of dopamine-related pathophysiology by a selective serotonin reuptake blocker. J Clin Psychopharmacol 11: 392–393, 1991 Lauterbach EC, Shillcutt SD: Dyskinesia with fluoxetine: tardive or lateonset persistent acute norfluoxetine dyskinesia? (letter). J Clin Psychiatry 58:85–86, 1997 Lauterbach EC, Price ST, Spears TE, et al: Serotonin responsive and nonresponsive diurnal depressive mood disorders and pathological affect in thalamic infarct associated with myoclonus and blepharospasm. Biol Psychiatry 35:488–490, 1994 Leo RJ: Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57:449–454, 1996 LeWitt PA, Walters A, Hening W, et al: Persistent movement disorders induced by buspirone. Mov Disord 8:331–334, 1993 Luchins DJ, Oliver AP, Wyatt RJ: Seizures with antidepressants: an in vitro technique to assess relative risk. Epilepsia 25:25–32, 1984
Psychiatric Management Principles in Neurological Disease
39
Mace NL, Rabins PV: The 36-Hour Day: A Family Guide to Caring for Persons With Alzheimer’s Disease, Related Dementing Illnesses, and Memory Loss in Later Life. Baltimore, MD, Johns Hopkins University Press, 1991 Mendez MF: The neuroanatomy of neurobehavioral syndromes. Lecture presented at The American Association for Geriatric Psychiatry 1996 Board Review Course for the Examination for Added Qualifications in Geriatric Psychiatry, Los Angeles, CA, October 1996 Montgomery EB Jr, Lieberman A, Singh G, et al: Patient education and health promotion can be effective in Parkinson’s disease: a randomized controlled trial (PROPATH Advisory Board). Am J Med 97:429–435, 1994 Nemeroff CB, De Vane CL, Pollock BG: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153:311–320, 1996 Ovsiew F: Bedside neuropsychiatry: eliciting the clinical phenomena of neuropsychiatric illness, in The American Psychiatric Press Textbook of Neuropsychiatry, 2nd Edition. Edited by Yudofsky SC, Hales RE. Washington, DC, American Psychiatric Press, 1992, pp 703–739 Ray WA, Griffin MR, Downey W: Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 262:3303–3307, 1989 Roose SP, Dalack GW, Glassman AH, et al: Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 148: 512–516, 1991 Roose SP, Glassman AH, Attia E, et al: Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 155:660–665, 1998 Rummans TA, Lauterbach EC, Coffey CE, et al: Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci 11:176–189, 1999 Shapiro PA, Lesperance F, Frasure-Smith N, et al: An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. Am Heart J 137:1100–1106, 1999 Singh AN, Golledge H, Catalan J: Treatment of HIV-related psychotic disorders with risperidone: a series of 21 cases. J Psychosom Res 42:489–493, 1997 Stoudemire A, Fogel BS: Psychopharmacology in the medically ill, in Principles of Medical Psychiatry. Edited by Stoudemire A, Fogel BS. Orlando, FL, Grune & Stratton, 1987, pp 79–112
40
Psychiatric Management in Neurological Disease
Stoudemire A, Moran MG, Fogel BS: Psychopharmacology in the medically ill patient, in The American Psychiatric Press Textbook of Psychopharmacology. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1995, pp 783–801 Sultzer DL: Mental status examination, in The American Psychiatric Press Textbook of Geriatric Neuropsychiatry. Edited by Coffey CE, Cummings JL. Washington, DC, American Psychiatric Press, 1994, pp 99–104 Vitek JL, Chockkan V, Zhang JY, et al: Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol 46:22–35, 1999 Weinstein EA, Friedland RP: Behavioral disorders associated with hemiattention. Adv Neurol 18:51–62, 1977 Williams DT, Ford B, Fahn S: Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol 65:231–257, 1995
C H A P T E R
2
Parkinson’s Disease Morgan L. Levy, M.D. Jeffrey L. Cummings, M.D.
P
arkinson’s disease (PD) is a common degenerative disease of unknown etiology that primarily affects subcortical brain structures. It produces motor, cognitive and psychiatric abnormalities. Motor symptoms include bradykinesia (slowness of movement), cogwheel rigidity, tremor, and gait dysfunction. Cognitive symptoms include bradyphrenia (slowness of thinking) and executive dysfunction, which involves deficits in problem solving, word list generation, abstracting ability, set shifting, and memory retrieval. More severe dementia syndromes may occur in about 40% of patients. Psychiatric symptoms include depression, anxiety, and reduced motivation. Several psychiatric symptoms may be associated with anti-PD therapy; these include hallucinations, delusions, confusional states, mania, increased libido, and sleep disturbances. In this chapter our focus is primarily on cognitive and psychiatric abnormalities in PD.
Prevalence The prevalence of PD varies widely by geographic location, ranging from 31 per 100,000 in Libya to 328 per 100,000 in India. Most Western countries report prevalence rates of approximately 110 per 100,000. This project was supported by a Department of Veterans Affairs Neuroscience Fellowship, a National Institute on Aging Alzheimer’s Disease Center grant (AG10123), and the Sidell-Kagan Research Fund.
41
42
Psychiatric Management in Neurological Disease
The mean age at onset is 58–62 years (range: 40–70 years) (Martilla 1987). The average time to death in untreated PD is 8 years (range: 1–30 years). Contemporary therapeutic interventions have extended the life expectancy of patients so that 50% are alive 16 years after disease onset (Di Rocco et al. 1996). Most cases are sporadic, and twins generally lack concordance. However, a family history of either PD or essential tremor is a risk factor for the disease. Increasing age is the only unequivocal risk factor; postulated risks include being exposed to pesticides or heavy metals (Fe, Mn, Al), drinking well water, and living in rural communities. Cigarette smoking and diets rich in vitamin E have been associated with reduced risk of PD (Tanner and Goldman 1996).
Clinical Recognition and Neurological Presentation Motor disturbances in PD include tremor, rigidity, bradykinesia, and loss of righting reflexes. Autonomic abnormalities and oculomotor dysfunction are found in most patients, although these are more subtle than the deficits found in progressive supranuclear palsy or Shy-Drager syndrome (see below). The typical PD tremor is a lowfrequency (4–5 cycles per second), large-amplitude rest tremor. Cogwheel rigidity results from the superposition of the tremor on increased muscle tone when the forearm or another joint is being moved through a full range of motion, whereas plastic rigidity is more common in the lower extremities, where there may be an increase in muscle tone and resistance to movement without apparent jerking or tremor. Bradykinesia is defined as slowness of movement and is one of the most pervasive elements of PD. Patients with bradykinesia have hesitation in initiating movements, impaired repetitive movements, freezing episodes, diminished arm swing, micrographia, facial masking, and sialorrhea. “En bloc” movements can be seen when patients attempt to turn while walking, a maneuver that may require multiple steps. PD patients often have a stooped posture with flexion of the trunk, knees, elbows, and neck, and their gait is characterized by short steps with diminished step height (“marche en petit pas”). Balance is impaired, and patients may lean and step backward (retropulsion) or forward (propulsion) and may fail to
Parkinson’s Disease
43
make the appropriate postural adjustments. Impotence, constipation, postural hypotension, and seborrheic dermatitis that is generally evident on the forehead are among the signs of autonomic dysfunction in PD; impaired convergence, limited up-gaze, and lid retraction are the most common neuro-ophthalmological abnormalities (Barbeau 1986). In addition to idiopathic PD, many disorders manifest parkinsonism (Table 2–1). These “Parkinson-plus” syndromes generally present with features of PD but manifest additional symptoms. Progressive supranuclear palsy is a syndrome that is similar to PD but that may produce impaired vertical gaze (up-gaze as well as downgaze), axial rather than distal rigidity, and hypererect rather than stooped posture. Shy-Drager syndrome is associated with severe autonomic dysfunction early in its course, and cerebellar or pyramidal symptoms suggest the presence of olivopontocerebellar atrophy or some other Parkinson-plus syndrome. A Parkinson-plus syndrome should be suspected when tremor is absent, atypical features are present, or a patient fails to respond to dopaminergic therapy (Koller and Megaffin 1994).
Gender and Pregnancy Gender does not appreciably affect PD expression. Although men predominated in two U.S. studies of PD (Hubble et al. 1993; Marder et al. 1996), the incidence of PD was slightly more common in women than in men in the Netherlands (Hofman et al. 1989). In pregnancy, exacerbations of parkinsonism have been observed in rare cases. PD poses no increased risk to the fetus except when amantadine has been administered to the mother.
Pathological Features Increased muscle tone results from an imbalance between competing inhibitory and disinhibitory neural pathways within the subcortical motor circuit, which projects from the sensorimotor cortex through the putamen, pallidum, thalamus, and back to the cortex (Figure 2–1). Between the striatum and thalamus are dynamically balanced circuits that both decrease and increase thalamic inhibition
44
Table 2–1.
Psychiatric Management in Neurological Disease
Differential diagnosis of parkinsonism
Degenerative disorders Idiopathic Parkinson’s disease
Metabolic causes of parkinsonism Hypothyroidism
Progressive supranuclear palsy Huntington’s disease (rigid variant)
Hypoparathyroidism
Striatonigral degeneration Shy-Drager syndrome Idiopathic basal ganglia calcification Guamanian parkinsonism– dementia complex Machado-Joseph disease
Wilson’s disease
Neuroacanthocytosis Lewy body dementia Hallervorden-Spatz disease Olivopontocerebellar atrophy Spinocerebellar degenerations Pallidal degeneration syndromes Ceroid lipofuscinosis Mitochondrial encephalopathy Type III (adult) GM1 gangliosidosis Vascular parkinsonism Lacunar state (a syndrome of punctate lesions in subcortical structures) Binswanger’s disease Infection-related parkinsonism Postencephalitic parkinsonism after epidemic encephalitis Transient parkinsonism after acute viral encephalitis Jakob-Creutzfeldt disease Human immunodeficiency virus encephalopathy Neurosyphilis
Non-Wilsonian hepatocerebral degeneration Drug-induced and toxic parkinsonism Neuroleptics Reserpine Alphamethyldopa Selective serotonin reuptake inhibitors Lithium Diazepam (high doses) Monoamine oxidase inhibitors Calcium channel–blocking agents Cytosine arabinoside Cyanide Organophosphates Manganese Carbon monoxide 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) Miscellaneous disorders Hydrocephalus Brain tumors Subdural hematomas Syringomesencephalia Trauma
Parkinson’s Disease
45
Figure 2–1. Frontal–subcortical circuits. *The indirect path includes the external segment of the globus pallidus and the subthalamic nucleus (DeLong 1990), although recent anatomic evidence suggests that this circuit may be more extensive (Parent and Hazrati 1995). + = excitation; − = inhibition.
(DeLong 1990; Parent and Hazrati 1995). Dopaminergic projections from the substantia nigra to the striatum appear to regulate or stabilize this inhibitory/disinhibitory balance (Saint-Cyr et al. 1995), and loss of dopamine results in unopposed thalamic inhibition and parkinsonism. Bradyphrenia and executive dysfunction are mediated by frontal–subcortical circuits that are parallel to but separate from the motor circuit. These originate in the frontal association cortex and project to the striatum at the caudate, whereas the “motor loop” originates in the supplementary motor cortex and connects to the putamen. Dopamine-mediated stabilization of the inhibitory/disinhibitory balance between direct and indirect pathways probably occurs in this circuit in the same fashion as described for the motor
46
Psychiatric Management in Neurological Disease
circuit (Saint-Cyr et al. 1995), and serotonergic and cholinergic projections also influence these loops. The principal neuropathological changes in PD are depigmentation and loss of dopamine-containing neurons in the substantia nigra, with protein- and sphingomyelin-containing cytoplasmic inclusions known as Lewy bodies developing in many of the remaining neurons. Similar but less severe changes also occur in the locus coeruleus (origin of norepinephrine projections), nucleus basalis (source of acetylcholine connections), and other subcortical nuclei. Deficiency of dopamine is the main neurotransmitter alteration; less-marked deficits of norepinephrine, acetylcholine, serotonin, glutamate, gamma-aminobutyric acid (GABA), and enkephalin also occur.
Neuroimaging Structural imaging has limited diagnostic utility in PD and most parkinsonian syndromes, but functional imaging, such as positron-emission tomography (PET), using [18F]fluorodopa as a tracer, can directly assess neurotransmitter activity in the nigrostriatal dopaminergic system. In contrast with normal aging or other causes of dementia, most causes of parkinsonism, including PD, are associated with reduced striatal [18F]fluorodopa. PD can be further differentiated from other causes of parkinsonism by its particularly low levels of putaminal [18F]fluorodopa. Fluorodopa PET is also useful for detecting preclinical PD and for following disease progression over time (Snow 1996) (Figure 2–2). [18F]fluorodeoxyglucose PET is used to measure cerebral metabolic rate; findings may be normal or may demonstrate global reduction in cerebral metabolism, reduced metabolism in the frontal lobes, or reduced parietal lobe activity.
Psychiatric Manifestations Dementias Cognitive dysfunction exists in a majority of PD patients, and 25%–40% have overt dementia (Aarsland et al. 1996). Bradyphrenia (slow thinking) and executive function impairment are the most
Parkinson’s Disease
A
47
B
Figure 2–2. [18F]Fluorodopa positron-emission tomography (PET) scans showing (A) dopamine uptake in the striatum (dark areas) in a normal control subject and (B) reduction in dopamine uptake in a patient with Parkinson’s disease. Source. Courtesy of Gary Small, M.D.
common aspects of cognitive dysfunction in nondemented PD patients. Bradyphrenia is usually apparent in the form of slowed response time. Executive dysfunction may be evidenced by impaired insight, judgment, planning, and abstracting ability and may be directly assessed by testing verbal and design fluency, delayed recall, alternating programs, multiple loops, and serial hand sequences (a detailed description of these and other executive function tests can be found in Cummings and Trimble 1995). Memory retrieval, visual constructions, verbal fluency, and naming may be mildly impaired, and the pattern of deficits in these domains also suggests frontal–subcortical system abnormalities or executive dysfunction. Cortical features of dementia, such as aphasia, amnesia, agnosia, and apraxia, can occur and likely signify the presence of cortical Lewy bodies, Alzheimer’s-type pathology, or both (Cummings and Benson 1992; Growdon et al. 1990). Lewy body dementia frequently presents with psychiatric symp-
48
Psychiatric Management in Neurological Disease
toms such as depression, agitation, delusions, and hallucinations early in the course (Beck 1995). Cognitive symptoms can progress rapidly and relentlessly but often fluctuate, and relatively lucid intervals may occur. Patients may have mild extrapyramidal symptoms, vivid visual hallucinations, gait disturbances, orthostatic hypotension, unexplained falls, and transient clouding and/or loss of consciousness. Most PD patients have at least a few cortical Lewy bodies, and most Lewy body dementia patients have brain-stem and diencephalic Lewy bodies in the same distribution as previously described for PD (Olichney et al. 1995).
Apathy and Bradyphrenia Apathy (lack of interest or motivation) and bradyphrenia (cognitive slowing) share many phenomenological and, possibly, physiological features. These symptoms occur frequently in PD and are associated with both cognitive impairment and depression; however, an association with bradykinesia (motor slowing) has not been demonstrated (Mayeux et al. 1987; Rogers et al. 1987). Apathy also occurs in a significant number of nondepressed PD patients and these patients have reduced cognitive speed (Starkstein et al. 1992b). One mechanism suggested to explain these symptoms focuses on forebrain dopaminergic systems, which are involved in motivation and reward and are damaged in PD (Rogers et al. 1987). Mayeux et al. (1987) proposed a role for noradrenergic dysfunction in producing bradyphrenia.
Mood Disorders Thirty percent to 50% of PD patients will develop symptoms of depression at some point during the course of their illness. Bipolar disorder is infrequent unless associated with drug treatment. Crosssectional studies of clinical samples report major depression in approximately 20% and minor depression in another 20% (Starkstein et al. 1990a). In contrast, epidemiological studies report lower rates of depression; in one study of 245 patients, 12 (5.1%) had moderateto-severe depressive symptoms, 19 (7.7%) had major depression, and 106 (45.5%) had mild depressive symptoms (Tandberg et al. 1996). Risk factors for depression in PD include female gender, personal but not family history of depression, early age at onset of PD,
Parkinson’s Disease
49
greater right-sided symptoms (i.e., left-hemisphere dysfunction), and prominence of bradykinesia and gait instability as opposed to tremor- dominant syndromes (Jankovic et al. 1990; Starkstein et al. 1990a). Depression can be reliably diagnosed in PD based on DSM-IV (American Psychiatric Association 1994) criteria, although anergia, motor retardation, and early awakening may be equally severe in PD patients with and without depression (Starkstein et al. 1990b). Depression may appear before the onset of motor symptoms (Mayeux et al. 1981), may be relatively stable over time (Brown et al. 1988; Mayeux et al. 1988), and may be associated with faster progression of the illness and a more rapid decline in ability to perform activities of daily living (Starkstein et al. 1992a). Distinguishing characteristics of the parkinsonian depressive syndrome include sadness without guilt or self-reproach, high levels of anxiety, a relative lack of psychotic features, and frequent suicidal ideation (albeit with a low suicide rate) (Cummings 1992). Cognitive performance is more severe in depressed than in nondepressed PD patients but involves similar deficits, with impairment affecting executive function, memory, and language (Mayeux et al. 1981; Starkstein et al. 1989, 1990a, 1990b; Troster et al. 1995b). However, PD patients with overt dementia have no greater frequency of depression than those without dementia (Huber et al. 1986). Serotonin and norepinephrine are regulatory neurotransmitters that are produced in the brain stem and project diffusely throughout the cerebral cortex. Abnormal mood likely results from a disruption in circuits that depend on these neurotransmitters. Predisposing factors include genetic loading and psychosocial stress. Patients with PD may be predisposed to the development of depression as a result of reduced dopaminergic stimulation of the orbitofrontal cortex, which is the primary source of cortical input to brain-stem serotonergic nuclei (Mayberg and Soloman 1995). The increased frequency of depression in PD may also be related to neuronal cell loss in noradrenergic and serotonergic nuclei (Perry et al. 1991). Psychological factors also appear to play a crucial role in protecting some individuals from depression while making others more susceptible to it. Overall disability, rather than stage of illness, accounts for more of the variance in depression (MacCarthy and
50
Psychiatric Management in Neurological Disease
Brown 1989). Other factors that have been identified include the availability and quality of social support, the types of strategies the individual uses to cope with stress, the explanatory cognitions and perceptions of control, and attitudes and beliefs about the self (Brown and Jahanshahi 1995). Depression may also fluctuate over the course of the illness in response to psychological factors. The initial discovery that one has a chronic disabling disease may result in intense depressive symptoms that abate as acceptance occurs but that may re-ignite in response to acute episodes of increased disability.
Anxiety Disorders In studies of anxiety disorders in PD patients, anxiety symptoms have been reported in 40% of PD patients and anxiety disorders in 29%–38%, with the most frequent diagnoses being simple phobia (34%–41%), panic disorder (8%–28%), social phobia (3%–17%), generalized anxiety disorder (4%–5%), and obsessive-compulsive disorder (0%–17%) (Menza et al. 1993; Stein et al. 1990). Anxiety in PD is more frequent and severe than in elderly patients with other chronic illnesses, and it is highly comorbid with depression (Henderson et al. 1992; Menza et al. 1993; Schiffer et al. 1988). In some patients, the onset of the motor arrests known as “freezing” attenuates the course of preexisting panic disorder, whereas other patients develop limited-symptom panic attacks with the onset of freezing (Lauterbach and Duvoisin 1991, 1993). Deficits in noradrenergic and possibly serotonergic function are theorized to mediate increased susceptibility to anxiety in PD patients (Henderson et al. 1992; Menza et al. 1993). Psychological factors also contribute to a heightened state of anxiety, and problems in social interaction are the most frequently cited as the reason for seeking counseling. The problems reported by more than 80% of PD patients in one study included reduced manual skills, reduced gestures and body language, slowness, reduced motivation and drive, anxiety about helplessness, increase of symptoms under minimal stress, disabling insecurity in social interactions, and fewer activities with partners and family (Ellgring et al. 1993).
Parkinson’s Disease
51
Sexual Disorders In a study by Brown et al. (1990) of PD patients, premature ejaculation and impotence occurred in 13 (65%) and 12 (60%), respectively, of the 20 male patients assessed; among the 11 female patients, 4 (36%) had anorgasmia and 3 (27%) had vaginismus. Nearly all of the patients in this study were taking antiparkinsonian medications. High levels of sexual dysfunction were documented in the spouses of PD patients as well as in the patients themselves, but couples in which the husband was the patient were the most severely affected. A diversity of biopsychosocial factors were important in explaining sexual dysfunction in this study. In another study, however, Lipe et al. (1990) found no difference in sexual desire, arousal, orgasm, and satisfaction between male patients with PD and male patients with arthritis. Sexual dysfunction was associated with increased age, illness severity, and depression in that study. A study of 50 patients with PD found that autonomic dysfunction was common, more common than depression, in those suffering from reduced sexual interest and functioning (Koller et al. 1990).
Medication-Induced Psychiatric Disorders Therapy with dopaminergic agents may be associated with formed visual hallucinations, persecutory delusions, anxiety, depression, mania, hypersexuality, and sleep disturbance; anticholinergic therapy may produce delirium with or without psychotic features (Cummings 1991; Factor et al. 1995; Koller and Megaffin 1994; Saint-Cyr et al. 1993) (Table 2–2). Psychosis is rare in untreated PD and usually indicates an adverse treatment response. Visual hallucinations are the most common neuropsychiatric side effect of PD treatment, occurring in approximately 30% of patients (Cummings 1991; Factor et al. 1995). Dopaminergic agents typically produce silent, nonthreatening visual hallucinations of fully formed human or animal figures in a clear sensorium, although frightening visions, altered sensoria, and hallucinations in other sensory modalities can be experienced. Hallucinations frequently occur at night and are more common in patients with sleep disturbance (Koller and Megaffin 1994). Predicting which patients are at risk for hallucinatory experiences is difficult;
52
Table 2–2.
Psychiatric side effects of antiparkinson medications Bromocriptine
Pergolide
Anticholinergics
Amantadine
Selegiline
+++ +++ + + ++ ++ ++
++++ ++ ++ + + + +
+++ ++ ++ + + + +
++ ++ ++++ − − + −
+ ++ + − − + +
+ + + − + + +
++
−
+
+
−
−
Note. + = weak association; ++ = moderate association; +++ = strong association; − = no association. Source. Cummings 1991; Factor 1995; Koller and Megaffin 1994; Saint-Cyr et al. 1993.
Psychiatric Management in Neurological Disease
Hallucinations Delusions Confusional state Depression Mania Anxiety Increased libido Sleep disturbance
L-dopa
Parkinson’s Disease
53
the only factors that have been identified are increasing age, premorbid history of psychiatric illness, more marked cognitive impairment, and longer duration of concomitant treatment with anticholinergic agents and amantadine (Glantz et al. 1987). Hallucinatory symptoms caused primarily by anticholinergic toxicity are usually associated with delirium and tend to be threatening, less well formed, and accompanied by hallucinations in other sensory modalities (Goetz et al. 1982). Delusions occur in approximately 10% of patients treated with dopaminergic agents but can be caused by any of the anti-PD medications (Cummings 1992). L-dopa/carbidopa (Sinemet) generally does not produce delusions before 2 years of continuous therapy (Klawans 1978), and delusions are more common among patients treated with higher doses of drugs. Other risk factors include older age and preexisting dementia (Fischer et al. 1990). Delusions often involve well-formed, complex belief systems and are frequently preceded by hallucinations. Although delusions are usually persecutory or paranoid in nature, misidentification syndromes and delusions of grandeur have also been reported (Cummings 1992). Confusional states, or “delirium,” with fluctuating arousal, impaired attention, and incoherent verbal output occur in 5%–25% of patients treated with anti-PD agents. Overt dementia and anticholinergic therapy are major risk factors and, when combined, may cause delirium in 93% of PD patients (de Smet et al. 1982). L-dopa may also produce confusion, but the higher-potency ergot derivatives such as bromocriptine (Parlodel) and pergolide (Permax) appear to cause it more frequently (Cummings 1992). Selegiline (Eldepryl) rarely produces psychiatric symptoms when used alone but can cause confusional states and/or psychosis when added to L-dopa. Depression is no more frequent in treated than in untreated PD patients when measured prospectively (Celesia and Wanamaker 1972), and it should be regarded as a comorbid condition rather than a drug-induced side effect (Factor et al. 1995). Mania, hypomania, and euphoria do not occur in untreated PD but are infrequent side effects of dopaminergic agents and, occasionally, selegiline. Patients with a history of bipolar disorder frequently experience an acute exacerbation when treated with these medications (Goodwin 1971).
54
Psychiatric Management in Neurological Disease
Symptoms may range from mild euphoria to an intense manic episode and typically subside when the offending agent is reduced or removed. Anxiety is frequent in untreated PD patients, and L-dopa does not appear to account for the extent of anxiety symptoms in treated patients. Nevertheless, symptoms ranging from mild jitteriness to panic attacks have been reported to occur in patients without anxiety prior to treatment, and panic attacks may not necessarily correlate with general levels of anxiety during treatment (Vazquez et al. 1993). Dopaminergic agents are the most frequent anxiety-inducing agents and may directly cause or worsen anxiety. Anxiety is common during “off” periods, when blood dopamine levels are rapidly decreasing. Finally, patients with PD may experience akathisia, a symptom that should be differentiated from drug-induced anxiety. Increased libido regularly occurs in patients treated with dopaminergic agents. In a small minority of patients, hypersexuality occurs and can result in increased masturbation, extramarital affairs, and paraphilic behavior such as sadomasochism, pedophilia, voyeurism, exhibitionism, scatological letter writing, and pederastic and rape fantasies. This complication occurs in 0.9%–3.0% of patients receiving L-dopa (Goodwin 1971; Lesser et al. 1979) and is more common in men with early-onset PD. Diminished prolactin levels are associated with dopaminergic therapy and may be involved in increased libido. Sleep disturbance is more common in patients with drug-related hallucinosis, delusions, confusional states, or depression than in those without these conditions. Vivid dreams and nightmares may be associated with dopaminergic agents, as may sleep architecture disturbances, including diminished stage III and stage IV with multiple arousals and awakenings (Emser et al. 1988).
Neurological Management Dopamine Agents The principal therapeutic modalities useful in the treatment of idiopathic PD and other parkinsonian syndromes caused by structural brain changes are dopamine precursor therapy and administration
Parkinson’s Disease
55
of dopamine receptor agonists. Dopamine does not cross the blood– brain barrier, but L-dopa, the biochemical precursor of dopamine, readily enters the brain through active-transport mechanisms. Coadministration of L-dopa/carbidopa results in higher brain levels of dopamine and limits the side effects produced by peripheral L-dopa catabolism. Potential central nervous system side effects of L-dopa therapy include chorea, tics, vivid dreams and nightmares, hallucinations, delusions, and confusional states. Early responses to dopamine therapy are often dramatic, with many PD patients having nearly complete resolution of symptoms. In contrast, people with non-PD causes of parkinsonism may respond poorly or not at all. Response failure and motor fluctuations may become apparent with prolonged therapy. For this reason, L-dopa therapy should be delayed until the disability begins to interfere with daily function. Precursor therapy depends on the integrity of at least a portion of the normal neuronal population of the substantia nigra to metabolize L-dopa to dopamine and transport the product to the synaptic terminals in the striatum. When the functioning cell population is too small, precursor therapy is ineffective, and other means of stimulating striatal receptors must be found. Bromocriptine (Parlodel), an ergot derivative, is a direct dopamine receptor agonist that is used in conjunction with L-dopa and may continue to provide relief of parkinsonism after the beneficial effects of L-dopa have been exhausted. Pergolide (Permax), a semisynthetic ergoline dopamine agonist, is 10 times more potent than bromocriptine. Ergots may also be effective for non-PD causes of parkinsonism. Dopamine agonist therapy may also be used early in the course of PD in order to delay introduction of L-dopa. Two recently approved D2-specific receptor agonists, ropinirole (Requip) and pramipexole (Mirapex), have fewer side effects than the nonspecific dopamine agonists bromocriptine and pergolide. These newer agents are effective in early (Adler et al. 1997; Shannon et al. 1997) and late PD, and they may be more effective than bromocriptine (Guttman 1997; Korczyn et al. 1998). Pramipexole may also have antidepressant properties (Maj et al. 1997).
56
Psychiatric Management in Neurological Disease
Monoamine Oxidase Type B Inhibitors Selegiline (L-deprenyl, Eldepryl) selectively inhibits monoamine oxidase type B (MAO-B) at low doses and may slow deterioration, reduce the amount of L-dopa required for symptomatic relief, and delay the need for L-dopa by 6–9 months (Olanow et al. 1995; Parkinson’s Study Group 1993). Selegiline’s effect may be due to catecholamine-mediated symptomatic relief, or it could confer neuroprotection through its antioxidant effect. It is recommended that all newly diagnosed PD patients be treated with 5 mg of selegiline twice daily (morning and noon) and that L-dopa be added when symptoms become more pronounced. The major side effect of selegiline is insomnia; for this reason, it is often given in the morning (5 mg) and at noon (5 mg). The 10-mg daily dose should not be exceeded, because selegiline loses its selectivity for MAO-B at higher doses.
Catechol-O-Methyltransferase Inhibitor Tolcapone (Tasmar) is a recently approved catechol-O-methyltransferase (COMT)–inhibiting medication for the treatment of PD that works by slowing the peripheral metabolism of L-dopa and reducing the wide fluctuations in blood level. The “wearing-off” phenomenon, which occurs in 50% of patients after 2–5 years of L-dopa therapy, is reduced by this medication. Also, less L-dopa is needed, and there is significant improvement in motor function and performance of activities of daily living (Waters et al. 1997).
Anticholinergic Agents and Amantadine Anticholinergic agents such as trihexyphenidyl (Artane) and benztropine (Cogentin) improve tremor, rigidity, and L-dopa–induced dystonia but have little effect on akinesia. They must be started at low doses and increased slowly to minimize dry mouth, urinary hesitancy, constipation, blurred vision, memory loss, confusion, disorientation, insomnia, and sedation. Amantadine has both dopaminergic and anticholinergic properties and can improve all symptoms of PD, although the effect may decline in 1–3 months.
Parkinson’s Disease
57
Anticholinergics and amantadine may be useful as adjunctive agents in the treatment of PD, but they are rarely sufficiently efficacious to be used alone (Gancher 1992).
Surgical Therapy Four surgical procedures may play increasingly larger roles in the therapy of PD. Pallidotomy (ventroposterolateral globus pallidus lesion) improves most PD symptoms, including bradykinesia, tremor, and L-dopa–induced dyskinesias. Thalamotomy (ventrolateral thalamic nucleus lesion) is effective primarily in reducing tremor. Both pallidotomy and thalamotomy carry a risk of damage to descending motor fibers, which currently restricts their bilateral use (Burchiel 1995). Electrical stimulation of the thalamus is most effective for tremor (Benabid et al. 1996); stimulation of the pallidum (Siegfried and Lippitz 1994) or of the subthalamic nucleus (Pollak et al. 1996) is effective for bradykinesia and rigidity. Neural grafts of fetal mesencephalic dopamine-producing cells into denervated striatum has proven successful in reducing akinesia but currently is still an experimental treatment (Barinaga 1995; Olanow et al. 1994).
Psychiatric Management The American Parkinson’s Disease Association (APDA; 60 Bay Street, Suite 401, Staten Island, NY 10301, 718-981-8001, 1-800-223-2732) has 47 Information and Referral Centers, 80 chapters, and more than 350 support groups located throughout the United States. They can help with referrals to neurologists, therapists, social workers, lawyers, and financial consultants, and many of the local groups offer patient education and peer support.
Treatment of Dementia Cognitive symptoms in PD may be partially improved early in the course of the illness by L-dopa therapy or by treatment of depression. L-dopa produces nonspecific arousal and may improve the performance of cognitive tasks that require effort. Depression in PD is associated with memory, visuospatial (Troster et al. 1995a), and executive function impairment (Cummings 1992). Later in the course of PD,
58
Psychiatric Management in Neurological Disease
Lewy body dementia or Alzheimer’s disease may emerge, and new treatments for the cognitive symptoms in Alzheimer’s disease— including cholinesterase inhibitors (tacrine and donepezil), antiinflammatory agents, estrogen replacement therapy, and vitamin E—may be effective. Patients with Lewy body dementia have been shown to have lower neocortical choline acetyltransferase levels than patients with Alzheimer’s disease, and these patients may respond particularly well to cholinomimetic therapy (Perry et al. 1994). Tacrine (Cognex) requires a liver function test every other week while doses are increasing. The starting dose is 10 mg qid for 6 weeks with an increase of 40 mg/day every 6 weeks up to a maximum dose of 160 mg/day. Donepezil (Aricept) does not require monitoring of liver functions. Patients may be started on 5 mg/day with an increase to 10 mg/day after 4 weeks; no further increase is required. The various cholinesterase inhibitors appear to have approximately equal efficacy, and all produce gastrointestinal side effects.
Treatment of Apathy Apathy is a common neuropsychiatric syndrome in PD. Although a variety of empirical treatment options are available, there have been no controlled trials that target apathy (Marin et al. 1995). The first step is to diagnose and treat depression or systemic illnesses such as hypothyroidism, if present. Next, if neuroleptics are in use, the dosages should be reduced or the patient should be switched to clozapine (Clozaril) or olanzapine (Zyprexa). Apathy is theorized to result from dysfunction in the basal forebrain mesolimbic and mesocortical dopaminergic system; therefore, any medication that improves dopaminergic activity may improve apathy. If severe apathy persists after motor symptoms have resolved, it may be reasonable to cautiously increase dopaminergic agents, taking care to avoid precipitating psychotic symptoms. L-dopa, bromocriptine, pergolide, ropinirole, and pramipexole are the most potent dopaminergic agents; other agents with dopaminergic activity include methylphenidate (Ritalin), amantadine (Symmetrel), and bupropion (Wellbutrin). Methylphenidate may be used specifically for treatment of apathy and can be started at 5 mg qam. It may be increased as tolerated up to 10 mg bid (morning and noon).
Parkinson’s Disease
59
Treatment of Psychosis Psychotic symptoms such as visual hallucinations and persecutory delusions in a patient with PD may be manifestations of delirium caused by anticholinergic agents, overmedication with dopaminergic agents, or underlying systemic disease such as urinary tract or respiratory system infection. Discontinuation of the offending agent or treatment of the underlying disease process usually resolves the psychotic symptoms, although they may persist for days or weeks. Psychotic symptoms are rare in the course of untreated PD; when psychotic symptoms occur prior to initiation of treatment, they may suggest the existence of Lewy body dementia. If a dementia is present, the patient should receive a trial of a cholinesterase inhibitor. Psychotic symptoms are commonly produced in a clear sensorium by dopaminergic agents, and these medications should be minimized as a first step in treating psychosis in PD. Traditional neuroleptics such as haloperidol (Haldol) and newer agents such as risperidone (Risperdal) frequently fail to ameliorate psychosis without producing significant extrapyramidal symptoms, but the atypical antipsychotics clozapine (Clozaril) and olanzapine (Zyprexa) have been shown to be both safe and effective in treating PD. These agents have relatively little impact on the nigrostriatal portion of the dopaminergic system, which may explain their lack of extrapyramidal effects. Hypotension is a concern, and clozapine should be started at 6.25 mg/day and increased as tolerated up to the lowest effective dose, usually under 100 mg/day in PD. Also, the risk of agranulocytosis increases with age, and patients must have weekly hematological monitoring. Olanzapine does not have these side effects.
Treatment of Depressive Mood Disorders Anti-PD medications have variable effects on depressive symptoms. Occasionally, an increase in L-dopa dosage or addition of an agonist may alleviate mild depressive symptoms. Amantadine and anticholinergics may also have a mild stimulatory effect. For moderate or severe depressions, tricyclic antidepressants or bupropion may be used. In the early stages of PD, imipramine (Tofranil) and desipra-
60
Psychiatric Management in Neurological Disease
mine (Norpramin) have been shown to improve rigidity and tremor, possibly as a result of these agents’ anticholinergic effects (Laitinen 1969; Strang 1965); in one study, 10 of 20 patients on bupropion experienced at least 30% improvement in their parkinsonism, possibly due to a dopaminergic effect (Goetz et al. 1984). Selegiline is not approved for treatment of depression in the United States, and the 10-mg dose does not appear to have an antidepressant effect in PD (Factor et al. 1995; Silver and Yudofsky 1992). Antidepressant medications have been used effectively in the treatment of depression in PD and should be tried after adjustments in anti-PD agents have failed or when the depression includes symptoms such as anhedonia, guilt, and suicidal ideation. Nortriptyline (Pamelor) and desipramine are relatively safe and effective, provided they are initiated at low doses (10–20 mg/day) to avoid potentiating the hypotensive effect of L-dopa. These agents can be titrated up to the usual therapeutic dosages over 1–2 weeks, although adequate blood levels (nortriptyline at 50–150 ng/mL, desipramine at >125 ng/mL; drawn 10–14 hours after last dose) can frequently be achieved in the elderly with doses as low as 50 mg/day. Nortriptyline and desipramine can also be effective for comorbid anxiety, especially panic disorder. Bupropion can be started at 75–100 mg/day and increased up to 100 mg tid. Other antidepressants have not been well studied in PD patients. Selective serotonin reuptake inhibitors (SSRIs), including fluoxetine (Prozac) and sertraline (Zoloft), are free of hypotensive and anticholinergic effects, and serotonin systems theoretically may play a significant role in the pathophysiology of depression in PD. Paroxetine (Paxil), another SSRI with no hypotensive effect, might also be a good choice because of its antianxiety and mild anticholinergic effects. Although fluoxetine has been reported to cause extrapyramidal side effects in a few patients, a recent series of 13 patients experienced no worsening of their parkinsonism with this agent (Montastruc et al. 1995). In elderly patients, fluoxetine, sertraline, and paroxetine should be started at 10 mg, 25 mg, and 10 mg, respectively, and the dose may be doubled after 1 week. Selegiline must be discontinued at least 14 days prior to initiation of antidepressant therapy, because adverse reactions can occur at the 10-mg dose. Antidepressant medications that are nonselective
Parkinson’s Disease
61
inhibitors of MAO are contraindicated because of the potential for an adverse interaction with L-dopa. Lithium (Eskalith) can be used to augment antidepressant therapy and may potentiate both the effects and the side effects of L-dopa. In the elderly, lithium should be started at 150 mg/day and gradually titrated to a therapeutic dose because it has been reported to occasionally produce extrapyramidal symptoms (Cummings 1992; Koller and Megaffin 1994; Silver and Yudofsky 1992). Electroconvulsive therapy (ECT) remains the safest and most effective treatment for depression in all age groups. About half of PD patients treated with ECT will experience a significant but usually temporary reduction in their motor symptoms independently of the effect on their psychiatric symptoms (Faber and Trimble 1991). Individual and group psychotherapy can be very helpful and should address at least six goals. First, patients should be educated about the course of the illness in order to ameliorate the effect of unexpected deteriorations. Second, strategies must be developed to reduce disability in the face of worsening motor symptoms. Third, social support should be maximized. Fourth, patients should be helped to develop healthy strategies for coping with stress. Fifth, they may need to work through feelings of worthlessness and be helped to appreciate that the illness is not their fault. Finally, caretakers should always be adequately evaluated for psychiatric morbidity, as PD patients usually become emotionally and physically dependent on their caretakers.
Treatment of Anxiety Disorders Anxiety in the elderly may be caused by infections of the urinary or respiratory systems or by emphysema, heart disease, thyroid disorder, arthritic pain, constipation, or other systemic disorders. Medications that frequently produce anxiety include anti-PD agents, thyroid replacement, steroids, and sympathomimetics such as pseudoephedrine and beta-agonists. Withdrawal from alcohol or sedatives and side effects from neuroleptics may also produce anxiety. Underlying systemic conditions should be diagnosed and treated first and the doses of anti-PD agents then adjusted. If anxiety symptoms persist, pharmacological and psychological
62
Psychiatric Management in Neurological Disease
approaches should be employed. Most antidepressants are effective for panic disorder and are a logical choice because of the frequent comorbidity of panic disorder with depression, but benzodiazepines may be required to control the initial stimulatory effects that antidepressants can produce. Benzodiazepines must be administered with caution, because they frequently cause impairments in gait, balance, and cognition that may lead to falls in the elderly. Also, rebound anxiety can occur with short-acting agents such as lorazepam (Ativan) and may require tid or qid dosing. Clonazepam (Klonopin) at 0.5 mg bid is usually adequate to control anxiety in the elderly and has a gradual onset of action with a steady plasma level over 24 hours; however, strict vigilance for drug accumulation and attendant side effects is critical in the elderly. Although buspirone (BuSpar) at 5 mg tid may be helpful for some patients, it requires several weeks to become effective. Buspirone should be given in three divided doses daily; the dose may be increased up to 40 mg/day as tolerated. More data regarding the effectiveness of buspirone is needed, however, because the drug was found to be without effect on anxiety in a small sample of PD patients (Ludwig et al. 1986) The main goal of psychological intervention is to help patients cope with stressful social situations. This goal can be achieved through either individual or group therapy, including relaxation techniques, cognitive restructuring, situational behavioral analysis, and training in social skills, with interventions specifically adapted to the disease (Ellgring et al. 1993).
Treatment of Sexual Disorders Brown et al. (1990) concluded that there is no simple approach to managing sexual disorders in patients with PD. As detailed above, a variety of factors have been implicated in these disorders, including illness severity, autonomic dysfunction, depression, and treatmentrelated side effects. A range of disease, psychological, social, and marital variables were evident in the study of Brown et al. (1990), and the authors advocated a multimodal therapeutic approach. Additional treatment data in PD are lacking. Absent these data, sexual dysfunction may be managed in the same manner as in primary sexual disorders.
Parkinson’s Disease
63
Treatment of Medication-Induced Psychiatric Disorders Confusional states are best managed by treating underlying infections and minimizing all medications, especially anticholinergic agents. Mania or hypomania caused by dopaminergic therapy typically subsides when drug dosage is reduced; some patients may require management on small doses of L-dopa/carbidopa alone without other agents to minimize manic behavior. Lithium administration benefits some patients but not others (Van Woert et al. 1971). Hypersexuality caused by dopaminergic therapy usually decreases with dose reduction (Uitti et al. 1989). If dose reduction is not possible, low-potency neuroleptics or antitestosterone agents may be tried (Factor et al. 1995), although there are no guidelines for these treatments. Sleep disturbances require assessment for a confusional state, reduction of dopaminergic therapy, or treatment for depression. Persistent sleep disturbance may be treated with the triazolopyridine antidepressant trazodone (Desyrel) (50 mg qhs), with a short-acting benzodiazepine such as temazepam (Restoril), or with zolpidem (Ambien).
Treatment of Psychiatric Consequences of Surgical Therapy Subcortical surgical lesions may produce psychiatric symptoms, but there are few reports in the literature of postoperative psychiatric morbidity. Masterman and colleagues at UCLA (personal communication) examined 20 patients at 3-month follow-up postpallidotomy and found essentially no change in depression, anxiety, psychosis, or other psychiatric symptoms. In contrast, Rossitch et al. (1988) observed cognitive and speech changes in patients who had undergone thalamotomy. Similar problems may be encountered with chronic electrical stimulation of subcortical structures but can be reduced with adjustment of frequency intensity (Benabid et al. 1996). Human fetal mesencephalic tissue transplantation appears to have few long-term psychiatric sequelae (Price et al. 1995), although psychotic features are common in the early postoperative period. These procedures are currently receiving intense investigation, and their impact on psychiatric morbidity will be better understood as they are used more widely.
64
Psychiatric Management in Neurological Disease
Summary PD is a progressive and disabling illness of the brain that affects motor, cognitive, and emotional function. Degenerative changes occur in subcortical structures where parallel circuits that modulate these three brain activities are in close proximity. Dopaminergic agents may improve cognitive speed, and cholinergic therapy is effective for both Alzheimer’s disease and Lewy body dementia. Depression, anxiety disorders, and apathy are frequent in PD. These symptoms are independent of anti-PD treatment and appear to respond to pharmacotherapy and psychotherapy; however, very few treatment studies have been done. Psychosis is generally associated with dopaminergic or anticholinergic therapy but may herald the onset of dementia. If psychosis persists after dosage adjustment, it is very difficult to treat but may respond to low doses of clozapine or olanzapine. PD affects its victims over the course of many years and causes considerable psychiatric morbidity; therefore, psychiatric evaluation and treatment are critical elements to the proper care of patients with this relentless illness.
References Aarsland D, Tandberg E, Larsen JP, et al: Frequency of dementia in Parkinson disease. Arch Neurol 53:538–542, 1996 Adler CH, Sethi KD, Hauser RA, et al: Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 49:393– 399, 1997 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994 Barbeau A: Parkinson’s disease: clinical features and etiopathology, in Handbook of Clinical Neurology, Vol 5 (49): Extrapyramidal Disorders. Edited by Vinken PJ, Bruyn GW, Klawans HL. New York, Elsevier Science Publishers, 1986, pp 87–152 Barinaga M: Researchers broaden the attack on Parkinson’s disease (news). Science 267:455–456, 1995 Beck BJ: Neuropsychiatric manifestations of diffuse Lewy body disease. J Geriatr Psychiatry Neurol 8:189–196, 1995
Parkinson’s Disease
65
Benabid AL, Pollak P, Gao D, et al: Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 84:203–214, 1996 Brown R, Jahanshahi M: Depression in Parkinson’s disease: a psychosocial viewpoint. Adv Neurol 65:61–84, 1995 Brown RG, MacCarthy B, Gotham AM, et al: Depression and disability in Parkinson’s disease: a follow-up study of 132 cases. Psychol Med 18:49– 55, 1988 Brown RG, Jahanshahi M, Quinn N, et al: Sexual function in patients with Parkinson’s disease and their partners. J Neurol Neurosurg Psychiatry 53:480–486, 1990 Burchiel KJ: Thalamotomy for movement disorders. Neurosurg Clin N Am 6:55–71, 1995 Celesia CG, Wanamaker WM: Psychiatric disturbances in Parkinson’s disease. Diseases of the Nervous System 33:577–583, 1972 Cummings JL: Behavioral complications of drug treatment of Parkinson’s disease. J Am Geriatr Soc 39:708–716, 1991 Cummings JL: Depression and Parkinson’s disease: a review. Am J Psychiatry 149:443–454, 1992 Cummings JL, Benson DF: Dementia: A Clinical Approach, 2nd Edition. Boston, MA, Butterworth-Heinemann, 1992 Cummings JL, Trimble MR: Concise Guide to Neuropsychiatry and Behavioral Neurology. Washington, DC, American Psychiatric Press, 1995 DeLong MR: Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281–285, 1990 de Smet Y, Ruberg M, Serdaru M, et al: Confusion, dementia and anticholinergics in Parkinson’s disease. J Neurol Neurosurg Psychiatry 45: 1161–1164, 1982 Di Rocco A, Molinari SP, Kollmeier B, et al: Parkinson’s disease: progression and mortality in the L-dopa era. Adv Neurol 69:3–11, 1996 Ellgring H, Seiler S, Perleth B, et al: Psychosocial aspects of Parkinson’s disease. Neurology 43 (12 suppl 6):S41–S44, 1993 Emser W, Brenner M, Stober T, et al: Changes in nocturnal sleep in Huntington’s and Parkinson’s diseases. J Neurol 235:177–179, 1988 Faber R, Trimble MR: Electroconvulsive therapy in Parkinson’s disease and other movement disorders. Mov Disord 6:293–303, 1991 Factor SA, Molho ES, Podskalny GD, et al: Parkinson’s disease: druginduced psychiatric states. Adv Neurol 65:115–138, 1995 Fischer P, Danielczuk W, Simanyi M, et al: Dopaminergic psychosis in advanced Parkinson’s disease. Adv Neurol 53:391–397, 1990
66
Psychiatric Management in Neurological Disease
Gancher ST: Pharmacology of Parkinson’s disease, in Parkinson’s Disease: Neurobehavioral Aspects. Edited by Huber SJ, Cummings JL. New York, Oxford University Press, 1992, pp 273–287 Glantz RH, Bieliauskas L, Paleologos N: Behavioral indicators of hallucinosis in levodopa treated Parkinson’s disease. Adv Neurol 45:417–420, 1987 Goetz CG, Tanner CM, Klawans HL: Pharmacology of hallucinations induced by long-term drug therapy. Am J Psychiatry 139:494–497, 1982 Goetz CG, Tanner CM, Klawans HL: Bupropion in Parkinson’s disease. Neurology 34:1092–1094, 1984 Goodwin FK: Psychiatric side effects of levodopa in man. JAMA 218: 1915–1920, 1971 Growdon JH, Corkin S, Rosen TJ: Distinctive aspects of cognitive dysfunction in Parkinson’s disease. Adv Neurol 53:365–376, 1990 Guttman M: Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole-Bromocriptine Study Group. Neurology 49:1060–1065, 1997 Hagell P, Odin P, Vinge E: Pregnancy in Parkinson’s disease: a review of the literature and a case report. Mov Disord 13:34–38, 1998 Henderson R, Kurlan R, Kersun JM, et al: Preliminary examination of the co-morbidity of anxiety and depression in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4:257–264, 1992 Hofman A, Collette HJ, Bartelds AI: Incidence and risk factors of Parkinson’s disease in the Netherlands. Neuroepidemiology 8:296–299, 1989 Huber SJ, Shuttleworth EC, Paulson GW: Dementia in Parkinson’s disease. Arch Neurol 43:987–990, 1986 Hubble JP, Cao T, Hassanein RE, et al: Risk factors for Parkinson’s disease. Neurology 43:1693–1697, 1993 Jankovic J, McDermott M, Carter J, et al: Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 40:1529–1534, 1990 Klawans HL: Levodopa-induced psychosis. Psychiatr Ann 8:447–451, 1978 Koller WC, Megaffin BB: Parkinson’s disease and parkinsonism, in The American Psychiatric Press Textbook of Geriatric Neuropsychiatry. Edited by Coffey CE, Cummings JL. Washington, DC, American Psychiatric Press, 1994, pp 433–456 Koller WC, Vetere-Overfield B, Williamson A, et al: Sexual dysfunction in Parkinson’s disease. Clin Neuropharmacol 13:461–463, 1990
Parkinson’s Disease
67
Korczyn AD, Brooks DJ, Brunt ER, et al: Ropinirole versus bromocriptine in the treatment of early Parkinson’s disease: a 6-month interim report of a 3-year study (053 Study Group). Mov Disord 13:46–51, 1998 Laitinen L: Desipramine in treatment of Parkinson’s disease: a placebocontrolled study. Acta Neurol Scand 45:109–113, 1969 Lauterbach EC, Duvoisin RC: Anxiety disorders in familial parkinsonism (letter). Am J Psychiatry 148:274, 1991 Lauterbach EC, Duvoisin RC: The locus coeruleus and anxiety disorders in demented and nondemented familial parkinsonisms (letter). Am J Psychiatry 150:994, 1993 Lesser RP, Fahn S, Snider SR, et al: Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29:1253–1260, 1979 Lipe H, Longstreth WT Jr, Bird TD, et al: Sexual function in married men with Parkinson’s disease compared to married men with arthritis. Neurology 40:1347–1349, 1990 Ludwig CL, Weinberger DR, Bruno G, et al: Buspirone, Parkinson’s disease and the locus ceruleus. Clin Neuropharmacol 9:373–378, 1986 MacCarthy B, Brown R: Psychosocial factors in Parkinson’s disease. Br J Clin Psychol 28:41–52, 1989 Maj J, Rogóz Z, Skuza G, et al: Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm 104:525–533, 1997 Marder K, Tang MX, Mejia H, et al: Risk of Parkinson’s disease among first-degree relatives: a community-based study. Neurology 47:155– 160, 1996 Marin RS, Fogel BS, Hawkins J, et al: Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 7:23–30, 1995 Martilla RJ: Epidemiology, in Handbook of Parkinson’s disease. Edited by Koller WC. New York, Marcel Dekker, 1987, pp 35–50 Mayberg HS, Soloman DH: Depression in Parkinson’s disease: a biochemical and organic viewpoint. Adv Neurol 65:49–60, 1995 Mayeux R, Stern Y, Rosen J, et al: Depression, intellectual impairment and Parkinson disease. Neurology 31:645–650, 1981 Mayeux R, Stern Y, Sano M, et al: Clinical and biochemical correlates of bradyphrenia in Parkinson’s disease. Neurology 37:1130–1134, 1987 Mayeux R, Stern Y, Sano M, et al: The relationship of serotonin to depression in Parkinson’s disease. Mov Disord 3:237–244, 1988 Menza MA, Robertson-Hoffman DE, Bonapace AS: Parkinson’s disease and anxiety: co-morbidity with depression. Biol Psychiatry 34:465–470, 1993
68
Psychiatric Management in Neurological Disease
Montastruc JL, Fabre N, Blin O, et al: Does fluoxetine aggravate Parkinson’s disease? A pilot prospective study. Mov Disord 10:355–357, 1995 Olanow CW, Marsden CD, Lang AE, et al: The role of surgery in Parkinson’s disease management. Neurology 44 (3 suppl 1):S17–S20, 1994 Olanow CW, Hauser RA, Gauger L, et al: The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 38:771– 777, 1995 Olichney JM, Galasko D, Corey-Bloom J, et al: The spectrum of diseases with diffuse Lewy bodies. Adv Neurol 65:159–170, 1995 Parent A, Hazrati LN: Functional anatomy of the basal ganglia, II: the place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Brain Res Rev 20:128–154, 1995 Parkinson’s Study Group: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328: 176–183, 1993 Perry EK, McKeith I, Thompson P, et al: Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson’s disease, and Alzheimer’s disease. Ann N Y Acad Sci 640: 197–202, 1991 Perry EK, Haroutunian V, Davis KL, et al: Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer’s disease. Neuroreport 5:747–749, 1994 Pollak P, Benabid AL, Limousin P, et al: Subthalamic nucleus stimulation alleviates akinesia and rigidity in parkinsonian patients. Adv Neurol 69:591–594, 1996 Price LH, Spencer DD, Marek KL, et al: Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson’s disease. Biol Psychiatry 38:498–505, 1995 Rogers D, Lees AJ, Smith E, et al: Bradyphrenia in Parkinson’s disease and psychomotor retardation in depressive illness: an experimental study. Brain 110:761–776, 1987 Rossitch E Jr, Zeidman SM, Nashold BS Jr, et al: Evaluation of memory and language function pre- and postthalamotomy with an attempt to define those patients at risk for postoperative dysfunction. Surg Neurol 29:11–16, 1988 Saint-Cyr JA, Taylor AE, Lang AE: Neuropsychological and psychiatric side effects in the treatment of Parkinson’s disease. Neurology 43 (12 suppl 6):S47–S52, 1993 Saint-Cyr JA, Taylor AE, Nicholson K: Behavior and the basal ganglia. Adv Neurol 65:1–28, 1995
Parkinson’s Disease
69
Schiffer RB, Kurlan R, Rubin A, et al: Evidence for atypical depression in Parkinson’s disease. Am J Psychiatry 145:1020–1022, 1988 Shannon KM, Bennett JP, Friedman JH: Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology 49:724–728, 1997 Siegfried J, Lippitz B: Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. Neurosurgery 35:1126–1130, 1994 Silver JM, Yudofsky SC: Drug treatment of depression in Parkinson’s disease, in Parkinson’s Disease: Neurobehavioral Aspects. Edited by Huber SJ, Cummings JL. New York, Oxford University Press, 1992, pp 240–254 Snow BJ: Fluorodopa PET scanning in Parkinson’s disease. Adv Neurol 69:449–457, 1996 Starkstein SE, Rabins PV, Berthier ML, et al: Dementia of depression among patients with neurological disorders and functional depression. J Neuropsychiatry Clin Neurosci 1:263–268, 1989 Starkstein SE, Preziosi TJ, Bolduc PL, et al: Depression in Parkinson’s disease. J Nerv Ment Dis 178:27–31, 1990a Starkstein SE, Preziosi TJ, Forrester AW, et al: Specificity of affective and autonomic symptoms of depression in Parkinson’s disease. J Neurol Neurosurg Psychiatry 53:869–873, 1990b Starkstein SE, Mayberg HS, Leiguarda R, et al: A prospective longitudinal study of depression, cognitive decline and physical impairments in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 55: 377–382, 1992a Starkstein SE, Mayberg HS, Preziosi TJ, et al: Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4:134–139, 1992b Stein MB, Heuser IJ, Juncos JL, et al: Anxiety disorders in patients with Parkinson’s disease. Am J Psychiatry 147:217–220, 1990 Strang RR: Imipramine in treatment of parkinsonism: a double-blind placebo study. BMJ 2:33–34, 1965 Tandberg E, Larsen JP, Aarsland D, et al: The occurrence of depression in Parkinson’s disease: a community-based study. Arch Neurol 53:175– 179, 1996 Tanner CM, Goldman SM: Epidemiology of Parkinson’s disease. Neurol Clin 14:317–335, 1996
70
Psychiatric Management in Neurological Disease
Troster AI, Paolo AM, Lyons KE, et al: The influence of depression on cognition in Parkinson’s disease: a pattern of impairment distinguishable from Alzheimer’s disease. Neurology 45:672–676, 1995a Troster AI, Stalp MA, Paolo AM, et al: Neuropsychological impairment in Parkinson’s disease with and without depression. Arch Neurol 52: 1164–1169, 1995b Uitti RJ, Tanner CM, Rajput AH, et al: Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12:375–383, 1989 Van Woert MH, Ambani LM, Weintraub MI: Manic behavior and levodopa (letter). N Engl J Med 285:1326, 1971 Vazquez A, Jimenez-Jimenez FJ, Garcia-Ruiz P, et al: “Panic attacks” in Parkinson’s disease: a long-term complication of levodopa therapy. Acta Neurol Scand 87:14–18, 1993 Waters CH, Kurth M, Bailey P, et al: Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 49:665–671, 1997
C H A P T E R
3
Huntington’s Disease Neal G. Ranen, M.D.
H
untington’s disease (HD) is an autosomal dominant inherited degenerative neuropsychiatric disorder caused by an expanded trinucleotide repeat (CAG) in a gene (IT15) on chromosome 4. The clinical features of HD can be thought of as a triad of motor, cognitive, and noncognitive psychiatric disturbances (McHugh and Folstein 1975). Although this triad is always present, there is considerable variability of clinical features among different patients. There is no currently available treatment that can halt or reverse the inexorable progression of HD. Furthermore, much of what is recommended with regard to the symptomatic treatment of HD has been arrived at by consensus of experts in the field rather than by controlled trials (Ranen et al. 1993). This is especially true for treatment of the psychiatric aspects of the disease. Nonetheless, rational treatment of specific psychiatric and motor symptoms can reduce unnecessary morbidity, which in turn can improve the quality of life of patients with HD.
Prevalence The prevalence of HD has been estimated to be in the range of 4.1–7.5 per 100,000 (Folstein et al. 1987). HD is seen throughout the world but is rare in Finland and Japan (Harper 1992). There are a few isolated populations of Western European origin that have a much higher prevalence of the disease, such as the much-studied HD population of Lake Maracaibo, Vene71
72
Psychiatric Management in Neurological Disease
zuela (Gusella et al. 1983; Penney et al. 1990; Wexler et al. 1987), where the prevalence of HD is estimated at 700 per 100,000.
Clinical Recognition and Neurological Presentation Clinical Course Symptoms begin insidiously (Penney et al. 1990), with onset typically between the ages of 35 and 50 years, but onset may occur anytime from childhood to old age (Folstein et al. 1987). The differential diagnosis of chorea is presented in Table 3–1. Adult-onset HD can be roughly divided into three stages. Early in the disease, manifestations include subtle changes in coordination, perhaps some minor involuntary movements, difficulty thinking through problems, and, often, a depressed or irritable mood. In the middle stage, chorea usually becomes prominent, and difficulty with voluntary motor activities will be more evident, with worsening dysarthria and dysphagia. As cognitive deficits increase, the paTable 3–1.
Differential diagnosis of chorea
Huntington’s disease Dentatorubro-pallidoluysian atrophy (DRPLA) Tardive dyskinesia Side effects of medications (e.g., L-dopa–induced dyskinesia) Neuroacanthocytosis Sydenham’s chorea Spinocerebellar ataxias Benign familial chorea Wilson’s disease (hepatolenticular degeneration) Paroxysmal choreoathetosis Senile chorea (diagnosis of exclusion) Stroke Thyrotoxicosis Closed head injury Infectious disease (AIDS/toxoplasmosis) Note.
AIDS = acquired immunodeficiency syndrome.
Huntington’s Disease
73
tient will be unable to hold a job or carry out most household responsibilities. Patients with late-stage disease may have severe chorea but are more often rigid and bradykinetic. They are largely nonverbal and bedridden, with a more global dementia, although they retain a significant degree of comprehension (Ranen et al. 1993). Psychiatric disorders may appear at any time during the course of the disease, even years before motor symptoms develop (Folstein et al. 1983). Death occurs an average of about 15 years after symptoms start, although some patients die early from falls or suicide, and others survive for 30–40 years, particularly if a feeding tube is placed (Folstein 1989).
The Movement Disorder The movement disorder in HD has two clinical components: a disturbance of involuntary movement and a disturbance of voluntary movement. In addition to chorea (or choreoathetosis), which consists of irregular jerky or writhing movements, other disturbances of involuntary movement consist of myoclonus and seizures. Myoclonus is more common in juvenile-onset HD and in the later stages of adult-onset HD, although it can be seen occasionally in less severely affected adult-onset patients. Epilepsy is also seen most commonly in juvenile-onset HD, but it is occasionally seen in adults with advanced disease. Disturbances of voluntary movement include abnormal eye movements (abnormal saccades and pursuit, among others); uncoordinated, arrhythmic, and slow fine motor movements; and dysphagia, dysarthria, bradykinesia, clumsiness, rigidity, and gait disturbance. In contrast to chorea, which often plateaus and even wanes in the later stages of the disease, disturbances in voluntary movement progress more steadily (Folstein 1989; Penney et al. 1990). The disturbance of voluntary movement is more highly correlated with functional disability than is the chorea (Brandt et al. 1984). The Quantified Neurologic Examination (QNE; Folstein et al. 1983) and the Unified Huntington’s Disease Rating Scale (Huntington Study Group 1996) have been developed as standardized measures of movement disorder in HD.
74
Psychiatric Management in Neurological Disease
Early patient complaints attributable to the motor disorder include clumsiness, difficulty with balance, and jerky movements or tremor. Patients may also note that they are dropping things, have difficulty typing, have noticed a change in their handwriting, have been tripping or stumbling more often, or have become aware that they are applying uneven pressure to the gas pedal in a car. In late-stage HD, patients are akinetic and largely nonverbal, with severe rigidity and joint contractures. At this point, they may have no involuntary movements except for occasional whole-body movements, resembling myoclonic jerks, when they are disturbed. Difficulties with swallowing commonly lead to death in HD, either directly from suffocation or aspiration or indirectly from starvation. HD that begins in childhood (i.e., juvenile-onset HD) often presents with a somewhat different set of signs and symptoms; for example, bradykinesia, rigidity, and dystonia (Van Dijk et al. 1986). Chorea may be completely absent. Involuntary movements may take the form of tremors, and seizures and myoclonus may occur. This rigid, akinetic form is termed the Westphal variant of HD.
Pathological Features Pathology The pathology of HD is restricted to the central nervous system, with selective neuronal vulnerability. Although the brains of patients with HD show some generalized atrophy, there is a particularly marked degeneration within the striatum (caudate and putamen) and in the deep layers of the cerebral cortex. Within the striatum, there is highly selective neuronal loss, with near-complete loss of medium spiny neurons and preservation of several classes of large interneurons. These striatal medium spiny neurons, which are GABAergic, project to the globus pallidus and receive glutamatergic inputs from the cerebral cortex and dopaminergic inputs from the substantia nigra (Albin et al. 1989). Severity of Huntington’s disease is rated with the Vonsattel score, which ranges from 0 to 4, with 4 representing the most severe degree of atrophy as determined by gross and microscopic examination (Vonsattel et al. 1985).
Huntington’s Disease
75
Much of the clinical presentation of HD can be appreciated in terms of the multiple frontal–subcortical circuits that unite specific regions of the frontal cortex with the basal ganglia and the thalamus and mediate motor activity, eye movements, and behavior (Alexander et al. 1986; Mega and Cummings 1994). Chorea can be appreciated as arising from a disturbance of the motor circuit, which has as its target the supplementary motor area; abnormal eye movements from a disturbance of the oculomotor circuit, which has as its target the frontal eye fields; dementia from a disturbance of the dorsolateral prefrontal cortex circuit, which is important in executive cognitive functions; irritability, disinhibition, and perhaps mania from a disturbance of the lateral orbitofrontal cortex circuit, which is tied to aspects of personality; and apathy from a disturbance of the anterior cingulate circuit, which is important in motivation.
Genetics and Theories of Pathogenesis HD demonstrates autosomal dominant transmission; homozygotes (i.e., individuals who have two copies of the mutated gene—an uncommon occurrence in HD) have no more severe disease than do heterozygotes (i.e., those who have one copy of the mutated gene) (Wexler et al. 1987). In 1983, the gene for HD was localized to the short arm of chromosome 4 (Gusella et al. 1983); 10 years later, the gene was isolated (Huntington’s Disease Collaborative Research Group 1993). The mutation causing HD is an expanded repeating sequence of three nucleotide base pairs, CAG, known as a trinucleotide or triplet repeat. Repeats in the range of 10–29 are normal, repeats of 30–36 are intermediate, and repeats of 37 and above are causative of HD (Duyao et al. 1993; Kremer et al. 1994). An expanded CAG repeat on IT15 is 100% specific and 98.8% sensitive for HD (Kremer et al. 1994). Some cases with signs and symptoms similar to HD but without the IT15 CAG expansion are thought to arise from as-yet-undefined genes (Andrew et al. 1994). Other such cases have been attributed to hysterical symptomatology (e.g., conversion reactions) (Ranen et al. 1997). The length of the trinucleotide repeat is highly correlated with age at onset of the disease (Duyao et al. 1993). Most of the correlation is accounted for by very long repeats. However, for fewer than 55 re-
76
Psychiatric Management in Neurological Disease
peats, which are most common, repeat length is a poor predictor of age at onset. Therefore, the utility of this correlation for individuals seeking presymptomatic genetic testing is limited. As with other triplet-repeat disorders, HD exhibits anticipation. Anticipation is the earlier onset of disease in successive generations within a pedigree. In HD, anticipation is a phenomenon of paternal transmission (Ranen et al. 1995; Ridley et al. 1988) and is associated with further expansion of the trinucleotide repeat when passed from father to child (Ranen et al. 1995). Study results vary as to whether the length of the repeat is associated with rate of progression, with some studies finding more rapid progression with longer repeats (Brandt et al. 1996) and others finding no such relationship (Kieburtz et al. 1994). The process by which the expanded trinucleotide repeat causes HD is unknown. It is known that the expanded CAG repeat is translated into the protein, named huntingtin, as a glutamine repeat (CAG codes for glutamine). The function of huntingtin is not known. Evidence to date suggests that the mutation results in a gain, rather than a loss, of function of the protein. This gain of function may be due to intensified or novel interactions with other proteins (Li et al. 1995). Basal ganglia pathophysiology in HD is depicted in Figure 1–2 in Chapter 1.
Neuroimaging The most striking finding from anatomic neuroimaging (computed tomography [CT] and magnetic resonance imaging [MRI]) of HD patients is striatal degeneration. However, this finding is often not seen early in the disease. With disease progression, ventricular dilatation (“boxcarring”) suggestive of caudate atrophy is seen on MRI. Using volumetric MRI measurements, Aylward et al. (1994) have demonstrated reduced basal ganglia size in presymptomatic, genepositive individuals. Mayberg et al. (1992) found that depression in HD is associated with frontal hypometabolism on positron-emission tomography (PET) scan.
Huntington’s Disease
77
Laboratory Investigation and Predictive Testing Results of controlled screening programs have been encouraging, with most individuals stating that they were relieved to know the results even if they were adverse (Brandt et al. 1989; Wiggins et al. 1992). A sense of relief regardless of whether the results revealed the presence or absence of the mutation may be due to reduced uncertainty. There have been a few case reports of dramatic adverse consequences of both positive and negative results (Wexler 1992). The International Huntington Association (IHA) and World Federation of Neurology (WFN) Research Group on Huntington’s Chorea have jointly developed guidelines for predictive testing (IHA–WFA Research Group on Huntington’s Chorea 1994). The guidelines include the concepts of full informed consent, presymptomatic counseling, face-to-face disclosure of results, and posttest counseling. A blood sample from the subject is all that is needed to test for the HD gene. The cost is usually about $400, and the test is available at several commercial and university laboratories. Predictive testing should be carried out at an approved center where patient and family anxiety can be best addressed, and where procedures are in place that follow the IHA recommendations. Family members’ questions about their genetic risk should be answered directly—a child of an affected parent has a 50% chance of inheriting the gene, and a grandchild has a 25% chance. It is helpful to express cautious optimism about the possibility that research developments will lead to specific treatments in the future. Despite the presence of guidelines, ethical questions will still arise. For example, should an individual whose grandparent was affected be tested if the parent, who is as yet unaffected, does not want to know his or her gene status? If that individual tests positive for the mutated gene, the parent will probably know that he or she has the mutated gene. A positive gene test does not indicate disease onset, only the likelihood that the disease will occur. Onset of disease remains a clinical diagnosis.
78
Psychiatric Management in Neurological Disease
Psychiatric Manifestations Although the cognitive disorder is well known, in his original manuscript in 1872 George Huntington noted that “the tendency to insanity, and sometimes that form of insanity which leads to suicide, is marked.” The most common noncognitive psychiatric disturbances in HD are mood disorders (depressive and bipolar disorders), irritability, and apathy (Folstein et al. 1987). Psychotic symptoms occur less frequently. Mood disorders have a variety of behavioral manifestations, including aggressive outbursts, impulsiveness, social withdrawal, and suicidal behavior.
Cognitive Impairment and Dementia The cognitive disorder in HD has less-striking aphasia and agnosia than in “cortical dementias” (e.g., Alzheimer’s disease), consistent with the features of “subcortical dementia” (McHugh and Folstein 1975). This is coded in DSM-IV (American Psychiatric Association 1994) as dementia due to HD. Initial cognitive changes involve loss of cognitive speed and flexibility (Mayeux et al. 1986). Patients may have trouble changing from one task to another or keeping track of serial tasks, and thus may need more time to think through a problem. Such cognitive inefficiency may result in patients having difficulty maintaining an accurate checkbook or accounts, trouble in keeping up with assigned work or school load, diminished concentration, and decreased quality of work. Such early HD patients usually perform within the normal range on IQ tests and may be impaired only on neuropsychological testing that requires speed, concentration, mental flexibility, and new verbal learning (Brandt 1994). On the Mini-Mental State Exam (MMSE; Folstein et al. 1975), the Serial Sevens Task (serially subtracting 7, starting from 100) is typically the first task affected (Brandt et al. 1988). Compared with Alzheimer’s disease patients, patients with HD appear to have a disturbance of retrieval rather than of storage of memories, and therefore they are more apt to recognize words from a list they were asked to remember or to respond to cues to help them remember (Brandt et al. 1992; Butters et al. 1986). Cognitive losses accumulate progressively. Deficits in memory,
Huntington’s Disease
79
visuospatial abilities, and judgment appear. Further along in the course, the dementia becomes more global. Advanced patients become nonverbal, and their cognitive state is more difficult to assess. The patient who presents with an unexpected rapid deterioration of cognition should be evaluated for causes of delirium. In HD, common causes of delirium include alcohol use, illicit substance abuse, dehydration, medications (especially those with anticholinergic effects), subdural hematoma, and infections. Patients taking lithium who become dehydrated may become delirious on dosages that were previously appropriate.
Irritability and Aggressiveness Severe irritability has been found to be present in about one-third of patients with HD (Folstein et al. 1987). In terms of DSM-IV, irritability can be coded as a personality change due to a general medical condition. Alternatively, episodic aggressive behavior can be coded as intermittent explosive disorder. In contrast to the more diffuse catastrophic reactions seen in Alzheimer’s disease, irritability in HD tends to be more specifically directed and to be associated with irritable traits premorbidly (Burns et al. 1990). Violent behavior—including assault, arson, and homicide attempts—in HD patients has been reported in the literature (Dewhurst et al. 1970; Rosenbaum 1941). Baxter et al. (1992) found that “anger/hostility” was higher in subjects at high risk for HD as determined by genetic markers and PET scans. Irritability can take different forms. One form is an overall increase in the patient’s baseline level of irritability punctuated by episodes of explosiveness. Irritable responses become exaggerated in intensity and duration. Patients develop a “short fuse” and are unable to tolerate a high degree of frustration. In another form, patients are not necessarily irritable in general, but they become agitated when they are unable to have their requests met immediately, no matter how inappropriate. These patients often perseverate relentlessly on a single desire or idea and become progressively more irritable when it is not indulged. Patients often will not report irritability in the clinic and when confronted will deny that they are irritable. Furthermore, spouses may be reluctant to report irritability in front of the patient out of fear. For this reason, informants should be interviewed separately.
80
Psychiatric Management in Neurological Disease
Apathy Patients can develop apathy at any time during the course of illness. Once present, it tends to persist or worsen. Performance at work or school becomes sluggish and can result in disciplinary actions. Like irritability, apathy can be thought of as a DSM-IV personality change due to a general medical condition. Apathy may coexist with irritability. Patients can sit around with little motivation to do anything except watch television but then become angry when someone tries to change the channel or asks them to take a bath or eat. Apathy can be a source of conflict when caregivers know that the patient is physically capable of activities but “won’t” do them. Consequently, the patient’s apathy may be inappropriately labeled as willful “laziness” rather than being seen as a symptom of a disease. The most important differential diagnosis for apathy is depression, especially in patients with alexithymia. Even though they appear to be experiencing intense emotional pain, alexithymic patients are unable to identify their emotional state and therefore do not complain that they are depressed. The apathetic patient should be asked not only about mood but also about other features of depression.
Psychosis Schizophrenia occurs in about 4% of patients with HD (Folstein et al. 1987). Patients presenting with hallucinations and delusions usually have coexisting depression, even if the delusions seem bizarre and mood incongruent. Patients who are delirious may also be hallucinating or delusional (see “Cognitive Impairment and Dementia” subsection above).
Mood Disorders Mood disorder is found in about 40% of patients with HD (Folstein et al. 1987). Although most of these patients suffer from major depression, about one-quarter of them (10% of HD patients overall) have bipolar disorder (manic-depressive illness). Depression, when present, frequently begins prior to the onset of the movement disorder (Folstein et al. 1987).
Huntington’s Disease
81
As with non-HD patients, depressed mood in HD patients can sometimes develop as an understandable reaction to life events such as diagnosis of HD, demoralization due to loss of self-esteem, loss of roles within and outside the family, loss of ability to work or care for one’s family, cessation of driving, or loss of bodily functions. However, these situational mood disturbances are usually short lived, do not meet diagnostic criteria for major affective disorder, and often respond to psychotherapeutic interventions. Patients with HD who have secondary major depression tend to have the same patterns of symptoms as those with idiopathic major depression, such as changes in self-attitude, feelings of worthlessness or guilt, self-blame, and changes in neurovegetative symptoms such as sleep and appetite. Delusions and hallucinations may occur and tend to be mood congruent (Ranen et al. 1993). The diagnosis of major depression may be difficult in patients with advanced disease. It helps to determine whether there has been a change in baseline mood, attitude, or level of functioning. For example, a patient with HD who suffers from moderate apathy and dementia may become completely withdrawn or unable to answer simple questions in the context of a superimposed depression. The suicide rate in patients with HD has been reported to be as high as 12.7% (Schoenfeld et al. 1984).
Anxiety Disorders The presentation of anxiety may range from generalized anxiety to panic disorder. There are many anxiety-provoking issues of concern to both at-risk and affected individuals; for example, engaging in “symptom searching” (i.e., constant concern over whether episodes of clumsiness are normal or actually represent disease onset). From early on in the illness, HD patients are prone to become anxious even about minor issues. Patients may worry for several days about what to wear to an event. Many HD patients are anxious about how their disease will progress, particularly if they remember their parent as having a difficult course. Panic disorder, although uncommon in HD, can be seen. The prevalence of anxiety disorders in HD has not been well studied.
82
Psychiatric Management in Neurological Disease
Obsessive-compulsive disorder. True obsessive-compulsive disorder (OCD) is uncommon in HD but has been reported (Cummings and Cunningham 1992). The exact prevalence is not known. The most common obsessions in HD patients are similar to those in other patients with OCD and relate to cleanliness or whether specific tasks have been carried out, such as having turned off the stove. Although not systematically studied, OCD appears to aggregate in certain HD families. More common than OCD is an obsessive preoccupation with particular ideas or requests (see “Irritability and Aggressiveness” subsection above). This latter behavior is more consistent with DSM-IV personality change due to a general medical condition than with OCD.
Sexual Disorders George Huntington, in his initial manuscript, wrote of two men with advancing disease who were “constantly making love to some young lady” and who, despite marked chorea, “never let an opportunity to flirt with a girl go past unimproved. The effect is ridiculous in the extreme” (Huntington 1872). Although most patients become uninterested in sexual contact (i.e., DSM-IV hypoactive sexual desire disorder due to a general medical condition) and male patients usually become impotent (i.e., male erectile dysfunction disorder due to a general medical condition), hypersexuality and paraphilias have been described by many investigators (Bolt 1970; Dewhurst et al. 1970; Watt and Seller 1993). Men may become aggressive toward their partners if their sexual demands are not met. The prevalence of sexual disorders in HD has not been well studied.
Neurological Management Treatment of Underlying Disease Progression Treatments aimed at retarding the underlying progression of HD have been largely unsuccessful in controlled clinical trials. Medications tested have included baclofen (Shoulson et al. 1989), an agent that attenuates glutamate neurotransmission, in part by inhibiting glutamate release, and idebenone (Ranen et al. 1996a), a benzo-
Huntington’s Disease
83
quinone antioxidant. d-alpha-Tocopherol (vitamin E) at 3,000 IU/day demonstrated no clear-cut benefit overall, although a post hoc analysis suggested a possible slowing of progression for early-stage HD patients (Peyser et al. 1995). Limitations of these clinical trials included small sample sizes that provided insufficient power to detect modest effects. Investigations into the utility of tissue transplantation are also under way. A protective effect of implanted encapsulated cells producing a neurotrophic factor (CNTF) in a monkey model of HD has been reported (Emerich et al. 1997).
Treatment of the Movement Disorder Neuroleptic medications such as haloperidol and fluphenazine are often used to treat chorea. However, these medications may exacerbate the disturbance of voluntary movement. Neuroleptics may contribute to increased morbidity by making patients more rigid, sedated, and apathetic. Therefore, nonpharmacological interventions should be considered first; for example, having the patient wear wrist weights while eating, thereby decreasing the amplitude of chorea. If pharmacological treatment is attempted, starting doses of neuroleptics, such as haloperidol and fluphenazine, should be low; for example, starting at 0.5–1.0 mg/day. Barr et al. (1988) found that haloperidol doses greater than 10 mg/day yielded little or no increased benefit over lower doses. Neuroleptic medication often has little or no effect on chorea in the later stages of the disease. A variety of medications have been used to manage rigidity, spasticity, and dystonia, but none with much success. An exception is botulinum toxin injections, which have been used with a fair degree of success for cervical dystonia in juvenile-onset HD.
Psychiatric Management Treatment of Cognitive Impairment and Dementia There are no specific treatments for the cognitive disorder in HD. Predictability, reduction of complexity of the environment, reduc-
84
Psychiatric Management in Neurological Disease
tion of the need for decision making, retirement, and providing cues can all be helpful. It is also important to reevaluate the medication regimen and stop all unnecessary medications, particularly those with sedating and/or anticholinergic properties.
Treatment of Irritability and Aggressiveness Underlying causes or triggers of the behavior should be identified if possible. Such factors include hunger, pain, inability to communicate, frustration with failing capabilities, boredom, difficult interpersonal relationships, and, in particular, minor unexpected changes in routine. Improvement in irritability can usually be seen if the patient is relieved of responsibilities, although this may be difficult to accomplish diplomatically and with preservation of the patient’s self-esteem. Often, symptoms of irritability will improve dramatically with retirement. Confrontations and ultimatums should be avoided as much as possible unless the issue is critical. Coping with an irritable patient can be difficult, and often family members will gain support from talking about these issues with other caregivers and family members. Lay organizations, such as the Huntington’s Disease Society of America (1-800-345-HDSA), coordinate local support groups. Other lay organizations include the Huntington Society of Canada (519-622-1002) and the International Huntington Association (315-733-1595). Where no Huntington’sspecific support group exists, caregivers for HD patients can still benefit from support groups for more prevalent dementing illnesses such as Alzheimer’s disease. Nonpharmacological interventions are not always effective in completely eliminating irritability, particularly in severe cases. Several medications have been used successfully. Selective serotonin reuptake inhibitors (SSRIs), particularly sertraline, have been demonstrated to be effective for irritability and severe, physically violent behavior (Ranen et al. 1996b). Prior to the use of the SSRIs, carbamazepine was the first-line agent for irritability. Both carbamazepine and divalproex sodium can be very helpful in the management of these patients. Clomipramine has been used in cases in which irritability seems to be tied to obsessions and perseveration on a particular topic. Clonazepam is occasionally effective at dosages
Huntington’s Disease
85
ranging from 0.5 mg to 4.0 mg/day (given in divided doses) in late-stage irritable and aggressive patients. Caution must be taken not to oversedate patients, which can predispose to aspiration. Benzodiazepines, including clonazepam, may also cause paradoxical disinhibition, but this seems to be uncommon in patients with HD. Some clinicians have found low-dose neuroleptics useful, although the same precautions regarding worsening of dysphagia and gait in treating patients with neuroleptics for chorea hold true for irritability (see “Treatment of the Movement Disorder” subsection above). Therefore, when antipsychotic agents are used to manage irritability, the newer atypical agents are preferable.
Treatment of Apathy Apathy not associated with depression tends to be unresponsive to medication therapy, even psychostimulant treatment. Although HD patients have difficulty initiating activities, they are often willing to help or participate if someone else suggests a project and works along with them to sustain energy and attention. Neuroleptics can cause or contribute to apathy and should be tapered if possible.
Treatment of Psychosis Psychoses presenting early in the course of disease tend to be more difficult to treat than late-onset psychotic features. Also, anecdotally, delusions tend to respond better than hallucinations to neuroleptic therapy (Ranen et al. 1993). Clozapine, because of its reduced extrapyramidal side effects, may be especially useful in HD (Bonucelli et al. 1994; Sajatovic et al. 1990). Risperidone and olanzapine may also be useful for this purpose. In cases of delirium presenting with psychotic features, lowdose, high-potency neuroleptics may be helpful in managing behavior while the underlying cause is being treated more definitively.
Treatment of Mood Disorders Treatment of bipolar disorder. HD patients may not need pharmacological treatment for their spells of elevated mood if these are brief and not associated with dangerous behavior. For those who re-
86
Psychiatric Management in Neurological Disease
quire treatment, lithium has been effective only rarely (Ranen et al. 1993). Furthermore, because patients with HD are vulnerable to dehydration, there is a greater risk for lithium toxicity. Carbamazepine has been the initial treatment of choice, but valproate has also been used for bipolar disorder. Again, neuroleptic medication or a benzodiazepine may be added to control disorganization or agitation in mania. Although there is less experience with electroconvulsive therapy (ECT) for mania than for depression in HD, it should nonetheless remain an option in refractory cases. Treatment of depression. Despite its high prevalence, depression in HD historically has been undertreated (Korenyi and Whittier 1967; Ringel et al. 1973). Major depression in HD responds to the same treatments used in idiopathic depression. Tricyclic antidepressants, particularly nortriptyline, and the SSRIs have traditionally represented the standard first-line agents for treatment of depression in patients with HD (Caine and Shoulson 1983; Ranen et al. 1993; Whittier et al. 1961). Sertraline has the added benefit of having been reported to successfully treat the irritability that often accompanies depression in HD patients (Ranen et al. 1996b). Although the greatest amount of clinical experience in HD patients has been with nortriptyline and the SSRIs, all of the marketed antidepressants are used, although, again, there are no systematic studies supporting their use. Some patients will respond to a monoamine oxidase inhibitor who have not responded to other agents (Ford 1986). Antipsychotic medication added to antidepressant medication is indicated for depression accompanied by delusions, hallucinations, or a high degree of agitation. If the goal is to also diminish chorea, a low-dose traditional antipsychotic agent could be used; otherwise, one of the newer atypical agents is preferable. Benzodiazepines such as clonazepam, or lorazepam if an intramuscular route is necessary, can be used in addition to or instead of neuroleptics, thus avoiding the risks of extrapyramidal reactions in patients who are very agitated. Neuroleptics and benzodiazepines should be tapered as soon as the clinical picture allows (Ranen et al. 1993). ECT is indicated for depressed patients who are refractory to treatment with medication, particularly patients who have delu-
Huntington’s Disease
87
sions, who are not eating or drinking because of their depression, or who are such a danger to themselves that immediate treatment is necessary. ECT is administered in the same way for depression in HD as it is for idiopathic affective disorder. As with idiopathic affective disorder, the presence of delusions seems to predict a favorable response (Ranen et al. 1994).
Treatment of Anxiety In addressing anxiety, as in addressing irritability, attempts should be made to decrease the complexity of the patient’s environment. Stopping a job that has become too difficult will usually result in a decline in symptoms. Assisting the caregiver in establishing a predictable routine for the patient is also helpful. Some caregivers find it useful to refrain from discussing any special events until the day before they occur. Patients should be assured that their symptoms will be followed carefully and that if any new ones arise, such as depression, they will be treated aggressively. Treatment of obsessive-compulsive disorder. Both clomipramine and the SSRIs have been effective in managing OCD in HD at doses similar to those used in idiopathic OCD.
Treatment of Sexual Disorders Successful treatments for sexual disorders have included oral medroxyprogesterone (Provera), parenteral medroxyprogesterone (Depo-Provera), and depot leuprolide (Lupron) (Rich and Ovsiew 1994).
Summary Patients with HD present with a triad of cognitive, noncognitive psychiatric, and movement disturbances. Although there are currently no treatments for the underlying course of HD, good symptomatic treatments are available, particularly for the psychiatric aspects of the disease.
88
Psychiatric Management in Neurological Disease
References Albin RL, Young AB, Penney JB: The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366–375, 1989 Alexander GE, DeLong MR, Strick PL: Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9:357–381, 1986 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994 Andrew SE, Goldberg YP, Kremer B, et al: Huntington disease without CAG expansion: phenocopies or errors in assignment? Am J Hum Genet 54:852–863, 1994 Aylward EH, Brandt J, Codori AM, et al: Reduced basal ganglia volume associated with the gene for Huntington’s disease in asymptomatic at-risk persons. Neurology 44:823–828, 1994 Barr AN, Fischer JH, Koller WC, et al: Serum haloperidol concentration and choreiform movements in Huntington’s disease. Neurology 38:84–88, 1988 Baxter LR, Mazziotta JC, Pahl JJ, et al: Psychiatric, genetic, and positron emission tomographic evaluation of persons at risk for Huntington’s disease. Arch Gen Psychiatry 49:148–154, 1992 Bolt JMW: Huntington’s chorea in the west of Scotland. Br J Psychiatry 116:259–270, 1970 Bonucelli U, Ceravolo R, Maremmani C, et al: Clozapine in Huntington’s chorea. Neurology 44:821–823, 1994 Brandt J: Cognitive investigations in Huntington’s disease, in Neuropsychological Explorations of Memory and Cognition: Essays in Honor of Nelson Butters. Edited by Cermak LS. New York, Plenum, 1994, pp 4135–4146 Brandt J, Strauss ME, Larus J, et al: Clinical correlates of dementia and disability in Huntington’s disease. J Clin Neuropsychol 6:401–412, 1984 Brandt J, Folstein SE, Folstein MF: Differential cognitive impairment in Alzheimer’s disease and Huntington’s disease. Ann Neurol 23:555–561, 1988 Brandt J, Quaid KA, Folstein SE, et al: Presymptomatic diagnosis of delayed onset disease with linked DNA markers: the experience in Huntington’s disease. JAMA 261:3108–3114, 1989 Brandt J, Corwin J, Krafft L: Is verbal recognition memory really different in Huntington’s and Alzheimer’s disease? J Clin Exp Neuropsychol 14: 773–784, 1992
Huntington’s Disease
89
Brandt J, Bylsma FW, Gross R, et al: Trinucleotide repeat length and clinical progression in Huntington’s disease. Neurology 46:527–531, 1996 Burns A, Folstein SE, Brandt J, et al: Clinical assessment of irritability, aggression, and apathy in Huntington and Alzheimer disease. J Nerv Ment Dis 178:20–26, 1990 Butters N, Wolfe J, Granholm E, et al: An assessment of verbal recall, recognition and fluency abilities in patients with Huntington’s disease. Cortex 22:11–32, 1986 Caine ED, Shoulson I: Psychiatric syndromes in Huntington’s disease. Am J Psychiatry 140:728–733, 1983 Cummings JL, Cunningham K: Obsessive-compulsive disorder in Huntington’s disease. Biol Psychiatry 31:263–270, 1992 Dewhurst K, Oliver JE, McKnight AL: Socio-psychiatric consequences of Huntington’s disease. Br J Psychiatry 116:255–258, 1970 Duyao M, Ambrose C, Myers R, et al: Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nat Genet 4:387–392, 1993 Emerich DF, Winn SR, Hantraye PM, et al: Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington’s disease. Nature 386:395–399, 1997 Folstein MF, Folstein SE, McHugh PR: “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198, 1975 Folstein SE: Huntington’s Disease: A Disorder of Families. Baltimore, MD, Johns Hopkins University Press, 1989 Folstein SE, Jensen B, Leigh RJ, et al: The measurement of abnormal movement: methods developed for Huntington’s disease. Neurobehav Toxicol Teratol 5:605–609, 1983 Folstein SE, Chase GA, Wahl WE, et al: Huntington disease in Maryland: clinical aspects of racial variation. Am J Hum Genet 41:168–179, 1987 Ford MF: Treatment of depression in Huntington’s disease with monoamine oxidase inhibitors. Br J Psychiatry 149:654–656, 1986 Gusella JF, Wexler NS, Conneally PM, et al: A polymorphic DNA marker genetically linked to Huntington’s disease. Nature 306:234–238, 1983 Harper PS: The epidemiology of Huntington’s disease. Hum Genet 89: 365–376, 1992 Huntington G: On chorea. Med Surg Rep 26:317–321, 1872 Huntington’s Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:917–983, 1993
90
Psychiatric Management in Neurological Disease
Huntington Study Group: The Unified Huntington’s Disease Rating Scale: reliability and consistency. Mov Disord 4:136–142, 1996 International Huntington Association and World Federation of Neurology Research Group on Huntington’s Chorea: Guidelines for the molecular genetics predictive test in Huntington’s disease. Neurology 44:1533– 1536, 1994 Kieburtz K, MacDonald M, Shih C, et al: Trinucleotide repeat length and progression of illness in Huntington’s disease. J Med Genet 31:872–874, 1994 Korenyi C, Whittier JR: Drug treatment in 117 cases of Huntington’s disease with special reference to fluphenazine (Prolixin). Psychiatr Q 41:203– 210, 1967 Kremer B, Goldberg P, Andrew SE, et al: A worldwide study of the Huntington’s disease mutation: the sensitivity and specificity of measuring CAG repeats. N Engl J Med 330:1401–1406, 1994 Li X-J, Li S-H, Sharp AH, et al: A Huntington-associated protein enriched in brain with implications for pathology. Nature 378:398–402, 1995 Mayberg HS, Starkstein SE, Peyser CE, et al: Paralimbic frontal lobe hypometabolism in depression associated with Huntington’s disease. Neurology 42:1791–1797, 1992 Mayeux R, Stern Y, Herman A, et al: Correlates of early disability in Huntington’s disease. Ann Neurol 20:727–731, 1986 McHugh PR, Folstein MF: Psychiatric syndromes of Huntington’s chorea: a clinical and phenomenological study, in Psychiatric Aspects of Neurologic Disease. Edited by Benson DF, Blumer D. New York, Grune & Stratton, 1975, pp 267–286 Mega MS, Cummings JL: Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 6:358–370, 1994 Penney JB Jr, Young AB, Shoulson I, et al: Huntington’s disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 5:93–99, 1990 Peyser CE, Folstein M, Chase GA, et al: Trial of d-alpha-tocopherol in Huntington’s disease. Am J Psychiatry 152:1771–1775, 1995 Ranen NG, Peyser CE, Folstein SE: A Physician’s Guide to the Management of Huntington’s Disease: Pharmacologic and Non-Pharmacologic Interventions. New York, Huntington’s Disease Society of America, 1993 Ranen NG, Peyser CE, Folstein SE: ECT as a treatment for depression in Huntington’s disease. J Neuropsychiatry Clin Neurosci 6:154–159, 1994
Huntington’s Disease
91
Ranen NG, Stine OC, Abbott MH, et al: Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. Am J Hum Genet 57:593–602, 1995 Ranen NG, Peyser CE, Coyle JT, et al: A controlled trial of idebenone in Huntington’s disease. Mov Disord 11:549–554, 1996a Ranen NG, Lipsey JR, Treisman G, et al: Sertraline in the treatment of severe aggressiveness in Huntington’s disease. J Neuropsychiatry Clin Neurosci 8:338–340, 1996b Ranen NG, Rosenblatt A, Ross CA: Differential diagnosis of Huntington’s disease. Poster abstract presented at the American Association of Geriatric Psychiatry 10th Annual Meeting, Orlando, FL, March 1997 Rich SS, Ovsiew F: Leuprolide acetate for exhibitionism in Huntington’s disease. Mov Disord 9:353–357, 1994 Ridley RM, Frith CD, Crow TJ, et al: Anticipation in Huntington’s disease is inherited through the male line but may originate in the female. J Med Genet 25:589–595, 1988 Ringel SP, Guthrie M, Klawans HL: Current treatment of Huntington’s chorea. Adv Neurol 1:797–801, 1973 Rosenbaum D: Psychosis with Huntington’s chorea. Psychiatr Q 15:93–99, 1941 Sajatovic M, Verbanac P, Ramirez LF, et al: Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington’s chorea. Neurology 41:156, 1990 Schoenfeld M, Myers RH, Cupples LA, et al: Increased rate of suicide among patients with Huntington’s disease. J Neurol Neurosurg Psychiatry 47:1283–1287, 1984 Shoulson I, Odoroff C, Oakes D, et al: A controlled trial of baclofen as protective therapy in early Huntington’s disease. Ann Neurol 25:252–259, 1989 Van Dijk JG, Van der Velde EA, Roos RA, et al: Juvenile Huntington disease. Hum Genet 73:235–293, 1986 Vonsattel JP, Myers RH, Stevens TJ, et al: Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 44:559–577, 1985 Watt DC, Seller A: A clinico-genetic study of psychiatric disorder in Huntington’s chorea. Psychol Med Suppl 23:1–46, 1993 Wexler NS: The Tiresias complex: Huntington’s disease as a paradigm for testing for late-onset disorders. FASEB J 6:2820–2825, 1992 Wexler NS, Young AB, Tranzi RE, et al: Homozygotes for Huntington’s disease. Nature 326:194–197, 1987
92
Psychiatric Management in Neurological Disease
Whittier J, Haydu G, Crawford J: Effect of imipramine (Tofranil) on depression and hyperkinesia in Huntington’s disease. Am J Psychiatry 118:79, 1961 Wiggins S, Whyte P, Huggins M, et al: The psychological consequences of predictive testing for Huntington’s disease. N Engl J Med 327:1401– 1405, 1992
C H A P T E R
4
Wilson’s Disease (Progressive Hepatolenticular Degeneration) Edward C. Lauterbach, M.D.
W
ilson’s disease (WD), an autosomal recessive disorder, is caused by copper deposition in the brain, liver, cornea, skeletal system, and, occasionally, other organs, such as the heart. The tendency toward cuprification of the liver and brain lenticular nucleus (putamen and globus pallidus) leads to the disorder’s alternative name, hepatolenticular degeneration. Specific treatments for WD exist in the form of decoppering agents. Although various aspects of the disease were described earlier, Wilson (1912) first linked liver cirrhosis with basal ganglia movement disorders, forming the modern conceptualization of this disease. Today, WD responds well to decoppering agents if detected early enough.
Prevalence WD occurs at a rate of approximately 1 per 40,000 births. The incidence is 12–30 cases per million population (mean of 20 per million) across the world. The somewhat higher prevalence of WD in Japan has been linked to greater consanguinity. The carrier frequency of the gene is about 1%. 93
94
Psychiatric Management in Neurological Disease
Clinical Recognition and Neurological Presentation While the potential manifestations of WD are legion, a rule of thirds applies, with approximately one-third of WD patients initially presenting with hepatic (hepatic WD), neurological (neurological WD), or psychiatric (psychiatric WD) symptomatology. The mean age at onset is 17 years (range: 5–35 years), and phenotypic presentations such as age at onset and initial manifestations sometimes vary between families. Disease progression varies but generally involves the liver initially (i.e., in childhood and adolescence) and the brain later (in the second to third decade of life). WD is divided into three stages: asymptomatic, early symptomatic (hepatic), and late symptomatic (extrahepatic). Prognosis depends on clinical manifestations once effective treatment is undertaken. Without treatment, patients can die within 5 years, but with treatment, they can live 20 years or longer. If left untreated, patients can die within 6 months after the onset of neurological signs. Liver manifestations are quite variable (Table 4–1). If hepatic WD is not treated, cirrhosis develops. Neurological manifestations (Tables 4–1 and 4–2) develop as the liver loses its ability to store copper. The frequency of neurological signs in 48 WD patients studied by Oder et al. (1991) is shown in Table 4–2. Symptoms begin with subtle abnormalities, including mild tremor, speech problems, and micrographia (small handwriting), that are usually accompanied by Kayser-Fleischer rings (see next paragraph), hypoceruloplasminemia, or thrombocytopenia (Brewer and Yuzbasiyan-Gurkan 1992). In one study that assessed 19 WD patients more than 10 years after the illness was first diagnosed, 17 (89%) of the patients had basal ganglia signs and 2 (11%) had oculomotor or cerebellar signs (Arendt et al. 1994). Dystonia and chorea are especially common in childhood-onset and end-stage WD (Walshe 1995). Seizures occur in 6% of WD patients, but remit with WD treatment in over 60% (Dening et al. 1988). Visual and sensory systems are curiously spared, despite observations of high copper concentrations in the sensory cortex. Without WD treatment, patients become dysarthric, bedridden, and unable to perform activities of daily living; develop flexion contractures; and die. Greater detail on liver manifestations
Wilson’s Disease
Table 4–1.
95
Hepatic and neurological manifestations in Wilson’s disease
Hepatic manifestations Primary Abnormal liver tests Hepatomegaly Acute hepatitis Chronic active hepatitis Chronic cirrhosis Secondary Portal hypertension Esophageal varices Hypersplenism Hepatorenal syndrome Jaundice Spider angiomata Palmar erythema Asterixis Hypoalbuminemia Ascites Hyperammonemia Hemolysis of cirrhosis Hepatic encephalopathy Reduced clotting factor synthesis Bleeding diatheses Gallstones Delayed puberty Amenorrhea Gonadal insufficiency Hyperpigmented skin
Neurological manifestations Oculomotor signs Cerebellar signs Ataxia Dysdiadochokinesia Other Dysarthria (dystonic, cerebellar, parkinsonian, or spastic types) Drooling Movement disorders Bradykinesia Parkinsonism Dystonia Dystonic arm posturing Risus sardonicus Chorea Tics Tremors Postural tremor Wing beating tremor Other Pyramidal tract signs Dysautonomia Seizures Pathological emotionality
Source. Brewer and Yuzbasiyan-Gurkan 1992a (hepatic manifestations); Arendt et al. 1994 and Oder et al. 1991 (neurological manifestations).
has been provided elsewhere (Hoogenraad 1996). Greenish-brown, muddy brown (Figure 4–1), or golden KayserFleischer (KF) rings resulting from copper deposition are best seen on slit-lamp ophthalmological exam but, when prominent, can also
96
Psychiatric Management in Neurological Disease
Table 4–2.
Frequency of neurological signs in Wilson’s disease patients (n = 45) No. Frequency, %
Neurological signs Dysdiadochokinesia Dysarthria Bradykinesia (in isolation) Postural tremor Parkinsonism Chorea/dystonia Ataxia Source.
27 25 23 17 14 8 3 1
60 56 51 38 31 18 7 2
Oder et al. 1991.
Figure 4–1. Kayser-Fleischer ring, most apparent at corneal junction with sclera. Source. Reproduced from Yanoff M, Fine BS: Ocular Pathology: A Color Atlas. Philadelphia, PA, JB Lippincott, 1988, p. 105. Copyright © 1988, Mosby International. Used with permission.
Wilson’s Disease
97
be seen with an ophthalmoscope near the junction of the cornea and the sclera. The rings initially appear superiorly and may be less apparent medially and laterally. In one study, 85% of patients with neurological WD manifested KF rings, in contrast to fewer than 15% of patients with hepatic WD (Oder et al. 1991). Sunflower cataracts can occur, and progressive lens and retinal changes vary with treatment. Some of the other less-prominent features of WD are listed in Table 4–3. Aside from the characteristics detailed in this table and the considerations mentioned below, no other clinically important interactions between WD and patient gender have been reported.
Pathological Features Pathology The physiological importance of copper is immense. Studies in rats indicate that copper is a potent releaser of catecholamines (Wang 1999) and a potent inhibitor of GABA-A receptors (Sharonova et al. 1998), possibly contributing to neuropathological or pathophysiological processes in WD. Copper is integral to cytochrome-c oxidase in the mitochondrial electron transport chain, catecholamine metabolism (tyrosine metabolism, dopamine beta-hydroxylase, and monoamine oxidase), melanin formation, collagen and elastin cross-linkage, and free radical deactivation (superoxide dismutase). Excessive copper accumulation can lead to cellular demise through a number of potential mechanisms. These include free radical–induced cellular oxidation, inhibited protein synthesis, inactivation of enzymes (in mitochondria, cytosol, and cell membrane), intracellular failure (of mitochondria, peroxisomes, microtubules, plasma membranes, enzymes, and DNA cross-linking), and induction of cellular injury, inflammation, and cell death due to unbound ionic copper (Hoogenraad and Van den Hamer 1996; Walshe 1995). Mitochondrial copper accumulation can produce premature oxidative aging and mitochondrial DNA mutations, further impairing cell function (Mansouri et al. 1997). A thorough review of normal copper metabolism can be found elsewhere (Hoogenraad and Van den Hamer 1996). Early hepatic intracellular fatty accumulations proceed to stea-
98
Table 4–3.
Psychiatric Management in Neurological Disease
Other nonpsychiatric features of Wilson’s disease
Renal Urolithiasis Hematuria Renal tubular dysfunction Hypokalemia Aminoaciduria Proteinuria Uricosuria Hypercalciuria Abnormal glucose tolerance Defective urinary acidification Fanconi syndrome Nephrolithiasis Hepatorenal syndrome Immunoglobulin A (IgA) glomerulonephritis Penicillamine immunoglobulin G (IgG) glomerulonephritis Musculoskeletal Osteoarthritis Osteomalacia Hypertrophic osteoarthropathy Chondrocalcinosis Arthralgias Stiffness of back, knee, hip, and wrist Rhabdomyolysis Muscle weakness of hypokalemia
Cardiac Cardiac interstitial fibrosis Myocarditis Cardiac arrhythmia Electrocardiogram (ECG) abnormalities Endocrinological Oligomenorrhea Amenorrhea Hyperglycemia Hypertestosteronemia Hyperestradiolemia Hypogonadism of cirrhosis Pancreatic disease Hypoparathyroidism Miscellaneous Orthostatic hypotension Skin abnormalities Cholelithiasis Dermatopathies Ruptured spleen Hemolysis
tosis in hepatic WD. Subsequently, inflammatory cellular infiltration (lymphocytes and histiocytes), collagen deposition, fibrosis, and necrosis ensue. Fibrosis progresses to nodular cirrhosis with cholestasis. Nodules can measure as large as 2 cm, and individual liver lobules vary in color (yellow, red, green, brown). Brain pathology in WD can include widespread copper deposi-
Wilson’s Disease
99
tion, gliosis, and astrocytic proliferation, especially in gray matter. Spongy necrosis, demyelination, and denervation may be evident in frontal, parietal, and occipital cortical areas. Macroscopically, ventricular dilatation, lenticular atrophy, yellowish or reddish-brown discoloration, softening, and spongy degeneration are seen. Cavitation is especially apparent in rapidly progressive juvenile dystonic forms of WD, whereas atrophy is more common in more slowly progressive adult forms. The pathology of hepatic encephalopathy is similar to WD pathology and is occasionally superimposed (Hoogenraad 1996). Liver failure can increase pallidal manganese concentrations.
Etiology and Genetics The ATP7B gene responsible for WD is located on band 14.1–21.1 of chromosome 13q14 (Nanji et al. 1997). The gene product is a copper-containing P-type adenosine triphosphatase (ATPase), important to the process of binding copper to apoceruloplasmin to form holoceruloplasmin. Holoceruloplasmin is integral to hepatobiliary copper excretion. In WD, however, apoceruloplasmin fails to bind copper (Kojimahara et al. 1995). Mutant forms of the ATPase in WD have difficulty migrating from the trans-Golgi network to cytoplasmic vesicles, where they would normally assist in binding excess copper to form holoceruloplasmin (Schaefer et al. 1999). Although WD patients have holoceruloplasmin in the liver, holoceruloplasmin is lacking in the biliary system (Chowrimootoo et al. 1997), reflecting impaired copper transport from hepatocytes to the biliary system. Biliary excretion normally accounts for 10% of daily copper loss (Hoogenraad and Van den Hamer 1996), and impaired biliary excretion soon leads to copper accumulation. WD differs from the other major abnormal P-type ATPase copper disease, X-linked Menkes’ disease. Menkes’ disease is caused by copper deficiency secondary to intestinal copper malabsorption resulting from mutations in the ATP7A gene. It leads to death in childhood (Walshe 1995). More than 100 mutations of the WD gene have been documented, some of which are associated with ethnicity, severity, age at onset, or presentation (Forbes and Cox 1998; Nanji et al. 1997; Walshe 1995). Highly dysfunctional mutations lead to early-onset,
100
Psychiatric Management in Neurological Disease
severe hepatic WD, whereas milder mutations lead to late-onset neurological WD (Houwen et al. 1995). A cytosine-to-adenine transversion may be responsible for 30% of North American WD cases (Hoogenraad and Houwen 1996). Animal models include the Bedlington terrier and the Long Evans Cinnamon rat. Recently, a strain of mice has been developed with a mutation of the ATP7B gene, resulting in the development of WD features in these mice (Buiakova et al. 1999).
Neuroimaging Increased putaminal signal (hyperintensity) due to copper deposition is usually present on magnetic resonance imaging (MRI) scan T2-weighted images (Figure 4–2). Increased T2 signal can also sometimes be seen in the thalamus, globus pallidus, caudate, cerebellum, subcortical white matter, midbrain, and pons. Although reduced T1 signal is common, increased pallidal T1 signal sometimes occurs and may correlate with hepatic demise (Saatci et al. 1997). MRI abnormalities occurred most frequently in the putamen and pons (present in 80%–90% of subjects) in two studies (King et al. 1996; Saatci et al. 1997), whereas pallidal abnormalities occurred in WD patients with portosystemic shunting in another study (van Wassenaer– van Hall et al. 1996). On computed tomography (CT), the most common findings are ventricular dilatation, basal ganglia hyperdensities, and atrophy of the cerebral cortex, brain stem, or cerebellum. Similar findings in other brain regions are sometimes seen. Basal ganglia MRI hypointensity and CT hypodensity are consistent with cavitation in more aggressive WD. On positron emission tomography (PET), glucose metabolism may be reduced in the cerebellum and striatum as well as in cortical and thalamic regions (Kuwert et al. 1992); reduced striatal glucose metabolism has been correlated with neurological severity (Schlaug et al. 1996). Dopamine D2 receptor binding on single-photon emission computed tomography (SPECT) imaging has correlated negatively with neurological severity (Oder et al. 1996; Schlaug et al. 1996).
Wilson’s Disease
101
Figure 4–2. Appearance of Wilson’s disease at two adjacent levels on T2-weighted magnetic resonance imaging (MRI). Note variegated increased signal in putamen and caudate heads due to copper deposition and reduced signal in globus pallidus. Source. Reproduced from Martin WRW, Snow B, Ashforth R: “Abnormalities of Movement and Posture Due to Disease of the Extrapyramidal Motor Systems,” in Neuroimaging: A Companion to Adams and Victor’s Principles of Neurology. Edited by Greenberg JO. New York, McGraw-Hill, 1995, pp. 5–24. Copyright © 1988, The McGraw-Hill Companies. Used with permission.
Clinical and Laboratory Investigation: Diagnosis Clinical suspicion is critical to diagnosing WD. The disease must be actively considered in the neuropsychiatric differential diagnosis in order to avoid missing the diagnosis. In a retrospective review of 136 cases of neurological WD, the diagnosis was missed in two-thirds of WD initial presentations, resulting in a 13-month delay in diagnosis (Walshe and Yealland 1992). In another series, two-thirds of patients with neurological WD exhibited psychiatric symptoms, but psychiatrists missed the diagnosis despite the uniform presence of KF rings (Brewer and Yuzbasiyan-Gurkan 1992). Clinicians must
102
Psychiatric Management in Neurological Disease
therefore remain vigilant for signs of WD, particularly because prompt detection is critical for successful treatment. Initial presentation with hepatic, neurological, or psychiatric symptoms, especially when accompanied by KF rings or a family history of WD, cirrhosis, or neurological disorder, warrants a diagnostic workup to exclude WD. Psychiatric features precede other symptoms in at least 20% of WD patients. In the remaining 80%, liver disease usually precedes other WD manifestations (Walshe 1995). Manifestations such as renal, endocrinological, hematological, cardiac, or joint disease may also elicit clinical suspicion. The diagnosis of WD is made by measuring blood ceruloplasmin and 24-hour urine copper levels. WD is confirmed by liver biopsy. Ceruloplasmin is reduced in 95% of cases, but it can also be normal or elevated, especially in early WD. Although urinary copper is usually elevated, 40% of presymptomatic homozygotes (i.e., future WD patients) have values lower than the 100 µg/day observed in typical WD patients (Lindahl and Sharp 1982). Hepatic needle biopsy disclosing copper is diagnostically definitive (although liver biopsy copper concentrations can vary in children) in early and end-stage WD (Hoogenraad 1996), and in different liver nodules (Faa et al. 1995). Although the finding of KF rings on slit-lamp exam supports the diagnosis, rings are usually absent when WD is confined to the liver (Akil and Brewer 1995). Serum copper levels are not of diagnostic utility. Once the diagnosis is established in a patient, definitive diagnoses in siblings can be made by DNA analysis (Roberts and Cox 1998) (see “Family Considerations and Genetic Testing” under “Neurological and Psychiatric Management” section later in chapter). Laboratory test values are summarized in Table 4–4 and are reviewed in detail elsewhere (Brewer and Yuzbasiyan-Gurkan 1992). Values vary somewhat among laboratories. Presymptomatic WD homozygotes generally exhibit low concentrations of ceruloplasmin, normal to high concentrations of urinary copper, and high concentrations of liver copper. The differential diagnosis of WD as it relates to disease signs and laboratory manifestations is summarized in Table 4–5. Although other diseases are associated with excessive copper accumulation, only WD results in copper deposition in the brain (Walshe 1995). False negatives and false positives can occur, as with all tests.
Laboratory investigation of Wilson’s disease
Test
Normal
Wilson’s disease
Heterozygous carriers
Ceruloplasmin 24-hour urinary copper Hepatic copper
20–35 mg/d 20–50 µg/d 20–50 µg/g
0–10 mg/d 100 µg/d 200 µg/g
0–35 mg/d 20–75 µg/d 20–150 µg/g
Wilson’s Disease
Table 4–4.
Note. Values for normal control subjects, homozygous Wilson’s disease patients, and asymptomatic carriers. mg/d = milligrams per day; µg/d = micrograms per day; µg/g = micrograms per gram of dry liver tissue.
103
104
Psychiatric Management in Neurological Disease
Table 4–5.
Differential diagnosis of Wilson’s disease
Heritable liver disorders Wilson’s disease Hemochromatosis Alpha-1 antiprotease (antitrypsin) deficiency Cystic fibrosis Excessive copper accumulation Wilson’s disease Primary biliary cirrhosis Indian childhood cirrhosis Non-Indian childhood cirrhosis Severe familial intrahepatic cholestasis Prolonged biliary obstruction Hypoceruloplasminemia Wilson’s disease homozygotes (patients) 10% of heterozygous Wilson’s disease carriers Normal infants up to age 6 years 1% of normal adults Menkes’ syndrome Hereditary hypoceruloplasminemias Copper deficiency High urinary copper levels Wilson’s disease Copper storage diseases other than Wilson’s Severe proteinuria Obstructive liver disease Primary biliary cirrhosis Cholestasis Indian childhood cirrhosis Non-Indian childhood cirrhosis High hepatic copper levels and high urinary copper levels Wilson’s disease Obstructive liver disease (see “High urinary copper levels” above for details) Kayser-Fleischer rings Wilson’s disease Obstructive liver disease (see “High urinary copper levels” above for details) Source.
Hoogenraad 1996; Kumar and Riely 1995; Walshe 1995.
Wilson’s Disease
105
Moreover, in hepatic WD, one-third of patients lack KF rings, abnormal ceruloplasmin, and urinary copper (Steindl et al. 1997). In ambiguous cases, DNA marker analysis can be helpful (see “Family Considerations and Genetic Testing” under “Neurological and Psychiatric Management” section later in chapter). DNA analysis can distinguish between homozygous WD patients and heterozygous WD carriers (Gaffney et al. 1992). Western blot analysis of ceruloplasmin has successfully distinguished WD homozygotes, WD heterozygotes, and non-WD hypoceruloplasminemic patients (Chowrimootoo et al. 1997). Although prenatal diagnosis is now possible, there is no reason to undertake this, given the excellent prognosis of well-treated presymptomatic homozygotes (Hoogenraad 1996). Although the biliary isoform of ceruloplasmin is reduced in neonates, reductions in the plasma isoform of ceruloplasmin in cord blood can assist in the neonatal diagnosis of WD (Chowrimootoo et al. 1998). Other tests are supportive but not diagnostic of WD. Putaminal abnormalities on MRI T2 images can suggest WD (see “Neuroimaging” section above). Although the neurological exam is more diagnostically sensitive than CT imaging (Roach et al. 1985), basal ganglia hypodensities on CT can also suggest the diagnosis of WD. Additional tests of suggestive or supportive diagnostic value include elevated serum transaminases, reduced serum alkaline phosphatase, slowing or epileptiform activity on electroencephalogram (EEG), abnormal auditory evoked responses (peaks I–IV), reduced striatal D2 receptor binding or basal ganglia hypometabolism on SPECT, and reductions in striatal, cerebellar, cortical, or thalamic glucose metabolism on PET (Kuwert et al. 1992). An abnormal 65Cu test (see Lyon et al. 1995 for a description of this test) at 72 hours is also supportive of a diagnosis of WD (Merli et al. 1998).
Psychiatric Manifestations Psychiatric symptoms are evident at initial presentation in between one-third and two-thirds of patients (including those with neurological WD), and psychiatric symptoms occur in isolation in about 20% (Akil and Brewer 1995; Dening and Berrios 1989a; Schwartz et al. 1993). Half of patients undergo psychiatric hospitalization before
106
Psychiatric Management of Neurological Diseases
WD is recognized (Akil et al. 1991; Rathbun 1996). Because improvement in WD depends on treatment within the first 5 years of disease onset, clinical vigilance and early diagnosis is critical. Cognitive, mood, and personality disturbances dominate psychiatric presentations (Table 4–6). Wilson observed prominent psychiatric symptoms in his patients, including silliness, euphoria, sexual preoccupation, hebephrenia, catatonia, occasional hallucinations, “hysterical” behavior, and “narrowing of mental horizons.” He concluded that “facility, docility, childishness, and emotional overaction form the chief features of the more chronic cases” (Wilson 1912). Among 129 WD patients examined in one study, the most common psychiatric symptoms were incongruous behavior, irritability, depression, and cognitive impairment (Dening and Berrios 1990). Akil and Brewer (1995) observed that personality disturbances, depression, and academic or employment failure were the most common psychiatric presentations. Thus, WD can profoundly affect intellectual, emotional, and behavioral aspects of the patient’s life. Table 4–6.
Frequency of psychiatric manifestations in Wilson’s disease Frequency, %
Psychiatric presentation frequencies across studies Pure psychiatric initial presentation Predominantly psychiatric initial presentation Psychiatric features present on initial presentation Psychiatric features present during illness course
20 33 33–67 50–100
Psychiatric feature frequencies across studies Any psychiatric features Depression Suicidality Irritability/aggression Elation Cognitive impairment Delusions Hepatocerebral syndrome and catatonia
65 27 4 46 13 <24 1–7 Rare
Source. Data approximated from Akil and Brewer 1995; Akil et al. 1991; Brewer and Yuzbasiyan-Gurkan 1992a; Dening and Berrios 1989a, 1989b; Oder et al. 1991; Scheinberg and Sternlieb 1984; Schwartz et al. 1993; Walshe 1995.
Wilson’s Disease
107
Two-thirds of Wilson’s original 12 patients had “psychical” abnormalities (Wilson 1912). Point prevalences of psychiatric disorders in WD range as high as 100%, but 50% may represent a better estimate (Dening and Berrios 1989a). Lifetime prevalences of cognitive impairment, psychosis, mood and anxiety disorders, impulsivity, and personality disturbances may, together, approach 100% (Scheinberg and Sternlieb 1984). In a retrospective review of 42 WD patients undergoing zinc treatment, irritable and aggressive personality disturbances occurred in 17 (45.9%) of the 37 symptomatic patients, whereas cognitive changes, anxiety, psychosis, and catatonia were less common (Akil et al. 1991). Of 24 neurological WD patients assessed in one study, 17 (71%) had various personality changes, 10 (42%) depression, 4 (17%) cognitive changes, 3 (13%) anxiety, 2 (8%) psychosis, 2 (8%) catatonia, and 5 (21%) other psychiatric presentations (Brewer and Yuzbasiyan-Gurkan 1992). Specific psychiatric disturbances are discussed in the following subsections. Psychiatric manifestations (Akil and Brewer 1995; Dening and Berrios 1989a) and neuropsychological impairment (Lang et al. 1990) usually occur with neurological rather than hepatic disease.
Cognitive Impairment Patients should be scrutinized for DSM-IV (American Psychiatric Association 1994) amnestic disorder due to Wilson’s disease and for cognitive disorder not otherwise specified. The rate of cognitive impairment varies, but overall, such impairment occurs in less than 25% of WD patients (Lauterbach et al. 1998). Impairment increases with disease duration (Knehr and Bearn 1956). In a study of 19 patients with neurological WD (Medalia et al. 1988), patients scored lower on the Full Scale IQ, Dementia Rating Scale, and Wechsler Memory Scale than did either 15 normal control subjects or 12 WD patients without neurological WD. Slowing on time-dependent psychometric tests increases with neurological WD severity (Arendt et al. 1994), but this may result from slowed motor speed rather than from reduced information-processing speed (Littman et al. 1995). Cognitive impairment also attends occasional hepatic encephalopathies (Tarter et al. 1987). Cognitive function, memory, and IQ can improve with treatment (references cited in Lauterbach et al. 1998).
108
Psychiatric Management in Neurological Disease
Pathological Affect Emotional lability with forced laughter and crying may occur in WD (see Chapter 1 for treatment approaches).
Behavioral and Personality Changes Among WD patients with significant psychiatric disturbances, the majority have antisocial or impulse-control features. Nearly half of WD patients manifest personality changes, including impulsivity, aggression, disinhibition, recklessness, emotionality, irritability, anger, bizarre and odd behavior, and other less easily definable presentations (references cited in Lauterbach et al. 1998). These presentations correspond to DSM-IV personality change due to Wilson’s disease, including disinhibited, labile, and aggressive types. In 42 patients treated with zinc, Akil et al. (1991) found that 37 were symptomatic; of these, 17 (45.9%) had irritable or aggressive personality disturbances. These personality features can lead to marital troubles and occasional criminality. Irritability, incongruous behavior, and personality disturbances are associated with brain-stem signs and dystonia but not with tremor (Dening and Berrios 1989a). Personality syndromes also correlate with dyskinesia, dysarthria, and putaminal and pallidal lesions (Oder et al. 1993). Psychopathic personality features, in particular, correlate with dysarthria (Dening and Berrios 1989b). Incongruous, disinhibited, aggressive, hyperactive, and hypersexual behaviors have improved with treatment of WD, but irritability has not (Akil and Brewer 1995; Dening and Berrios 1990).
Functional Decline A common problem in WD is deterioration in work or academic performance (Akil and Brewer 1995). Such deterioration can lead patients to drop out of school or to quit or be fired from their jobs, more as a result of attentional deficits than of intellectual impairments or personality disturbances (Akil and Brewer 1995). Diminished functional capacity correlates with ataxia, tremor, and focal thalamic lesions (Oder et al. 1993). Occasionally, WD is mistaken for a psychiatric diagnosis.
Wilson’s Disease
109
Walshe and Munro (1995) reported the case of a 17-year-old with intractable vomiting who was misdiagnosed with anorexia nervosa for 9 years. In reality, the patient was suffering from gastrointestinal manifestations of WD.
Psychosis Psychosis can be the presenting sign of WD—hence the clinical admonition to exclude WD in first-onset psychosis. Although early studies suggested an association of psychosis and WD related to basal ganglia pathology (Slater and Cowie 1971), later studies indicated that schizophreniform disorders, catatonia, and hallucinations are not increased in WD (Dening and Berrios 1989a; Oder et al. 1991). Delusions occurred in 3 (7%) of 45 WD patients in a prospective study by Oder et al. (1991). In a study of 24 patients with neurological WD, psychosis and catatonia each occurred in 2 (8%) (Brewer and Yuzbasiyan-Gurkan 1992). Psychotic features occasionally reverse with WD treatment, and incongruous behavior can improve over the disease course (Dening and Berrios 1990). Great care is necessary when using antipsychotics in patients with neurological WD (see “Psychotropic Treatment” under “Neurological and Psychiatric Management” section later in chapter). Occasionally, reversible psychosis is precipitated after commencing WD treatment (McDonald and Lake 1995). Although this treatment complication would likely be diagnosed in DSM-IV as a psychotic disorder due to a general medical condition, the exact diagnoses corresponding to psychotic features observed in WD have not yet been determined.
Mood Disorders Mania WD affects brain structures associated with mania, including the striatum, thalamus, and cerebellum (see Chapter 7 in this volume). Elation occurs in about 13% of WD patients across studies (Akil et al. 1991; Dening and Berrios 1989a; Oder et al. 1991). Although manic presentations have been observed ever since Wilson’s original report (1912), the prevalences of such presentations have yet to be determined. In conducting future epidemiological studies, it will be im-
110
Psychiatric Management in Neurological Disease
portant to distinguish the various DSM-IV bipolar disorders and mood disorder due to Wilson’s disease with manic features, because WD personality changes can also resemble mania (see “Behavioral and Personality Changes” subsection above). Whereas irritability tends not to respond to WD treatment (Dening and Berrios 1990), hypersexuality, hyperactivity, and aggression occasionally improve with such intervention (Akil and Brewer 1995). Depression Depressive illness occurs in about 30% (Akil et al. 1991; Dening and Berrios 1989a, 1989b; Oder et al. 1991) or more of WD patients (Akil and Brewer 1995). In a prospective study of 45 patients with WD, 12 (27%) had mood disorders consistent with major depression; in all of these subjects, the major depression was attended by the features of neurological WD (Oder et al. 1991). Some depressive symptoms correlate with hepatic dysfunction (Dening and Berrios 1989b). Depression may evolve over the disease course, eventually occurring in perhaps all WD patients (Arendt et al. 1994) and coexisting with (Oder et al. 1993) or without (Arendt et al. 1994) cognitive impairment. In a follow-up study of 129 WD patients, neither depression nor irritability improved with WD treatment, especially in patients with neurological and hepatic WD (Dening and Berrios 1990). Nevertheless, some case reports indicate that depression can improve with treatment. Major depression in WD can be associated with delusions, suicide attempts, and personality disturbances. Across studies, suicidal behavior is observed in 4%–16% of patients (references cited in Lauterbach et al. 1998). Disinhibited, impulsive, and aggressive WD personality changes may compound the risk of suicide. Consequently, depressed WD patients should be thoroughly evaluated for suicide potential. Mild depression correlates with cognitive impairment, parkinsonian rigidity, bradykinesia, and third-ventricle dilatation (Oder et al. 1993) as well as with gait disorders (Dening and Berrios 1989b). Mood disturbances have not been found to correlate with evoked potential abnormalities (Arendt et al. 1994). Whether depression is a psychological reaction to illness or a biological event is unresolved
Wilson’s Disease
111
(Akil and Brewer 1995), but both mechanisms probably apply to varying degrees in individual patients. Consequently, as for psychoses and mania, it is unclear what percentage of depressive disorders in WD represent DSM-IV mood disorders due to WD. Future studies using diagnostic criteria will be useful in separating out adjustment disorders from major depression and dysthymia.
Anxiety Disorders Although several reports have identified anxiety in WD subjects (Akil and Brewer 1995; Akil et al. 1991; Loiseau and Demangeat 1956), the prevalence, clinical and pathological correlates, psychosocial determinants, and treatment of specific anxiety disorders in WD remain to be determined.
Impulse Control Disorders In one study of 124 WD patients, 6 (4.8%) displayed increased sexual preoccupation and reduced sexual inhibition (Akil and Brewer 1995). Sexual behaviors included exhibitionism and promiscuity. Hypersexual, disinhibited, aggressive, and hyperactive behavior can improve with treatment of WD (Akil and Brewer 1995; Dening and Berrios 1990). Impulsive behavior was discussed earlier in this chapter (see “Behavioral and Personality Changes” subsection above). The types, prevalences, clinical and pathological correlates, psychosocial determinants, and treatment of impulse control disorders in WD need elucidation.
Substance Abuse Disorders Reports of substance abuse in WD patients have been published (Akil et al. 1991; Hawkins et al. 1987; Lhermitte and Muncie 1980). Personality disturbances and mood disorders may pose special risk, but prevalences, correlates, determinants, and special treatment issues associated with substance abuse in WD are unknown. Further work is needed to delineate substance abuse disorders in WD patients.
112
Psychiatric Management in Neurological Disease
Neurological and Psychiatric Management Three aspects of treatment merit discussion: 1) psychotherapeutic considerations, 2) treatment of the underlying neurological disease, and 3) treatment of psychiatric manifestations.
Psychotherapeutic Considerations Clinicians should attempt to provide psychological support to patients, and help them to grieve and adapt to the illness. Patients should be assisted in the process of working through the issues of disease acceptance. They should be encouraged to maintain their daily routines to the extent possible. Denial of illness and noncompliance with treatment may be particular problems in younger patients or those with behavioral disinhibition. Poor insight into both the illness and its consequences is another issue that complicates treatment. Practical aspects of coping with the disease and with the limitations of lifestyle imposed by its attendant disabilities and its treatment should be addressed. Hope can be offered with treatment, but it is important to guard against unrealistic expectations. Enlisting the patient’s support system may be helpful for adaptation and adjustment to the illness, as well as for monitoring compliance to the treatment regimen. Vigilance for suicide is important in those who are depressed. Evaluation of depression is particularly indicated for those with parkinsonism or gait disturbance. Conventional psychotherapeutic strategies should be employed as indicated for the specific psychiatric disorders identified in the individual patient. Support groups can also be very helpful, providing camaraderie and education for the patient and family. Such groups reduce fear of the unknown about the disease, provide practical tactics useful for coping with WD, and can also help patients gain a sense of mastery over the illness by allowing them to actively do something about the disease rather than feel like its passive victim. Support groups provide a forum wherein the patient can confront the illness, grieve it, and come to terms with it. Some patients derive added benefit from organizing these groups or serving in leadership positions. Although WD is an uncommon illness, referral can be made to support groups for Parkinson’s disease, dystonia, or stroke, depending on the patient’s neurological features. Further information on support
Wilson’s Disease
113
groups and informational resources for patients and their families can be obtained by contacting the Wilson’s Disease Association (P.O. Box 75324, Washington, DC 20012-5324) or the National Center for the Study of Wilson’s Disease (432 West 58th Street, Suite 614, New York, NY 10019, phone 212-523-8717, fax 212-523-8708).
Treatment of the Underlying Neurological Disease First-Line Treatments The introduction of functional ATP7B protein by recombinant adenovirus-mediated gene delivery holds promise as a future treatment of Wilson’s disease (Terada et al. 1998). However, at present, treatment options are limited to agents that reduce the level of toxic copper in the body. First-line agents for treating WD include Dpenicillamine, zinc, trientine, and tetrathiomolybdate. Early recognition and treatment of WD is paramount, because improvement with treatment is usually limited to the first 5 years of symptomatic illness and the first 2 years of treatment (Akil and Brewer 1995; Dening and Berrios 1990). Improvement generally occurs only after the first 6 months of treatment. Both psychiatric and other manifestations can improve with WD treatment. Gastroenterological, neurological, or other consultation is advisable, depending on disease manifestations. WD treatments include copper chelating agents that increase urinary copper excretion (e.g., penicillamine and trientine) and copper depleting agents (zinc and thiomolybdate). Specific indications for the various drugs are controversial (e.g., LeWitt 1999). Some experts recommend using penicillamine and switching to trientine followed by dimercaprol in the event of side effects or lack of efficacy. Brewer (1995a) has outlined indications for the use of these agents. A combination of trientine and zinc is advised for patients with mild liver failure. Zinc is recommended for maintenance therapy, presymptomatic treatment, and treatment during pregnancy. Tetrathiomolybdate may be the treatment of choice for neurological disease because it infrequently causes neurological exacerbations (Brewer and Yuzbasiyan-Gurkan 1992). Zinc monotherapy is suboptimal for the initial treatment of neurological WD, because improvement occurs too slowly.
114
Psychiatric Management in Neurological Disease
Recent reports suggest the utility of plasma exchange and peritoneal dialysis in fulminant WD and hemolytic anemia, but these are rarely necessary and may foster neurological exacerbations. Penicillamine. Walshe introduced D-penicillamine (Cuprimine, Depen) in 1956, and for many years it remained the drug of first choice for the treatment of WD. Because of its many side effects, the drug is gradually titrated upward to 8.3 mg/kg tid (250 mg qid to 500 mg tid in adults) over several weeks. It is given at least 30 minutes before meals and no sooner than 2 hours after meals. Pyridoxine 25 mg/day is coadministered to prevent penicillamine-induced deficiency. Copper–penicillamine complexes are excreted in the urine, resulting in an initially large cupruresis of several milligrams per day that declines to 0.5 mg/day after several months (Brewer and Yuzbasiyan-Gurkan 1992). Baseline complete blood counts and renal function tests should be obtained before commencing treatment, because both WD and penicillamine can produce leukopenia and thrombocytopenia. If either of these conditions is present, the initial dose should be smaller and more gradually titrated. The majority of WD patients treated with penicillamine make an excellent recovery in hepatic, neurological, and psychiatric function and can return to gainful employment (Walshe 1986a). Of 137 WD patients undergoing chelation in one study, 57 (42%) became asymptomatic, another 36 (26%) experienced significant neurological improvement, and only 24 (18%) failed to recover function (Walshe and Yealland 1993). Penicillamine treatment leads to regression of copper depositions in the brain seen on T2-weighted MRI imaging and improvement in D2 dopamine receptor binding (Schwarz et al. 1994). Improved motor function after penicillamine therapy correlates with increased cerebral glucose metabolism and dopamine receptor binding (Schlaug et al. 1994). Adverse side effects occur in 10%–30% of patients, and 10% of patients are unable to tolerate long-term penicillamine therapy (Saito et al. 1991). Major side effects are summarized in Table 4–7. Gastrointestinal upset is common. Switching to zinc (Barbosa et al. 1992), dimercaprol, or trientine (Castellano et al. 1992) has been useful in the event of D-penicillamine–induced renal exacerbations. The two most important side effects of penicillamine therapy are
Wilson’s Disease
Table 4–7.
115
Side effects of penicillamine
Gastrointestinal conditions Anorexia Nausea Vomiting Pyridoxine deficiency Lysyl oxidase inhibition Dermatological conditions Collagen-elastin damage Cutis laxa Dermal atrophy, wrinkling, and bleeding Elastosis performans serpiginosa Aphthous stomatitis Gingival hyperplasia Conjunctival inflammation Follicular conjunctivitis Penicillamine dermatopathy Pemphigus Lichen planus Pseudoxanthoma elasticum Abnormal collagen development Abnormal wound healing Pleural effusion Fever Lymphadenopathy Rash
Immunologically induced conditions Goodpasture’s syndrome Systemic lupus erythematosus Rash Immune complex nephritis Fatality Polyarthritis Myasthenia gravis Optic neuritis Nephrotic syndrome Proteinuria Hypersensitivity Urticaria Urticaria with hematuria Immunoglobulin A (IgA) deficiency Endocrinological conditions Hirsutism Mastodynia Hematological conditions Pancytopenia Bone marrow depression Aplastic anemia Retinal hemorrhages Acute polyarthritis
Source. Brewer and Yuzbasiyan-Gurkan 1992; Hoogenraad 1996; Karkos 1996; Katz 1967; Walshe 1986a.
hypersensitivities (in 30% of patients) and neurological exacerbations (Brewer and Yuzbasiyan-Gurkan 1992). Both can lead to death. Among immune reactions, urticaria is the most common, and only immune nephritis responds to drug withdrawal. Therefore, brief courses of an antihistamine or prednisolone are sometimes necessary before resuming a lower dose of penicillamine, with more gradual dose titration (Walshe 1986a).
116
Psychiatric Management in Neurological Disease
Even with gradual titration, a serious concern with this drug is initial exacerbation of neurological symptoms in up to 21% of WD patients (Walshe and Yealland 1993) and in about 50% of patients with neurological WD (Brewer and Yuzbasiyan-Gurkan 1992). Neurological exacerbations have included seizures, movement disorders, neuropsychiatric disturbances, and, sometimes, irreversible neurological disability (Brewer et al. 1994c). Neurological exacerbations can occur in patients free of neurological manifestations. Possible psychiatric exacerbations (new onset of psychosis) may also occur (McDonald and Lake 1995). Switching to zinc (Huang and Chu 1996) or continuing treatment with penicillamine (McDonald and Lake 1995) has sometimes led to resolution. In the latter case, the established procedure is to discontinue penicillamine for 1 week and then resume treatment at a lower dose. To monitor penicillamine treatment, some authorities recommend following serial plasma free copper (see “Zinc,” below), maintaining levels below 10 µg/dL and measuring ceruloplasmin levels every 6 weeks for the first year and annually thereafter. Zinc. Indications for zinc include maintenance therapy, initial treatment in presymptomatic patients, and treatment of pregnant patients (Brewer 1995b). Zinc is administered as zinc acetate (50 mg po tid) or zinc sulfate (300 mg po tid) as far between meals as possible (at least 1 hour before or after meals) (Brewer et al. 1990; Hoogenraad 1996). Lower doses are insufficient for effective treatment of WD (Brewer 1995b), and higher doses may be required in some patients. Zinc induces the production of intestinal and hepatic metallothionein (Sturniolo et al. 1999), thereby reducing intestinal absorption of copper and binding circulating copper to a nontoxic pool in the liver (Brewer 1995b; Brewer et al. 1994b). Side effects of zinc include nausea, epigastric pain, occasional vomiting, and the potential for sideroblastic anemia (Walshe 1995). Zinc acetate (Galzin) is better tolerated by the stomach than is zinc sulfate (Brewer et al. 1990). Tolerance to gastrointestinal irritation develops within a few weeks of commencing treatment, and morning nausea can be avoided by giving the first dose of the day between breakfast and lunch. If food must be taken with zinc to reduce irritation, meat is associated with the least reduction in zinc absorp-
Wilson’s Disease
117
tion (Brewer et al. 1990). Hemolysis, dermatitis, mild serum amylase elevation, and reductions in high-density lipoprotein cholesterol have been reported with zinc therapy (Hoogenraad 1996). Although some authorities recommend zinc as the initial treatment in neurological WD (Bona et al. 1993), fatal neurological deterioration can occur (Lang et al. 1993). Improvement in the neurological exam as well as on MRI has been documented with zinc treatment (Heckmann et al. 1994). Neurological exacerbations occurring during zinc therapy have been effectively treated by combining penicillamine with dimercaprol and a zero-copper diet (Walshe and Munro 1995). Zinc’s effect on copper balance takes at least 3 weeks to become evident on laboratory testing. Treatment compliance is critical, because patients who discontinue therapy develop serious medical conditions or can even die within several months (Brewer 1995b). Compliance and copper balance can be monitored by means of the oral 64Cu uptake test, urinary copper and zinc levels, and plasma free copper concentrations. In patients who are compliant with their zinc regimens, the peak blood concentration 1–2 hours after 64Cu ingestion is reduced to an average of 1.2% of the administered dose; in patients who are noncompliant, however, the peak blood concentration increases back up toward 6% of the administered dose (as in untreated WD) and reduces when they again become compliant. The desired values are ≤125 µg/24 hours for urinary copper and ≥2 mg/24 hours for urinary zinc in WD patients taking zinc (Brewer et al. 1990). Plasma free copper should be kept at ≤25 µg/dL. Plasma free copper (i.e., copper not bound to ceruloplasmin) can be determined by measuring plasma copper and ceruloplasmin levels and subtracting 3 µg of copper for each milligram of ceruloplasmin from the total plasma copper value. An increase suggests noncompliance. Percutaneous liver biopsies may reveal increased copper over the first 3 years of zinc treatment, but liver copper levels eventually return to normal with continued treatment (Brewer et al. 1990). Trientine. Trientine (triethylene tetramine dihydrochloride; Syprine) is usually given as 600 mg tid between meals (not sooner than 30 minutes before meals and 2 hours after meals), with reduction in dose to 600 mg/day once evidence of treatment response is seen
118
Psychiatric Management in Neurological Disease
(Brewer and Yuzbasiyan-Gurkan 1992; Walshe 1986a). Trientine reduces gastrointestinal copper absorption and increases urinary copper excretion (Siegemund et al. 1991). Both transient (Saito et al. 1991) and irreversible (Dahlman et al. 1995) neurological exacerbations have occurred with trientine therapy, suggesting that dosages should be titrated upward very gradually. Although side effects are minimal, iron deficiency, sideroblastic anemia, hepatic adenocarcinoma, colitis, and duodenitis have been associated with trientine (Dahlman et al. 1995), and it is expensive (Walshe 1995). Tetrathiomolybdate. Tetrathiomolybdate combines with copper to form a tripartite complex with protein, reducing intestinal copper absorption and inactivating circulating copper (Brewer 1995b). Ammonium tetrathiomolybdate is used as an initial treatment in neurological presentations because it infrequently causes neurological exacerbations and produces more rapid improvement than does zinc (Brewer 1995b). Most patients make good to excellent neurological recovery (Brewer et al. 1996). Tetrathiomolybdate is given both with meals (to prevent absorption) and between meals (to complex plasma copper). The drug is begun at 20 mg tid with meals, with the between-meal dose escalated over 1 week (usually to 20–60 mg tid between meals) until all non– ceruloplasmin-bound plasma free copper is complexed (see “Zinc,” above, for explanation of plasma free copper). After 8 weeks of treatment, maintenance zinc therapy is begun, and tetrathiomolybdate is discontinued 2 weeks later (Brewer 1995b). Alternatively, the drug can be chronically administered at 40 mg bid, although it is no more effective than zinc when given this way and is not considered useful in hepatic WD (Hoogenraad 1996). However, long-term maintenance therapy is useful in patients refractory to other treatments (Walshe 1995). Because tetrathiomolybdate can cause epiphyseal plate destruction, its use is generally contraindicated in children (Walshe 1995); if absolutely necessary, however, the total daily dose is usually ≥2.9 mg/kg (Brewer and Yuzbasiyan- Gurkan 1992). In addition to requiring special synthesis for clinical use in individual patients, tetrathiomolybdate is unstable, requiring storage under argon gas to prevent deterioration (Brewer et al. 1994a). Other
Wilson’s Disease
119
drawbacks include bone marrow suppression and intestinal lesions, which have been reported in a few patients (Harper and Walshe 1986; Hoogenraad 1996). The drug is not yet available in the United States and is currently under U.S. Food and Drug Administration (FDA) review. Other Treatments Dimercaprol. In 1951, Cumings proposed dimercaprol (British anti-Lewisite, or BAL) as the first WD treatment. When used alone, dimercaprol is administered in painful daily intramuscular injections (300 mg in oil) for 20 consecutive days every 4 weeks for up to 4 courses (Hoogenraad 1996). As supplemental therapy, the dosage is 200 mg bid with D-penicillamine 500 mg tid (Walshe and Munro 1995). Although dimercaprol is initially effective, tachyphylaxis usually soon leads to inefficacy, and penicillamine provides a more sustained response (Brewer and Yuzbasiyan-Gurkan 1992; Saito et al. 1991). Other side effects include headache, fever, nausea, vomiting, salivation, and lacrimation; hallucinosis, delirium, coma, and death have also been reported (Walshe 1995). Other drugs. Drugs of yet-unproven value include potassium disulfide, ascorbic acid (vitamin C), and d-alpha-tocopherol (vitamin E). The chelating agent sodium 2,3-dimercaptopropane sulfonate is used in Russia and China (Hoogenraad 1996). Combination strategies. Some investigators recommend commencing treatment with D-penicillamine or trientine and switching to zinc after the first several months (Brewer and YuzbasiyanGurkan 1992). Regardless of the agent used, once therapy is initiated, it should be continued without interruption throughout life (Brewer and Yuzbasiyan-Gurkan 1992; McIntyre 1991). If neurological exacerbation or side effects require a switch from penicillamine, that agent can be stopped and zinc (acetate 40 mg tid or sulfate 200 mg tid) can be started the same day (Hoogenraad 1996). Simultaneous administration of chelators with zinc does not increase effectiveness and is theoretically counterproductive (Brewer et al. 1993), although this combination has sometimes been used in severely ill patients.
120
Psychiatric Management in Neurological Disease
Drinking water and diet. Deionized or distilled water may be helpful in communities with high levels of copper in the drinking water (Brewer and Yuzbasiyan-Gurkan 1992). A “low copper diet” is ineffective in preventing WD and is not usually necessary in patients undergoing decoppering therapy (Scheinberg and Sternlieb 1996). Most patients absorb no more than 1 mg/day of copper, an amount that poses no problem for decoppering therapy. However, some authorities recommend that WD patients limit their consumption of shellfish to no more often than once a week and of liver to no more than half an ounce each month (Brewer and Yuzbasiyan-Gurkan 1992). There is some evidence that a vegetarian diet may be sufficient for adequate maintenance therapy (Hoogenraad 1996). Liver transplantation. When liver disease is irreversible, transplantation should be considered. Acute hepatic failure, complications of cirrhosis, and a factor V reduction of greater than 25% are considered indications for transplantation (Cuthbert 1995; Hoogenraad 1996; Khanna et al. 1999; Walshe 1995). Graft survival rate in WD exceeds 73%, and patient survival rate exceeds 80%. Survival is better with chronic advanced liver disease (90%) than with fulminant hepatic failure (73% survival rate) (Bellary et al. 1995). Liver transplantation provides a phenotypic cure, sometimes reversing brain abnormalities (Bax et al. 1998; Bellary et al. 1995). Neurological improvement may be evident as early as 4–6 weeks after transplantation (Schumacher et al. 1997). Psychiatric improvement following liver transplantation has not been systematically studied. Specific Patient Populations Patients with liver disease. Penicillamine or trientine is recommended in hepatic WD, sometimes in combination with each other or with zinc (Brewer 1995b; Schilsky 1996). Patients with portal hypertension should not be switched from penicillamine to zinc (Hoogenraad 1996). Of course, management of ascites, edema, coagulopathy, and other complications of liver disease is necessary. Secondary manifestations of hepatic disease can reverse with WD treatment (Schilsky et al. 1991; Santos Silva et al. 1996). Plasmapheresis (Milovanovic et al. 1998) and peritoneal dialysis (Kuno et al. 1998) have been employed to treat acute hepatic complications in WD.
Wilson’s Disease
121
Neurological patients. Tetrathiomolybdate produces good to excellent recovery, usually without any functional deterioration in neurological or psychiatric WD, and it is preferred by some authorities (Brewer 1995b; Brewer et al. 1994a). Although zinc may act too slowly to be given as the sole treatment to the neurological patient (Brewer and Yuzbasiyan-Gurkan 1992), it may be useful during exacerbations (Barbosa et al. 1992). Among 137 neurological WD patients treated with chelators, 57 (42%) became symptom free, 36 (26%) improved substantially, 24 (17%) were disabled, and 20 (15%) died; across groups, 30 (22%) suffered initial neurological exacerbations (Walshe and Yealland 1993). Psychiatric patients. Although research is needed, psychiatric WD should probably be treated in the same manner as neurological WD. In a study of WD patients with psychiatric initial presentations treated with thiomolybdate, exacerbations did not occur and most made a good recovery over a 1-year treatment course (Brewer 1995b). Incongruous behavior and cognitive impairment improve more than do irritability and depression with WD treatment (Dening and Berrios 1990). Psychiatric symptoms may resolve more often in patients lacking dysarthria, incongruous behavior, and hepatic symptoms. Other features resolving with WD treatment have included amnestic disorder, dementia, hypersexuality, aggression, hyperactivity, and disinhibition. In evaluating treatment responses, clinicians should remember that patients experience “good” days and “bad” days (as a function of stress, fatigue, etc.) in terms of neuropsychiatric symptom severity. Pregnant patients. A review of contraceptive options and their effects on hepatic function is provided elsewhere (Haimov-Kochman et al. 1997). Lack of WD treatment can lead to amenorrhea and infertility in female patients and can result in miscarriage in pregnant patients (Schagen van Leeuwen et al. 1991). WD is one disease in which the pregnant patient should be treated. Successful pregnancies have been documented in patients receiving D-penicillamine (Berghella et al. 1997), zinc acetate, and trientine (Walshe 1986b). Zinc is preferred, because penicillamine is associated with teratogenic birth defects, including cutis laxa, micrognathia, low-set ears, inguinal hernias, hy-
122
Psychiatric Management in Neurological Disease
drocephalus, and cerebral palsy. Assuming that the mother received adequate decoppering prior to conception, the dose can be reduced to 25 mg tid during pregnancy and re-increased to 50 mg tid after lactation (Brewer 1995b; Brewer and Yuzbasiyan-Gurkan 1992). Zinc may actually protect against some forms of birth defects (Nunns et al. 1995). Trientine is also considered useful in pregnancy. Obviously, consultation with an obstetrician is indicated, especially in the presence of severe liver disease. Presymptomatic patients. Zinc is recommended for initial treatment in presymptomatic patients, starting with half the usual dose (in children, one-quarter of the usual adult dose) and adjusting the dose according to plasma copper levels (Hoogenraad 1996). Penicillamine can induce neurological symptoms and other side effects and is not recommended (Hoogenraad 1996). Monitoring Disease Progression and Treatment Efficacy Clinical methods of following WD include videotaped quantitative neurological exam, audiotaped speech examination, T2 MRI (Schwarz et al. 1994; Thuomas et al. 1993), photographed KF rings, and liver function tests (Brewer et al. 1990). Auditory and somatosensory evoked potentials detect treatment-related neurological improvement but may not correlate with psychiatric improvement (references cited in Lauterbach et al. 1998). Glucose metabolism and dopamine receptor binding have correlated with improved motor function (Schlaug et al. 1994), but metabolic improvements may precede clinical improvements (Cordato et al. 1998). A reduction in KF rings may occur within several years after commencing treatment. Monitoring a reduction in positive copper balance can be useful, and a negative copper balance can signify deterioration (Hoogenraad 1996). Plasma free copper concentration can be monitored, maintaining the level at 10 µg/dL (for other measures, see “Zinc” under “Treatment of Underlying Disease” subsection earlier in chapter). Measurement of urinary copper is not useful in patients treated with chelating agents, because urinary copper is complexed with the chelator. Serial liver biopsies have been used to follow WD, but their results can be quite variable (Faa et al. 1995).
Wilson’s Disease
123
Family Considerations and Genetic Testing When WD is detected, siblings should also be screened, because one in four will have presymptomatic WD (Brewer 1995b). The risk of WD is approximately 1 in 200 in the patient’s children, 1 in 800 in cousins, and 1 in 600 in nieces and nephews (Bachmann et al. 1991). Presymptomatic molecular genetic diagnosis is useful in studying siblings (Maier-Dobersberger et al. 1995). For example, the 5-year-old sister of a WD patient was asymptomatic and had normal ceruloplasmin, serum copper, and 24-hour urinary copper excretion. Nevertheless, restriction fragment length polymorphisms and polymerase chain reaction–based analysis with microsatellite markers disclosed her to be homozygous for disease-associated markers. A liver biopsy revealed a 20-fold increased liver copper content, confirming WD and allowing diagnosis before irreparable liver damage occurred. Genetic polymorphic satellite markers identified a heterozygous asymptomatic patient who had previously been assumed to be homozygous, allowing discontinuation of lifetime treatment with penicillamine (Vidaud et al. 1996). Unfortunately, the applicability of DNA analysis is limited to siblings of patients with established diagnoses of WD. Genetic diagnosis in the absence of a relative affected with WD is unlikely, because there are so many different mutations that can cause the illness.
Treatment of Psychiatric Manifestations Psychotropic Treatment Controlled studies of psychotropic treatment in psychiatric WD have not been reported (Rummans et al. 1999). Thus, the usual pharmacological armamentarium would seem to apply in WD, with the added consideration of potential copper deposition in the brain, liver, kidney, heart, and bone marrow (see Chapter 1 in this volume for a discussion of management principles in the context of specific organ system disease). Basal ganglia cuprification may lead to a heightened susceptibility to dystonia brought on by neuroleptics or selective serotonin reuptake inhibitors (SSRIs). Neuroleptic malignant syndrome and parkinsonism are more likely in WD patients, and atypical antipsychotics may be safer in this regard. Psycho-
124
Psychiatric Management in Neurological Disease
tropics that lower the seizure threshold may increase the likelihood of seizures in WD, especially in patients receiving WD treatment (Dening et al. 1988). Patients on anticonvulsants are at risk for the many drug interactions that can occur between these agents and psychotropics (Stoudemire and Fogel 1987; Stoudemire et al. 1995). Liver disease may affect the metabolism of psychotropics and prolong the functional half-life of the drug, leading to dose accumulation and toxic blood levels. Use of shorter-half-life drugs, lower doses, and drugs that are minimally metabolized before elimination may circumvent this problem. There is some evidence that the benzodiazepine antagonist flumazenil may have utility in treating the delirium of hepatic encephalopathy (Bostwick and Masterson 1998). Renal dysfunction in WD may lead to elevated lithium concentrations. Cardiac copper deposition can affect conduction pathways, leading to dysrhythmias, including tachycardia or bradycardia, with reduced cardiac efficiency (Hilz et al. 1990). Electrocardiogram abnormalities occur in about 30% of patients with WD, and orthostatic hypotension and sudden death have been reported. Therefore, use of psychotropics with low dysrhythmogenic and hypotensive potentials will be critical in some cases (Stoudemire and Fogel 1987; Stoudemire et al. 1995) (see “Heart disease” under “General Pharmacological Concerns” subsection in Chapter 1). Bone marrow suppression can occur with certain psychotropics as well as in WD. Attention must also be given to the effects of psychotropics on nonpsychotropic drugs that the medically ill patient is taking. For example, SSRIs can inhibit the metabolism of many drugs, leading to toxic elevations of plasma levels, which then can act upon already-diseased organs such as the heart or brain. Identifying targets of treatment. Absent specific empirical data regarding psychotropic use in psychiatric WD, several considerations germane to subcortical disease are of potential importance. These include the potential for delayed evolution, forme fruste presentations, compound syndromes, differential responsivity, and atypical responsivity of psychiatric disorders. Both neurological and psychiatric manifestations of a subcortical lesion can develop after a delay of months or years (Lauterbach et al. 1994, 1997a), and greater scrutiny of patients is therefore needed over a longer follow-up period than
Wilson’s Disease
125
usual. Psychiatric forme fruste syndromes (limited-symptom presentations) can develop after subcortical lesions (Lauterbach et al. 1997b), requiring thorough evaluation for detection. Compound forms of illness may also exist, such as several different types of depression simultaneously coexisting after thalamic lesions. Moreover, different simultaneously coexisting depressions may selectively respond to different serotonergic and noradrenergic antidepressants (Lauterbach et al. 1994). Thus, the clinician should be alert to compound syndromes with differential or atypical responses. In addition, certain psychotropics may be ineffective in certain lesions, necessitating alternative treatment approaches. For example, lithium may be useful in cases of neuroleptic-refractory psychosis in basal ganglia disease (Munir 1986). A novel and creative pharmacological approach may therefore be necessary. Treatment should commence with lower doses, and doses should be titrated upward more gradually than in disease-free patients. It should be borne in mind that no controlled trials regarding psychotropic treatment of psychiatric manifestations of WD have been carried out. Antipsychotics. Because of the danger of severe extrapyramidal syndromes with neuroleptic use in WD (Hoogenraad 1996), quetiapine, clozapine, olanzapine, or risperidone might be preferable. Furthermore, these 5-HT2A receptor antagonists, which may act in part at the cortex, may be useful when subcortical dopaminergic systems are unresponsive. Moreover, clozapine can attenuate parkinsonian and dystonic features, although bone marrow suppression, seizure risk, and exacerbation of impaired liver function should be considered. In light of the paucity of data for these agents and mixed findings in Parkinson’s disease, however, patients treated with these agents deserve intensive monitoring (see Chapter 1 in this volume). Vigilance for cognitive impairment, cardiac dysrhythmia, and hypotension is necessary with the more anticholinergic agents (e.g., lowpotency neuroleptics, clozapine). Chlorpromazine has multiple metabolites, some with very long half-lives. These may accumulate in the context of hepatic failure. High-potency neuroleptics can either exacerbate or improve the various types of dystonia (see Chapter 6 in this volume), but there are no good predictors of effect. In one case report, neuroleptic malignant syndrome in WD responded to dan-
126
Psychiatric Management in Neurological Disease
trolene and bromocriptine (Kontaxakis et al. 1988). Given the potentially lethal impact of antipsychotic treatment in WD, a thorough discussion of benefits, risks, and side effects should be undertaken as part of informed consent, as with any drug treatment in WD. Mood stabilizers. For mania, disinhibited behavior, aggression, neuroleptic-refractory psychosis, and irritability, lithium may be of value if there is no renal impairment, seizure proclivity, or exacerbation of a tremor or a gait disorder. Anticonvulsants and benzodiazepines may be useful if gait, cognitive, liver, and bone marrow status do not contraindicate. Patients with the psychiatric manifestations of mania, disinhibited behavior, or irritability coupled with dystonia may benefit from lithium or anticonvulsants (see Chapter 6 in this volume). Similarly, WD patients with tremor and aggression may benefit from propranolol if cardiovascular status does not contraindicate. Of course, patients should be screened for the usual contraindications to beta-blockers before enlisting these agents in the treatment regimen. Antidepressants. SSRIs (see below) and antidepressants may be of value for mood disorders, obsessive-compulsive disorder, and panic disorder. Because of the possibility of unmasking subclinical cognitive impairment, sedating and strongly anticholinergic tricyclic antidepressants should be reserved for later trials. The same caveats listed for low-potency neuroleptics should be regarded for tricyclics, particularly those with tertiary amine structures. Amoxapine should be used cautiously, because it metabolizes to loxapine and can provoke extrapyramidal reactions (dystonia, parkinsonism, neuroleptic malignant syndrome). Bupropion may prove useful in dysautonomia or sexual dysfunction, but the risk of seizures should be considered. Buspirone and selective serotonin reuptake inhibitors. Patients with impulse control disorders, aggression, irritability, anxiety, or substance abuse may also benefit from serotonergic agents such as SSRIs or buspirone. However, these agents occasionally worsen akathisia, parkinsonism, dystonia, and other movement disorders such as myoclonus (see Chapters 1 and 6 in this volume). Cyto-
Wilson’s Disease
127
chrome P450 drug interactions are another consideration in SSRI administration (see Chapter 1). Benzodiazepines. Benzodiazepines that have short half-lives (e.g., oxazepam, triazolam) or that are glucuronidated but not oxidized (e.g., lorazepam) may be of value in patients with liver disease. The possibility of precipitating or worsening cognitive impairment, disinhibition, reaction-time delays, ataxia, or substance abuse should be considered when using benzodiazepines. Nevertheless, benzodiazepines may have utility in treating catatonia (Davis and Borde 1993), anxiety, aggression, mania, postural tremor, and dystonia in selected patients. The long half-life of clonazepam, which can result in toxic dose accumulation, calls for frequent blood-level monitoring, especially in the presence of hepatic disease. Electroconvulsive Therapy Although experience is limited, electroconvulsive therapy (ECT) can be risky in WD. Negro Junior and Lousa Neto (1995) described a case in which a 46-year-old man with WD and major depression with mood-incongruent psychotic symptoms was treated with ECT after 2 years of treatment with penicillamine. He also exhibited disorganized behavior, disorientation, negativism, loose associations, persecutory and control delusions, and evidence of dementia. CT showed cortical atrophy but no enlargement of the lateral ventricles, and the EEG was normal. The patient was given one bilateral briefpulse ECT (12.4 J of charge), leading to a 3-minute motor seizure. He switched to mania the next day. When the depression recurred several days later, the patient was successfully treated with imipramine 150 mg/day and haloperidol 10 mg/day. The authors of the case report caution that ECT should be used with care, especially in untreated WD patients, who may have higher brain copper levels. They suggest that such patients may be more sensitive to ECT. The protracted 3-minute seizure in this case is consistent with the increased risk of seizures in this disease.
Summary Clinicians must remain vigilant for signs of hepatic and neurological disease. If WD is suspected, appropriate laboratory investigation and
128
Psychiatric Management in Neurological Disease
consultation should be obtained. If WD is diagnosed, siblings and family members of patients should be evaluated for WD. Early recognition and treatment is crucial for optimal outcome. WD is an illness presenting a panoply of psychiatric conditions that can be treated with a variety of modalities, including interventions targeting both the underlying neurological disease and the psychiatric manifestations of the disease. In the patient with WD, the clinician is confronted with an intriguing array of psychiatric manifestations with the potential for novel presentations, illness courses, and treatments. The co-occurrence of neurological and other WD manifestations can challenge the clinician’s pharmacological and therapeutic skills. Certain psychiatric conditions in WD may improve with decoppering treatments. WD can be a devastating disease, and improvement after psychiatric intervention is rewarding to both the clinician and the patient.
References Akil M, Brewer GJ: Psychiatric and behavioral abnormalities in Wilson’s disease. Adv Neurol 65:171–178, 1995 Akil M, Schwartz JA, Dutchak D, et al: The psychiatric presentations of Wilson’s disease. J Neuropsychiatry Clin Neurosci 3:377–382, 1991 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994 Arendt G, Hefter H, Stremmel W, et al: The diagnostic value of multimodality evoked potentials in Wilson’s disease. Electromyogr Clin Neurophysiol 34:137–148, 1994 Bachmann H, Lössner J, Kühn HJ, et al: Diagnostic strategies in Wilson’s disease, in Proceedings of the 5th Symposium on Wilson’s Disease. Edited by Czlonkowska A, Van den Hamer CJA. Delft, Netherlands, University Press, 1991, pp 79–86 Barbosa ER, Burdmann E de A, Cancado ER, et al: Zinc in the treatment of hepatolenticular degeneration: report of 3 cases. Arq Neuropsiquiatr 50:99–103, 1992 Bax RT, Hassler A, Luck W, et al: Cerebral manifestation of Wilson’s disease successfully treated with liver transplantation. Neurology 51:863–865, 1998
Wilson’s Disease
129
Bellary S, Hassanein T, Van Thiel DH: Liver transplantation for Wilson’s disease. J Hepatol 23:373–381, 1995 Berghella V, Steele D, Spector T, et al: Successful pregnancy in a neurologically impaired woman with Wilson’s disease. Am J Obstet Gynecol 176:712–714, 1997 Bona I, Broussolle E, Neuschwander P, et al: Treatment of Wilson’s disease with zinc: 5 cases. Rev Neurol (Paris) 149:393–397, 1993 Bostwick JM, Masterson BJ: Psychopharmacological treatment of delirium to restore mental capacity. Psychosomatics 39:112–117, 1998 Brewer GJ: Practical recommendations and new therapies for Wilson’s disease. Drugs 50:240–249, 1995a Brewer GJ: Interactions of zinc and molybdenum with copper in therapy of Wilson’s disease. Nutrition 11 (1 suppl):114–116, 1995b Brewer GJ, Yuzbasiyan-Gurkan V: Wilson disease. Medicine (Baltimore) 71:139–164, 1992 Brewer GJ, Yuzbasiyan-Gurkan V, Lee DY: Use of zinc-copper metabolic interactions in the treatment of Wilson’s disease. J Am Coll Nutr 9: 487–491, 1990 Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, et al: Treatment of Wilson’s disease with zinc, XI: interaction with other anticopper agents. J Am Coll Nutr 12:26–30, 1993 Brewer GJ, Dick RD, Johnson V, et al: Treatment of Wilson’s disease with ammonium tetrathiomolybdate, I: initial therapy in 17 neurologically affected patients. Arch Neurol 51:545–554, 1994a Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, et al: Treatment of Wilson’s disease with zinc, XIII: therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med 123:849–858, 1994b Brewer GJ, Turkey A, Yuzbaziyan-Gurkan V: Development of neurologic symptoms in a patient with asymptomatic Wilson’s disease treated with penicillamine. Arch Neurol 51:304–305, 1994c Brewer GJ, Johnson V, Dick RD, et al: Treatment of Wilson disease with ammonium tetrathiomolybdate, II: initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 53:1017– 1025, 1996 Buiakova OI, Xu J, Lutsenko S, et al: Null mutation of the murine ATP7B (Wilson disease) gene results in intracellular copper accumulation and late-onset hepatic nodular transformation. Hum Mol Genet 8:1665– 1671, 1999 Castellano G, Blasco A, Ballesta F, et al: Wilson’s disease: a retrospective analysis of 12 cases [in Spanish]. Rev Clin Esp 190:223–228, 1992
130
Psychiatric Management in Neurological Disease
Chowrimootoo GF, Andoh J, Seymour CA: Western blot analysis in patients with hypocaeruloplasminaemia. Q J Med 90:197–202, 1997 Chowrimootoo GF, Scowcroft H, Seymour CA: Caeruloplasmin isoforms in Wilson’s disease in neonates. Arch Dis Child Fetal Neonatal Ed 79: F198–F201, 1998 Cordato DJ, Fulham MJ, Yiannikas C: Pretreatment and posttreatment positron emission tomographic scan imaging in a 20-year-old patient with Wilson’s disease. Mov Disord 13:162–166, 1998 Cuthbert JA: Wilson’s disease: a new gene and an animal model for an old disease. J Investig Med 43:323–336, 1995 Dahlman T, Hartvig P, Lofholm M, et al: Long-term treatment of Wilson’s disease with triethylene tetramine dihydrochloride (trientine). Q J Med 88:609–616, 1995 Davis EJ, Borde M: Wilson’s disease and catatonia. Br J Psychiatry 162: 256–259, 1993 Dening TR, Berrios GE: Wilson’s disease: psychiatric symptoms in 195 cases. Arch Gen Psychiatry 46:1126–1134, 1989a Dening TR, Berrios GE: Wilson’s disease: a prospective study of psychopathology in 31 cases. Br J Psychiatry 155:206–213, 1989b Dening TR, Berrios GE: Wilson’s disease: a longitudinal study of psychiatric symptoms. Biol Psychiatry 28:255–265, 1990 Dening TR, Berrios GE, Walshe JM: Wilson’s disease and epilepsy. Brain 111:1139–1155, 1988 Faa G, Nurchi V, Demelia L, et al: Uneven hepatic copper distribution in Wilson’s disease. J Hepatol 22:303–308, 1995 Forbes JR, Cox DW: Functional characterization of missense mutations in ATP7B: Wilson disease mutation or normal variant? Am J Hum Genet 63:1663–1674, 1998 Gaffney D, Walker JL, O’Donnell JG, et al: DNA-based presymptomatic diagnosis of Wilson disease. J Inherit Metab Dis 15:161–170, 1992 Haimov-Kochman R, Ackerman Z, Anteby EY: The contraceptive choice for a Wilson’s disease patient with chronic liver disease. Contraception 56:241–244, 1997 Harper PL, Walshe JM: Reversible pancytopenia secondary to treatment with tetrathiomolybdate. Br J Haematol 64:851–853, 1986 Hawkins RA, Mazziotta JC, Phelps ME: Wilson’s disease studied with FDG and positron emission tomography. Neurology 37:1707–1711, 1987 Heckmann JM, Eastman RW, De Villiers JC, et al: Wilson’s disease: neurological and magnetic resonance imaging improvement on zinc treatment (letter). J Neurol Neurosurg Psychiatry 57:1273–1274, 1994
Wilson’s Disease
131
Hilz MJ, Druschky KF, Bauer J, et al: Wilson’s disease—critical deterioration under high-dose parenteral penicillamine therapy [in German]. Dtsch Med Wochenschr 115:93–97, 1990 Hoogenraad TU: Wilson’s Disease. London, WB Saunders, 1996 Hoogenraad TU, Houwen RHJ: Prevalence and genetics, in Wilson’s Disease. Edited by Hoogenraad TU. London, WB Saunders, 1996, pp 14–24 Hoogenraad TU, Van den Hamer CJA: Copper metabolism, copper toxicity and pathogenesis of Wilson’s disease, in Wilson’s Disease. Edited by Hoogenraad TU. London, WB Saunders, 1996, pp 25–44 Houwen RH, Juyn J, Hoogenraad TU, et al: H714Q mutation in Wilson disease is associated with late, neurological presentation. J Med Genet 32: 480–482, 1995 Huang CC, Chu NS: Wilson’s disease: resolution of MRI lesions following long-term oral zinc therapy. Acta Neurol Scand 93:215–218, 1996 Karkos C, Moore A, Manche A, et al: Pleural effusion associated with D-penicillamine therapy: a case report. J Clin Pharm Ther 21:15–17, 1996 Katz R: Penicillamine-induced skin lesions: a possible example of human lathyrism. Arch Dermatol 95:196–198, 1967 Khanna A, Jain A, Eghtesad B, et al: Liver transplantation for metabolic liver diseases. Surg Clin North Am 79:153–162, 1999 King AD, Walshe JM, Kendall BE, et al: Cranial MR imaging in Wilson’s disease. AJR Am J Roentgenol 167:1579–1584, 1996 Knehr CA, Bearn AG: Psychological impairment in Wilson’s disease. J Nerv Ment Dis 124:251–255, 1956 Kojimahara N, Nakabayashi H, Shikata T, et al: Defective copper binding to apo-ceruloplasmin in a rat model and patients with Wilson’s disease. Liver 15:135–142, 1995 Kontaxakis V, Stefanis C, Markidis M, et al: Neuroleptic malignant syndrome in a patient with Wilson’s disease (letter). J Neurol Neurosurg Psychiatry 51:1001–1002, 1988 Kumar A, Riely CA: Inherited liver diseases in adults. West J Med 163: 382–386, 1995 Kuno T, Hitomi T, Zaitu M, et al: Severely decompensated abdominal Wilson disease treated with peritoneal dialysis: a case report. Acta Paediatr Jpn 40:85–87, 1998 Kuwert T, Hefter H, Scholz D, et al: Regional cerebral glucose consumption measured by positron emission tomography in patients with Wilson’s disease. Eur J Nucl Med 19:96–101, 1992 Lang C, Muller D, Claus D, et al: Neuropsychological findings in treated Wilson’s disease. Acta Neurol Scand 81:75–81, 1990
132
Psychiatric Management in Neurological Disease
Lang CJ, Rabas-Kolominsky P, Engelhardt A, et al: Fatal deterioration of Wilson’s disease after institution of oral zinc therapy. Arch Neurol 50:1007–1008, 1993 Lauterbach EC, Price ST, Spears TE, et al: Serotonin responsive and nonresponsive diurnal depressive mood disorders and pathological affect in thalamic infarct associated with myoclonus and blepharospasm. Biol Psychiatry 35:488–490, 1994 Lauterbach EC, Jackson JG, Wilson AN, et al: Major depression after left posterior globus pallidus lesions. Neuropsychiatry Neuropsychol Behav Neurol 10:9–16, 1997a Lauterbach EC, Jackson JG, Price ST, et al: Clinical, motor, and biological correlates of depressive disorders after focal subcortical lesions. J Neuropsychiatry Clin Neurosci 9:259–266, 1997b Lauterbach EC, Cummings JL, Duffy J, et al: Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington’s, Wilson’s, and Fahr’s diseases. J Neuropsychiatry Clin Neurosci 10:249–266, 1998 LeWitt PA: Penicillamine as a controversial treatment for Wilson’s disease. Mov Disord 14:555–556, 1999 Lhermitte J, Muncie WS: Hepatolenticular degeneration: a report of three unusual cases. Arch Neurol Psychiatry 23:750–760, 1980 Lindahl JA, Sharp HL: Screening asymptomatic family members for Wilson’s disease. Minn Med 65:473–475, 1982 Littman E, Medalia A, Senior G, et al: Rate of information processing in patients with Wilson’s disease. J Neuropsychiatry Clin Neurosci 7:68–71, 1995 Loiseau P, Demangeat M: Syndrome Wilsonien atypique avec troubles mentaux d’allure schizophrenique: remission spectaculaire des troubles mentaux au stade pre-agonique. Ann Med Psychol (Paris) 114: 413–420, 1956 Lyon TD, Fell GS, Gaffney D, et al: Use of a stable copper isotope (65Cu) in the differential diagnosis of Wilson’s disease. Clin Sci (Colch) 88: 727–732, 1995 Maier-Dobersberger T, Mannhalter C, Rack S, et al: Diagnosis of Wilson’s disease in an asymptomatic sibling by DNA linkage analysis. Gastroenterology 109:2015–2018, 1995 Mansouri A, Gaou I, Fromenty B, et al: Premature oxidative aging of hepatic mitochondrial DNA in Wilson’s disease. Gastroenterology 113:599– 605, 1997
Wilson’s Disease
133
Martin WRW, Snow B, Ashforth R: Abnormalities of movement and posture due to disease of the extrapyramidal motor systems, in Neuroimaging: A Companion to Adams and Victor’s Principles of Neurology. Edited by Greenberg JO. New York, McGraw-Hill, 1995, pp 5–24 McDonald LV, Lake CR: Psychosis in an adolescent patient with Wilson’s disease: effects of chelation therapy. Psychosom Med 57:202–204, 1995 McIntyre N: Wilson’s disease. Kayser and Fleischer’s sign and Walshe’s treatment. Br J Clin Pract 45:135–140, 1991 Medalia A, Isaacs-Glaberman K, Scheinberg IH: Neuropsychological impairment in Wilson’s disease. Arch Neurol 45:502–504, 1988 Merli M, Patriarca M, Loudianos G, et al: Use of the stable isotope 65Cu test for the screening of Wilson’s disease in a family with two affected members. Ital J Gastroenterol Hepatol 30:270–275, 1998 Milovanovic DD, Tomasevic R, Bogdanovic G: Treatment of chronic Wilson’s disease in 2 patients using plasmapheresis: clinico-biochemical observations [in Serbo-Croatian (Cyrillic)]. Srp Arh Celok Lek 126(9–10):327–334, 1998 Munir KM: The treatment of psychotic symptoms in Fahr’s disease with lithium carbonate. J Clin Psychopharmacol 6:36–38, 1986 Nanji MS, Nguyen VT, Kawasoe JH, et al: Haplotype and mutation analysis in Japanese patients with Wilson disease. Am J Hum Genet 60:1423– 1429, 1997 Negro Junior PJ, Louza Neto MR: Results of ECT for a case of depression in Wilson’s disease (letter). J Neuropsychiatry Clin Neurosci 7:384, 1995 Nunns D, Hawthorne B, Goulding P, et al: Wilson’s disease in pregnancy. Eur J Obstet Gynecol Reprod Biol 62:141–143, 1995 Oder W, Grimm G, Kollegger H, et al: Neurological and neuropsychiatric spectrum of Wilson’s disease: a prospective study of 45 cases. J Neurol 238:281–287, 1991 Oder W, Prayer L, Grimm G, et al: Wilson’s disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology 43:120–124, 1993 Oder W, Brucke T, Kolleger H, et al: Dopamine D2 receptor binding is reduced in Wilson’s disease: correlation of neurological deficits with striatal 123I–iodobenzamide binding. J Neural Transm 103:1093–1103, 1996 Rathbun JK: Neuropsychological aspects of Wilson’s disease. Int J Neurosci 85:221–229, 1996 Roach ES, Ford CS, Spudis EV, et al: Wilson’s disease: evoked potentials and computed tomography. J Neurol 232:20–23, 1985
134
Psychiatric Management in Neurological Disease
Roberts EA, Cox DW: Wilson disease. Baillieres Clin Gastroenterol 12: 237–256, 1998 Rummans TA, Lauterbach EC, Coffey CE, et al: Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci 11:176–189, 1999 Saatci I, Topcu M, Baltaoglu FF, et al: Cranial MR findings in Wilson’s disease. Acta Radiol 38:250–258, 1997 Saito H, Watanabe K, Sahara M, et al: Triethylene–tetramine (trien) therapy for Wilson’s disease. Tohoku J Exp Med 164:29–35, 1991 Santos Silva EE, Sarles J, Buts JP, et al: Successful medical treatment of severely decompensated Wilson disease. J Pediatr 128:285–287, 1996 Schaefer M, Hopkins RG, Failla ML, et al: Hepatocyte-specific localization and copper-dependent trafficking of the Wilson’s disease protein in the liver. Am J Physiol 276(3 pt 1):G639–G646, 1999 Schagen van Leeuwen JH, Christiaens GC, et al: Recurrent abortion and the diagnosis of Wilson disease. Obstet Gynecol 78:547–549, 1991 Scheinberg IH, Sternlieb I: Wilson’s disease, in Major Problems in Internal Medicine, Vol 23. Edited by Smith LH Jr. Philadelphia, PA, WB Saunders, 1984 Scheinberg IH, Sternlieb I: Wilson disease and idiopathic copper toxicosis. Am J Clin Nutr 63:842S–845S, 1996 Schilsky ML: Wilson disease: genetic basis of copper toxicity and natural history. Semin Liver Dis 16:83–95, 1996 Schilsky ML, Scheinberg IH, Sternlieb I: Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 100:762–767, 1991 Schlaug G, Hefter H, Nebeling B, et al: Dopamine D2 receptor binding and cerebral glucose metabolism recover after D-penicillamine therapy in Wilson’s disease. J Neurol 241:577–584, 1994 Schlaug G, Hefter H, Engelbrecht V, et al: Neurological impairment and recovery in Wilson’s disease: evidence from PET and MRI. J Neurol Sci 136:129–139, 1996 Schumacher G, Platz KP, Mueller AR, et al: Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson’s disease. Clin Transplant 11:217–224, 1997 Schwartz M, Fuchs S, Polak H, et al: Psychiatric manifestation in Wilson’s disease [in Hebrew]. Harefuah 124:75–77, 1993 Schwarz J, Antonini A, Kraft E, et al: Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson’s disease. Neurology 44:1079–1082, 1994
Wilson’s Disease
135
Sharonova IN, Vorobjev VS, Haas HL: High-affinity copper block of GABA(A) receptor-mediated currents in acutely isolated cerebellar Purkinje cells of the rat. Eur J Neurosci 10:522–528, 1998 Siegemund R, Lossner J, Gunther K, et al: Mode of action of triethylenetetramine dihydrochloride on copper metabolism in Wilson’s disease. Acta Neurol Scand 83:364–366, 1991 Slater E, Cowie V: The Genetics of Mental Disorders. London, Oxford University Press, 1971 Steindl P, Ferenci P, Dienes HP, et al: Wilson’s disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology 113: 212–218, 1997 Stoudemire A, Fogel BS: Psychopharmacology in the medically ill, in Principles of Medical Psychiatry. Edited by Stoudemire A, Fogel BS. Orlando, FL, Grune & Stratton, 1987, pp 79–112 Stoudemire A, Moran MG, Fogel BS: Psychopharmacology in the medically ill patient, in The American Psychiatric Press Textbook of Psychopharmacology. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1995, pp 783–801 Sturniolo GC, Mestriner C, Irato P, et al: Zinc therapy increases duodenal concentrations of metallothionein and iron in Wilson’s disease patients. Am J Gastroenterol 94:334–338, 1999 Tarter RE, Switala J, Carra J, et al: Neuropsychological impairment associated with hepatolenticular degeneration (Wilson’s disease) in the absence of overt encephalopathy. Int J Neurosci 37:67–71, 1987 Terada K, Schilsky ML, Miura N, et al: ATP7B (WND) protein. Int J Biochem Cell Biol 30:1063–1067, 1998 Thuomas KA, Aquilonius SM, Bergstrom K, et al: Magnetic resonance imaging of the brain in Wilson’s disease. Neuroradiology 35:134–141, 1993 van Wassenaer–van Hall HN, van den Heuvel AG, Algra A, et al: Wilson disease: findings at MR imaging and CT of the brain with clinical correlation. Radiology 198:531–536, 1996 Vidaud D, Assouline B, Lecoz P, et al: Misdiagnosis revealed by genetic linkage analysis in a family with Wilson disease. Neurology 46:1485–1486, 1996 Walshe JM: Wilson’s disease, in Handbook of Clinical Neurology, Vol 5 (49): Extrapyramidal Disorders. Edited by Vinken PJ, Bruyn GW, Klawans HL. Amsterdam, Elsevier Science BV, 1986a, pp 223–238 Walshe JM: The management of pregnancy in Wilson’s disease treated with trientine. Q J Med 58:81–87, 1986b
136
Psychiatric Management in Neurological Disease
Walshe JM: Copper: not too little, not too much, but just right. Based on the triennial Pewterers Lecture delivered at the National Hospital for Neurology, London, on 23 March 1995. J R Coll Physicians Lond 19:280–288, 1995 Walshe JM, Munro NA: Zinc-induced deterioration in Wilson’s disease aborted by treatment with penicillamine, dimercaprol, and a novel zero copper diet (letter). Arch Neurol 52:10–11, 1995 Walshe JM, Yealland M: Wilson’s disease: the problem of delayed diagnosis. J Neurol Neurosurg Psychiatry 55:692–696, 1992 Walshe JM, Yealland M: Chelation treatment of neurological Wilson’s disease. Q J Med 86:197–204, 1993 Wang JK: Cu2+ induces Ca2+-dependent neurotransmitter release from brain catecholaminergic nerve terminals. Eur J Pharmacol 373(2–3): 163–169, 1999 Wilson SAK: Progressive lenticular degeneration, a familial nervous disease associated with cirrhosis of the liver. Brain 34:295–507, 1912 Yanoff M, Fine BS: Ocular Pathology: A Color Atlas. Philadelphia, PA, JB Lippincott, 1988
C H A P T E R
5
Fahr’s Syndrome Edward C. Lauterbach, M.D.
C
alcification of the basal ganglia has been variably referred to as Fahr’s disease, Fahr’s syndrome (FS), striopallidodentate calcification, striatopallidodentate calcification, and calcinosis nucleorum cerebri, among other terms. The course of FS is progressive. In adult FS, calcium deposition generally begins in the third decade of life, with neurological deterioration developing two decades later. FS has also been reported to occur in pediatric populations. The condition has been known since the middle 1800s, and Fahr (1931) actually was not the first to describe the illness. Ostertag (1922), Spatz (1922), and Weimann (1922) had previously published extensive reviews (Lowenthal 1986).
Prevalence A number of studies have determined the frequency of basal ganglia calcification (BGC) on computed tomography (CT) in patients undergoing radiological neuroimaging. Averaging these frequencies yields a BGC rate of 0.93% (274 BGC cases from a combined sample of 29,484 scans) (references cited in Lauterbach et al. 1998). The radiological prevalence of calcification is higher in children (15%) than in adults (Kendall and Cavanagh 1986). As discussed in the following section, the prevalence of FS depends on how the syndrome is defined. To avoid confusion with incidental BGC, it is advisable to require the presence of clinical findings ascribable to the calcification. Viewed from this perspec137
138
Psychiatric Management in Neurological Disease
tive, the prevalence of FS is probably somewhat less than 50 patients per 10,000 population, or 0.5%. In a review of 6,348 subjects’ CT scans, 62 (0.98%) had BGCs, but only 31 (0.49%) actually had FS (Konig 1989). There is some variance in this estimate of FS prevalence, because clinical findings vary widely among CT studies of FS. For example, in a study of 33 patients with calcification, none had clinical signs (Vles et al. 1981). In another study of 72 patients with calcification, extrapyramidal manifestations occurred in 15 (20.8%) and seizures in 13 (18.1%) (Kazis 1985). Psychiatric and neurological findings are inconsistently reported in prevalence studies of BGC ascertained by CT. The prevalences of specific etiological types of FS, including idiopathic Fahr’s disease, remain to be clarified.
Clinical Recognition and Neurological Presentation FS can be distinguished from other brain calcifications (e.g., calcified angiomas, infections, encephalitides, Addison’s disease lesions) by its greater severity and characteristic distribution (see “Neuroimaging” section later in chapter). FS should not be confused with normal calcification of cerebral structures such as the petroclinoid ligaments, falx cerebri, tentorium, choroid plexus, and pineal body. Non-FS calcification can also accompany phacomatosis, Hallervorden-Spatz disease, and paramyloidosis and can occur as a sequel to intoxication with lead or carbon monoxide. The term Fahr’s syndrome has been applied to BGC regardless of etiology, whereas Fahr’s disease has been used to refer to primary, heretofore idiopathic FS (Delplace et al. 1989). Lowenthal (1986) has set forth criteria defining FS (including Fahr’s disease): 1) the calcification must have a characteristic distribution, involving at least the globus pallidus, with or without cerebellar calcification, 2) the calcification must be evident on CT, and 3) the calcification must be of sufficient size to be detected on macroscopic pathological exam. Supportive nondiagnostic findings include 1) a definable clinical presentation and 2) an underlying metabolic abnormality, especially hypoparathyroidism (Lowenthal 1986). Subsequent definitions (Beall et al. 1989; Trautner et al. 1988) have required the presence of certain neurological features to allow FS to be distinguished from
Fahr’s Syndrome
139
incidental BGC. Some specify that bilateral calcifications be present for the diagnosis of FS (Trautner et al. 1988); however, clinical manifestations vary widely, and calcifications occasionally present unilaterally (Kashihara and Yabuki 1992). Moreover, presymptomatic patients and patients with pure psychiatric presentations would be missed by these definitions. Perhaps a better clinical approach to diagnosing FS would be to require the presence of neurological or neuropsychiatric sequelae known to occur in FS in patients with radiological evidence of bilateral calcifications of the basal ganglia or cerebellum. In contrast to the clinician’s viewpoint, radiologists view BGCs as a common, generally asymptomatic finding on CT (Flint and Goldstein 1992). However, the presence of psychiatric or neurological manifestations associated with basal ganglia disease should dissuade the clinician from accepting the radiological finding as merely “incidental” and without clinical significance. Moreover, the patient may develop symptoms at some later date, even if he or she is asymptomatic at the time of the scan. Consequently, incidental discovery of BGC before age 50 years merits diagnostic investigation (Rasmussen et al. 1991). Despite variable calcification distributions and severities, certain clinical FS findings demonstrate remarkable constancy (Lowenthal 1986); these include seizures of all types, electroencephalogram (EEG) abnormalities, movement disorders (see “Neurological Features” subsection below), and cognitive and other psychiatric disorders (see “Psychiatric Manifestations” section later in chapter). Clinical features vary among FS cases, and other presentations are known. Endocrinological findings consistent with calcium metabolism disorders are present when these disorders constitute the disease etiology. Other than sex-linked inherited and intrauterine causes of FS, no important effects between FS and either gender or pregnancy have been reported.
Neurological Features A variety of neurological features are associated with FS. (Infantile and childhood manifestations are discussed later in this chapter in
140
Psychiatric Management in Neurological Disease
the subsection titled “Infantile and Juvenile Basal Ganglia Calcification.”) In adults, loss of consciousness, seizures, and cardiomyopathy have been reported in the context of FS associated with hypoparathyroid hypocalcemia (Arias Mayorga et al. 1991; Arranz Perez et al. 1992). The tetany of hypocalcemia is sometimes difficult to distinguish from the occasional fused tetanic myoclonus of some epileptic disorders. Paresthesias are not infrequent. Other associated features include spasticity, gait disorder, speech impairment, dementia, parkinsonism, chorea, tremor, dystonia, myoclonus, and coma (Lauterbach et al. 1998). Papilledema of intracranial hypertension and cerebrospinal fluid (CSF) pleocytosis may be present. Paroxysmal choreoathetosis (Klein et al. 1997) and paroxysmal dystonic choreoathetosis (Yamamoto and Kawazawa 1987) have also been reported. The reported prevalences of neurological sequelae in FS vary among studies. Kazis (1985) studied 72 patients in whom symmetrical intracranial calcifications had been identified by CT and found extrapyramidal syndromes in 15 (20.8%). In a literature review of 213 FS cases undertaken by Konig (1989), seizures were present in 46 (22%) and extrapyramidal movement disorders in 119 (56%). Konig found similar frequencies in his follow-up study (Table 5–1). Patients with complex partial seizures may manifest bizarre behavior, such as screaming or crying. Seizures may be due to underlying etiologies (e.g., hypoparathyroidism, hypocalcemia) or the brain pathology of FS itself. Dysarthria ranges from slow, slurred speech to Table 5–1.
Neurological presentations in Fahr’s syndrome
Headache/vertigo Extrapyramidal movement disorder Paresis/apoplexy Transient ischemic attacks Seizures Syncope
Initial (n = 62), no. (%)
Follow-up (n = 35), no. (%)
8 (13.0) 6 (10.0)
21 (60.0)
6 (10.0) 4 (6.0) 4 (6.0) 3 (5.0)
6 (17.1)
Note. Data from Konig (1989) indicating prevalence of neurological disorders on initial presentation and on long-term follow-up.
Fahr’s Syndrome
141
marked impairment attributable to cerebellar and putaminal calcification. In a door-to-door study of parkinsonism in 982 rural Bavarians, 1 (5.9%) of 17 parkinsonian subjects had FS (Trenkwalder et al. 1995). Neurological features may be confined to one side of the body despite the presence of bilateral calcifications (el Maghraoui et al. 1995). In the study of Konig (1989), about half of FS patients had neurological symptoms (see Table 5–1), as opposed to about one-third of patients in the study of Kazis (1985). These studies suggest that the prevalence of neurological symptoms may vary in FS. Most studies conclude that there is little relation between the extent or localization of calcifications and the extent or type of neurological manifestations (Kazis 1985; Taxer et al. 1986), apart from suggestions of greater severity of extrapyramidal features and dementia in patients with more extensive calcifications (Taxer et al. 1986). Although clinical findings may sometimes correlate with calcification location (e.g., parkinsonism with midbrain, globus pallidus, or thalamus calcification), the presence of calcification in structures that are traditionally associated with particular clinical findings does not predict the manifestation of those findings in FS. In a study of 18 ambulatory FS patients identified by CT and then evaluated clinically (LópezVillegas et al. 1996), 2 (11.1%) had parkinsonism (both with pallidal calcification, 1 with additional thalamic and cerebellar dentate calcification), 7 (38.9%) had seizures (7 with pallidal calcification, 1 with putaminal calcification), 4 (22.2%) had transient ischemic attacks (3 with pallidal calcification, 1 with putaminal calcification), and 1 (5.6%) had dysarthria and orthostatic hypotension (caudate and putaminal calcification). The lesion locations in this study included the globus pallidus in 16 (88.9%), the putamen in 3 (16.7%), the caudate in 2 (11.1%), the thalamus in 1 (5.6%), and the cerebellar dentate nucleus in 1 (5.6%) (López-Villegas et al. 1996). In another study (Taxer et al. 1986), neurological features led to faster diagnosis of FS than did psychiatric manifestations.
Pathological Features Pathology is similar in infantile and adult-onset FS (Matsui et al. 1992). Microscopic examination reveals perivascular granules above
142
Psychiatric Management in Neurological Disease
the midbrain but not in the pituitary or pia mater. In a review of 30 patients with globus pallidus calcifications demonstrated on CT, Adachi et al. (1994) found that the lateral pallidum was more often calcified than the medial pallidum. However, in another study of 72 patients with symmetrical intracranial calcifications, Kazis (1985) found a subgroup with isolated medial pallidal calcification. It is not clear why calcifications develop in certain brain structures and not others. Defective iron transport and free radical production may damage tissue, initiating calcification (Beall et al. 1989). Calcium is then increased several hundredfold. Calcific deposits are composed of calcium phosphate and carbonate; glycoproteins; mucopolysaccharides; and metals, including iron, copper, magnesium, zinc, aluminum, silver, and cobalt (Kobayashi et al. 1987; Lowenthal 1986). Calcification mineral composition varies by anatomic site and by proximity to vasculature (Bouras et al. 1996). Deposits occur mainly in blood vessel adventitial cells and, occasionally, glial cells. Deposits are connected by filamentous cytoplasmic processes between cells. Attempts to find a unifying pathophysiological explanation for calcifications resulting from diverse etiologies have failed.
Idiopathic and Primary Fahr’s Disease Until recently, primary Fahr’s disease has been considered to be idiopathic in origin. However, study of a multigenerational family using polymorphic microsatellite markers has led to linkage of primary Fahr’s disease to chromosome 14q between D14S75 and D14S306 (Geschwind et al. 1999). The age at onset decreased by more than 20 years with each transmission, consistent with genetic anticipation. This is a new finding and it will be interesting to follow this important development. It is possible that multiple mutations of this gene will be found. Other genes may be linked to Fahr’s disease in the future. It will be of value to study the neuropsychiatric sequelae of specific types of Fahr’s disease as these gene linkages emerge.
Etiologies of Secondary FS In addition to the 14q gene for primary Fahr’s disease, several patterns of inheritance have been observed in FS (see “Genetic Asso-
Fahr’s Syndrome
143
ciations” subsection below). FS is associated with a diversity of conditions (Table 5–2). Several problems arise when one attempts to catalogue FS etiologies from the literature. First, few reports actually examine causal relationships between the associated condition and FS. Second, variable nosologies are applied, with FS diagnosed in the absence of clinical features in some reports. Third, attribution difficulties arise when clinical features are present, because it is difficult to discern whether the clinical findings are manifestations of FS itself or, instead, of the underlying associated condition (e.g., seizures in FS due to hypoparathyroidism). Finally, case ascertainment is problematic, because calcifications reported to be asymptomatic may subsequently progress to become symptomatic. In view of these problems and the need to diagnostically investigate BGC in patients younger than age 50 years regardless of whether clinical signs or symptoms are in attendance (Rasmussen et al. 1991), conditions associated with BGC (rather than conditions associated with documented FS) are detailed in the following subsections. These include endocrine, vitamin D, genetic, mitochondrial, neurological, infectious, neoplastic, dermatological, and pharmacological conditions (see Table 5–2). Similarly, an array of clinical conditions are associated with juvenile presentations of BGC, including many of the ones just listed, as well as inborn errors of metabolism and several other unique associations. Each of these conditions is discussed in turn in the subsections that follow. The term FS is used when the condition clearly represents FS. Otherwise, BGC is used when it is unclear whether the clinical presentation of FS was actually apparent in the report. Until the case ascertainment problems enumerated in the preceding paragraph can be resolved, the precise etiological differential diagnosis of FS per se will remain obscure. From a clinical viewpoint, it is therefore safer and more conservative to consider the broader differential diagnosis of BGC in patients with clinical manifestations of FS.
Endocrine Disorders Parathyroid and endocrine disturbances are the conditions most commonly associated with FS (Table 5–3). In particular, the clinician should be alert for idiopathic hypoparathyroidism, secondary hypoparathyroidism (e.g., postthyroidectomy), pseudohypoparathyroidism, pseudo-
144
Table 5–2.
Psychiatric Management in Neurological Disease
Causes of Fahr’s syndrome (FS)
Adult FS Primary Fahr’s disease 14q (between D14S75 and D14S306) Idiopathic Endocrine disorders Hypoparathyroidism Primary hypoparathyroidism Postthyroidectomy hypoparathyroidism Pseudohypoparathyroidism Defective parathormone binding Defective guanine nucleotide binding protein Pseudo-pseudohypoparathyroidism Vitamin D disorders Genetic causes Associated with parathyroid disturbances Associated with ataxia and pigmentary macular degeneration Associated with hypertension Trisomy 21 (Down syndrome) Trisomy 5 Autosomal recessive FS With spondyloenchondrodysplasia With reduced homocarnosine and histidine With encephalopathy, microcephaly, dwarfism, retinal degeneration, or demyelination Aicardi-Goutieres syndrome Autosomal dominant FS With elevated homocarnosine With 25-hydroxyvitamin D3 deficiency With normal calcium metabolism With psychiatric disturbances Mitochondrial myopathies and encephalopathies MELAS MERRF Kearns-Sayre syndrome Mitochondrial ophthalmoplegia Alport syndrome (continued)
Fahr’s Syndrome
Table 5–2.
145
Causes of Fahr’s syndrome (FS) (continued)
Degenerative diseases Motoneurone disease Early-onset Alzheimer’s disease Infectious diseases Neurobrucellosis AIDS Toxoplasmosis Encephalitis Inflammatory diseases CNS lupus Tuberous sclerosis Anoxia Trauma Neoplastic diseases Multiple myeloma Metastatic astrocytoma Dermatopathies Lipoid proteinosis (Urbach-Wiethe disease) Hidrotic ectodermal dysplasia Lipomembranous polycystic osteodysplasia Drugs Anticonvulsants Pediatric FS Genetic causes With neurological signs Without neurological signs Metabolic causes Abnormal calcium metabolism Biotinidase deficiency Dihydropteridine reductase deficiency with hyperphenylalaninemia Folate deficiency with dihydropteridine reductase Hyperammonemia with reduced ornithine transcarbamylase activity Propionic acidemia (continued)
146
Table 5–2.
Psychiatric Management in Neurological Disease
Causes of Fahr’s syndrome (FS) (continued)
Metabolic causes (continued) Type I GM1 gangliosidosis Mitochondrial myopathies MERFF Diffuse cerebral microangiopathy with leukodystrophy Infantile neuraxonal dystrophy Infectious diseases AIDS Epstein-Barr virus Pertussis encephalitis Cocksackie encephalitis Meningitis Acute hemorrhagic leukoencephalitis Congenital encephalopathy Anoxic Prenatal viral Intrauterine transfusion Juvenile rheumatoid arthritis Coats’ disease Juvenile nephronolithiasis and pancreatic lipomatosis Neurofibromatosis Neoplasia Tuberous sclerosis Myotonic muscular dystrophy Note. AIDS = acquired immunodeficiency syndrome; CNS = central nervous system; MELAS = mitochondrial myopathy, encephalopathy, lactacidosis, and stroke-like syndromes; MERRF = myoclonic epilepsy and myopathy with ragged red fibers.
pseudohypoparathyroidism, and hyperparathyroidism. Bruyn et al. (1964) reviewed the literature of 150 FS cases and found that 35 (23.3%) had idiopathic hypoparathyroidism, whereas 23 (15.3%) had postthyroidectomy hypoparathyroidism. In 62 FS subjects identified clinically and subsequently diagnosed following CT imaging, Taxer et al.
Fahr’s Syndrome
147
(1986) found that 9 (14.5%) had undergone thyroidectomy an average of 25 years prior to FS presentation. Among studies of CTidentified FS-type calcifications regardless of FS clinical signs (Brannan et al. 1980; Harrington et al. 1981; Kazis 1985; Murphy 1979; Vles et al. 1981), meta-analysis reveals a lower prevalence (18 [8.4%] of 215 cases) of parathyroid disturbances than in the earlier literature review of Bruyn et al. (1969). Consequently, parathyroid disorders constitute a more important cause of FS than of BGC without neurological signs. In a review of the reported endocrinological literature, Danowski et al. (1960) found that BGC occurred in 20 (21.5%) of 93 patients with idiopathic hypoparathyroidism, 26 (42.6%) of 61 patients with pseudohypoparathyroidism, and 2 (6.1%) of 33 patients with pseudo-pseudohypoparathyroidism. Review of a series of 41 cases of postsurgical hypoparathyroidism revealed 2 (4.9%) with BGC (Basser et al. 1969). Reduced parathormone (in hypoparathyroidism) or reduced renal response to parathormone (in pseudohypoparathyroidism) decreases renal tubular phosphorus excretion, with consequent hyperphosphatemia and hypocalcemia, which, in turn, promote calcification (Lowenthal 1986). More rarely, hyperparathyroidism is associated with FS (Lowenthal 1986). Each of these parathyroid disorders (see Table 5–3) can be recognized by clinical features and laboratory evidence. The laboratory values most instructive in differentiating these disorders are serum calcium, phosphorus, and parathyroid hormone levels. Hypoparathyroidism is of either primary or secondary (postthyroidectomy) origin. Primary hypoparathyroidism usually presents within the first six decades of life and is genetically transmitted through several modes, including autosomal dominant, recessive, and X-linked inheritance. Multiple forms of mutation can occur for each mode of inheritance, with different mutation forms in different families. Hypoparathyroidism can be clinically recognized by cataracts, tetany, seizures (or EEG abnormalities), dysarthria, increased intracranial pressure, papilledema, soft tissue calcification, congestive heart failure, pernicious anemia, and a variety of autoimmune, extrapyramidal, and psychiatric features. Not all of these features would be expected to be present in a given patient, because different
148
Table 5–3.
Psychiatric Management in Neurological Disease
Endocrine disorders
Hypoparathyroidism Clinical features Cataracts Tetany Seizures EEG abnormalities Dysarthria Increased intracranial pressure Papilledema Extrapyramidal signs (parkinsonism, chorea) Psychiatric features Dementia Delirium Psychosis Bipolar disorders Depression Anxiety (panic, hyperventilation) Soft tissue calcifications Congestive heart failure Variable autoimmune disorders (especially against endocrine organs) Pernicious anemia Onset First to sixth decades of life Laboratory evidence Hypocalcemia Hyperphosphatemia Low parathyroid hormone (parathormone [PTH]) Reduced 1,25-dihydroxyvitamin D3 Variable thyroid, ovary, or thymus dysfunction (in primary hypoparathyroidism) Genetics Autosomal dominant, recessive, and X-linked involving multiple mutations Treatment Vitamin D and oral calcium; thiazide diuretics (continued)
Fahr’s Syndrome
Table 5–3.
149
Endocrine disorders (continued)
Pseudohypoparathyroidism Clinical features Resemble hypoparathyroidism Moon facies Short stature Thickset body type Shortened metacarpals and metatarsals Soft tissue calcification Dental abnormalities Laboratory evidence Parathormone levels normal or quite high Hypocalcemia Hyperphosphatemia Genetics Linked to chromosome 20 Several subtypes exhibiting variable clinical and laboratory features Treatment Similar to hypoparathyroidism Pseudo-pseudohypoparathyroidism Clinical features Resembles pseudohypoparathyroidism Blue sclerae Laboratory evidence Normocalcemia Normophosphatemia Normal parathormone response Genetics Usually first-degree relatives of patients with pseudohypoparathyroidism Possible pseudohypoparathyroidism variant Hyperparathyroidism Clinical features Nephrolithiasis Proximal muscle weakness, atrophy (continued)
150
Psychiatric Management in Neurological Disease
Table 5–3.
Endocrine disorders (continued)
Hyperparathyroidism (continued) Clinical features (continued) Abdominal complaints Chondrocalcinosis Pseudogout Osteopenia (rare) Laboratory evidence Hypercalcemia Fasting morning hypophosphatemia Elevated parathormone Osteitis fibrosa cystica on bone biopsy Treatment Medical referral Surgical treatment may be necessary Note.
EEG = electroencephalogram.
signs occur in different patients. When present, autoimmune disorders can involve a variety of tissues, but immunity is most often directed against endocrine organs. Extrapyramidal disorders usually involve parkinsonism or chorea. Psychiatric manifestations include dementia, delirium, psychosis, bipolar disorders, depression, and anxiety disorders. Anxiety symptoms have included panic and hyperventilation. Because extrapyramidal and psychiatric disturbances occur as manifestations of hypoparathyroidism, psychiatric findings in patients with hypoparathyroid FS may be caused by hypoparathyroidism, FS, or both. Laboratory findings indicative of hypoparathyroidism include hypocalcemia, hyperphosphatemia, low parathyroid hormone levels, and reduced 1,25-dihydroxyvitamin D levels. In primary hypoparathyroidism, variably present additional hormonal disturbances of the thyroid, ovary, or thymus may also be evident. Treatment involves oral vitamin D supplementation, calcium supplementation, and thiazide diuretic administration. Pseudohypoparathyroidism has been linked to chromosome 20. Several subtypes exist, with variable clinical and laboratory features. Clinical signs include those of hypoparathyroidism, as well as short stature, thick-set body type, moon facies, shortened metacarpals
Fahr’s Syndrome
151
and metatarsals, and dental abnormalities. Although laboratory evidence of pseudohypoparathyroidism involves hypocalcemia and hyperphosphatemia, just as in hypoparathyroidism, parathyroid hormone levels are either normal or elevated in pseudohypoparathyroidism. Other laboratory findings differ among the various subtypes. One subtype involves defective parathyroid hormone binding to endorgans; another type involves defective guanine nucleotide binding protein. Despite these differences, treatment is essentially the same as for hypoparathyroidism. Pseudo-pseudohypoparathyroidism may represent a variant of pseudohypoparathyroidism, because that condition is usually present in first-degree relatives. Moreover, the clinical features of the two conditions are identical, except for the finding of blue sclerae on ophthalmological exam in patients with pseudo-pseudohypoparathyroidism. In light of the normal laboratory values for calcium, phosphorus, and parathyroid hormone in individuals with pseudopseudohypoparathyroidism, no treatment is indicated. Hyperparathyroidism can be recognized by the clinical features of proximal muscle weakness and atrophy, chondrocalcinosis, pseudogout, abdominal complaints, and nephrolithiasis. Osteopenia may occasionally be present. Laboratory evidence includes hypercalcemia, fasting morning hypophosphatemia, elevated parathyroid hormone level, and the finding of osteitis fibrosa cystica on bone biopsy. Medical referral can assist with determining whether surgical treatment is indicated.
Vitamin Disorders Vitamin D is involved in calcium metabolism. In view of the role of disturbed calcium metabolism in FS (discussed above under “Endocrine Disorders”), it is not surprising that derangements of vitamin D metabolism—for example, 25-hydroxyvitamin D3 deficiency—have also been associated with FS (Martinelli et al. 1993).
Genetic Associations Genetic causes of FS are diverse, and manifestations vary. Many investigators have reported familial cases, reviewed elsewhere (Lowenthal 1986). No specific gene has yet been identified. Modes of inheritance include autosomal dominant (Kobari et al. 1997) and re-
152
Psychiatric Management in Neurological Disease
cessive forms, X-linked dominant (one form of pseudohypoparathyroidism), and possibly others. Fried syndrome is linked to Xp22 and involves severe mental retardation, spastic diplegia, ventricular dilatation, and BGC (Strain et al. 1997). BGC is associated with trisomy 5 (5q35,1→qter) (Nakayama et al. 1993), Down syndrome (trisomy 21) (Okano et al. 1992), and consanguinity. Trisomy 5 is associated with obesity, short stature, extremity and facial malformations, mental retardation, and eczema. Familial BGCs have been associated with hypoparathyroidism (Garcia Urra et al. 1990), ataxia and pigmentary macular degeneration (Strobos et al. 1957), and elevated serum alpha-fetoprotein (Tokoro et al. 1993). Autosomal dominant FS (Ellie et al. 1989; Rossi et al. 1993) is sometimes associated with elevated homocarnosine, a central nervous system (CNS)–specific peptide (Manyam et al. 1992), or with 25-hydroxyvitamin D3 deficiency (Martinelli et al. 1993). FS has been observed in patients with Alport syndrome (Schafer and Ferbert 1998), an autosomal dominant nephritis associated with nerve deafness and occasional ocular defects, including cataracts and defects of the lens, cornea, and retina. Males are more affected than females, and patients usually die of renal failure before the age of 40 years. Autosomal recessive BGC (Rysz et al. 1988) in children is often attended by encephalopathy, microcephaly, dwarfism or short stature, retinal degeneration or optic atrophy, or symmetrical patchy demyelination (Billard et al. 1989). Another form of autosomal recessive BGC is associated with short stature and spondylometaphyseal skeletal dysplasia and can be seen in consanguineous families (Frydman et al. 1990). Other specific types of autosomal recessive BGC involve associations with reduced homocarnosine and histidine levels and the Aicardi-Goutieres syndrome (see “Infantile and Juvenile Basal Ganglia Calcification” subsection below). X-linked dominant BGC is associated with various psychiatric disorders (Francis 1979; Francis and Freeman 1984). Many cases of genetically related BGC have their onset in childhood.
Mitochondrial Myopathies BGC can occur in mitochondrial myopathies. In some mitochondrial myopathies, serum lactic acid is increased and CSF proteins and
Fahr’s Syndrome
153
calcium metabolism may be abnormal. One of these, Kearns-Sayre syndrome, is associated with BGC, progressive external ophthalmoplegia, pigmentary retinal degeneration, and increased CSF protein. BGC has also been associated with an infantile variant of mitochondrial ophthalmoplegia (Bastiaensen et al. 1984). In a review by Pavlakis et al. (1984) of 11 patients with MELAS (mitochondrial myopathy, encephalopathy, lactacidosis, and stroke-like syndromes) and MERRF (myoclonic epilepsy and myopathy with ragged red fibers on histological muscle examination), 5 (45.4%) had BGCs and 3 (27.3%) had symptoms consistent with FS. A recent study of 24 subjects from six kindreds with MELAS revealed BGC to be the most common radiological finding in this mitochondrial disease (Sue et al. 1998).
Neurological and Degenerative Diseases BGC has been described in association with CNS infections (see below) and CNS lupus (Matsumoto et al. 1998), as well as following head injury and anoxia. Although FS is associated with seizure disorders, it may also be associated with anticonvulsant treatment (see “Drugs” subsection below). Several diseases of a progressive or neurodegenerative nature have been associated with BGC. These include earlyonset Alzheimer’s disease, motor neuron disease, and tuberous sclerosis.
Infectious and Immunological Diseases Neurobrucellosis is linked to BGC. Of 65 patients presenting with neuropsychiatric manifestations of brucellosis in one study, 9 (13.8%) had BGC (Mousa et al. 1987). BGC has also been associated with encephalitis and with toxoplasmosis (Lishman 1987). BGC in acquired immunodeficiency syndrome (AIDS) may occur in patients with abnormal calcium metabolism, possibly augmenting the vascular pathology of AIDS and hastening calcification (Fenelon et al. 1993).
Neoplastic Diseases BGC has been associated with malignancies, particularly with multiple myeloma (probable FS), metastatic astrocytoma, and radiation
154
Psychiatric Management in Neurological Disease
therapy (see “Infantile and Juvenile Basal Ganglia Calcification” subsection below).
Dermatological Disorders BGC is associated with dermatological diseases, a sometimes important clinical tip-off (Lowenthal 1986). One of these conditions is lipoid proteinosis (Urbach-Wiethe disease), with manifestations including seizures, dementia, hyalinosis of the skin and mucosa, alopecia, photosensitivity, and dwarfism (Newton et al. 1971). BGC has also been associated with hidrotic-ectodermal dysplasia and mental retardation (Copeland et al. 1977) and with lipomembranous polycystic osteodysplasia and dementia (Matsuo et al. 1982).
Medications Given the utility of anticonvulsants in managing psychiatric disorders, it is worth emphasizing that anticonvulsant treatment has been associated with BGC. Of 72 subjects with BGC identified on CT, 13 (18%) were taking anticonvulsants, of whom 11 were on phenytoin with or without barbiturates and 2 were on carbamazepine (Kazis 1985). It was suggested that anticonvulsant effects on calcium or phosphorus, or the activity of alkaline phosphatase, may relate to this finding.
Infantile and Juvenile Basal Ganglia Calcification Microencephaly, pigmentary macular degeneration, progeria, and abnormal calcium metabolism are variably associated with infantile and juvenile BGC. Infantile FS is rare and heterogeneous in etiology, but it can be associated with infantile spasms, microcephaly, blindness, a burstsuppression pattern on EEG, early death, hyperammonemia, reduced hepatic ornithine transcarbamylase activity, and consanguinity (Matsui et al. 1992). Aicardi-Goutieres syndrome (familial early-onset encephalopathy with BGC and chronic CSF lymphocytosis) is an autosomal recessive disorder characterized by increased CSF interferon-alpha and en-
Fahr’s Syndrome
155
cephalopathy evident shortly after birth and associated with developmental arrest (Tolmie et al. 1995). In a retrospective study of 27 patients with Aicardi-Goutieres syndrome, 19 experienced onset within the first 4 months of life, with microcephaly and severe, progressive brain atrophy developing between 3 and 12 months of age (Goutieres et al. 1998). CSF lymphocytosis persisted beyond 12 months of age in 7 of the children. The 19 patients still alive (6 older than 10 years) at the time of the study were profoundly disabled. There were individual variations in disease severity, rapidity of evolution, and imaging features. Neuropathological examination revealed only focal necrosis and widespread demyelination. High levels of interferon-alpha were found in the serum and CSF in 14 patients, suggesting intrathecal synthesis and the possibility that interferon-alpha may play a role in the pathogenesis of the disorder. Consistent with this hypothesis, transgenic mice have been developed that produce interferon-alpha(l) from astrocytes (Campbell et al. 1999). These mice develop depletion of cholinergic neurons, gliosis, and progressive calcification of the basal ganglia and cerebellum, along with hippocampal hyperexcitability and seizures. Thus, interferon-alpha may foster the development of FS occurring in the context of the Aicardi-Goutieres syndrome. Bode and Rudin (1995) reported a case of human immunodeficiency virus (HIV) infection in a 4-month-old with BGC that they thought might relate to lenticulostriate arteriopathy. Seizures occurred 3 years later in association with then-evident BGC. Infantile BGC has also been reported after intrauterine herpes simplex virus infection. The major associations of juvenile-onset BGC include metabolic, endocrine, genetic, mitochondrial, neurological, systemic, infectious, and neoplastic diseases. A variety of metabolic diseases have been implicated, including abnormal calcium metabolism, dihydropteridine reductase deficiency (with hyperphenylalaninemia or with folate deficiency), biotinidase deficiency, proprionic acidemia, and hyperammonemia with reduced ornithine transcarbamylase activity. Recently, FS was found to be associated with Type I GM1 gangliosidosis presenting in a 10-month-old boy with diffuse cerebral atrophy, craniofacial and skeletal malformations, hepatosplenomegaly, poor oculomotor control, profound hypo-
156
Psychiatric Management in Neurological Disease
tonia, weakness, and brisk reflexes (Chen et al. 1999). Childhood BGC linked to abnormal calcium metabolism can occur with seizures and encephalopathy (Guerreiro and Scotoni 1992). Cases associated with Down syndrome and trisomy 5 may have pediatric presentations. In some cases, presentation may be delayed until puberty (Francis 1979). BGC has been associated with congenital anomalies. Some mitochondrial diseases (see “Mitochondrial Myopathies” subsection earlier in this chapter) may present with BGC in pediatric patients, particularly MERRF. In a study by Legido et al. (1988) involving 4,283 children undergoing CT scans, tuberous sclerosis was present in 14 (29%) of 48 children with radiologically identified BGC. Other neurological disease associations include infantile neuraxonal dystrophy, diffuse cerebral microangiopathy with leukodystrophy, acute hemorrhagic leukoencephalitis, pertussis encephalitis, Cocksackie encephalitis, meningitis, congenital encephalopathies of anoxic and prenatal viral origins, myotonic muscular dystrophy, and neurofibromatosis. Systemic diseases associated with juvenile BGC involve juvenile rheumatoid arthritis, juvenile nephronolithiasis and pancreatic lipomatosis, and intrauterine transfusion. The chief infectious association documented is AIDS. Chronic Epstein-Barr viral infection is also associated with BGC. In the study of Legido et al. (1988) mentioned above, neoplasms of various types were found in 16 (33%) of 48 children with radiologically identified BGC. All of these patients had received radiation therapy to the diencephalon. Coats’ disease, a retinopathy of obscure etiology occurring mainly during the first decade of life, has recently been reported in association with BGC (Goutieres et al. 1999). Occasionally, intraocular bone formation can also occur in Coats’ disease (Senft et al. 1994). Given the substantial number of conditions associated with BGC, it is likely that many more conditions will be identified in the future. It will be important to distinguish between chance associations and causal relationships with BGC. Hopefully, future work will determine which of these conditions cause FS. In the meantime, it is wise to consider the numerous associations of BGC when evaluating patients with FS.
Fahr’s Syndrome
157
Neuroimaging Radiological findings on CT vary from barely noticeable dustlike opacification to more significant radiodensities (Lowenthal 1986). The distribution of calcification is generally limited to the pallidum (i.e., globus pallidus) and striatum (putamen and caudate), cerebellar dentate nucleus, thalamus, centrum semiovale, cerebral cortex, and cerebellar cortex. The pallidum is most commonly involved (Taxer et al. 1986), although the cerebellum is sometimes calcified in isolation (Koller and Klawans 1980). Cortical calcification occurs at the base of the sulci, especially in the frontal, frontoparietal, and posterior temporal areas (Lowenthal 1986). BGC is usually bilaterally symmetrical (Lowenthal 1986) but can present unilaterally (Kashihara and Yabuki 1992). CT has greater diagnostic specificity for FS than does magnetic resonance imaging (MRI), but MRI correlates better with functional impairment (Avrahami et al. 1994; Manyam et al. 1992). CT lesions appear as hyperdensities (Figure 5–1), but deposits can be exaggerated (Kulczycki et al. 1994) and do not correlate well with neurological features (Avrahami et al. 1994). Blood flow to calcified regions is markedly decreased and correlates with clinical condition (Uygur et al. 1995). T2 hyperintensity of white matter and, sometimes, gray matter on MRI is consistent with FS (Avrahami et al. 1994); however, MRI appearance of calcification varies by site, disease stage, and metabolic state. BGCs (Figure 5–2) exhibit reduced signal (Scotti et al. 1985). In children, MRI findings resemble those seen in Hallervorden-Spatz disease (Okano et al. 1992). After birth hypoxia, calcification can be evident by 5 months of age (Akimov 1991). Postanoxic calcification can actually develop within 17 days (Midroni and Willinsky 1992). Calcification in primary hypoparathyroidism is more diffuse than that in BGC of other etiologies (Kazis 1985; Ogata et al. 1987), but postthyroidectomy hypoparathyroidism calcifications are more focal (Konig 1989). Among subjects with postthyroidectomy BGC in the study of Konig (1989), 70% had pallidal calcifications; 12% both pallidal and putaminal calcifications; 6% pallidal and cerebellar calcifications; 3% pallidal, putaminal, caudate, and thalamic calcifications; 5% calcifications of the caudate
158
Psychiatric Management in Neurological Disease
Figure 5–1. Appearance of globus pallidus calcification at several levels, as viewed on computed tomography (CT). Source. Reproduced from Lauterbach EC, Spears TE, Prewett MJ, et al.: “Neuropsychiatric Disorders, Myoclonus, and Dystonia in Calcification of Basal Ganglia Pathways.” Biological Psychiatry 35:345–351, 1994a. Copyright © 1994, Elsevier Science, Inc., 655 Avenue of the Americas, New York, NY 10010-5107. Used with permission.
alone; and 4% pontine calcifications (Konig 1989). Among the patients with BGC who had not undergone thyroidectomy, 53% had pallidal calcifications; 23% pallidal, putaminal, caudate, thalamic, cerebellar, and white matter calcifications; 14% pallidal and cerebel-
Fahr’s Syndrome
159
Figure 5–2. Reduced signal in the globus pallidus due to calcification, as viewed on T2-weighted magnetic resonance imaging (MRI). Source. Reproduced from Lauterbach EC, Spears TE, Prewett MJ, et al.: “Neuropsychiatric Disorders, Myoclonus, and Dystonia in Calcification of Basal Ganglia Pathways.” Biological Psychiatry 35:345–351, 1994a. Copyright © 1994, Elsevier Science, Inc., 655 Avenue of the Americas, New York, NY 10010-5107. Used with permission.
160
Psychiatric Management in Neurological Disease
lar calcifications; and 10% pallidal and caudate calcifications. In Kazis’ study of 72 patients with BGC, selective calcification of the globus pallidus was not associated with parathyroid disturbances, in contrast to the findings in Konig’s study.
Clinical and Laboratory Investigation FS must be actively considered by the clinician in order to avoid missing the diagnosis. For example, a 60-year-old patient diagnosed with delusional disorder and tardive dyskinesia was later found to have Fahr’s disease with secondary delusions and choreoathetosis (Chiu et al. 1993). Gradually progressive symptoms with atypical onset, neurological signs, or family history of neuropsychiatric diagnoses, especially in patients with conditions known to be associated with BGC, warrant workup. One guideline is that every first-onset case of dementia, psychosis, or mood disorder deserves an MRI scan. Mineralization on MRI should be evaluated by CT scan. The presence of calcification on imaging in patients under 50 years of age merits an etiological workup (Rasmussen et al. 1991). Following clinical and radiological ascertainment of FS, serum calcium, ionized calcium, magnesium, parathormone (i.e., PTH or parathyroid hormone), and fasting morning phosphorus levels should be obtained to exclude the disorders of calcium metabolism detailed above (Avrahami et al. 1994). The clinician should determine whether the patient has undergone thyroidectomy (parathyroid glands are sometimes removed with thyroid tissue); look for the clinical features of these disorders (see “Endocrine Disorders” under “Etiologies” section earlier in chapter); and obtain endocrinological consultation if endocrinological signs are present or laboratory findings are abnormal. Following this initial evaluation, the clinician should consider clinical features consistent with other causes. The EEG displays many different abnormalities in FS; there is no characteristic pattern. Triphasic EEG waves with normal brainstem auditory evoked responses and somatosensory evoked potentials have been observed in Fahr’s disease (Aguglia et al. 1990). Other tests of potential diagnostic value include alkaline phosphatase, 24-hour urinary calcium and phosphorus excretion, calcitonin, serum cyclic adenosine monophosphate (cAMP), urinary cAMP,
Fahr’s Syndrome
161
serum creatine, osteocalcin, serum lactic acid at rest and after exercise, and 1,25-dihydroxyvitamin D3 (Martinelli et al. 1993).
Psychiatric Manifestations A wide variety of psychopathology has been associated with FS. Cognitive disturbances, dementia, delirium, hallucinations, delusions, ideas of reference and influence, paranoia, catatonia, and mood disorders are not infrequent (Lowenthal 1986). Symptomatic features and age at onset can vary from patient to patient, regardless of FS etiology. Clinical features may change over time, progressing from psychosis to frank dementia (Rosenberg et al. 1991) as basal ganglia–thalamofrontal and other circuits become calcified (Lauterbach et al. 1994a). Psychiatric symptoms are common in FS. Among 62 subjects with FS studied by Konig (1989), about half had psychiatric symptoms. Mental disorders are more common with more extensive calcification (Kazis 1985; Konig 1989) and subarachnoid space dilatation (Kazis 1985), although psychiatric symptoms have not been found to correlate with calcific distribution (Konig 1989). Prevalences of specific DSM-III (American Psychiatric Association 1980) psychiatric diagnoses from the study of Konig (1989) are listed in Table 5–4. Prevalences of psychiatric disorders grow over the disease course, especially those of cognitive, mood, and compulsive disorders. Possible pathophysiologies underlying psychiatric phenomena in FS have been discussed elsewhere (Lauterbach et al. 1994a). More evidence is needed to determine whether the underlying etiologies of FS influence the frequency of psychiatric presentation. Konig (1989) compared the rates of psychiatric disorders in cases of parathyroid disorder (n = 418) and BGC of other etiologies (n = 213) reported in the literature and found that the rates were similar. Kazis (1985), however, found mental disorders in 7 (50%) of 14 patients with hypoparathyroid BGC, in contrast to 20 (34.5%) of 58 patients with BGC of other etiologies.
Cognitive Impairment and Dementia Follow-up of 18 subjects within 2 years after CT identification of BGC revealed impaired motor speed, executive function, visuospatial
162
Table 5–4.
Psychiatric presentations and their frequencies in Fahr’s syndrome Follow-up (n = 35), no. (%)
FS lit, %
PT lit, %
5 (7.6) 1 (1.6) 13 (21.0) 1 (1.6) 5 (8.0)
12 (34.3) 1 (2.9) 23 (65.7) 4 (11.4)
24 5 12 1
22 7 11 1
3 (8.6)
2
1
Note. Data from Konig (1989) indicating prevalences of DSM-III (American Psychiatric Association 1980) and ICD-9 (World Health Organization 1978) disorders on initial presentation (n = 62) and on long-term follow-up (n = 35), as well as rates from a literature review of 213 Fahr’s syndrome (FS lit) and 418 parathyroid (PT lit) patients.
Psychiatric Management in Neurological Disease
Dementia/mental retardation Organic paranoia/hallucinations Organic affective disorder Compulsions Alcoholism Addictions/personality alterations
Initial (n = 62), no. (%)
Fahr’s Syndrome
163
skills, and selected memory functions in patients with BGC compared with matched controls. These findings were consistent with neuropsychological impairment attributable to basal ganglia, frontal, and limbic dysfunction (López-Villegas et al. 1996). Cognitive impairment may occur in association with depression, dysarthria, postural tremor, and parkinsonism, all of which have been observed in autosomal dominant FS with striopallidodentate calcifications and 25-hydroxyvitamin D3 deficiency (Martinelli et al. 1993). Apathy (Seidler 1985) and amnesia (Lauterbach et al. 1994a) can also occur. FS may present as a dementia with subcortical features (poor memory retrieval, movement disorder, and amotivation) occurring in the sixth decade of life (Cummings 1985). Patients may develop dementia as lesions progress. Dementia and associated emotional lability and anxiety are progressive (Lowenthal 1986). For example, in a case reported by Rosenberg et al. (1991), a patient with FS experienced psychosis at age 19 years, with subsequent development of intellectual impairment and speech dyscoordination by age 50 years and dementia with impaired calculations, abstraction, construction, and praxis by age 63 years. The dementia was attended by agitation and dehydration. The neuropathology of the dementia of FS involves frontotemporal atrophy, neocortical neurofibrillary tangles, and neuronal loss in the nucleus basalis of Meynert, but senile plaques are absent (Shibayama et al. 1992). Other neuropathological features of the dementia include calcareous deposition, white matter demyelination, and fibrous gliosis. In a follow-up study of 35 patients with FS, nearly all of the patients showed intellectual impairment, and almost one-third had dementia or mental retardation (Konig 1989). This represented nearly a fivefold increase in dementia relative to the initial evaluation. More severe mental deterioration has been correlated with more extensive calcification (Konig 1989; Taxer et al. 1986). Dementia has also been associated with centrum semiovale calcification (Avrahami et al. 1994).
Psychosis Paranoid and psychotic features often present between the ages of 20 and 40 years (Cummings 1985). Symptoms include auditory halluci-
164
Psychiatric Management in Neurological Disease
nations (sometimes musical), complex visual hallucinations, perceptual distortions, paranoid delusions or trends, and fugue states (Lauterbach et al. 1994a; Rosenberg et al. 1991; Wodarz et al. 1995). In a study of a kindred with FS, seven family members with autosomal dominant probable FS exhibited schizophreniform psychoses over four generations, with variable constellations of hallucinations, delusions, thought disorders, and abnormal sensitivity to neuroleptic extrapyramidal side effects; one child had developmental delays (Francis 1979; Francis and Freeman 1984). A statistical association between psychosis and BGC has been disputed (Flint and Goldstein 1992). The frequency of psychotic features in BGC patients is not significantly higher than that in subjects lacking such lesions (Forstl et al. 1991, 1992; Konig 1989). However, nonspecific paranoia occurs more commonly in BGC patients than in control subjects who have neuropsychiatric disorders but lack BGC (Forstl et al. 1991). Even if schizophrenia is not increased in BGC, BGC may be increased in schizophrenia (Fernandez-Bouzas et al. 1990). Cummings (1985) has suggested that psychosis is associated with FS initially presenting during the third decade of life. It is possible that the lack of a formal association (Forstl et al. 1991) may relate to the low frequency of psychosis and its limitation to the early stages of BGC.
Mood Disorders Mood disorders are the most common feature of FS. Among subjects with BGC, mood disorders are initially present in one-fifth, eventually develop in two-thirds, and occur more commonly than in control subjects who have neuropsychiatric disorders but lack BGC (Forstl et al. 1991; Konig 1989). Mania eventually develops in up to 20%, with unipolar mania occurring in an additional 11% (Konig 1989; LópezVillegas et al. 1996; Trautner et al. 1988). Reduced excitation of temporo-orbitofrontal areas in the context of subcortical or cerebellar calcifications may lead to bipolar syndromes (Lauterbach 1996; Lauterbach et al. 1992). Perhaps half of patients with BGC will develop depression at some point over the illness course. One study found DSM-III depressive disorders in 13 (37%) of 35 BGC patients (Konig 1989), and another found DSM-III-R (American Psychiatric
Fahr’s Syndrome
165
Association 1987) minor depressive symptomatology in 3 (16.7%) of 18 patients (López-Villegas et al. 1996). Pathophysiological mechanisms leading to depression in FS are discussed in Figure 5–3.
Anxiety Disorders Up to one-third of patients with BGC have DSM-III-R obsessivecompulsive disorder (Konig 1989; López-Villegas et al. 1996). The exact rates of other anxiety disorders in BGC patients remain to be determined. In our own studies of patients with focal basal ganglia vascular lesions, left external pallidal lesions occurred significantly more often in patients with secondary generalized anxiety than in patients with focal basal ganglia lesions but no anxiety (Lauterbach et al. 1994c); however, the lesions were not attributable to BGC. The correlates of anxiety in FS remain to be defined.
Other Psychiatric Disorders Substance abuse and personality alterations occurred in 3 (8.6%) of 35 patients with BGC in the study of Konig (1989), similar to rates in the general population. Rates of other disorders in FS patients have not been reported.
Neurological and Psychiatric Management Early detection of FS and treatment of the underlying cause may be critical in some cases and may abate the calcification process. For example, Chow and Lu (1989) described a case in which the discovery of hypoparathyroidism with subsequent prompt treatment led to reversal of mental retardation in a 3-year-old. In other cases, treating the underlying etiology can result in symptomatic improvement. Seizures and movement disorders (e.g., hemichorea) in FS attributable to parathyroid disorders may improve with correction of phosphate and calcium levels (el Maghraoui et al. 1995). For example, treatment with alpha-hydroxyvitamin D3 markedly improved neurological manifestations in one patient with BGC associated with hypoparathyroidism (Abe et al. 1996). In another patient with BGC associated with MELAS, corticosteroid treatment reversed neurological deficits (Gubbay et al. 1989). Genetic etiologies of FS should be
166
Psychiatric Management in Neurological Disease
Fahr’s Syndrome
167
Figure 5–3. Depression in Fahr’s syndrome may occur through any of several neural circuitry mechanisms: 1. Calcification (signified by diagonal shading) of the internal globus pallidus (GPi) disinhibits magnocellular mediodorsal (MDmc) thalamic stimulation to the orbitofrontal cortex (OBFC), leading to inhibition of the dorsal prefrontal cortex (DPFC) and the medial frontal cortex (MFC). Reduced DPFC function has been correlated with both depression and dementia (explained in Lauterbach et al. 1994a). 2. Calcification of the external globus pallidus (GPe) disinhibits noncalcified GPi neurons, thereby inhibiting parvocellular mediodorsal (MDpc) thalamic stimulation to the DPFC, reducing DPFC function, consistent with physiological findings in depression and cognitive dysfunction (discussed in Lauterbach et al. 1997a, 1997b). This physiological state results because GPi circuitry directly regulated by the caudate nucleus projects to the MDmc thalamic neurons that regulate the OBFC, whereas GPi circuitry directly regulated by GPe projects to the MDpc thalamic neurons that regulate the DPFC (reviewed in Lauterbach et al. 1997a). Consistent with this second mechanism, recent data suggest that in Fahr’s syndrome, the external pallidum is more often calcified than the internal pallidum (see “Pathological Features” section); furthermore, depression correlated best with left external pallidal lesions among patients with focal basal ganglia infarcts (Lauterbach et al. 1997a). 3. Calcification of thalamic projections to the DPFC, the MFC, and the lateral frontal regions would result in the frontal dysfunction that attends depressive and cognitive disorders. In addition, destruction of pulvinar or central thalamic nuclei can lead to depression, possibly through connections with limbic structures (Lauterbach et al. 1994b). Thus, it is possible that several mechanisms could lead to the development of different types of depressive disorders. Legend: Lines ending in arrowheads signify excitatory connections; lines ending in bars indicate inhibitory connections. Dashed lines indicate reduced transmission; other lines indicate increased transmission. Source. Reproduced from Lauterbach EC, Jackson JG, Wilson AN, et al.: “Major Depression After Left Posterior Globus Pallidus Lesions.” Neuropsychiatry, Neuropsychology, and Behavioral Neurology 10:9–16, 1997a. Copyright © 1997, Lippincott-Raven Publishers. Used with permission.
168
Psychiatric Management in Neurological Disease
considered as a possible cause, especially in the absence of nongenetic causes, and family members of patients with FS should be screened for FS and genetic causes (e.g., familial hypoparathyroidism). Beyond treating the underlying conditions, there are no treatments capable of limiting calcification progression, although a theoretically appealing but unconfirmed report has described beneficial effects with chelators (xydifon, penicillamine, deferoxamine) used with antioxidants and calcium antagonists (Skvortsov et al. 1987). Loeb (1998) described a patient with Fahr’s disease who was treated with disodium etidronate. Despite improvement in gait and speech, there was no improvement in calcifications, spasticity, dystonia, or ataxia. No systematically conducted controlled studies have examined psychotropic treatment in FS (Rummans et al. 1999). Given this lack of data, treatment depends on the manifestations present as well as on the presence of features that may limit treatment options (e.g., dementia is worsened by anticholinergic side effects, parkinsonism is worsened by neuroleptics). Thus, patients should be thoroughly evaluated medically and neurologically. Knowing the neurological and psychiatric problems for which FS patients are at risk (Tables 5–1 and 5–4) can assist the clinician in planning treatment. Patients with FS may also have heart, renal, or other organ system diseases that influence the use of psychotropics (see Chapter 1 in this volume). No specific gender-related treatment concerns exist; however, the usual caveats regarding pharmacotherapy during pregnancy apply. Assignment to support groups depends on the type of symptomatology present (see Chapter 1 for information on support group resources). Patients may or may not respond to conventional treatments. Most FS parkinsonisms have been reported to respond to L-dopa, but some fail to respond to either L-dopa or treatment of underlying hypoparathyroidism (Lauterbach et al. 1998). Patients with psychosis may be unresponsive to neuroleptics and may be predisposed to neuroleptic malignant syndrome (NMS). NMS may at times be refractory to bromocriptine but responsive to dantrolene (Rosenberg et al. 1991). In treating psychosis (especially in parkinsonian FS patients), 5-HT2A receptor antagonists (olanzapine, risperidone, quetiapine,
Fahr’s Syndrome
169
clozapine) may be useful, because they are less likely to cause extrapyramidal syndromes. Atypical antipsychotics may offer a distinct advantage in treating patients with FS and psychosis; however, the caveats discussed in Chapter 1 of this volume should be borne in mind. Although clozapine can improve some parkinsonian features, it can also produce cognitive impairment and seizures, conditions for which FS patients are at special risk. Some cases of FS may respond in an unconventional manner to treatment. Munir (1986) described the case of a 20-year-old man with Fahr’s disease and psychosis. The psychosis was refractory to haloperidol pharmacotherapy but responded to lithium carbonate. In contrast, Trautner et al. (1988) reported the case of a patient with Fahr’s disease and chronic mania who failed to respond to lithium, haloperidol, and carbamazepine. Despite a possible theoretical association of anticonvulsants with FS as suggested by Kazis (1985) (see “Drugs” under “Etiologies” section earlier in chapter), there is no evidence at present to suggest that anticonvulsant therapy hastens the progression of calcifications. Caution is indicated when using lithium, because it can further increase the risk of seizures in patients with FS. Treatment of seizure, bipolar, behavioral, and anxiety disorders requires special vigilance in FS. Sedating drugs such as carbamazepine, benzodiazepines, and barbiturates may exacerbate underlying cognitive impairment and gait disorders. Because of its lower propensity to impair cognition, valproate may be particularly useful in treating epilepsy with psychosis, and it may also be effective in treating the psychotic element of bipolar psychoses (McElroy et al. 1996). Patients with subcortical lesions may exhibit forme fruste (limited-symptom) presentations, complex hybrid disorders, and unusual responses. For example, we encountered a patient with a thalamic lesion who developed pathological laughter, two different diurnally varying major depressions occurring simultaneously, and superimposed bouts of atypical depression. These syndromes (excepting the evening major depression) responded well to fluoxetine. The evening major depression responded selectively to bupropion (Lauterbach et al. 1994b). Given the multiple lesion sites in FS, including the thalamus, a flexible pharmacological approach may be needed in some patients.
170
Psychiatric Management in Neurological Disease
Absent controlled data, conventional antidepressant and anxiolytic agents may be used for the variety of psychiatric disorders that can beset the FS patient, but the psychiatrist must remain vigilant for side effects, especially neurological side effects, which may be precipitated at a lower threshold in FS patients than in individuals without the syndrome. Of four patients with Fahr’s disease and depression whose cases were reported by Trautner et al. (1988), three responded in a conventional manner to antidepressant treatments, including imipramine and electroconvulsive therapy (ECT). Because selective serotonin reuptake inhibitors and buspirone can elicit dystonia (see Chapter 6 in this volume), caution is indicated. Bupropion and tricyclic antidepressants can increase seizure risk. Tricyclics and benzodiazepines can impair cognition. Whether tacrine or donepezil has utility is unknown. Although ECT has been successfully used in depressed FS patients (Trautner et al. 1988), it is probably best avoided, given the risk of seizures associated with the syndrome, the presence of an intracranial mass in the form of calcification, and the variably increased intracranial pressure seen in some FS patients. In any event, vigilance and careful attention are indicated in treating patients with FS and psychiatric manifestations.
Summary FS is a disorder involving basal ganglia calcification, especially the globus pallidus. Calcifications are best seen on CT. Various neuropsychiatric manifestations occur, ranging from seizures and extrapyramidal reactions to dementia and other psychiatric syndromes. Mood disorders are especially common. Psychiatric manifestations vary from individual to individual and may relate to variable degrees of calcification. There are many potential causes of FS, some genetic and others related to clinical conditions. The age of presentation can range from infancy to late adulthood, depending on the cause. It is essential to exclude disorders of calcium metabolism (e.g., hypoparathyroidism) as well as other etiologies. Treatment consists of addressing the underlying cause and treating the neuropsychiatric sequelae. Treatment of these sequelae poses special considerations, necessitating considerable vigilance in anticipating and monitoring side effects. Much more data are needed regarding psychiatric
Fahr’s Syndrome
171
sequelae, their treatment, and interventions aimed at preventing progression of the lesions when treatable underlying etiologies are absent.
References Abe S, Tojo K, Ichida K, et al: A rare case of idiopathic hypoparathyroidism with varied neurological manifestations. Intern Med 35:129–134, 1996 Adachi M, Hosoya T, Yamaguchi K: Non-calcified line in calcification of the globus pallidus [in Japanese]. Nippon Igaku Hoshasen Gakkai Zasshi 54:1347–1351, 1994 Aguglia U, Gambardella A, Oliveri RL, et al: Nonmetabolic causes of triphasic waves: a reappraisal. Clin Electroencephalogr 21:120–125, 1990 Akimov OV: Fahr’s syndrome and infantile cerebral palsy—the sequelae of very severe hypoxia at birth in a child [in Russian]. Arkh Patol 53:59–61, 1991 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition. Washington, DC, American Psychiatric Association, 1980 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised. Washington, DC, American Psychiatric Association, 1987 Arias Mayorga J, Gonzalez Martin T, Escorial Miguel C, et al: Intracranial calcifications in the differential diagnosis of epileptic disease [in Spanish]. Rev Clin Esp 189:425–427, 1991 Arranz Perez M, Ergueta Martin P, Gonzalez Sarmiento E, et al: Fahr’s disease and hypocalcemic syndromes: presentation of a clinical case [in Spanish]. Anales de Medicina Interna (Madrid) 9:495–497, 1992 Avrahami E, Cohn DF, Feibel M, et al: MRI demonstration and CT correlation of the brain in patients with idiopathic intracerebral calcification. J Neurol 241:381–384, 1994 Basser LS, Neale FC, Ireland AW, et al: Epilepsy and electroencephalographic abnormalities in chronic surgical hypoparathyroidism. Ann Intern Med 71:507–515, 1969 Bastiaensen LAK, Stadhouders AM, Ter Laak HJ, et al: Kearns-Sayre syndrome. Neuro-Ophthalmology 4:55–63, 1984 Beall SS, Patten BM, Mallette L, et al: Abnormal systemic metabolism of iron, porphyrin, and calcium in Fahr’s syndrome. Ann Neurol 26:569– 575, 1989
172
Psychiatric Management in Neurological Disease
Billard C, Dulac O, Bouloche J, et al: Encephalopathy with calcifications of the basal ganglia in children: a reappraisal of Fahr’s syndrome with respect to 14 new cases. Neuropediatrics 20:12–19, 1989 Bode H, Rudin C: Calcifying arteriopathy in the basal ganglia in human immunodeficiency virus infection. Pediatr Radiol 25:72–73, 1995 Bouras C, Giannakopoulos P, Good PF, et al: A laser microprobe mass analysis of trace elements in brain mineralizations and capillaries in Fahr’s disease. Acta Neuropathol (Berl) 92:351–357, 1996 Brannan TS, Burger AA, Chaudhary MY: Bilateral basal ganglia calcifications visualised on CT scan. J Neurol Neurosurg Psychiatry 43:403–406, 1980 Bruyn GW, Bots GT, Staal A: Familial bilateral vascular calcification in the central nervous system. Psychiatry Neurol Neurochir 67:342–376, 1964 Campbell IL, Krucker T, Steffensen S, et al: Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. Brain Res 835:46–61, 1999 Chen CC, Chiu PC, Shieh KS: Type I GM1 gangliosidosis with basal ganglia calcification: a case report. Chung Hua I Hsueh Tsa Chih (Taipei) 62:40– 45, 1999 Chiu HF, Lam LC, Shum PP, et al: Idiopathic calcification of the basal ganglia. Postgrad Med J 69:68–70, 1993 Chow KS, Lu DN: Primary hypoparathyroidism with basal ganglia calcification: report of a case [in Chinese]. Acta Paediatr Sin 30:129–33, 1989 Copeland DD, Lamb WA, Klintworth GK: Calcification of basal ganglia and cerebellar roof nuclei in a mentally defective patient with hidrotic ectodermal dysplasia. Neurology 27:1029–1033, 1977 Cummings JL: Clinical Neuropsychiatry. Orlando, FL, Grune & Stratton, 1985 Danowski TS, Lasser EC, Wechsler RL: Calcification of basal ganglia in post-thyroidectomy hypoparathyroidism. Metabolism 9:1064–1065, 1960 Delplace PO, Wery D, Lemort M, et al: A case of multiple brain calcifications associated with hypoparathyroidism [in French]. J Belge Radiol 72:263–266, 1989 el Maghraoui A, Birouk N, Zaim A, et al: Fahr syndrome and dysparathyroidism: 3 cases [in French]. Presse Med 24:1301–1304, 1995 Ellie E, Julien J, Ferrer X: Familial idiopathic striopallidodentate calcifications. Neurology 39:381–385, 1989 Fahr T: Idiopathische verkalkung der hirngefässe. Centralbl F Allg Path U Path Anat 50:129–133, 1931
Fahr’s Syndrome
173
Fenelon G, Gray F, Paillard F, et al: A prospective study of patients with CT detected pallidal calcifications. J Neurol Neurosurg Psychiatry 56:622– 625, 1993 Fernandez-Bouzas A, Angrist B, Hemdal P, et al: Basal ganglia calcification in schizophrenia (letter). Biol Psychiatry 27:682–685, 1990 Flint J, Goldstein LH: Familial calcification of the basal ganglia: a case report and review of the literature. Psychol Med 22:581–595, 1992 Forstl H, Krumm B, Eden S, et al: What is the psychiatric significance of bilateral basal ganglia mineralization? Biol Psychiatry 29:827–833, 1991 Forstl H, Krumm B, Eden S, et al: Neurological disorders in 166 patients with basal ganglia calcification: a statistical evaluation. J Neurol 239:36– 38, 1992 Francis AF: Familial basal ganglia calcification and schizophreniform psychosis. Br J Psychiatry 79:360–362, 1979 Francis A, Freeman H: Psychiatric abnormality and brain calcification over four generations. J Nerv Ment Dis 172:166–170, 1984 Frydman M, Bar-Ziv J, Preminger-Shapiro R, et al: Possible heterogeneity in spondyloenchondrodysplasia: quadriparesis, basal ganglia calcifications, and chondrocyte inclusions. Am J Med Genet 36:279–284, 1990 Garcia Urra D, Barquero Jimenez MS, Varela de Seijas E, et al: Calcification of the basal ganglia and hypoparathyroidism: Fahr disease. Study of a family [in Spanish]. Arch Neurobiol (Madr) 53:18–22, 1990 Geschwind DH, Loginov M, Stern JM: Identification of a locus on chromosome 14q for idiopathic basal ganglia calcification (Fahr disease). Am J Hum Genet 65:764–772, 1999 Goutieres F, Aicardi J, Barth PG, et al: Aicardi-Goutieres syndrome: an update and results of interferon-alpha studies. Ann Neurol 44:900–907, 1998 Goutieres F, Dollfus H, Becquet F, et al: Extensive brain calcification in two children with bilateral Coats’ disease. Neuropediatrics 30:19–21, 1999 Gubbay SS, Hankey GJ, Tan NT, et al: Mitochondrial encephalomyopathy with corticosteroid dependence. Med J Aust 151:100–103, 1989 Guerreiro MM, Scotoni AE: Basal ganglia calcifications in children [in Portuguese]. Arq Neuropsiquiatr 50:513–518, 1992 Harrington MG, MacPherson P, McIntosh WB, et al: The significance of the incidental finding of basal ganglia calcification on computed tomography. J Neurol Neurosurg Psychiatry 44:1168–1170, 1981 Kashihara K, Yabuki S: Unilateral choreic movements in idiopathic hypoparathyroidism [in Japanese]. No To Shinkei 44:477–480, 1992
174
Psychiatric Management in Neurological Disease
Kazis AD: Contribution of CT scan to the diagnosis of Fahr’s syndrome. Acta Neurol Scand 71:206–211, 1985 Kendall B, Cavanagh N: Intracranial calcification in pediatric computed tomography. Neuroaudiology 28:324–330, 1986 Klein C, Vieregge P, Kompf D: Paroxysmal choreoathetosis in a patient with idiopathic basal ganglia calcification, chorea, and dystonia. Mov Disord 12:254–255, 1997 Kobari M, Nogawa S, Sugimoto Y, et al: Familial idiopathic brain calcification with autosomal dominant inheritance. Neurology 48:645–649, 1997 Kobayashi S, Yamadori I, Miki H, et al: Idiopathic nonarteriosclerotic cerebral calcification (Fahr’s disease): an electron microscopic study. Acta Neuropathol (Berl) 73:62–66, 1987 Koller WC, Klawans HL: Cerebellar calcification on computerized tomography. Ann Neurol 7:193–194, 1980 Konig P: Psychopathological alterations in cases of symmetrical basal ganglia sclerosis. Biol Psychiatry 25:459–468, 1989 Kulczycki J, Boguslawska-Staniaszczyk R, Kozlowski P: The image of intracerebral calcification in CT and MR studies: a case report of Fahr syndrome [in Polish]. Neurol Neurochir Pol 28:915–920, 1994 Lauterbach EC: Bipolar disorders, dystonia, and compulsion after dysfunction of the cerebellum, dentatorubrothalamic tract, and substantia nigra. Biol Psychiatry 40:726–730, 1996 Lauterbach EC, Spears TE, Price ST: Bipolar disorder in idiopathic dystonia: clinical features and possible neurobiology. J Neuropsychiatry Clin Neurosci 4:435–439, 1992 Lauterbach EC, Spears TE, Prewett MJ, et al: Neuropsychiatric disorders, myoclonus, and dystonia in calcification of basal ganglia pathways. Biol Psychiatry 35:345–351, 1994a Lauterbach EC, Price ST, Spears TE, et al: Serotonin responsive and nonresponsive diurnal depressive mood disorders and pathological affect in thalamic infarct associated with myoclonus and blepharospasm. Biol Psychiatry 35:488–490, 1994b Lauterbach EC, Wilson AN, Price ST, et al: Post-stroke generalized anxiety: parkinsonism, dystonia, and the globus pallidus (abstract). Biol Psychiatry 35:681, 1994c Lauterbach EC, Jackson JG, Wilson AN, et al: Major depression after left posterior globus pallidus lesions. Neuropsychiatry Neuropsychol Behav Neurol 10:9–16, 1997a
Fahr’s Syndrome
175
Lauterbach EC, Jackson JG, Price ST, et al: Clinical, motor, and biological correlates of depressive disorders after focal subcortical lesions. J Neuropsychiatry Clin Neurosci 9:259–266, 1997b Lauterbach EC, Cummings JL, Duffy J, et al: Neuropsychiatric correlates and treatment of lenticulostriatal diseases: a review of the literature and overview of research opportunities in Huntington’s, Wilson’s, and Fahr’s diseases. J Neuropsychiatry Clin Neurosci 10:249–266, 1998 Legido A, Zimmerman RA, Packer RJ, et al: Significance of basal ganglia calcification on computed tomography in children. Pediatr Neurosci 14:64–70, 1988 Lishman WA: Organic Psychiatry, 2nd Edition. Oxford, UK, Blackwell Scientific Publications, 1987 Loeb JA: Functional improvement in a patient with cerebral calcinosis using a bisphosphonate. Mov Disord 13:345–349, 1998 López-Villegas D, Kulisevsky J, Deus J, et al: Neuropsychological alterations in patients with computed tomography-detected basal ganglia calcification. Arch Neurol 53:251–256, 1996 Lowenthal A: Striopallidodentate calcifications, in Handbook of Clinical Neurology, Vol 5 (49): Extrapyramidal Disorders. Edited by Vinken PJ, Bruyn GW, Klawans HL. Amsterdam, Elsevier Science BV, 1986, pp 417–436 Manyam BV, Bhatt MH, Moore WD, et al: Bilateral striopallidodentate calcinosis: cerebrospinal fluid, imaging, and electrophysiological studies. Ann Neurol 31:379–384, 1992 Martinelli P, Giuliani S, Ippoliti M, et al: Familial idiopathic strio-pallidodentate calcifications with late onset extrapyramidal syndrome. Mov Disord 8:220–222, 1993 Matsui K, Yamada M, Kobayashi T, et al: An autopsy case of Fahr disease (infantile form) [in Japanese]. No To Hattatsu 24:358–363, 1992 Matsumoto R, Shintaku M, Suzuki S, et al: Cerebral perivenous calcification in neuropsychiatric lupus erythematosus: a case report. Neuroradiology 40:583–586, 1998 Matsuo T, Suetsugu M, Eguchi M, et al: Membranous lipodystrophy: a case report. Arch Psychiatr Nervenkr 231:123–130, 1982 McElroy SL, Keck PE, Stanton SP, et al: A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 57:142–146, 1996 Midroni G, Willinsky R: Rapid postanoxic calcification of the basal ganglia. Neurology 42:2144–2146, 1992
176
Psychiatric Management in Neurological Disease
Mousa AM, Muhtaseb SA, Reddy RR, et al: The high rate of prevalence of CT-detected basal ganglia calcification in neuropsychiatric (CNS) brucellosis. Acta Neurol Scand 76:448–456, 1987 Munir KM: The treatment of psychotic symptoms in Fahr’s disease with lithium carbonate. J Clin Psychopharmacol 6:36–38, 1986 Murphy MJ: Clinical correlations of CT scan–detected calcifications of the basal ganglia. Ann Neurol 6:507–511, 1979 Nakayama T, Sakakihara Y, Hanaoka S, et al: Calcification of basal ganglia in a patient with partial trisomy 5q and partial monosomy 18q. Acta Paediatr Jpn 35:340–344, 1993 Newton FH, Rosenberg RN, Lampert PW, et al: Neurologic involvement in Urbach-Wiethe’s disease (lipoid proteinosis): a clinical, ultrastructural, and chemical study. Neurology 21:1205–1213, 1971 Ogata A, Ishida S, Wada T: A survey of 37 cases with basal ganglia calcification (BGC): CT-scan findings of BGC and its relationship to underlying diseases and epilepsy. Acta Neurol Scand 75:117–124, 1987 Okano S, Takeuchi Y, Kohmura E, et al: Globus pallidus calcification in Down syndrome with progressive neurologic deficits. Pediatr Neurol 8:72–74, 1992 Ostertag B: Über die besondere Lokalisation gebundenen Konkremente des ZNS und ihre Beziehungen zur Verkalkung intrazerebraler Gefässe Erkrankungen. Virchows Arch Path Anat 275:829–859, 1922 Pavlakis SG, Phillips PC, Di Mauro S, et al: Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive syndrome. Ann Neurol 16:481–488, 1984 Rasmussen MJ, Pilo L, Nielsen HR: Basal ganglia calcifications demonstrated by CT: is further investigation necessary when this is found incidentally? [in Danish]. Ugeskr Laeger 153:2051–2053, 1991 Rosenberg DR, Neylan TC, El-Alwar M, et al: Neuropsychiatric symptoms associated with idiopathic calcification of the basal ganglia. J Nerv Ment Dis 179:48–49, 1991 Rossi M, Morena M, Zanardi M: Calcification of the basal ganglia and Fahr disease: report of two clinical cases and review of the literature [in Italian]. Recenti Prog Med 84:192–198, 1993 Rummans TA, Lauterbach EC, Coffey CE, et al: Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci 11:176–189, 1999 Rysz A, Gajkowski K, Empel A: Familial occurrence of calcinosis of the basal ganglia [in Polish]. Neurol Neurochir Pol 22:459–462, 1988
Fahr’s Syndrome
177
Schafer M, Ferbert A: Calcinosis of the basal ganglia and hypoparathyroidism [in German]. Nervenarzt 69:873–878, 1998 Scotti G, Scialfa G, Tampieri D, et al: MR imaging in Fahr disease. J Comput Assist Tomogr 9:790–792, 1985 Seidler GH: Psychiatric and psychological aspects of Fahr syndrome [in German]. Psychiatr Prax 12:203–205, 1985 Senft SH, Hidayat AA, Cavender JC: Atypical presentation of Coats disease. Retina 14:36–38, 1994 Shibayama H, Kobayashi H, Nakagawa M, et al: Non-Alzheimer non-Pick dementia with Fahr’s syndrome. Clin Neuropathol 11:237–250, 1992 Skvortsov IA, Rudenskaia GE, Karaseva AN, et al: Effectiveness of the therapeutic use of complexones in various diseases of the extrapyramidal system in children [in Russian]. Zh Nevropatol Psikhiatr 87:1457–1462, 1987 Spatz H: Über den Eisennachweis im Gehirn, besonders in Zentren des extrapyramidal-motorischen Systems. Zentralbl Gesamte Neurol Psychiatry 77:261, 1922 Strain L, Wright AF, Bonthron DT: Fried syndrome is a distinct X-linked mental retardation syndrome mapping to Xp22. J Med Genet 34:535– 540, 1997 Strobos RRJ, De La Torre E, Martin JF: Symmetrical calcification of the basal ganglia with familial ataxia and pigmentary macular degeneration. Brain 80:313–318, 1957 Sue CM, Crimmins DS, Soo YS, et al: Neuroradiological features of six kindreds with MELAS tRNA(Leu) A2343G point mutation: implications for pathogenesis. J Neurol Neurosurg Psychiatry 65:233–240, 1998 Taxer F, Haller R, Konig P: Clinical early symptoms and CT findings in Fahr syndrome [in German]. Nervenarzt 57:583–588, 1986 Tokoro K, Chiba Y, Ohtani T, et al: Pineal ganglioglioma in a patient with familial basal ganglia calcification and elevated serum alpha-fetoprotein: case report. Neurosurgery 33:506–511, 1993 Tolmie JL, Shillito P, Hughes-Benzie R, et al: The Aicardi-Goutieres syndrome (familial, early onset encephalopathy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis). J Med Genet 32:881–884, 1995 Trautner RJ, Cummings JL, Read SL, et al: Idiopathic basal ganglia calcification and organic mood disorder. Am J Psychiatry 145:350–353, 1988
178
Psychiatric Management in Neurological Disease
Trenkwalder C, Schwarz J, Gebhard J, et al: Starnberg trial on epidemiology of parkinsonism and hypertension in the elderly: prevalence of Parkinson’s disease and related disorders assessed by a door-to-door survey of inhabitants older than 65 years. Arch Neurol 52:1017–1022, 1995 Uygur GA, Liu Y, Hellman RS, et al: Evaluation of regional cerebral blood flow in massive intracerebral calcifications. J Nucl Med 36:610–612, 1995 Vles JS, Lodder J, van der Lugt PJ: Clinical significance of basal ganglia calcifications detected by CT (a retrospective study of 33 cases). Clin Neurol Neurosurg 83:253–256, 1981 Weimann W: Zur Kenntnis der Verkalkungen intracerebraler Gefässe. Zentralbl Gesamte Neurol Psychiatry 76:533–567, 1922 Wodarz N, Becker T, Deckert J: Musical hallucinations associated with post-thyroidectomy hypoparathyroidism and symmetric basal ganglia calcifications (letter). J Neurol Neurosurg Psychiatry 58:763–764, 1995 Yamamoto K, Kawazawa S: Basal ganglion calcification in paroxysmal dystonic choreoathetosis (letter). Ann Neurol 22:556, 1987
C H A P T E R
6
Dystonia Edward C. Lauterbach, M.D.
D
ystonia is generally best understood as a clinical manifestation of disturbed basal ganglia physiology. The history of a relation between psychiatry and dystonia is as old as the concept of dystonia itself. The condition was first alluded to by Destarac (1901) as dystonia with functional spasms. Schwalbe (1908), who first described dystonia, considered it a hereditary psychiatric manifestation. Today, dystonia continues to be misdiagnosed as a psychiatric disorder in more than 25% of patients because of its bizarre nature (Marsden 1995).
Prevalence Dystonia is a syndrome of forceful, sustained muscle contractions, resulting in twisting and repetitive movements or abnormal postures. Occasionally, fast dystonic movements are present that can resemble chorea. Dystonic movements can be activated by voluntary movements. The prevalence of primary dystonia is about 250 per 1 million population (Nutt et al. 1988). 179
180
Psychiatric Management in Neurological Disease
Clinical Recognition and Neurological Presentation Forms and Distribution of Dystonia Primary dystonia is dystonia due to a genetic cause, whereas nonprimary dystonia is secondary to or symptomatic of some other underlying cause (see “Etiologies” section later in this chapter and Table 6–1). The distribution of dystonia varies with its etiology and age at onset. Primary dystonia is more often bilateral than is nonprimary dystonia. Primary dystonia presenting in childhood usually begins in the lower extremities and, over several years, progresses bilaterally up the body to involve at least several contiguous body parts (i.e., generalized dystonia). Often, the entire body becomes involved. Synonyms for generalized dystonia have included dystonia musculorum deformans, dysbasia lordotica progressiva, torsion dystonia, torsion spasms, torsion neurosis, hereditary torsion dystonia, and progressive torsion spasm of childhood. The average age at onset is 8 years (Bruyn and Roos 1986). The earlier the onset, the more severe the disorder. Dysarthria, dysphagia, and total disability may complicate the course. Adult presentations of primary dystonia generally are either focal (involving a single body region) or segmental (involving two contiguous body parts). Average onset is between the ages of 30 and 50 years. Of the various primary dystonias, 90% initially present in midlife with minimally progressive focal or segmental dystonia (Nutt et al. 1988) involving the upper extremities, neck, or face. Blepharospasm involves involuntary closure of the eyelids. Oromandibular dystonia (Brueghel’s or Meige’s syndrome) involves jaw and mouth muscles and is usually accompanied by blepharospasm. Neck dystonia (torticollis) usually occurs after age 30 years in women (Bruyn and Roos 1986). Focal wrist/hand dystonia (writer’s cramp) often interferes with handwriting. Spasmodic dysphonia is vocal cord dystonia; abductor spasm produces a whispering or intermittent breathy voice, whereas adductor spasm results in a hoarse, forced vocal quality. The presence of multifocal dystonia (affecting several noncontiguous body parts) suggests nonprimary dystonia symptomatic of some
Dystonia
Table 6–1.
181
Causes of dystonia
Primary dystonia Oppenheim’s dystonia (DYT1 gene on 9q34 between D9S2161 and D9S63) Italian non-DYT1 autosomal dominant dystonia with nearly complete penetrance Adult-onset cervical dystonia (DYT7 gene on 18p near D18S1098) Familial cranial dystonia Adult-onset cervical-cranial dystonia Familial cranial-limb dystonia Whispering dysphonia (DYT4 gene) Mennonite mixed dystonia (DYT6 gene on 8p21–q22) Autosomal recessive dystonia (DYT2 gene) Other familial dystonia Sporadic torsion dystonia Dystonia-plus syndromes Dopa-responsive dystonia GTP–cyclohydrolase I mutation (DYT5 gene on 14q22.1) 6-Pyruvoyltetrahydropterin synthase deficiency (I114V mutation) Tyrosine hydroxylase mutations (gene on 11p) Rapid-onset dystonia–parkinsonism (19q13) Myoclonic dystonia (11q23) Neurodegenerative and heredodegenerative disorders Lubag dystonia–parkinsonism (DYT3 gene on Xq13.1) Huntington’s disease (IT15 huntingtin gene on 4p16.3) Wilson’s disease (copper–ATPase gene on 13q14.3) GM1 and GM2 gangliosidosis Metachromatic leukodystrophy Glutaric aciduria type I Homocystinuria Guanidinoacetate methyltransferase deficiency 3-Methylcrotonyl–CoA carboxylase deficiency 3-Methylglutaconic aciduria Hexosaminidase A and B deficiency Triosephosphate isomerase deficiency Lesch-Nyhan syndrome Methylmalonic aciduria (continued)
182
Table 6–1.
Psychiatric Management in Neurological Disease
Causes of dystonia (continued)
Neurodegenerative and heredodegenerative disorders (continued) Hartnup’s disease Juvenile neuronal ceroid lipofuscinosis Adult neuronal ceroid lipofuscinosis (Kufs’ disease) Dystonic lipidosis (Niemann-Pick disease, sea-blue histiocytosis) Neuroacanthocytosis Ataxia–telangiectasia Neuronal intranuclear inclusion disease Mitochondrial encephalopathies Leigh’s syndrome Other Familial basal ganglia calcifications (Fahr’s syndrome) Hallervorden-Spatz disease Pelizaeus-Merzbacher disease Dystonia with striatal lucencies Infantile bilateral striatal necrosis Progressive pallidal degeneration (pure pallidal atrophy, pallidoluysian atrophy, other) Progressive supranuclear palsy Olivopontocerebellar degeneration Machado-Joseph disease Spinocerebellar degeneration Parkinson’s disease Multiple system atrophy Cortical–basal ganglionic degeneration Rett syndrome Hereditary spastic paraplegia Dystonia secondary to environmental and other etiologies Perinatal injury Athetoid cerebral palsy Delayed-onset dystonia Hypoxia Encephalitis and postinfectious diseases Reye’s syndrome AIDS Subacute sclerosing leukoencephalopathy (continued)
Dystonia
Table 6–1.
183
Causes of dystonia (continued)
Brain abscess Head trauma Arteriovenous malformation Lesions (especially putamen, pallidum, thalamus, and brain stem) Focal cerebral vascular injury Brain tumor Multiple sclerosis Epilepsy Ictal dystonia Postictal dystonia Cervical cord injury Peripheral injury (including dental extraction) Hemolytic uremic syndrome Influenza Wasp sting Toxins Manganese Carbon monoxide Carbon disulfide Methanol Cyanide 3-Nitroproprionic acid Substance abuse Cocaine Alcoholic hepatocerebral degeneration Psychogenic dystonia Drugs D2 receptor antagonists (neuroleptics, metoclopramide) Risperidone Clozapine SSRIs Levodopa Ergot alkaloids Sumatriptan Anticonvulsants Disulfiram (continued)
184
Table 6–1.
Psychiatric Management in Neurological Disease
Causes of dystonia (continued)
Dystonia secondary to environmental and other etiologies (continued) Ranitidine Rh(D) immune globulin Note. Further elaboration can be found in Fahn 1997; Fahn et al. 1997, 1998; and Calne and Lang 1988. AIDS = acquired immunodeficiency syndrome; ATPase = adenosine triphosphatase; GTP = guanosine 5′-triphosphate; SSRIs = selective serotonin reuptake inhibitors.
identifiable cause. In contrast to primary dystonias, nonprimary dystonias are often unilateral and are attended by additional focal neurological signs. Peripheral dystonia can occur after peripheral trauma relating to nerve, plexus, or root injury in the absence of central nervous system (CNS) pathology.
Initial Signs and Associated Features Dystonia onset is usually gradual and subtle, sometimes beginning with clumsiness, tension or pulling sensations, vague pains, intermittent foot inversion, finger hyperextension, or intermittent shoulder hunching. Initially, dystonia occurs only with particular muscle actions. Later, additional actions may evoke dystonia. Still later, the activity of distant, uninvolved muscle groups may trigger dystonia. In the final stages, dystonia may be present even at rest. Features sometimes associated with dystonia include gait disorders (e.g., hyperlordotic gait), tortipelvis, kyphoscoliosis, increased or decreased extrapyramidal tone, striatal toe (spontaneous extension of the big toe), and action-postural tremor (Bruyn and Roos 1986). Hypertrophy of the involved muscle groups develops over time. Parkinsonism–dystonia syndromes usually occur in childhood but may appear later in life. In nonprimary dystonias, other neurological features may add to the clinical findings.
Gender Considerations and Pregnancy In clinical samples, adult-onset dystonia is more common in women than in men. Writer’s cramp is more common in men. Generalized dystonia with childhood onset occurs with equal frequency in both genders. In primary dystonia, maternal transmission is more com-
Dystonia
185
mon than paternal transmission (LaBuda et al. 1993). The penetrance of guanosine 5′-triphosphate (GTP)–cyclohydrolase I mutations associated with dopa-responsive dystonia (see “Etiologies” section and Table 6–1) is 2.3 times greater in females than in males (Furukawa et al. 1998). Tardive dystonia was more common in men in a large Italian study (Raja and Azzoni 1996). The presence of dystonia does not appear to compromise pregnancy, although the effects of botulinum toxin and some of the other dystonia treatments are not yet definitively known. Lurie et al. (1996) described a woman with dopa-responsive dystonia who successfully gave birth to two children despite taking L-dopa throughout both pregnancies. Kumar et al. (1997) published an interesting case report of cervical dystonia that occurred after Rh(D) immune globulin administration but improved with steroids.
Conversion Disorder or Dystonia? The bizarre features of dystonia can lead to an erroneous diagnosis of conversion disorder. Action specificity refers to the fact that only certain actions of affected muscles evoke dystonia (e.g., dystonia may occur while walking forward but not while walking sideways or backward or while dancing or running). Although this phenomenon might be interpreted as signaling inconsistencies indicative of a conversion disorder, it is actually quite consistent with dystonia. Unusual dystonia distributions and disabilities can also lead to misdiagnosis. An inability to eat, speak, walk, write, or open the eyes or mouth, and turning away of the head or other functional disabilities, each can errantly suggest conversional symptomatology. Exercise, environmental stimuli, and stress can trigger dystonic spasms. Sensory stimulation (sensory tricks) and countering movements (geste antagonistique) can be employed by some patients to attenuate dystonic spasms. For example, a woman in her late 40s with severe cervicotruncal dystonia found that the spasms attenuated with a light touch to the skin of the back of her neck (sensory trick) or with elevation of her left shoulder (geste antagonistique). She discovered that if she assumed a model’s posture, with her left hand positioned behind her neck, her dystonic spasms were markedly relieved. Occasionally, in some patients, dystonia spontaneously remits, but it
186
Psychiatric Management in Neurological Disease
usually recurs subsequently. These features can lead to a false impression that the disorder is of psychogenic origin. In contrast, conversional psychogenic dystonia is often more abrupt in onset. Although there is no pathognomonic presentation of psychogenic dystonia, two broad guiding diagnostic principles are 1) a presentation less than consistent with organic dystonia and 2) a “guilt by association” with other suspicious findings suggestive of conversional origin (e.g., recent psychosocial stressor, previous conversion disorder, extant psychiatric disorder). However, organic dystonia should first be suspected to avoid misdiagnosis. Complicating matters further, psychogenic movement disorders can also develop in patients with organic dystonias (Ranawaya et al. 1990). Moreover, psychiatric disorders are prevalent in primary dystonia, and their presence cannot be relied on to establish the diagnosis of psychogenic dystonia. The prevalence of psychogenic dystonia at dystonia referral centers is approximately 1%–3% (Marsden 1995). Psychogenic dystonia is discussed in more detail below (see “Somatoform Disorders and Psychogenic Dystonia” under “Psychiatric Manifestations” section later in chapter).
Pathological Features Reductions in plasma dopamine beta-hydroxylase (autosomal dominant dystonia), cerebrospinal fluid (CSF) homovanillic acid (adult dystonia), and CSF methoxyhydroxyphenylglycol (childhood dystonia) suggest reduced dopamine and norepinephrine turnover (Bruyn and Roos 1986). Reduced CSF tetrahydrobiopterin (especially in dopa-responsive dystonia) has been found, and some cases of dystonia respond markedly, albeit transiently, to tetrahydrobiopterin (LeWitt et al. 1986). Despite numerous investigations, no histopathological abnormalities have been observed in primary dystonia (Zeman 1976). Consequently, primary dystonia is presumed to represent a functional disturbance of basal ganglia circuits. Pathological findings in nonprimary dystonias are the pathological features of their individual causes. Although the pathophysiology of dystonia is still emerging and may not be unitary, dystonia is thought to arise from reduced internal pallidal inhibition of the thalamus (see Figure 1–2 in Chapter 1)
Dystonia
187
resulting from a simultaneous increase of putaminopallidal GABAergic inhibition and either a decrease (Crossman and Brotchie 1997) or an increase (Vitek et al. 1999) in subthalamic glutamatergic stimulation of the internal pallidum. Electromyography (EMG) studies indicate that reciprocal inhibition of antagonist musculature is lost in dystonia. Normally, contraction of agonist musculature leads to reciprocal inhibition of opposing muscle groups (e.g., contraction of the biceps leads to relaxation of the triceps muscle). However, in dystonia, both sets of opposing muscle groups (e.g., biceps and triceps) contract simultaneously because of this loss of reciprocal inhibition. There is some evidence from evoked potential studies of an excessive response by the precentral cortex to somatosensory inputs because of basal ganglia dysfunction (Tinazzi et al. 1999). This excessive response may be related to deficient intracortical inhibition (Siebner et al. 1999) resulting from abnormal basal ganglia input or other influences. Thus, basal ganglia dysfunction may result in deficient neuronal inhibition, leading to dystonic spasms and loss of reciprocal inhibition (Berardelli et al. 1998).
Etiologies Dystonia can be of primary origin (genetic or idiopathic etiology), associated with dystonia-plus syndromes, or secondary to a wide variety of causes, including neurodegenerative and heredodegenerative disorders (see Table 6–1). Primary dystonia runs in families. A recent case–control study of primary dystonia revealed risk factors including concussive head injury, local injury, and family histories of dystonia and postural tremor, whereas hypertension and cigarette smoking constituted protective factors (Defazio et al. 1998). Several distinct genetic associations have been found (see Table 6–1). The dystonia gene DYT1 is autosomal dominant with approximately 30% penetrance in Ashkenazi Jews (Pauls and Korczyn 1990) and 40% in non-Jews (Fahn et al. 1998). DYT1 codes for torsin A, an adenosine triphosphate (ATP)–binding protein, but the pathological relation of this protein to dystonia remains unknown. In Ashkenazi Jews, DYT1 mutations arise from GAG deletions in this gene on chromosome 9q34.1. The carrier frequency is between 1 in 1,000 and
188
Psychiatric Management in Neurological Disease
1 in 5,000 in Jews and one-third this rate in non-Jews. European Jews have a higher prevalence of the gene than do Afro-Asian Jews (Korczyn et al. 1980). Multiple DYT1 mutations appear to be involved in non-Jewish populations (Bressman 1997). Genetic anticipation implicates trinucleotide repeats in DYT1 dystonia (Cheng et al. 1996). Presymptomatic testing can be performed, but low penetrance reduces the odds of developing dystonia even if the gene is present. Genetic testing for DYT1 (i.e., for the associated haplotype of alleles D9S62, D9S63, and ASS) costs about $350 per sample. There is no need to involve other family members in testing Ashkenazi Jews with childhood-onset dystonia because of the consistency of the mutation form. However, because of the variety of mutations in non-Jewish patients, simultaneous testing of 8–10 other family members with dystonia is necessary to accurately determine the presence of a DYT1 mutation (Bressman 1997; Harding 1994). A variety of genetic dystonias are listed in Table 6–1. These include several primary dystonias, particularly DYT1 dystonia (Oppenheim’s dystonia). Sporadic primary torsion dystonia is usually focal with cranial or cervical distribution and is only rarely familial. Among dopa-responsive dystonias, Segawa’s syndrome usually begins before age 16 years in girls (female:male ratio = 19:6), may show diurnal variation with worsening of leg dystonia or gait disorder later in the day, is associated with parkinsonian features, and responds to L-dopa. The two most common forms include autosomal (14q) dominant GTP–cyclohydrolase I (GCI) and autosomal (11p) recessive tyrosine hydroxylase mutations. Segawa’s syndrome is linked to multiple mutations of the gene for GCI. GCI synthesizes a precursor of tetrahydrobiopterin, a cofactor for tyrosine hydroxylase. Tyrosine hydroxylase is critical to the synthesis of dopamine. GCI dysfunction can therefore reduce tyrosine hydroxylase activity, resulting in dopamine deficiency. Similarly, mutations in the genes for 6pyruvoyl-tetrahydrobiopterin synthase and tyrosine hydroxylase have also been linked to dopa-responsive dystonia. Recently, the gene for autosomal dominant rapid-onset dystonia–parkinsonism has been linked to 19q13 at D19S198, between D19S587 and D19S900 (P. L. Kramer et al. 1999). Myoclonic dystonia is rare, is associated with myoclonic jerking (arms, shoulders, neck, or trunk), is improved by
Dystonia
189
alcohol consumption, and exhibits autosomal dominant transmission (Kyllerman et al. 1990). Myoclonic dystonia has recently been linked to chromosome 11q23 at D11S897, a region containing the gene for the D2 dopamine receptor (Klein et al. 1999). X-linked dystonia–parkinsonism (Lubag) is a hereditary basal ganglia degeneration affecting adult Filipino males. Dystonia is also a component of other genetic syndromes not listed in Table 6–1. Dystonia occurs in the Xq22-linked recessive syndrome, a disorder associated with sensorineural deafness, cortical blindness, fractures, and mental deficiency (Jin et al. 1996). The gene is linked to Xq22 locus DXS101 (Tranebjaerg et al. 1995). The gene product is a mitochondrial protein, DDP, that mediates the import of metabolite transporters from the cytoplasm to the mitochondrial inner membrane (Koehler et al. 1999). Dystonia more rarely has been associated with the 18q22.2 deletion syndrome, which is linked to mental retardation, seizures, nystagmus, incoordination, and chorea. Gordon et al. (1995) have described a case report of a 36-year-old woman with an 18q deletion who presented with adolescent onset of mandibular dystonia, retrocollis, and writer’s cramp, associated with postural tremor, hypothyroidism, diabetes mellitus, borderline intelligence, short stature, short neck, sensorineural hearing loss, and sensorimotor ataxia (Gordon et al. 1995). Deletion of 18p11.1 has been associated with progressive dystonia, mental retardation, seizures, tremor, chorea, and androgen insensitivity (Awaad et al. 1999). Dystonia can occur in a wide variety of hereditary, neurological, metabolic, and other diseases (Janavs and Aminoff 1998; Hartmann et al. 1998). CNS pathology may predispose to dystonia. Persistent dystonia has occurred in a patient with acquired immunodeficiency syndrome (AIDS) dementia complex after brief exposure to lowdose neuroleptic therapy (Factor et al. 1994). Generalized encephalitis and substantial neural loss in both the medial and the lateral globus pallidus was evident in the patient at autopsy. Substance abuse, notably cocaine, can precipitate dystonia or aggravate primary dystonia (Cardoso and Jankovic 1993). Alcoholic hepatocerebral degeneration can lead to dystonia, and acute alcohol intoxication can precipitate neuroleptic-induced acute dystonic reactions (Neiman et al. 1990).
190
Psychiatric Management in Neurological Disease
A variety of medications can also cause dystonia (Table 6–1), an important fact to consider when evaluating patients. Neuroleptics can produce acute dystonia, tardive dystonia, and neuroleptic malignant syndrome. Delirium with dystonia may represent a variant of neuroleptic malignant syndrome (Dowling and Patrick 1989). Dystonia has also been reported with risperidone and clozapine treatment and on clozapine withdrawal (Radford et al. 1995). Leaning truncal dystonia, the Pisa syndrome (Yassa 1985), can occur during chronic neuroleptic maintenance therapy (Guy et al. 1986) and in documented tardive dystonia (Saxena 1986). Acute administration of selective serotonin reuptake inhibitors (SSRIs) may trigger dystonia (Leo 1996), as may SSRI withdrawal (Stoukides and Stoukides 1991). Buspirone may lead to intractable movement disorders, including dystonia (LeWitt et al. 1993).
Neuroimaging Nonprimary dystonia most commonly occurs after putaminal and pallidal lesions. Putaminal increased signal on magnetic resonance imaging (MRI) (in 35%) is the most common finding in dystonias, but putaminal decreased signal and, more rarely, mixed signal in the globus pallidus can also be seen (Rutledge et al. 1988). Positron-emission tomography (PET) studies indicate pallidothalamic and cortical abnormalities. Evidence suggests that medial pallidal inhibition of the thalamus is reduced in dystonia, leading to overactivation of premotor areas such as the supplementary motor cortex (Playford et al. 1998). A reduction in putaminal dopamine D2 receptor binding on PET was found in a study of focal dystonia (Perlmutter et al. 1997), in contrast to a finding of elevated D2 binding in a study of doparesponsive dystonia (Kishore et al. 1998). These findings suggest that not all types of dystonia have the same pathophysiology.
Clinical and Laboratory Investigation Dystonia should be distinguished from muscle spasms, which generally develop abruptly. Unilateral hemidystonia suggests a nonprimary etiology. Pyramidal tract signs (spasticity, Babinski sign, clonus, hyperreflexia), sensory deficits, and other neurological fea-
Dystonia
191
tures (cranial nerve signs) also usually suggest an etiology other than primary dystonia. MRI or computed tomography (CT) of the brain may then be revealing. Structural pathology is lacking in primary dystonia, however. The workup of dystonia in children is more aggressive than that in adults and has been explicitly detailed elsewhere (Marsden 1988). It involves Wilson’s disease studies (see Chapter 4 in this volume), serology, complete blood count with differential, erythrocyte sedimentation rate, antinuclear antibody test, routine chemistry profiles, and MRI or CT scan. Uric acid elevation can indicate LeschNyhan syndrome as an etiology. Striatal lesions on MRI or CT can reflect Wilson’s disease, Leigh’s syndrome, mitochondrial cytopathy, postanoxic state, infection, allergic reactions, toxin ingestion (e.g., methanol), hemolytic uremic syndrome, sickle-cell disease, acidosis (e.g., methylmalonic acidemia), and striatal necrosis. Striatal atrophy can occur in neuroacanthocytosis and Huntington’s disease (see Chapter 3 in this volume). Pallidal mineralization occurs in Fahr’s syndrome and hypoparathyroidism (see Chapter 5 in this volume). Thus, the workup reflects the possible causes of nonprimary dystonia. The workup in adults is similar, including CT or MRI, complete blood count with differential, erythrocyte sedimentation rate, routine chemistry profile, serology, and exclusion of Wilson’s disease; however, if the dystonia conforms to the typical course and features of primary dystonia, many clinicians defer the workup in adults because of low yield, unless the condition progresses unexpectedly. The presence of additional features suggesting nonprimary dystonia (e.g., hemidystonia, pyramidal signs), however, merits investigation. If the etiology remains cryptic after these preliminary considerations, further evaluation is undertaken (Marsden 1988). Somatosensory evoked potential abnormalities can be consistent with ceroid lipofuscinosis. An electroretinogram may reveal pigmentary retinopathy, as has been observed in Hallervorden-Spatz disease and ceroid lipofuscinosis. Electromyography can reveal a peripheral neuropathy. Lysosomal enzymes may elucidate GM1 or GM2 gangliosidoses or metachromatic leukodystrophy. Alpha-fetoprotein and immunoglobulin A (IgA) levels can disclose ataxia telangiectasia. Ar-
192
Psychiatric Management in Neurological Disease
terial blood gases with pH, lactate, and pyruvate levels can suggest Leigh’s syndrome. A fresh blood smear showing acanthocytes suggests neuroacanthocytosis, especially in consanguineous families. Twenty-four-hour urine collection for amino acids, organic acids, and oligosaccharides can disclose other metabolic disorders, including homocystinuria. Although most of these disorders occur in childhood, some may insidiously become symptomatic in adult life and lead to dystonia. When these tests do not lead to etiological discovery, biopsies of liver (for Wilson’s disease), bone marrow (for dystonic lipidosis), muscle (for mitochondrial cytopathies), or skin or conjunctiva (for ceroid lipofuscinosis) may be revealing (Marsden 1988). Karyotype analysis should be undertaken in nonprimary dystonia associated with features suggestive of chromosomal aberrancies, such as short stature or endocrinopathies (Gordon et al. 1995).
Psychiatric Manifestations Primary psychiatric features are associated with primary dystonia. Many nonprimary dystonia etiologies are associated with their own psychiatric morbidities (unrelated to the dystonia), such as mental retardation, dementia, other cognitive disturbances, psychoses, mood disorders, personality disturbances, and possibly anxiety and other disorders. The neuropsychiatry of primary dystonia is reviewed in the following subsections.
Cognitive Impairment Although early studies suggested greater intelligence in primary dystonia, later work has not supported this impression (Imperio et al. 1979). Neither is intelligence diminished by primary dystonia. Intellectual deterioration can occur secondary to underlying pathology in nonprimary dystonia, as seen in striatopallidal degeneration (Stehbens 1972) and progressive supranuclear palsy (Barclay and Lang 1997).
Psychosis Thought disorders have been described in two patients with dystonia (Kraft 1966), and elevated scores on the Minnesota Multi-
Dystonia
193
phasic Personality Inventory (MMPI; Hathaway and McKinley 1970) Schizophrenia scale were reported in a study of 30 patients with primary dystonia (Imperio et al. 1979). However, systematic studies in untreated primary dystonia, like those in untreated Parkinson’s disease, have not revealed diagnosable psychoses. In primary psychoses, however, acute neuroleptic-induced ocular dystonia is associated with exacerbated auditory hallucinosis (Chiu 1989; Thornton and McKenna 1994). Similar attenuating mechanisms for dystonia and psychotic symptoms may involve dopamine (Chiu 1989) and the basal ganglia (Lauterbach 1990).
Mood Disorders Elevated prevalences of mood disorders have been observed in dystonia. Determination of lifetime prevalences of DSM-III-R (American Psychiatric Association 1987) mood disorders in 28 subjects with primary dystonia from a movement disorder referral center identified 5 (18%) subjects with bipolar disorders, 8 (29%) with major depression, 4 (14%) with dysthymia (1 also had major depression), and 1 (4%) with atypical depression (Lauterbach et al. 1992a). Mood disorders tended to occur after the onset of dystonia and were significantly more common in dystonia patients than in normal populations. Subjects with dystonia were compared with demographically matched controls from the Epidemiologic Catchment Area (ECA) study (Robins and Regier 1991). The prevalences of bipolar disorders and unipolar major depression in patients with dystonia were increased to the levels seen in Huntington’s disease, suggesting a relationship between these mood disorders and underlying basal ganglia pathophysiology. Dystonic severity, disability, and pain did not predict these disorders. Consequently, vigilance for a variety of DSM-IV (American Psychiatric Association 1994) mood disorders due to a general medical condition as well as primary mood disorders seems indicated in dystonia patients. Although illness-related psychosocial variables were not associated with the clear elevation of mood disorder rates, the possibility that other psychosocial variables contribute to mood disorders in dystonia patients cannot be excluded at present. In another study, DSM-III-R mood disorders were assessed in
194
Psychiatric Management in Neurological Disease
23 subjects with dystonia secondary to focal lesions of the basal ganglia, thalamus, or cerebellum. Two (8.7%) dystonia subjects had bipolar disorder not otherwise specified, and 4 (17.4%) had major depression (Lauterbach et al. 1994a). Thus, bipolar disorders and major depression were also more common in poststroke dystonia than in the population at large (i.e., matched ECA controls). Bipolar disorders. Rapid-cycling bipolar disorders have been associated with cervicocranial primary dystonia. In one study of patients presenting to a movement disorder referral center, subjects were found to have developed bipolar disorders soon after the initial manifestations of dystonia (Lauterbach et al. 1992b). Dystonia with rapid-cycling bipolar disorder has been reported in patients after lesions associated with abnormal cerebellar function (Lauterbach 1996). Tardive dystonia has been reported to alternate with mania (Lal et al. 1988). Although retrospective data have suggested that acute neuroleptic-induced dystonia occurs more commonly in bipolar disorder than in schizophrenia (Nasrallah et al. 1988), prospective studies have not confirmed this (Khanna et al. 1992; Remington et al. 1990). Depression. Depression may vary with the anatomic distribution of the dystonia. Depression of any type occurs in 20%–80% of patients with blepharospasm (Diamond et al. 1984; Trobe et al. 1985; Volow 1985). In Meige’s syndrome, depression affects 25%–41% (Jankovic and Ford 1983; Tolosa 1981). In contrast, in two studies of patients with writer’s cramp dystonia, depression prevalences were not increased despite occupational and functional disabilities (Grafman et al. 1991; Sheehy and Marsden 1982). As detailed above, multifold increases in DSM-III (American Psychiatric Association 1980) and DSM-III-R depressive disorders have been documented in patients with predominantly craniocervical primary dystonia (Lauterbach et al. 1991). In a study of 22 patients with primary torticollis, Beck Depression Inventory (BDI) scores were higher than in age- and sexmatched healthy controls (Bihari et al. 1992), although another study found no difference (Matthews et al. 1978). In yet another study, 33 (39%) of 85 patients with torticollis had moderate or severe
Dystonia
195
BDI depression scores, and the depression was more severe than that in patients with cervical spondylosis (Jahanshahi and Marsden 1988b). Depression in torticollis is characterized by cognitions involving self-blame, self-accusation, self-punishment, and negative body image. Perceived disfigurement was found to predict depression in one study (Jahanshahi and Marsden 1990); improvement in torticollis with botulinum toxin treatment reduced depression and disability in another study, although body concept and self-esteem did not improve (Jahanshahi and Marsden 1992).
Anxiety Disorders Anxiety is common in dystonia patients, and certain anxiety disorders are especially prevalent. Analysis of DSM-III anxiety disorders in 28 patients with primary cervicocranial dystonia disclosed anxiety diagnoses in 20 (71.4%), including panic disorder in 1 (3.6%), agoraphobia in 3 (10.7%), social phobia in 5 (17.9%), simple phobia in 7 (25%), obsessive-compulsive disorder (OCD) in 0 (0%), generalized anxiety disorder (GAD) in 7 (25%), and atypical anxiety (GAD-like) in 4 (14.3%) (Lauterbach et al. 1993a). Thus, these patients exhibited more than a fourfold increase in GAD and GAD-like anxiety and a greater tendency to manifest phobias than that in normal (ECA) populations. These findings contrast with results from a study of Parkinson’s disease that used the same methodology, in which the prevalence of DSM-III panic disorder was found to be five times higher than that in normal (ECA) populations (Lauterbach and Duvoisin 1987). In the study of DSM-III anxiety disorders (Lauterbach et al. 1993a), primary dystonia patients with social phobia, agoraphobia without panic, and simple phobia often showed bilateral dystonic muscle involvement. Findings similar to those of the DSM-III dystonia study obtained for all of the DSM-III-R anxiety disorders (Lauterbach et al. 1993c) except panic disorder and agoraphobia (diagnoses of panic disorder without agoraphobia in 2 patients [7.1%] and of agoraphobia in 2 [7.1%]). Although the rates of certain anxiety disorders in dystonia patients are well above the rates observed in the ECA study (Robins and Regier 1991) and in patients with Parkinson’s disease, psychosocial factors may contribute to
196
Psychiatric Management in Neurological Disease
these findings. Clinicians who treat patients with dystonia should be on the alert for DSM-IV anxiety disorders, especially GAD, specific phobias, and anxiety disorder due to a general medical condition (“with generalized anxiety” specifier). In contrast to the case for primary dystonia, GAD was no more common in poststroke dystonia than in the general population (Lauterbach et al. 1994a). Of 45 subjects with focal subcortical infarcts, 4 (8%) had DSM-III-R generalized anxiety disorders (2 subjects with GAD and 2 with forme fruste GAD) (Lauterbach et al. 1994b). All 4 had pallidal lesions. Posterior pallidal lesions tended to be associated with more severe GAD and parkinsonism, whereas more anterior pallidal lesions tended to be associated with less severe, forme fruste GAD and dystonia. All 4 subjects had major depression and lower mental status scores than control subjects with subcortical lesions (Lauterbach et al. 1994c). Anxiety may be especially common in patients with cervicocranial and generalized dystonias. Rorschach findings suggesting anxiety are seen in as many as one-third of blepharospasm patients (Diamond et al. 1984; Trobe et al. 1985), although not all studies have reported this result (Tarbox and Morse 1985). One study found that 50% of dystonia patients had twice as many nonspecific neurotic symptoms as controls, although it was concluded that, overall, there was no increase in psychopathology (Sheehy and Marsden 1982). Among childhood generalized dystonia patients, other investigators have noted Rorschach anxiety findings (Riklan et al. 1976) and elevations on the MMPI Psychasthenia scale (Imperio et al. 1979), which they attributed to difficulties in adjusting to disability (Riklan et al. 1976). Clinical anxiety has been reported in a study of Meige’s syndrome; however, specific diagnoses and their prevalences were not reported (Jankovic and Ford 1983). Focal hand/wrist dystonia has not been found to be associated with increased anxiety (Harrington et al. 1988). Obsessions and compulsions. OCD and obsessive-compulsive symptomatology have been observed in dystonia, especially in patients in whom putaminal abnormalities are observed on MRI (Rothfeld 1995). Although none of the 28 patients in one study of primary dystonia met the disability criteria for OCD, 2 (7.1%) had obses-
Dystonia
197
sions and 4 (14.3%) had compulsions (Lauterbach et al. 1993a). This contrasts with findings from a study in Parkinson’s disease patients, in whom the prevalence of DSM-III OCD was found to be five times greater than that in demographically matched controls from the ECA study (Lauterbach and Duvoisin 1987). In the foregoing dystonia study, dystonia patients with obsessive-compulsive symptomatology showed more cerebellar signs and fewer basal ganglia signs than did dystonia patients without obsessive-compulsive symptomatology (Lauterbach et al. 1993b). In a study of torticollis patients, Symptom Checklist—90—Revised obsessionality scores were higher in patients with primary spasmodic torticollis than in age- and sexmatched controls (Bihari et al. 1992). Obsessive-compulsive symptomatology may, therefore, be linked to dystonia and may possibly relate pathophysiologically to striatal dysfunction in dystonia or to cerebellar–frontal dysfunction.
Eating Disorders Eating disorders have also been identified in dystonia. In a study of primary cervicocranial dystonia, DSM-III atypical eating disorder, bulimic type (DSM-III-R eating disorder not otherwise specified) was diagnosed in 2 (7.1%) of 28 subjects (Lauterbach et al. 1993b, 1993d). No patient had diagnosable classical anorexia nervosa or bulimia.
Somatoform Disorders and Psychogenic Dystonia About two-thirds of patients with psychogenic dystonia present with continuous dystonia; the remaining one-third have paroxysmal dystonia. In one study of 21 psychogenic dystonia patients, females predominated (10:1), and many of them worked in the health care field (Fahn and Williams 1988). All but 4 of these patients experienced improvement or resolution of their symptoms. The most common features of psychogenic dystonia are listed in Table 6–2. (Additional signs pointing to a psychogenic etiology are presented in Chapter 1 of this volume.) In a retrospective chart review of psychogenic dystonia patients (n = 18), all subjects were found to have features inconsistent or in-
198
Psychiatric Management in Neurological Disease
Table 6–2.
Clinical tip-offs to psychogenic dystonia: atypical features of dystonia
Findings in psychogenic dystonia Movements inconsistent with dystonia Onset with dystonia at rest False weakness Pain spontaneously or on passive movement Multiple somatizations Bizarre tremors or other movements Sudden weakness False sensory changes (e.g., blindness) Excessively slow voluntary movement Tenderness on light touch Startle-induced elaborate movements Source.
Frequency in psychogenic dystonia patients, % 86 79 67 43 38 33 29 24 24 19 10
Fahn and Williams 1988.
congruous with organic dystonia (Lang 1995). Although 14 patients had clear precipitants, many of the precipitating events (particularly injuries) were ones that can also precede organic dystonia. Most patients had abrupt onset and rapid progression, often to the point of fixed dystonic postures. Rapid progression to fixed postures can occur with organic rapid-onset dystonia; however, this is a rare condition in which other psychogenic signs would usually be absent. Other common psychogenic features included pain, leg dystonia despite adult onset, paroxysmal worsening of the dystonia, other coexisting psychogenic movement disorders, multiple somatizations, and psychogenic neurological signs. The outcomes were quite variable, with some dystonias completely resolving and others persisting. Other clinical tip-offs to psychogenic dystonia include variable movement patterns that occur when performing the same provocative action and severe, spreading causalgic pain with dystonia after trivial injury (Marsden 1995). The presence of reciprocal inhibition on EMG (see “Pathological Features” section earlier in chapter) suggests psychogenic dystonia, whereas dystonia occurring during the early stages of sleep suggests an organic etiology (Marsden 1995). The psychopathological origins and psychiatric diagnoses un-
Dystonia
199
derlying psychogenic dystonias are diverse and can include a history of abuse and diagnoses of conversion disorder, somatization disorder, factitious disorder, and malingering, usually attended by dysthymic or adjustment disorders (Williams et al. 1995). Secondary conversion and other psychogenic disorders can also occur in primary organic movement disorders (Ranawaya et al. 1990).
Substance Abuse Disorders Dystonia can lead to alcohol abuse and dependence (Neiman et al. 1990). In one study, 7 of 26 subjects with myoclonic dystonia (a condition often improved by alcohol) developed alcohol abuse (Kyllerman et al. 1990). The frequencies of anxiety, depression, and alcohol-related symptom improvement in dystonia may contribute to findings of increased alcoholism in primary dystonia. In our study of DSM-III substance abuse disorders in 28 dystonia patients, 5 (17.9%) of the patients had alcohol diagnoses (3 [10.7%] with abuse and 2 [7.1%] with dependence) (Lauterbach et al. 1993b). Patients with alcohol abuse had less dystonia at rest than did subjects without alcoholism. Dependence was associated with longer dystonia duration and greater dystonia severity and disability. All of the patients with alcohol dependence began drinking after the onset of their dystonia. Similar results were obtained when we applied DSM-III-R criteria (Lauterbach et al. 1993d). As a result of the greater sensitivity of the newer criteria, alcohol abuse was diagnosed in 3 (10.7%) of the patients and alcohol dependence in 5 (17.9%). Drinking began after dystonia onset in 4 (80%) of the dystonia patients with dependence and in 1 (33%) of those with abuse. These findings in dystonia patients contrast with those in Parkinson’s disease patients, in whom DSM-III alcoholism was found to be one-fifth as common as in demographically matched control subjects from the ECA study (Lauterbach and Duvoisin 1987.).
Personality Disorders Dystonia patients may have obsessional, schizoid, and sociopathic personality traits. In blepharospasm patients evaluated in one study,
200
Psychiatric Management in Neurological Disease
elevated MMPI Hysteria scale and F − K Defensiveness Index scores were found in 9 (69%) of 13, suggesting an effort to appear normal (Diamond et al. 1984; Trobe et al. 1985). In addition, histrionic personality features were found in about two-thirds of female patients. Obsessive-compulsive and schizoid personality characteristics have been noted in Meige’s syndrome (Jankovic and Ford 1983). Writer’s cramp patients have been characterized as tense, strong, sensitive, conscientious, precise, and emotionally overcontrolled with obsessive- compulsive personality features (Crisp and Moldofsky 1965). Rates of diagnosable personality disorders in dystonia patients, however, have not yet been determined. Study results of personality profiles in torticollis vary, with researchers reporting more, less, or no difference in obsessivecompulsive personality features relative to control subjects (Cockburn 1971; Crisp and Moldofsky 1965; Jahanshahi and Marsden 1988a; Matthews et al. 1978; Meares 1971b). “Neuroticism” is a common finding in torticollis patients (Choppy-Jacolin et al. 1977; Jahanshahi and Marsden 1988a; Meares 1971a). In one study, the only MMPI difference between patients with spasmodic torticollis and control subjects with Parkinson’s disease was that the torticollis patients endorsed items on the MMPI Psychopathic Deviate scale significantly more often (Naber et al. 1986). In a patient with dystonia due to striatopallidal degeneration, MMPI Schizophrenia, Psychasthenia, Hypomania, and Depression scales were elevated (Stehbens 1972).
Behavioral Disorders Dystonia can be painful and can produce agitation. In one report, agitated behavior in a demented patient remitted after treatment of cervical dystonia (Auchus et al. 1995). Dystonia treatments can also lead to delirium and disordered behavior.
Medication-Induced Psychiatric Disorders When evaluating dystonia patients, psychiatrists should be alert for delirium and psychotic disorders precipitated by oral dystonia medications, particularly the anticholinergics, benzodiazepines, and dopamine agonists (see “Neurological Management” section below).
Dystonia
201
Illusions, hallucinations, paranoia, inattention, cognitive impairment, and agitation may be particularly common in patients treated with these agents. Medication-induced mood and anxiety disorders may also be present. Mood disorders can result from dystonia medications such as anticholinergics and benzodiazepines (often administered at very high doses), as well as from L-dopa, dopamine agonists, and other agents (see “Neurological Management” section below). Neuroleptics in particular have been associated with mood disturbances (Young et al. 1994).
Neurological Management Focal dystonia is now commonly treated by administration of local injections of botulinum A toxin (Botox, Dysport) approximately every 3 months. This agent reduces local cholinergic neuromuscular transmission at dosages low enough to only occasionally induce mild signs of systemic botulism (dose depends on muscle size). Antibody resistance, which occurs in about 10% of dystonia patients, is managed by switching to a different serotype (e.g., F or B). In a study of 303 patients who had been undergoing treatment with botulinum A toxin for at least 5 years, no long-term adverse events occurred (Kessler et al. 1994). Transient dysphagia after injections was the most common side effect, and loss of response occurred in only 5% of patients, with antibodies to the toxin in only 2%. Many patients require concomitant treatment with oral systemic agents, especially when the dystonia is generalized. These agents include anticholinergics, benzodiazepines, dopamine agonists, baclofen, and, on occasion, neuroleptics, lithium, carbamazepine, valproic acid, and clozapine. Some knowledge of the medications used to treat dystonia is necessary because of these agents’ critical impact on psychiatric conditions. Anticholinergics are usually the most effective oral agents for the treatment of dystonia, except in Meige’s syndrome, where baclofen is superior (Greene et al. 1988). Dopamine agonists (e.g., lisuride, bromocriptine) are effective in cranial dystonias but less so in torticollis (Lang 1988). In one study, Lang (1988) found that haloperidol
202
Psychiatric Management in Neurological Disease
was effective in 37 (46%) of 81 torticollis patients and 16 (34%) of 47 cranial dystonia patients, while phenothiazines produced improvement in 9 (53%) of 17 patients with generalized or segmental dystonia. Benzodiazepines are especially useful in paroxysmal dystonic choreoathetosis, whereas anticonvulsants are indicated in paroxysmal kinesogenic dystonia, a dystonic movement triggered by exercise or activity (Marsden 1988). Dosages needed for successful treatment can be quite high for anticholinergics (e.g., up to 120 mg/day for trihexyphenidyl) and benzodiazepines (up to 30 mg/day for clonazepam). Drugs are started at conventional doses and then, if there is no response, are gradually titrated upward, allowing time for the patient to develop a therapeutic response and tolerance to side effects. Anticholinergics and benzodiazepines are the most effective agents overall for dystonia, but because dystonia patients occasionally respond to L-dopa, an initial brief trial of L-dopa/carbidopa (e.g., Sinemet) is recommended, beginning at half of a 25-mg/250-mg tablet tid for 1 week and then advancing the dose to a whole 25-mg/250-mg tablet qid for 2 weeks. A small percentage of dystonia patients respond to L-dopa, especially patients with early-onset childhood dystonia, dystonia associated with juvenile parkinsonism, or Segawa’s syndrome. If no response is seen, L-dopa should be discontinued and anticholinergic treatment initiated (e.g., trihexyphenidyl 2 mg tid for 1–2 weeks, advancing the dose as indicated). Monotherapy trials with other agents may be sequentially attempted when inadequate responses occur. Neuroleptics can improve or worsen dystonia. Beta-blockers are useful for dystonic tremor. More recently, four patients with severe generalized dystonia and one with Meige’s syndrome underwent an open trial of clozapine (Karp et al. 1999). All subjects evidenced significant improvement with clozapine on a dystonia rating scale as well as by subjective report. Although sedation and orthostatic hypotension occurred in all five patients, these side effects interfered with treatment in only one subject. In patients benefiting from the employment of sensory tricks, mechanical devices can be fashioned to provide the same therapeutic effect (Krack et al. 1998). Although intrathecal infusions of baclofen have helped some patients with severe dystonia, it is not yet
Dystonia
203
apparent which patients benefit. When dystonia is very severe and other treatments have failed, surgical procedures are considered. Surgical treatments are not definitively curative but often have an additive therapeutic effect when combined with pharmacotherapy. Surgical procedures include myectomy, anterior spinal rhizotomy, selective peripheral denervation, posterior ramisectomy, limb tendon section or transfer, and thalamotomy. More recently, posteroventral pallidotomy and ansotomy have proven effective (Iacono et al. 1997; Ondo et al. 1998; Vitek et al. 1997). Myectomy (Anderson procedure) is used for blepharospasm but carries the side effects of disfigurement, infections, and corneal erosions. Rhizotomy in torticollis can produce an unstable neck and requires multiple laminectomies. Posterior ramisectomy usually requires several operations, because dystonia may recur in other muscles. Denervation of a vocal cord is called the Dedo procedure. Tendon transfers or sections usually are not very helpful, because dystonia involves co-contraction of agonist and antagonist musculature, resulting in either flexion or extension, depending on which muscle group is disconnected. Thalamotomy leads to mild or moderate improvement but has a high complication rate, including dysarthria, dysphagia, cerebral infarction, and death.
Psychiatric Management When confronted with a dystonia patient, clinicians must consider the etiology of the dystonia (including tardive or psychogenic origin), the need for workup, the patient’s psychiatric vulnerabilities, the treatment regimen for the dystonia, the psychiatric and other effects of this regimen, the effects of psychiatric treatment on the dystonia, the potential benefit of psychotherapy, and the possibility of referral to support groups. Because of the complex nature of these management issues, psychiatrists may wish to seek neurological consultation for management of the dystonia itself, leaving them free to focus on psychiatric concerns. Information on support groups and informational resources for patients and their families can be obtained by contacting the National Spasmodic Torticollis Association (P.O. Box 424, Mukwonago, WI 53149-0424, phone 1-800-487-8385, fax 414-662-9887) or the Dystonia Medical Research Foundation
204
Psychiatric Management in Neurological Disease
(One East Wacker Drive #2430, Chicago, IL 60601-2001, phone 1-800-377-DYST or 312-755-0198, fax 312-803-0138).
General Supportive Treatment Complications of dystonia can be stressful. Activities of daily living may be impeded by the movements. Embarrassment can occur, especially when the face or speech is involved. In one study, nearly all torticollis patients experienced social embarrassment, with reluctance to go out in public (Matthews et al. 1978). Social ostracization may occur (e.g., harmful teasing) in childhood, although siblings can be important allies. Educating the patient and family members about the nature, course, and prognosis of dystonia can be helpful. Some experienced clinicians find value in informing the patient and family that the condition is not usually painful and that cognition is typically preserved, alleviating the fear of the unknown (Marsden 1995). In adult-onset dystonia, the clinician can help the patient maintain hope by explaining that progression is uncommon. Similarly, educating primary care physicians, pediatricians, teachers, and school authorities about dystonia may be useful. Encouragement to develop abilities not dependent on motor function can help individuals with dystonia to develop successful careers in computers, publishing, languages, or library science (Marsden 1995). Vigilance for psychiatric disorders is indicated, especially adjustment disorders in adolescence or early adulthood. Genetic counseling for families may be helpful.
Pharmacological Treatment There are no controlled studies of psychotropic treatment in dystonia (Rummans et al. 1999). Some psychotropics improve dystonia; others worsen it. Both neuroleptics and SSRIs can either improve or worsen dystonia. Buspirone may lead to persistent dystonia (LeWitt et al. 1993). Thus, psychotropic treatment involves choosing an effective medication for the psychiatric condition and selecting the agent least likely to worsen dystonia or associated conditions. Coadministration of antipsychotics and metoclopramide has been associated with severe, sometimes fatal dystonia (Lauterbach 1992). Patients with nonprimary dystonia may have underlying conditions (e.g.,
Dystonia
205
heart disease, dysautonomia) that can be worsened by psychotropics (see Chapter 1 of this volume). Psychotropics may also interact with dystonia treatments. Attention must therefore be given to the management principles outlined in Chapter 1. Blood levels should be monitored, because high-dose dystonia therapies may have unpredictable pharmacokinetic effects on psychotropic levels. Unpredictable pharmacodynamic effects may also occur, necessitating a switch to a different class of psychotropic medication (e.g., atypical antipsychotics rather than neuroleptics). Atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine) may be of particular value in patients with psychotic or bipolar disorders who experience dystonic exacerbations with conventional neuroleptics. However, data are currently insufficient to make any clear recommendations about these agents in patients with dystonia and psychiatric disturbances (see “Treatment of psychosis,” below). Treatment of psychosis. Clozapine may be of value for patients who experience uncontrollable dystonia when taking high-potency antipsychotic agents. Clozapine is useful in primary psychoses with tardive dystonia, including those unresponsive to thioridazine (Wolf and Mosnaim 1994). Moreover, preliminary clinical evidence (Karp et al. 1999) indicates that clozapine is a promising agent for the treatment of primary dystonia (see “Neurological Management” section above). Dystonia has been observed following clozapine withdrawal (Dickson et al. 1994; Wolf and Mosnaim 1994). Clozapine withdrawal dystonia has responded to reinstituting clozapine or treating the patient with risperidone or olanzapine (Ahmed et al. 1998). Clozapine can also trigger dystonia, but the condition is usually responsive to anticholinergics and benzodiazepines (Kastrup et al. 1994). In the event of clozapine-induced dystonia, it is possible that conventional neuroleptics may then be useful. Although neuroleptics improve dystonia in about one-third of patients (Greene et al. 1988; Lang 1988), they can also worsen the disorder. Persistent dystonia can develop in psychiatric AIDS patients after only brief neuroleptic exposure (Factor et al. 1994). Because patients with CNS disease may be at increased risk for neuroleptic-induced dystonia and neuroleptic malignant syndrome (Stoudemire et al. 1995), cau-
206
Psychiatric Management in Neurological Disease
tion is indicated when using these agents in such populations. When high-potency neuroleptics worsen dystonia, low-potency agents may be useful if not otherwise contraindicated (e.g., the risk of cardiovascular compromise). One further caveat is that tardive dyskinesia or tardive dystonia can develop in dystonia patients just as it can in any other patients taking antipsychotics. It is too early to determine the role of other atypical antipsychotics in managing patients with dystonia. Although tardive dystonia and other movement disorders are perhaps less likely than with traditional neuroleptics, atypical antipsychotics nevertheless can still cause these disorders. Tardive torticollis has been reported with risperidone (Fdhil et al. 1998). Moreover, in a prospective study of 350 consecutive neuroleptic-naive patients admitted to an acutecare psychiatry service (34 treated with risperidone at a mean dose of 3.2 mg/day and 212 treated with haloperidol at 3.7 mg/day), Rosebush and Mazurek (1999) found that the incidences of dystonic reactions and of other acute movement disorders were similar between the two drugs. Notwithstanding these data, however, some patients may benefit from switching drugs. Yoshida et al. (1998) reported the case of a patient with schizophrenia who experienced marked improvement in tardive dystonia after haloperidol was replaced with risperidone. Much more data are needed before inferences can be drawn about the role of atypical antipsychotics in managing psychiatric disorders in dystonia patients. Treatment of bipolar disorders. In bipolar disorder, conventional treatments may have a salutary effect on dystonia, may have no effect, or may even worsen it (Lauterbach et al. 1992b). In addition to the effects of neuroleptics and clozapine discussed above, lithium, carbamazepine, and valproate may, in a minority of patients, produce improvement in dystonia (Greene et al. 1988). More rarely, these agents have also triggered acute dystonia, but a beneficial effect on dystonia is more likely. In one patient with myoclonic tardive dystonia, calcium channel blockers dramatically improved the dystonia (Abad and Ovsiew 1993). This is of interest in dystonia patients with bipolar disorders, given the occasional utility of these agents in this psychiatric condition. Benzodiazepines may also benefit dystonia, especially clonazepam, although conventional anti-
Dystonia
207
manic doses may not be high enough to render improvement. Propranolol is useful for both dystonic tremor and lithium tremor (Lauterbach et al. 1992b). Electroconvulsive therapy (ECT) improved dystonia in a patient with parkinsonism–dystonia syndrome (Lauterbach and Moore 1990) and in another patient with tardive dystonia (Adityanjee et al. 1990). Treatment of depression. All commercially available SSRIs have been associated with acute dystonic reactions (Al-Adwani 1995; Dave 1994; George and Trimble 1993; Shihabuddin and Rapport 1994). Serotonin reuptake–inhibiting tricyclic antidepressants have also been associated with dystonia (Lee 1988). In one case report, trazodone precipitated acute lingual dystonia, disorientation, tachycardia, diaphoresis, and incontinence at 400 mg/day, progressing to akathisia, facial dyskinesia, catatonia, and parkinsonism (M. S. Kramer et al. 1986). The effect of noradrenergic antidepressants on dystonia is less clear. In secondary dystonia, however, fluoxetine is sometimes beneficial (Lauterbach 1995). In a case report, Kato et al. (1994) found that trazodone improved frontal blood flow and ameliorated nuchal dystonia in progressive supranuclear palsy. Dystonia and autonomic disturbance following fluoxetine withdrawal has also been reported (Stoukides and Stoukides 1991). Treatment of anxiety disorders. For coexisting obsessive-compulsive symptoms, panic attacks, and GAD, serotonin reuptake–inhibiting agents, other antidepressants, and benzodiazepines may be helpful, as discussed previously. Circumspection is indicated when prescribing benzodiazepines, given the proclivity of dystonia patients toward substance abuse. Buspirone, however, has triggered dystonia refractory to anticholinergics and responsive only to clonazepam (Ritchie et al. 1988). There are other reports of dystonia and intractable movement disorders with buspirone (LeWitt et al. 1993). Treatment of substance abuse disorders. In treating substance abuse, disulfiram intoxication has produced dystonia in association with lenticular nucleus lesions, which were possibly attributable to the metabolite carbon disulfide (Krauss et al. 1991). The effects of
208
Psychiatric Management in Neurological Disease
naltrexone on dystonia are not clear. Alcohol withdrawal is associated with movement disorders, and alcohol alleviates some forms of dystonia (Neiman et al. 1990), an effect that may potentially reinforce certain forms of substance abuse in dystonia patients.
Psychogenic Dystonia When confronted with apparent psychogenic dystonia, clinicians must be careful to establish the correct underlying diagnosis (see “Somatoform Disorders and Psychogenic Dystonia” under “Psychiatric Manifestations” section earlier in chapter). About 25% of patients with psychogenic dystonia experience full remission; conversion disorders and depressive illnesses respond best, whereas somatization, factitious disorders, and malingering rarely improve with treatment (Marsden 1995). Antidepressants may help, given the high rates of mood disorders in this population (Williams et al. 1995). Among 21 patients undergoing treatment for psychogenic dystonia, 15 patients (71%) benefited from suggestion, 12 (57%) from formal psychotherapy, 10 (48%) from physiotherapy, 10 (48%) from placebo, 5 (24%) from antidepressants, and 3 (14%) from behavior modification (Fahn and Williams 1988). In psychotherapy, clinicians should look for and attend to abuse issues, which are common in patients with psychogenic dystonia. Hypnosis is sometimes useful (Williams et al. 1995). In 4 patients with psychogenic dystonia, a combined hypnobehavioral approach involving postural hypnotic differential muscle retraining, hierarchical desensitization, sensory imaging conditioning, and ego-boosting suggestions was reported to be successful (De Benedittis 1996). Good to excellent outcomes were reported, with reductions in torticollis, muscle hypertrophy, and functional disability.
Summary Dystonia is an intriguing disorder with many unusual features and strange phenomena that can lead to misdiagnosis. It has many forms, with more generalized dystonias occurring earlier in life. Dystonia can have many etiologies, and causes of nonprimary dystonias can be determined by history, physical, and laboratory workup. A num-
Dystonia
209
ber of genetic types exist. Patients with primary dystonia are at high risk for mania, depression, generalized anxiety disorder, and alcohol dependence; in addition, they possess distinguishing personality profiles. Principles of psychotherapy and psychopharmacology are complex and require careful planning and monitoring. Psychiatric treatment can improve the course and outcome of dystonia.
References Abad V, Ovsiew F: Treatment of persistent myoclonic tardive dystonia with verapamil. Br J Psychiatry 162:554–556, 1993 Adityanjee, Jayaswal SK, Chan TM, et al: Temporary remission of tardive dystonia following electroconvulsive therapy. Br J Psychiatry 156: 433– 435, 1990 Ahmed S, Chengappa KN, Naidu VR, et al: Clozapine withdrawal–emergent dystonias and dyskinesias: a case series. J Clin Psychiatry 59:472– 477, 1998 Al-Adwani A: Brain damage and tardive dyskinesia. Br J Psychiatry 167: 410–411, 1995 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition. Washington, DC, American Psychiatric Association, 1980 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised. Washington, DC, American Psychiatric Association, 1987 American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994 Auchus AP, Freeman A, Green RC: Agitated behavior relieved following treatment of cervical dystonia in dementia. Neurology 45:393, 1995 Awaad Y, Munoz S, Nigro M: Progressive dystonia in a child with chromosome 18p deletion, treated with intrathecal baclofen. Presse Med 28:312–315, 1999 Barclay CL, Lang AE: Dystonia in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry 62:352–356, 1997 Berardelli A, Rothwell JC, Hallett M, et al: The pathophysiology of primary dystonia. Brain 121 (pt 7):1195–1212, 1998 Bihari K, Hill JL, Murphy DL: Obsessive-compulsive characteristics in patients with idiopathic spasmodic torticollis. Psychiatry Res 42:267–272, 1992
210
Psychiatric Management in Neurological Disease
Bressman SB: Clinical features of DYT1 and non-DYT1 primary dystonia. Mov Disord 12:15–16, 1997 Bruyn GW, Roos RAC: Dystonia musculorum deformans, in Handbook of Clinical Neurology, Vol 5 (49): Extrapyramidal Disorders. Edited by Vinken PJ, Bruyn GW, Klawans HL. Amsterdam, Elsevier Science BV, 1986, pp 519–528 Calne DB, Lang AE: Secondary dystonia. Adv Neurol 50:9–33, 1988 Cardoso FE, Jankovic J: Cocaine-related movement disorders. Mov Disord 8:175–178, 1993 Cheng JT, Liu A, Wasmuth J, et al: Clinical evidence of genetic anticipation in adult-onset idiopathic dystonia. Neurology 47:215–219, 1996 Chiu LP: Transient recurrence of auditory hallucinations during acute dystonia. Br J Psychiatry 155:110–113, 1989 Choppy-Jacolin M, Ferrey G, Demaria C: A psychometric study of 34 patients afflicted with spasmodic torticollis. Acta Neurol Scand 55:483– 492, 1977 Cockburn JJ: Spasmodic torticollis: a psychogenic condition. J Psychosom Res 15:471–477, 1971 Crisp AH, Moldofsky H: A psychosomatic study of writers’ cramp. Br J Psychiatry 111:841–858, 1965 Crossman AR, Brotchie JM: Pathophysiology of dystonia. Mov Disord 12:7–8, 1997 Dave M: Fluoxetine-associated dystonia (letter). Am J Psychiatry 151:149, 1994 De Benedittis G: Hypnosis and spasmodic torticollis—a report of four cases: a brief communication. Int J Clin Exp Hypn 44:292–306, 1996 Defazio G, Berardelli A, Abbruzzese G, et al: Possible risk factors for primary adult onset dystonia: a case-control investigation by the Italian Movement Disorders Study Group. J Neurol Neurosurg Psychiatry 64:25–32, 1998 Destarac M: Torticollis spasmodique et spasmes fonctionels. Rev Neurol 9:591–597, 1901 Diamond EL, Trobe JD, Belar CD: Psychological aspects of essential blepharospasm. J Nerv Ment Dis 172:749–756, 1984 Dickson R, Williams R, Dalby JT: Dystonic reaction and relapse with clozapine discontinuation and risperidone initiation (letter). Can J Psychiatry 39:184, 1994 Dowling JJ, Patrick V: Delirium with dystonia: a variant of neuroleptic malignant syndrome? (letter) Am J Psychiatry 146:276–277, 1989
Dystonia
211
Factor SA, Podskalny GD, Barron KD: Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: a clinico-pathological case report. J Neurol Sci 127:114–120, 1994 Fahn S: Third international dystonia symposium introduction. Mov Disord 12:1–2, 1997 Fahn S, Williams DT: Psychogenic dystonia. Adv Neurol 50:431–455, 1988 Fahn S, Bressman S, Marsden CD: Classification of dystonia. Mov Disord 12:3–5, 1997 Fahn S, Bressman SB, Marsden CD: Classification of dystonia. Adv Neurol 78:1–10, 1998 Fdhil H, Krebs MO, Bayle F, et al: Risperidone-induced tardive dystonia: a case of torticollis [in French]. Encephale 24:581–583, 1998 Furukawa Y, Lang AE, Trugman JM, et al: Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology 50:1015–1020, 1998 George MS, Trimble MR: Dystonic reaction associated with fluvoxamine (letter). J Clin Psychopharmacol 13:220–221, 1993 Gordon MF, Bressman S, Brin MF, et al: Dystonia in a patient with deletion of 18q. Mov Disord 10:496–499, 1995 Grafman J, Cohen LG, Hallett M: Is focal hand dystonia associated with psychopathology? Mov Disord 6:29–35, 1991 Greene P, Shale H, Fahn S: Experience with high dosages of anticholinergic and other drugs in the treatment of torsion dystonia. Adv Neurol 50:547–556, 1988 Guy N, Raps A, Assael M: The Pisa syndrome during maintenance antipsychotic therapy (letter). Am J Psychiatry 143:1492, 1986 Harding AE: Movement disorders: genetic aspects, in Movement Disorders 3. Edited by Marsden CD, Fahn S. Oxford, UK, Butterworth-Heinemann, 1994, pp 46–64 Harrington RC, Wieck A, Marks IM, et al: Writer’s cramp: not associated with anxiety. Mov Disord 3:195–200, 1988 Hartmann A, Pogarell O, Oertel WH: Secondary dystonias. J Neurol 245: 511–518, 1998 Hathaway SR, McKinley JC: Minnesota Multiphasic Personality Inventory, Revised. Minneapolis, MN, University of Minnesota, 1970 Iacono RP, Kuniyoshi S, Lonser R, et al: Posteroventral pallidotomy in the treatment of primary and secondary dystonia (abstract). Mov Disord 12 (suppl):32, 1997
212
Psychiatric Management in Neurological Disease
Imperio AM, Cullinan TF, Riklan M: MMPI characteristics associated with cerebral palsy and dystonia musculorum deformans. Percept Mot Skills 48:1003–1007, 1979 Jahanshahi M, Marsden CD: Personality in torticollis: a controlled study. Psychol Med 18:375–387, 1988a Jahanshahi M, Marsden CD: Depression in torticollis: a controlled study. Psychol Med 18:925–933, 1988b Jahanshahi M, Marsden CD: Body concept, disability, and depression in patients with spasmodic torticollis. Behav Neurol 3:117–131, 1990 Jahanshahi M, Marsden CD: Psychological functioning before and after treatment of torticollis with botulinum toxin. J Neurol Neurosurg Psychiatry 55:229–231, 1992 Janavs JL, Aminoff MJ: Dystonia and chorea in acquired systemic disorders. J Neurol Neurosurg Psychiatry 65:436–445, 1998 Jankovic J, Ford J: Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 13:402–411, 1983 Jin H, May M, Tranebjaerg L, et al: A novel X-linked gene, DDP, shows mutations in families with deafness (DFN-1), dystonia, mental deficiency and blindness. Nat Genet 14:177–180, 1996 Karp BI, Goldstein SR, Chen R, et al: An open trial of clozapine for dystonia. Mov Disord 14:652–657, 1999 Kastrup O, Gastpar M, Schwarz M: Acute dystonia due to clozapine (letter). J Neurol Neurosurg Psychiatry 57:119, 1994 Kato E, Takahashi S, Abe T, et al: A case of progressive supranuclear palsy showing improvement of rigidity, nuchal dystonia and autonomic failure with trazodone [in Japanese]. Rinsho Shinkeigaku 34:1013–1017, 1994 Kessler KR, Skutta M, Benecke R: Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246:265–274, 1999 Khanna R, Das A, Damodaran SS: Prospective study of neuroleptic- induced dystonia in mania and schizophrenia. Am J Psychiatry 149: 511–513, 1992 Kishore A, Nygaard TG, de la Fuente-Fernandez R, et al: Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography. Neurology 50:853–855, 1998
Dystonia
213
Klein C, Brin MF, Kramer P, et al: Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Natl Acad Sci U S A 96:5173–5176, 1999 Koehler CM, Leuenberger D, Merchant S, et al: Human deafness dystonia syndrome is a mitochondrial disease. Proc Natl Acad Sci U S A 96: 2141–2146, 1999 Korczyn AD, Kahana E, Zilber N: Torsion dystonia in Israel. Ann Neurol 8:387–391, 1980 Krack P, Schneider S, Deuschl G: Geste device in tardive dystonia with retrocollis and opisthotonic posturing. Mov Disord 13:155–157, 1998 Kraft IA: A psychiatric study of two patients with dystonia musculorum deformans. South Med J 59:284–288, 1966 Kramer MS, Marcus DJ, Diferdinando J, et al: Atypical acute dystonia associated with trazodone treatment (letter). J Clin Psychopharmacol 6: 117–118, 1986 Kramer PL, Mineta M, Klein C, et al: Rapid-onset dystonia–parkinsonism: linkage to chromosome 19q13. Ann Neurol 46:176–182, 1999 Krauss JK, Mohadjer M, Wakhloo AK, et al: Dystonia and akinesia due to pallidoputaminal lesions after disulfiram intoxication (letter). Mov Disord 6:166–170, 1991 Kumar R, Maraganore DM, Ahlskog JE, et al: Treatment of putative immune-mediated and idiopathic cervical dystonia with intravenous methylprednisolone. Neurology 48:732–735, 1997 Kyllerman M, Forsgren L, Sanner G, et al: Alcohol-responsive myoclonic dystonia in a large family: dominant inheritance and phenotypic variation. Mov Disord 5:270–279, 1990 LaBuda MC, Fletcher NA, Korczyn AD, et al: Genomic imprinting and anticipation in idiopathic torsion dystonia. Neurology 43:2040–2043, 1993 Lal KP, Saxena S, Mohan D: Tardive dystonia alternating with mania. Biol Psychiatry 23:312–316, 1988 Lang AE: Dopamine agonists and antagonists in the treatment of idiopathic dystonia. Adv Neurol 50:561–570, 1988 Lang AE: Psychogenic dystonia: a review of 18 cases. Can J Neurol Sci 22:136–143, 1995 Lauterbach EC: Humming, auditory hallucinations, and dystonia (letter). Biol Psychiatry 27:934–935, 1990 Lauterbach EC: Haloperidol-induced dystonia and parkinsonism on discontinuing metoclopramide: implications for differential thalamocortical activity. J Clin Psychopharmacol 12:442–443, 1992
214
Psychiatric Management in Neurological Disease
Lauterbach EC: Fluoxetine, buspirone, myoclonus, and dystonia (letter). Am J Psychiatry 152:1697, 1995 Lauterbach EC: Bipolar disorders, dystonia, and compulsion after dysfunction of the cerebellum, dentatorubrothalamic tract, and substantia nigra. Biol Psychiatry 40:726–730, 1996 Lauterbach EC, Duvoisin RC: Neuropsychiatric correlates of familial parkinsonism (abstract). Neurology 37 (suppl 1):267, 1987 Lauterbach EC, Moore NC: Parkinsonism-dystonia syndrome and ECT (letter). Am J Psychiatry 147:1249–1250, 1990 Lauterbach EC, Freeman A, Spears TE, et al: Increased prevalence of affective disorders in dystonia does not correlate with motor disability (abstract). Neurology 41 (suppl 1):293, 1991 Lauterbach EC, Freeman A, Spears TE, et al: Increase in affective disorders in dystonia (paper session 16: Depression in Brain Disorders). Presented at the American Psychiatric Association Annual Meeting, Washington, DC, May 5, 1992a Lauterbach EC, Spears TE, Price ST: Bipolar disorder in idiopathic dystonia: clinical features and possible neurobiology. J Neuropsychiatry Clin Neurosci 4:435–439, 1992b Lauterbach EC, Price ST, Freeman A, et al: DIS-diagnosed DSM-III anxiety disorders in primary dystonia (abstract). Biol Psychiatry 33:149A, 1993a Lauterbach EC, Price ST, Freeman A, et al: DIS-diagnosed DSM-III compulsive disorders in primary dystonia (abstract). Biol Psychiatry 33:149A, 1993b Lauterbach EC, Price ST, Freeman A, et al: SCID-diagnosed DSM-III-R anxiety disorders in primary dystonia (abstract). Biol Psychiatry 33:151A, 1993c Lauterbach EC, Price ST, Freeman A, et al: SCID-diagnosed DSM-III-R compulsive disorders in primary dystonia (abstract). Biol Psychiatry 33: 151A–152A, 1993d Lauterbach EC, Price ST, Wilson AN, et al: Dystonia after subcortical lesions: clinical and pathophysiological implications (abstract). Mov Disord 9 (suppl 1):43, 1994a Lauterbach EC, Price ST, Wilson AN, et al: Poststroke anxiety: relations to globus pallidus, dystonia, and parkinsonism (abstract). J Neuropsychiatry Clin Neurosci 6:316–317, 1994b Lauterbach EC, Wilson AN, Price ST, et al: Post-stroke generalized anxiety: parkinsonism, dystonia, and the globus pallidus (abstract). Biol Psychiatry 35:681, 1994c
Dystonia
215
Lee HK: Dystonic reactions to amitriptyline and doxepin (letter). Am J Psychiatry 145:649, 1988 Leo RJ: Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57:449–454, 1996 LeWitt PA, Miller LP, Levine RA: Tetrahydrobiopterin in dystonia: identification of abnormal metabolism and therapeutic trials. Neurology 36: 760–764, 1986 LeWitt PA, Walters A, Hening W, et al: Persistent movement disorders induced by buspirone. Mov Disord 8:331–334, 1993 Lurie S, Priscu V, Hagay Z: The perinatal emphasis of Segawa’s syndrome. J Perinat Med 24:699–701, 1996 Marsden CD: Investigation of dystonia. Adv Neurol 50:35–44, 1988 Marsden CD: Psychogenic problems associated with dystonia. Adv Neurol 65:319–326, 1995 Matthews WB, Beasley P, Parry-Jones W, et al: Spasmodic torticollis: a combined clinical study. J Neurol Neurosurg Psychiatry 41:485–492, 1978 Meares R: Features which distinguish groups of spasmodic torticollis. J Psychosom Res 15:1–11, 1971a Meares R: “Ego boundary” and the “barrier score.” Br J Med Psychol 44: 179–180, 1971b Naber D, Weinberger DR, Bullinger M: Spasmodic torticollis: a study of symptoms, course, family history and psychopathology. Nervenarzt 57:238–243, 1986 Nasrallah HA, Churchill CM, Hamdan-Allan GA: Higher frequency of neuroleptic-induced dystonia in mania than in schizophrenia. Am J Psychiatry 145:1455–1456, 1988 Neiman J, Lang AE, Fornazzari L, et al: Movement disorders in alcoholism: a review. Neurology 40:741–746, 1990 Nutt JG, Muenter MD, Aronson A, et al: Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 3:188–194, 1988 Ondo WG, Desaloms JM, Jankovic J, et al: Pallidotomy for generalized dystonia. Mov Disord 13:693–698, 1998 Pauls DL, Korczyn AD: Complex segregation analysis of dystonia pedigrees suggests autosomal dominant inheritance. Neurology 40:1107– 1110, 1990 Perlmutter JS, Stambuk MK, Markham J, et al: Decreased [18F]spiperone binding in putamen in idiopathic focal dystonia (abstract). Mov Disord 12 (suppl):23, 1997
216
Psychiatric Management in Neurological Disease
Playford ED, Passingham RE, Marsden CD, et al: Increased activation of frontal areas during arm movement in idiopathic torsion dystonia. Mov Disord 13:309–318, 1998 Radford JM, Brown TM, Borison RL: Unexpected dystonia while changing from clozapine to risperidone (letter). J Clin Psychopharmacol 15:225– 226, 1995 Raja M, Azzoni A: Tardive dystonia: prevalence, risk factors and clinical features. Ital J Neurol Sci 17:409–418, 1996 Ranawaya R, Riley D, Lang A: Psychogenic dyskinesias in patients with organic movement disorders. Mov Disord 5:127–133, 1990 Remington GJ, Voineskos G, Pollock B, et al: Prevalence of neurolepticinduced dystonia in mania and schizophrenia. Am J Psychiatry 147: 1231–1233, 1990 Riklan M, Cullinan T, Cooper IS: Psychological studies in dystonia musculorum deformans. Adv Neurol 14:189–200, 1976 Ritchie EC, Bridenbaugh RH, Jabbari B: Acute generalized myoclonus following buspirone administration. J Clin Psychiatry 49:242–243, 1988 Robins LN, Regier DA (eds): Psychiatric Disorders in America. New York, Free Press, 1991 Rosebush PI, Mazurek MF: Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone. Neurology 52:782–785, 1999 Rothfeld JM: Generalized dystonia and obsessive-compulsive disorder associated with bilateral circumscribed magnetic resonance signal changes in the putamen. J Nerv Ment Dis 183:113–114, 1995 Rummans TA, Lauterbach EC, Coffey CE, et al: Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci 11:176–189, 1999 Rutledge JN, Hilal SK, Silver AJ, et al: Magnetic resonance imaging of dystonic states. Adv Neurol 50:265–275, 1988 Saxena S: Tardive dystonia and Pisa syndrome (letter). Br J Psychiatry 149: 524, 1986 Schwalbe W: Eine eigentümliche tonische krampf-form mit hysterischen symptomen. Inaugural Dissertation. Berlin, G Schadé, 1908 Sheehy MP, Marsden CD: Writers’ cramp—a focal dystonia. Brain 105: 461–480, 1982 Shihabuddin L, Rapport D: Sertraline and extrapyramidal side effects (letter). Am J Psychiatry 151:288, 1994
Dystonia
217
Siebner HR, Tormos JM, Ceballos-Baumann AO, et al: Low-frequency repetitive transcranial magnetic stimulation of the motor cortex in writer’s cramp. Neurology 52:529–537, 1999 Stehbens JA: Striato-pallidonigral degeneration (a diagnostic dilemma— case report). Diseases of the Nervous System 33:387–391, 1972 Stoudemire A, Moran MG, Fogel BS: Psychopharmacology in the medically ill patient, in The American Psychiatric Press Textbook of Psychopharmacology. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1995, pp 783–801 Stoukides JA, Stoukides CA: Extrapyramidal symptoms upon discontinuation of fluoxetine (letter). Am J Psychiatry 148:1263, 1991 Tarbox AR, Morse CS: Psychological aspects of chronic disease, in Advances in Ophthalmic Plastic and Reconstructive Surgery, Vol 4: Blepharospasm. Edited by Bosniak SL, Smith BC. New York, Pergamon, 1985, pp 147–161 Thornton A, McKenna PJ: Acute dystonic reactions complicated by psychotic phenomena. Br J Psychiatry 164:115–118, 1994 Tinazzi M, Frasson E, Polo A, et al: Evidence for an abnormal cortical sensory processing in dystonia: selective enhancement of lower limb P37–N50 somatosensory evoked potential. Mov Disord 14:473–480, 1999 Tolosa ES: Clinical features of Meige’s disease (idiopathic orofacial dystonia): a report of 17 cases. Arch Neurol 38:147–151, 1981 Tranebjaerg L, Schwartz C, Eriksen H, et al: A new X linked recessive deafness syndrome with blindness, dystonia, fractures, and mental deficiency is linked to Xq22. J Med Genet 32:257–263, 1995 Trobe JD, Diamond EL, Belar CD: Psychological abnormalities in essential blepharospasm, in Advances in Ophthalmic Plastic and Reconstructive Surgery, Vol 4: Blepharospasm. Edited by Bosniak SL, Smith BC. New York, Pergamon, 1985, pp 137–145 Vitek JL, Evatt M, Zhang J, et al: Pallidotomy is an effective treatment for patients with medically intractable dystonia (abstract). Mov Disord 12 (suppl):31, 1997 Vitek JL, Chockkan V, Zhang JY, et al: Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol 46:22–35, 1999 Volow MR: Psychiatric aspects of blepharospasm, in Advances in Ophthalmic Plastic and Reconstructive Surgery, Vol 4: Blepharospasm. Edited by Bosniak SL, Smith BC. New York, Pergamon, 1985, pp 163–174
218
Psychiatric Management in Neurological Disease
Williams DT, Ford B, Fahn S: Phenomenology and psychopathology related to psychogenic movement disorders. Adv Neurol 65:231–257, 1995 Wolf ME, Mosnaim AD: Improvement of axial dystonia with the administration of clozapine. Int J Clin Pharmacol Ther 32:282–283, 1994 Yassa R: The Pisa syndrome: a report of two cases. Br J Psychiatry 146:93–95, 1985 Yoshida K, Higuchi H, Hishikawa Y: Marked improvement of tardive dystonia after replacing haloperidol with risperidone in a schizophrenic patient. Clin Neuropharmacol 21:68–69, 1998 Young CS, Stewart JB, Fenton GW: Neuroleptic medication for dystonia: reciprocal relationship between effects on motor function and mood. Br J Psychiatry 165:384–386, 1994 Zeman W: Dystonia: an overview. Adv Neurol 14:91–103, 1976
C H A P T E R
7
Stroke Robert G. Robinson, M.D.
C
erebral infarction, or stroke, represents a major health problem facing the geriatric population in the United States. It is the third leading cause of death in the United States and most European countries. Approximately 77% of strokes are thromboembolic, with 30% thrombotic, 22% embolic, and 25% uncertain. The remaining 23% of strokes are hemorrhagic, with 11% intracranial hemorrhage and 12% subarachnoid hemorrhage (Caplan and Stein 1986). Hypertension is the greatest risk factor for stroke.
Prevalence The annual incidence of stroke in the United States is approximately 400,000. The prevalence rises steadily with each decade of life, increasing from 810 per 100,000 at ages 55–65 years to 5,970 per 100,000 after age 75 years (Wolf et al. 1984). Due primarily to the greatly improved control of hypertension, the incidence of stroke declined steadily from the 1940s through the 1970s (Garraway et al. 1979). This work was supported in part by National Institute of Mental Health Research Scientist Award MH00163 and by NIMH grants MH52879 and MH53592. The author thanks Thomas R. Price, John R. Lipsey, Rajesh Parikh, Carlos Castillo, Krishna Rao, Godfrey D. Pearlson, Lynn Book Starr, and Paula Andrezewski, who participated in many of the studies described. 219
220
Psychiatric Management in Neurological Disease
Clinical Recognition, Neurological Presentation, Pathological Features, Neuroimaging, and Laboratory Investigation A discussion of these topics is quite involved and is beyond the scope of this chapter but is available elsewhere (Adams 1993; Bogousslavsky and Caplan 1995).
Psychiatric Manifestations Cognitive Impairment Cognitive impairment is probably the most frequent mental consequence of stroke. A discussion of the cognitive impairments resulting from stroke is the topic of textbooks of neuropsychology and is well beyond the scope of this chapter. Multi-infarct disease, found in 15%–20% of dementia cases, is second only to Alzheimer’s disease as the leading cause of dementia in the United States (Herskovits and Figueroa 1988). There is, however, one form of poststroke cognitive impairment that appears to be amenable to treatment, and that is cognitive impairment associated with poststroke depression. Several studies have demonstrated that patients with poststroke major depression display a greater degree of cognitive impairment than nondepressed patients with comparable lesions (Bolla-Wilson et al. 1989; House et al. 1990a; Robinson 1998; Starkstein et al. 1988c) (Figure 7–1). Among patients with left-hemisphere lesions, a neuropsychological test battery revealed that patients with major depression had greater overall cognitive impairment in the domains of orientation, language, visuoconstruction, executive function, and frontal lobe functioning compared with nondepressed patients with comparable lesions. In contrast, among patients with right-hemisphere lesions, overall severity of cognitive impairment did not differ significantly between depressed and nondepressed patients. These findings suggest that left-hemisphere stroke may produce a neurophysiological response that leads to both major depression and cognitive dysfunction and right-hemisphere stroke may lead to depression by a very different mechanism.
Stroke
221
Figure 7–1. Mean (±SD) Mini-Mental State Exam (MMSE; Folstein et al. 1975) scores of patients with major depression, minor depression, or no mood disorder following acute stroke. Patients with major depression were significantly more impaired than those in the other two groups. *F2, 272 = 6.99, P = .001.
Apathy Apathy—the absence or lack of feeling, emotion, interest, or concern—has been reported frequently among patients with brain injury. Using an apathy scale, we examined a consecutive series of 80 patients with single-stroke lesions and no significant impairment in comprehension (Starkstein et al. 1993). Of these patients, 9 (11%) manifested only apathy (without depression), and another 9 (11%) had both apathy and depression. The only demographic correlate of apathy was age; apathetic patients (with or without depression) were significantly older than nonapathetic patients. Also, apathetic patients showed significantly more severe deficits in activities of daily living (ADL), and there was a significant interaction between depression and apathy on ADL scores, with the greatest impairment
222
Psychiatric Management in Neurological Disease
found in patients who were both apathetic and depressed. Nondepressed patients with apathy also had a significantly higher frequency of lesions involving the posterior limb of the internal capsule compared with patients with no apathy (Starkstein et al. 1993). A clinical example will illustrate some of these characteristics. The patient, a 58-year-old man, had bilateral infarctions of the caudate nuclei. He had been a very active and hard-working florist; however, after the strokes, which occurred within a few weeks of each other, he became uninterested in his business and his home. He stopped working, and his wife couldn’t even get him to mow their small yard. He would stop in the middle of jobs and would have no explanation. Although he denied depression, he stated that he got no pleasure from doing tasks and was content just sitting. His condition did not improve with antidepressants but showed some improvement after treatment with stimulant medication.
Pathological Emotions Pathological laughing and crying represent a severe form of emotional lability characterized by episodes of laughing and/or crying that are not appropriate or that are markedly excessive to the situation. They may appear spontaneously or may be elicited by nonemotional events, and they do not correspond or are excessive to underlying emotions. Pseudobulbar affect is another name that has been applied to pathological laughing and crying. This disorder has classically been explained as secondary to the bilateral interruption of neocortical upper motor neuron innervation of bulbar motor nuclei (Poeck 1969). Several investigators have examined the prevalence of this disorder in patients with stroke. Morris and colleagues (1993b) found that pathological emotions occurred in 12 (18%) of 66 patients examined 2–3 months poststroke in a rehabilitation hospital.
Psychosis The phenomena of hallucinations and delusions in stroke patients have been described in patients with agitated delirium, acute atypical psychosis, peduncular hallucinosis, release hallucinations, or acute organic psychosis. In a study of psychosis after stroke lesions,
Stroke
223
Rabins et al. (1991) found a very low prevalence of psychosis among stroke patients (only five cases in 5 years of geriatric psychiatric admissions). All five patients, however, had right-hemisphere lesions, primarily involving frontoparietal regions. When compared with five age-matched patients with cerebrovascular lesions in identical locations but no psychosis, patients with secondary psychosis had significantly greater subcortical atrophy, as manifested by significantly larger areas of the frontal horn and body of the lateral ventricle (measured on the side contralateral to the brain lesion). Several other investigators have reported a high frequency of seizures among patients with secondary psychosis (Levine and Finklestein 1982). These seizures usually started after the brain lesion but before the onset of psychosis. The Rabins et al. study (1991) found seizures in three of five patients with poststroke psychosis compared with none of five poststroke nonpsychiatric control subjects. We have hypothesized that three factors may be important in the mechanism of organic hallucinations: a right-hemisphere lesion involving the temporoparietal cortex, seizures, and/or subcortical brain atrophy (Starkstein et al. 1992). Another clinical example will illustrate the presentation and correlates of psychosis following stroke. The patient, a 72-year-old right-handed woman with no prior psychiatric history, had experienced the sudden onset of a right occipital headache, followed by numbness of her left arm and left facial droop. She had focal seizures of her left arm. Two days after this event, the patient heard a buzzing noise she thought was made by a bee. She later heard the voice of a relative saying that he was going to kill her, and she hid in the closet. She also saw people sitting at her kitchen table discussing her. The patient was oriented and had no sign of delirium. She improved following treatment with haloperidol and after 1 month had no further hallucinations.
Mood Disorders Mania. Manic symptoms following stroke occur much less frequently than depressive symptoms. In our studies of patients over the first 2 years after a stroke, we found only 3 cases among more than 400 patients seen at various times following stroke (Robinson et al.
224
Psychiatric Management in Neurological Disease
1988). We and others have had to use patients with cerebral injury resulting from one of several etiologies in order to archive an adequate sample size. When we compared 11 patients with secondary mania and 25 patients with functional (i.e., no known neuropathology) mania, both groups of patients showed similar frequencies of elation, pressured speech, flight of ideas, grandiose thoughts, insomnia, hallucinations, and paranoid delusions (Starkstein et al. 1987a). Thus, secondary mania had the same phenomenological appearance as primary mania. Cummings and Mendez (1984) described two patients who developed mania following right thalamic lesions. We subsequently examined 17 patients with secondary mania, 31 stroke patients with major depression, and 28 stroke controls with no mood disturbance (Robinson et al. 1988). Compared with patients with poststroke major depression or no mood disorder following stroke, a significantly greater number of manic patients had right-hemisphere lesions involving either cortical limbic areas (i.e., orbitofrontal cortex or basotemporal cortex) or subcortical nuclei (i.e., head of the caudate or thalamus) (Figure 7–2). In another study involving 45 highly selected poststroke patients, all 3 with mania had left cerebellar or cerebellothalamic tract lesions, presumably affecting cerebellar connections with the right caudate or thalamus (Lauterbach 1996). Occasionally, secondary mania has been followed by recurrent manic episodes, whereas in other instances the mania has been followed or preceded by episodes of depression. In an effort to determine which factors affect this bipolar course, we examined 19 patients with the diagnosis of secondary mania (Starkstein et al. 1991). Subjects were divided into two groups, one with bipolar disorder (i.e., mania preceded by depression) and the other with single or recurrent episodes of mania. The bipolar group (n = 7) was found to have greater cognitive impairment than the mania-only group (n = 12), and 5 of the bipolar patients had lesions restricted to the subcortical area of the right hemisphere. In contrast, 11 of the mania-only patients had cortical lesions of the right hemisphere (only 1 patient had a subcortical lesion) (P < .05). These interesting findings suggest that disruption of subcortical mechanisms in the right hemisphere may be important in bipolar disorder, whereas disruption of right cortical mechanisms may mediate a unipolar mania.
Stroke
225
Figure 7–2. Frequency of lesions restricted to the right hemisphere in patients with mania, major depression, or no mood disorder following acute stroke. Patients with mania were significantly more likely to have a right-hemisphere lesion than were patients with depression or no mood disturbance. *P < .01.
Depressive disorders. Depression is probably the most common poststroke emotional disorder, occurring in 20%–50% of patients following acute stroke (Burvill et al. 1995; Morris et al. 1990). DSM-IV (American Psychiatric Association 1994) now categorizes poststroke depression as a mood disorder due to a general medical condition (i.e., stroke), with the following specifiers: 1) with depressive features, 2) with major depressive–like episode, 3) with manic features, or 4) with mixed features (American Psychiatric Association 1994). Prior to the publication of DSM-IV, two types of depressive disorders associated with cerebral ischemia had been identified under DSM-III (American Psychiatric Association 1980) criteria: 1) major depression, which occurs in about 20% of patients, and 2) minor depression, which also occurs in about 20% of patients (Robinson et al. 1983). In prior studies, we defined minor depression as meeting DSM-III-R
226
Psychiatric Management in Neurological Disease
(American Psychiatric Association 1987) symptom criteria for dysthymic depression (excluding duration) criteria. There are now DSM-IV research criteria for minor depression—i.e., depressed mood or loss of interest and 2–4 symptoms of major depression of at least 2 weeks’ duration (American Psychiatric Association 1994, pp. 720–721). Diagnosis. A study of depressive symptoms among stroke patients found that, except for early morning awakening, all of the psychological as well as vegetative symptoms of depression occurred more frequently among depressed stroke patients than among comparable stroke patients without a depressed mood (Fedoroff et al. 1991). Therefore, the use of DSM-IV criteria in an acutely medically ill population does not appear to produce significant numbers of falsepositive or false-negative cases. The difficulty of assessing symptomatology in the presence of language impairment is another aspect of the poststroke patient that may influence phenomenology. Virtually all studies of patients with depression following stroke have excluded patients with impaired language comprehension. The obvious question raised by the exclusion of patients with comprehension deficits from systematic studies of poststroke depression is whether the exclusion of these patients has significantly influenced the clinical or lesion correlates of poststroke depression. Although this question cannot be definitively answered, our assessments of patients with mild comprehension deficits did not reveal a high frequency of depression (Starkstein and Robinson 1988). Numerous investigators have assessed the prevalence of poststroke depression. Representative publications from institutional and community survey studies are shown in Table 7–1. Overall, about 20%–40% of patients may develop depression within the first few months after an acute stroke. The rates depend on whether the general population or specific institutionalized patients are studied. Approximately half of patients who develop poststroke depression will meet criteria for major depression; the remaining half will have the less severe form of minor depression. A number of studies have assessed the duration of poststroke depression (Astrom et al. 1993; House et al. 1991; Morris et al. 1990; Rob-
Stroke
Table 7–1.
227
Prevalence of poststroke depression
Setting/investigator Community studies Burvill et al. 1995 House et al. 1991 Rehabilitation hospital Eastwood et al. 1989 Morris et al. 1990 Acute care hospital Astrom et al. 1993 Castillo et al. 1993 Note.
No.
Major Minor Overall depression, depression, depression, % % %
294 89
15 11
8 12
23 23
87 99
10 14
40 21
50 35
80 291
25 20
NR 18
25+ 38
NR = not reported.
inson et al. 1987). In all of these studies, the majority of patients with major depression experienced remission within the first year, with a minority of cases becoming chronic major depression persisting up to 3 years following stroke. For example, Morris et al. (1990) found a mean duration of major depression of 42 weeks, whereas Astrom et al. 1993) reported that 5 of 14 patients (36%) with in-hospital major depression were still depressed at 3-year follow-up. Three factors have been identified that can influence the natural course of poststroke depression: 1) active treatment of the depression with antidepressant medication (Lipsey et al. 1984), 2) the location of the stroke lesion (Starkstein et al. 1988b), and 3) the presence or absence of adequate social support (Morris et al. 1991). A recent study examined the effect of gender on the frequency of poststroke depression (Paradiso et al. 1998). In a consecutive series of 301 patients with acute stroke, women were significantly more likely to develop major depression than were men (24% versus 12%). Among men, major depression was associated with impairments in ADL and social functioning. Among women, however, major depression was associated with left anterior brain lesions, prior history of psychiatric disorder, and cognitive impairment. These findings suggest that the etiology of major depression may be different in men and women. The first study to report a significant clinical–pathological corre-
228
Psychiatric Management in Neurological Disease
lation in poststroke depression found a significant inverse correlation between the severity of depression and the distance of the anterior border of the lesion from the left frontal pole (r = − 0.76) as measured on computed tomography (CT) imaging (Robinson and Szetela 1981) (Figure 7–3). This surprising finding led to a number of subsequent investigations both of this phenomenon and of the laterality of lesion location. Many studies have confirmed the association of poststroke major depression with left anterior brain injury (Astrom et al. 1993; Eastwood et al. 1989; Herrmann et al. 1993; Morris et al. 1996; Robinson et al. 1984), but several have not (Dam et al. 1989; House et al. 1990b; Sinyor et al. 1986); however, some of the latter studies have supported the correlation of severity of depression with frontal proximity of the lesion without the association with left-hemisphere lesions (House et al. 1990b; Sinyor et al. 1986). Longitudinal assessment has suggested that the association of major depression with left anterior lesions is a phenomenon of the acute poststroke period, whereas the correlation of depression with proximity of the lesion to the frontal pole lasts for about 6–9 months following stroke (Shimoda and Robinson 1999). Subsequent work has examined the effect of cortical and subcortical lesion location on the severity and presence of depressive symptoms following stroke (Starkstein et al. 1987b). Patients with acute ischemic lesions in the left hemisphere were found to have significantly higher rates of both major and minor depression than patients with right-hemisphere lesions, regardless of the cortical or subcortical location of the lesion (Figure 7–4). Additionally, correlations between depression scores and the distance of the lesion from the frontal pole were significant for patients with either left cortical or left subcortical lesions. These clinical–pathological correlations, however, were not significant for patients with acute right-hemisphere lesions. Among patients with left subcortical lesions, the frequency of major depression was found to be significantly greater in patients with left basal ganglia lesions than in patients with left thalamic lesions (Starkstein et al. 1988a). Lauterbach et al. (1997a) examined 45 patients with focal subcortical lesions and found a 20% frequency of major depression and a 4% frequency of minor depression. Left posterior globus pallidus lesions were significantly associated with major depression (Lauterbach et al. 1997b).
Stroke
229
Figure 7–3. Scatter plot of the relationship between severity of depression in patients with stroke or traumatic brain injury, as measured by three depression rating scales, and distance of the anterior border of the lesion from the frontal pole, as measured on computed tomography (CT) scan. For both stroke and trauma lesions, depression increased with proximity of the lesion to the frontal pole (r = .76, P < .01). Source. Reproduced from Robinson RG, Szetela B: “Mood Change Following Left Hemispheric Brain Injury.” Annals of Neurology 9:447–453, 1981. Copyright © 1981, Lippincott-Raven Publishers. Used with permission.
Another study that examined the lesion correlates of poststroke depression compared patients with brain-stem cerebellar lesions (posterior circulation) and patients with cerebral hemisphere lesions (middle cerebral artery circulation) (Starkstein et al. 1988b). This study found that patients with brain-stem cerebellar lesions had a significantly lower frequency of major depression than patients with middle cerebral artery infarcts and that the duration of major depression was also significantly shorter (Starkstein et al. 1988b) (Figure 7–5). Noradrenergic and serotonergic cell bodies located within the brain stem send ascending projections through the median fore-
230
Psychiatric Management in Neurological Disease
Figure 7–4. Frequency of depression in patients with acute first-ever stroke lesions restricted to cortical or subcortical brain regions. Lefthemisphere cortical (LC) and subcortical (LS) lesions were associated with a greater frequency of depression than were right-hemisphere cortical (RC) and subcortical (RS) lesions. *χ2 = 4, P < .05.
brain bundle to the frontal cortex. These axons then run longitudinally through the deep layers of the cortex (Morrison et al. 1979). Based on these neuroanatomic facts and the clinical finding that the severity of depression correlates with the proximity of the lesion to the frontal pole, we have suggested that poststroke depression may be the consequence of severe depletion of norepinephrine and/or serotonin resulting from interruption of these ascending biogenic amine pathways by left frontal or left basal ganglia lesions (Robinson et al. 1984). We also found a lateralized biochemical response to ischemia in human subjects (Mayberg et al. 1988). Right-hemisphere lesions resulted in significantly higher amounts of ipsilateral spiperone binding (presumably 5-HT2 [serotonin] receptor binding) in the noninjured temporal and parietal cortex compared with left-hemisphere lesions. Patients with left-hemisphere lesions, on the other hand, showed a decrement in serotonin binding in the left temporal cortex that inversely correlated with depression scores. These find-
Stroke
231
Figure 7–5. Percentage of patients who remained depressed 6 months and 12–24 months following a brain-stem cerebellar (BST/CB) lesion or a hemispheric middle cerebral artery (MCA) infarct. Patients with MCA infarcts were significantly more likely to remain depressed at 6 and 12–24 months follow-up than were patients with BST/CB lesions.
ings are intriguing and suggest that, from a biochemical standpoint, the left hemisphere recovers from injury less robustly than the right hemisphere. Consequently, the left hemisphere may be in some way more vulnerable to lesion-induced biogenic amine depletion than the right hemisphere.
Anxiety Disorders Anxiety disorder is an important but rarely studied consequence of stroke. Depending upon the population being studied, the prevalence of generalized anxiety disorder (GAD) varies from 1% in community studies (House et al. 1991) to 28% of patients hospitalized with acute stroke (Astrom 1996). We examined a consecutive series of 98 patients with acute stroke lesions for the presence of both anxiety and depressive disorders (Starkstein et al. 1990). Modified DSM-III criteria for GAD (M-GAD; i.e., excluding 6-month-duration criteria)
232
Psychiatric Management in Neurological Disease
were used for the diagnosis of anxiety disorder. Of 98 patients with first-episode stroke, only 6 met the M-GAD criteria in the absence of any other mood disorder. The only finding that distinguished these patients from the others was a significantly higher frequency of prior history of alcohol abuse. Although alcohol withdrawal may be associated with anxiety, only 9 of 29 patients with M-GAD had a history of alcoholism. On the other hand, 23 of 29 patients (79%) with M-GAD also met criteria for major depression. Examination of CT scans obtained during the initial hospitalization revealed that patients with both major depression and M-GAD had a significantly higher frequency of cortical lesions than did either depressed patients without anxiety or nondepressed, nonanxious patients (Figure 7–6). On the other hand, depressed patients without anxiety were noted to have a significantly higher frequency of subcortical lesions compared with the anxious–depressed group (Figure 7–6).
Sexual Disorders Several studies have found marked impairment in sexual functioning after stroke. Fewer than one-third of men and women enjoyed their sex lives after a stroke, in contrast to 85% and 60%, respectively, before the stroke (Monga et al. 1986). This study identified reductions in desire, excitement, and orgasm. The most commonly identified factor explaining these reductions was fear of elevating blood pressure during sex, thereby causing another stroke. Women with righthemisphere lesions had the least impairment in sexual function. In men, in contrast, sexual dysfunction was significantly more common after right-hemisphere strokes than after left-hemisphere strokes (Coslett and Heilman 1986). Another study found that the degree of need for assistance with ADL and impaired cutaneous sensibility were major factors leading to reduced sexual intercourse (Sjogren and Fugl-Meyer 1982). Consequently, both physical and psychological factors may contribute to reduced sexuality after a stroke.
Neurological Management Neurological management of stroke is a rapidly evolving field. Acute management involves the maintenance of adequate respiration and
Stroke
233
Figure 7–6. Frequency of basal ganglia or cortical lesions among acute poststroke patients with major depression, major depression plus generalized anxiety disorder, or no mood or anxiety disorder. Major depression without anxiety was associated with basal ganglia infarcts, whereas anxious depression was associated with cortical infarcts. * P < .05 compared with other groups.
234
Psychiatric Management in Neurological Disease
blood circulation. Over the first day or two, blood pressure must be monitored and cerebral edema and increased intracranial pressure must be controlled. Longer-term concerns include cardiac function and skin care; development of pulmonary embolism, pneumonia, and other infectious processes; and prevention of recurrence through control of hypertension, smoking, and other risk factors (Brott 1993). Perhaps the most exciting developments, however, involve the antithrombotic and thrombolytic treatment of acute ischemic stroke. Antithrombotic agents have been demonstrated to significantly reduce the frequency of completed infarction in patients who had previously suffered a transient ischemic attack (TIA) (Marler 1993). Thrombolytic therapy, which has been demonstrated to be so effective in the acute treatment of myocardial infarction, has been more problematic in the treatment of acute cerebral infarction. Although some patients treated within the first 2 hours following stroke have made remarkable recovery from the effects of stroke, many patients have suffered intracerebral hemorrhages leading to further complication or death (Hacke et al. 1995). Thus, the neurological management of acute stroke is still evolving, and safer, more specific agents need to be developed. Other treatments for stroke are being developed that aim at reducing the amount of neuronal damage produced by the ischemia. Some of these treatments include the use of gangliosides, opiate receptor antagonists, N-methyl-D-aspartate receptor antagonists, and free radical scavengers (Candelise 1993). All of these treatments have shown promise in preliminary human studies or animal studies, but none have become standard treatment for acute stroke. There are numerous texts available for those seeking a more detailed discussion of neurological management in stroke (Adams 1993; Bogousslavsky and Caplan 1995).
Psychiatric Management Treatment of Cognitive Impairment The finding that cognitive impairment is associated with the presence of poststroke major depression (Bolla-Wilson et al. 1989) sug-
Stroke
235
gests that treatment of depression may result in improvement in cognitive functioning. Our study of nortriptyline treatment of poststroke depression did not show a significant difference in MiniMental State Exam (MMSE; Folstein et al. 1975) scores between the nortriptyline-treated and the placebo-treated patients over 6 weeks of treatment. Patients were, on average, 6 months poststroke, however, and the relatively long period since stroke may have contributed to the lack of improvement following antidepressant treatment (Lipsey et al. 1984). Another study, however, did assess cognitive function during the first 3 months following stroke in patients with major or minor depression (Gonzalez-Torrecillas et al. 1995). This study involved 6 weeks of open-label treatment with either nortriptyline or fluoxetine. Both antidepressants produced significantly greater improvement in MMSE scores than placebo. In this study, patients were given nortriptyline (increasing weekly doses from 20 mg to 100 mg) (n = 11) or fluoxetine (20 mg) (n = 26). Thus, although there are no controlled trials specifically addressing the effect of antidepressant treatment on cognitive function, preliminary evidence suggests that during the first few months following stroke, cognitive impairment may improve with treatment of depression.
Treatment of Apathy Although apathy is a relatively common consequence of stroke, no controlled trials of the treatment of poststroke apathy have been conducted, and there are few anecdotal reports in the literature. We have treated patients with nortriptyline, apomorphine, and amphetamine with only marginal success (R. G. Robinson and S. E. Starkstein, unpublished data, 1988). Treatment trials are urgently needed to address this condition, which can be devastating to the recovery of physical and social activities following stroke.
Treatment of Pathological Emotions We developed a Pathological Laughter and Crying Scale (PLACS; Robinson et al. 1993) to assess the existence and severity of poststroke emotional lability. Using the PLACS, a double-blind drug trial of nortriptyline (n = 14) versus placebo (n = 14) was conducted to deter-
236
Psychiatric Management in Neurological Disease
mine the responsiveness of this condition to tricyclic antidepressants (TCAs) (Robinson et al. 1993). The dose of nortriptyline was titrated from 20 mg/day (week 1) to 50 mg/day (weeks 2 and 3), 70 mg/day (week 4), and 100 mg/day (weeks 5 and 6). Of the 28 patients who completed the 6-week protocol (4 dropped out), those on nortriptyline showed significantly greater improvement in PLACS scores than did placebo-treated controls (Figure 7–7). These group differences were statistically significant at weeks 4 and 6. Citalopram, a selective serotonin reuptake inhibitor (SSRI), has also been evaluated in the treatment of pathological emotions (Andersen et al. 1993). Sixteen patients were evaluated in a double-blind, placebo-controlled crossover study. Three patients were dropped from the study. Citalopram (20 mg) was given for 3 weeks after a week of washout. All of the citalopram-treated patients reported a greater than 50% reduction in the number of crying episodes. Of the 13 patients who completed treatment, 8 responded within 24 hours of taking citalopram, and 3 responded within 3 days. Thus, citalopram as well as nortriptyline appears to be an effective method of treatment for pathological crying following stroke.
Treatment of Psychosis There are no controlled treatment trials among patients with delusions or hallucinations following stroke. Anecdotal reports have suggested two basic approaches to treatment, one using anticonvulsant therapy and the other using neuroleptic therapy. The rationale for the use of anticonvulsants is the frequent coexistence of seizures with psychotic disorders following stroke. In Levine and Finklestein’s series (1982), however, secondary psychotic features did not usually respond to anticonvulsant treatment. Price and Mesulam (1985), on the other hand, described a patient whose repeated psychotic episodes (lasting from 1 day to 1 week) were controlled with phenobarbital. The second approach to the treatment of hallucinations and delusions is the use of neuroleptic medications. Although some patients have been noted to be resistant to neuroleptic medications (e.g., trifluoperazine up to 80 mg/day [Levine and Finklestein 1982]),
Stroke
237
Figure 7–7. Pathological Laughter and Crying Scale (PLACS; Robinson et al. 1993) scores during 6 weeks of double-blind treatment (nortriptyline or placebo) of poststroke pathological emotions. * Repeated-measures analysis showed significant treatment effects, with nortriptyline being superior to placebo at 4 and 6 weeks of treatment. Source. Reprinted from Robinson RG, Parikh RM, Lipsey JR, et al.: “Pathological Laughing and Crying Following Stroke: Validation of a Measurement Scale and a Double-Blind Treatment Study.” American Journal of Psychiatry 150:286–293, 1993. Copyright © 1993, American Psychiatric Association. Used with permission.
many patients with secondary psychotic disorders have improved with neuroleptics. The atypical antipsychotics await study in stroke patients.
Treatment of Poststroke Mania There are no systematic studies on the treatment of mania following brain injury, and the existing case reports reflect anecdotal treatments and responses. Overall, the consensus is that secondary mania is inherently more difficult to treat than primary mania (Evans et al.
238
Psychiatric Management in Neurological Disease
1995). Some reports have also suggested that although patients who develop secondary mania (particularly manias associated with seizure disorders) may not be as responsive to lithium as patients with primary mania, they may respond to treatment with anticonvulsant drugs such as carbamazepine and valproate (Shukla et al. 1987). Thus, if lithium is not effective, carbamazepine, clonidine, valproate, verapamil, and neuroleptic augmentation may be useful alternatives. The anticonvulsants, such as carbamazepine and valproate, may also be particularly beneficial for stroke patients because of the risk of seizures in this population.
Treatment of Poststroke Depression Despite early anecdotal reports suggesting the clinical utility of TCAs or stimulant medications in the treatment of poststroke depression, only a few randomized double-blind treatment studies of the efficacy of antidepressant treatment have been published. The first published study involved 14 poststroke depressed patients treated with nortriptyline and 20 poststroke depressed patients given placebo (Lipsey et al. 1984). In the group treated with nortriptyline (20 mg/ day for week 1, 50 mg/day for weeks 2 and 3, 75 mg/day for week 4, and 100 mg/day for weeks 5 and 6), the 11 patients who completed the 6-week study showed significantly greater improvement in their scores on the Hamilton Rating Scale for Depression (HAMD; Hamilton 1960) compared with the 15 placebo-study completers (Figure 7–8). Nortriptyline levels in the treated group were between 50 and 150 ng/mL following 2 weeks of treatment with 100 mg of nortriptyline per day. Of the 6 noncompleters taking nortriptyline, 5 dropped out because of side effects, including delirium (2 patients), dizziness (1 patient), and sedation (2 patients), and 1 experienced a second stroke. Thus, although side effects were a significant problem, this study demonstrated by double-blind methodology that depression can be effectively treated with nortriptyline in patients with stroke. Reding et al. (1986) reported that patients with either a clinical diagnosis of depression or an elevated Zung Self-Rating Depression Scale (Zung 1965) score treated with trazodone (target dosage of 200 mg/day) showed greater improvement in ADL scores, as measured by the Barthel Index (Barthel and Mahoney 1965), over
Stroke
239
Figure 7–8. Hamilton Rating Scale for Depression (HAMD; Hamilton 1960) scores during 6 weeks of double-blind treatment (nortriptyline or placebo) of poststroke depression. *Repeated-measures analysis showed significant treatment effects, with nortriptyline being superior to pla